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Alzheimer disease (AD) attacks the brain and is the most common cause of 
dementia worldwide and it is classified to be the main cause of cognitive 
impairment in elderly people. Beta-amyloids (Aβ) and tau are aggregated to 
produce respectively plaques and tangles that are classified to be prime suspects 
for cell deaths in Alzheimer’s brain. Plaques target nerve cells to prevent their 
ability to contact each other in the correct way while tangles attack the transport 
system made of protein to be destroyed. However, the mechanisms that link Aβ 
and tau are still not fully understood. A recent proposed model (known 
immunization in AD model) not only examines pathways (DNA damage, p53 
regulation, GSK3β activity, Aβ production and aggregation and tau dynamic and 
aggregation) involved in this relationship, but also how passive and active 
immunization against Aβ can indirectly reduce the level of tau pathologies.   
In this research, we stochastically model immunization in AD for better 
understanding of the relationship between Aβ and tau since noise in biology is a 
rule rather than expectation. This modelling is done using a proposed approach 
that combines Mapping Reduction Method (MRM) and Gillespie Stochastic 
Simulation Algorithm (GSSA). This combination increases the performance of 
GSSA by accelerating a single run of GSSA and explicitly includes concurrency 
feature. To validate MRM/GSSA, we compare it with GSSA itself and the modified 
Tau leap method classified to be one of the fastest version of GSSA. MRM/GSSA is 
 iii 
not only faster than GSSA and comparable with the modified Tau-leap method, 
but also has more ability to represent stochastic feature and more reliable to be 
used for modelling any biochemical system than the modified tau leap method.  
Local sensitivity analysis (LSA) is stochastically and deterministically performed 
using MRM/GSSA and ordinary differential equations (ODEs) to investigate the 
behaviour of the immunization in AD model when parameters are perturbed, one 
at a time. A finite difference approximation method (FDM) is used to 
deterministically to perform LSA while FDM in conjunction with the common 
random number (CRN) is used to stochastically perform LSA. LSA is performed to 
(1) determine the maximum and minimum ranges of each parameter, (2) classify 
the most important species that contribute to the overall behaviour of the system 
and (3) identify pathways that dramatically changed in response to parameter 
perturbation. LSA using ODEs and MRM/GSSA indicates that p53 regulation, DNA 
damage pathway and GSK3β activity are not contributing to the overall behaviour 
of the system. Aβ production and aggregation, Tau dynamic and aggregation and 
immunisation pathways (passive and active) are the most important pathways that 
dramatically contribute to the overall behaviour of the system. LSA also 
demonstrates that parameters specific to p53, Mdm2 and Aβ are the most 
important parameters that contribute most to the variation in the system.  
Latin Hypercube Sampling and Partial Rank Correlation Coefficient (LHS/PRCC) are 
powerful tool employed with a minimum number of computer simulations in 
uncertainty analysis to monotonically relate the model outputs to the input 
parameters. We use LHS/PRCC to not only deterministically (ODEs), but also 
stochastically (MRM/GSSA) investigate the epistemic uncertainties of parameters 
of immunization in AD model.  We explore at three different time points the effects 
of parameters on the key outputs of immunization in AD model (selected from the 
included pathways). This is to discover the most important parameters that 
uncertainties contribute to predication imprecision and rank these parameters by 
their importance in contributing to this imprecision. PRCC analysis using ODEs and 
MRM/GG demonstrates that binding relationship between p53 and Mdm2 and 
Mdm2 synthesis are the most important reactions that contribute to the behaviour 
of nearly all selected species in response to combination of LHS matrix. PRCC 
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analysis using MRM/GSSA indicates some other parameters such as kgenROSGila 
and kbinE2UB also have strong correlation with the key outputs. 
Keywords: Alzheimer’s disease, Gillespie stochastic simulation algorithm, Mapping 
reduction method, ordinary differential equations, Amyloid-β production, tau 
dynamic, p53 regulation, DNA damage, immunization in Alzheimer’s disease,  finite 
difference approximation method, LHS/PRCC.  
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1.1 Alzheimer’s disease  
Alzheimer’s disease (AD) attacks the brain and is the most common cause of 
dementia worldwide. Dementia is the general term for a chronic or persistent 
disorder in mental processes caused by brain disease or injury that is enough to 
interfere with daily life. Alzheimer’s disease patients slowly, but surely, lose their 
memory and their cognitive abilities; their personalities could also change 
dramatically (Mattson, 2004). These changes are a result of the dysfunction and 
death of the nerve cells that have the responsibility to store and process 
information in the brain. 
1.1.1 History 
Dr Alois Alzheimer was a German neurologist and psychiatrist. He discovered AD 
in 1906. He initially observed this disease in a 51-year-old woman named Auguste 
Deter. In 1901, her family noticed changes in her personality and behaviour so 
they brought her to him. After five years of looking after her, Dr  Alzheimer noted 
many abnormal symptoms, including difficulty speaking, confusion and impaired 
comprehension (Khachaturian & Radebaugh, 1996). Later, Dr Alzheimer described 
her as a person with an aggressive form of dementia, language deficits and a 
malfunctioning memory. He did an autopsy after her death, in 1906, and found 
that there were not only fatty deposits in her blood vessels but also an intense 
shrinkage of the cerebral cortex. At that time, neurofibrillary tangles and senile 
plaques were discovered; these species have since become indicative of AD 
(Possin et al., 2013).  
1.1.2 Biological Background 
The reason for the cell deaths in Alzheimer’s brain is not fully understood but 
scientists classify plaques and tangles prime suspects for these deaths (McCarter, 
2014).  Plaques are formed when protein pieces called beta-amyloids (A𝛽) (BAY-
TUH-AM-uh-loyeds) clump together and begin to build up between nerve cells 
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and prevent their ability to contact each other in the correct way. Figure 1.1 






Figure 1.1: The difference between healthy cells and Alzheimer’s cells. Plaques in 
Alzheimer’s cells are clusters of Amelyod beta proteins that build up between 
nerve cells. Tangles cause death of nerve cells. Retrieved from 
https://www.alz.org/braintour/plaques.asp. 
Tangles attack the transport system made of proteins to be destroyed. The 
transport system is used for food, cell parts and other materials to travel between 
nerve cells. As shown in Figure 1.2, in healthy cells, the tau proteins help this 
system to be organized into parallel strands. In Alzheimer’s cells, these tracks can 
no longer be straight because tau collapses into twisted strands called tangles. 
Cells eventually die because the transport system is not able to transfer nutrients 
and other materials through the cell any more. As a result of the increasing 
number of tangles and plaques, healthy neurons start to function less effectively 
and are progressively unable to communicate and, eventually, they die (Theofilas 
et al., 2018). 
Changes in the brain associated with AD commence years before any signs of the 
disease. This time period is referred to as preclinical AD. AD, itself, also progresses 
gradually and can last for decades (Yang, Mufson, & Herrup, 2003). Three 
different stages of AD have been discovered, each with its own symptoms and 
challenges (Goedert & Spillantini, 2006).  These stages, as described in Table 1.1, 
are the mild-, moderate-, and severe-stages. 
 








Figure 1.2: Transport system in healthy and Alzheimer cells. This system is used 
for food, cell parts and other materials to be travelled along the tracks. In 
healthy cells, tau helps this system to be organized in parallel strands. In 
Alzheimer’s cells, the tracks can no longer be straight because tau collapses into 
twisted strands called tangles. Cells will not be able to survive since the 
transport system is no able any more to transfer nutrients and other materials 
through the cell.  Retrieved from https://www.alz.org/braintour/plaques.asp.  
 
Table 1.1: Stages of AD. Retrieved from www.emedicinehealth.com. 
Mild-stage Moderate-stage Severe-stage 
Lasts two to four years lasts for many years lasts for one to three years 
# of tangles and plaques are 
small 
# of tangles and plaques start 
to increase and tend to 
spread throughout the 
cortex.  
# many plaques and tangles 
that are spread throughout 
the cortex 
Patients have difficulties in - 
 Retaining new information 
 Solving problems 
 Making decisions 
 Managing finances 
Patients have difficulties in - 
 Making progressively poor 
judgments 
 Achieving hard tasks  
 Remembering their personal 
history. 
Patients have difficulties in  
 Communicating. 
















For more details about these stages see (Dubois et al., 2010; Jack Jr et al., 2011; 
Mangialasche, Solomon, Winblad, Mecocci, & Kivipelto, 2010). 
For better understanding of AD whether how it is caused or treated, cellular 
mechanisms are involved to increase or decrease the level of plaques and tangles 
need to be investigated and analysed. Modelling approaches and sensitivity 
analysis techniques have been increasingly recognized as worthy tools to 
investigate and analyse the cellular mechanisms involved in ageing and age-
related diseases (Proctor, Boche, Gray, & Nicoll, 2013). Different modelling 
approaches and sensitivity analysis techniques have been proposed to investigate 
and analyse the cellular mechanisms involved in AD.  In the next section we briefly 
describe the most popular approaches and analysis techniques that have been 
used to investigate the cellular mechanisms. In Chapter 2, we provide a historical 
overview about the existing approaches and analysis methods that are used to 
investigate AD.  
1.2 Modelling Approaches and Sensitivity Analysis methods 
Four different types of mathematical modelling approaches are used to 
determine the overall behaviour of biochemical systems or cellular mechanisms. 
These approaches are: (1) discrete deterministic; (2) continuous deterministic; (3) 
stochastic; and (4) hybrid. They are used to investigate and understand system 
activities, such as regulators, oscillations and feedback loops. (Klipp, 
Liebermeister, Wierling, Kowald, & Herwig, 2016; Szallasi, Stelling, & Periwal, 
2006). For more details about these approaches see (Herajy, Liu, Rohr, & Heiner, 
2017; Thieme, 2018; Veliz-Cuba, Jarrah, & Laubenbacher, 2010; Wattis, 2006). The 
most popular approaches are continuous deterministic, based on ordinary 
differential equations (ODE) and stochastic models, using Gillespie stochastic 
simulation algorithm (GSSA) or one of its variants since they have been intensively 
used to model biochemical systems.  
ODEs are used in a track the exact concentration of biological components 
through the continuous representation of system dynamics over time (Fuβ, 
Dubitzky, Downes, & Kurth, 2005). The ODEs are used to describe the reaction 
rates of interactions between species according to chemical kinetic theory (Cloez 
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et al., 2017; Fuβ et al., 2005; Heath & Kavraki, 2009; Tyson, Novak, Odell, Chen, & 
Thron, 1996). Recently, the use of ODEs has intensified significantly for biological 
systems, especially with the advent of experimental techniques, such as whole 
genome sequencing and high throughput flow cytometry that are capable of 
providing a wealth of new biological data. Stochastic models are frequently used 
to model biochemical systems, which are classified as small systems (<100 
particles for each species in a given system). The denotational semantics of 
stochastic models define rules to describe how the system modelled moves from 
one state to another state. Therefore, stochastic models are used to 
quantitatively describe the states of the modelled system by determining the 
initial state, and the procedure to be applied, to give a new system state (Fisher & 
Henzinger, 2007). More relevant details about these two approaches are given in 
Chapter 2.  
The behaviour of any biological model can be strongly dependent on its 
parameters. If some of these parameters are not precisely known, the uncertainty 
of these parameters is taken into the model output (Kitano, 2002). Therefore, 
using sensitivity analysis methods to address the lack of precise parameter values 
and incorporate the uncertainty of these parameters into the model helps to 
quantify the uncertainty in the output (Kiparissides, Kucherenko, Mantalaris, & 
Pistikopoulos, 2009; Kulasiri, Liang, He, & Samarasinghe, 2017).  
Sensitivity analysis, in the context of biological systems, is defined as how much 
the behaviour of a biochemical system depends on the parametrization of the 
model (Kulasiri et al., 2017). A comprehensive set of predictions is generated by 
sensitivity analysis to indicate how model's output is affected quantitatively by 
changes in any of its parameters. This procedure is able to: (1) Identify predictions 
that could be consistent or inconsistent with the experiment data; (2) Validate the 
model; and (3) Reduce the model complexity by identifying pathways that are not 
dramatically affected when parameters are perturbed (Lee, Liu, Hwang, 
Knollmann, & Sobie, 2013). 
Local sensitivity analysis (LSA) methods belong to the class of one-at-a-time (OAT) 
methods because in each run of the model just one parameter is given a new 
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value, while assuming that all other parameters remain at their baseline values. 
However, one-at-a-time methods could not only be of limited use, but also be 
outright misleading especially when the relative importance of uncertain factors 
needed to be assessed. To cope with this limitation, the influence of simultaneous 
changes in parameter values needs to be investigated (Saltelli, Ratto, Tarantola, & 
Campolongo, 2005).  
Global sensitivity analysis (GSA) addresses the behaviour of a biochemical system 
over a wide range of parameter values. These ranges are not only based on a 
rough estimation of parameter values, but also the upper and lower bounds may 
be used to specify them. Statistical methods are always used to sample the values 
of these parameters within the specified domains of the parameter spaces 
(Saltelli et al., 2008). More relevant details about sensitivity analysis techniques 
are given in Chapter 2.  
1.3 Immunisation in AD 
In 2013, Proctor and his colleagues developed a mathematical model to study 
how a patient with AD could be immunized against plagues and tangles (Proctor 
et al., 2013). As shown in Figure 1.1, they used two different types of 
immunization systems, passive and active; using antibodies and Glia, respectively. 
The mechanisms which link Aβ and tau are still not fully known although many 
suggestions&have been&made by (Ittner et al., 2010; Rapoport, Dawson, Binder, 
Vitek, & Ferreira, 2002; Roberson et al., 2007; Small & Duff, 2008). 
Proctor et al. (2013) examined not only some of the key pathways involved in the 
mechanisms link Aβ and tau, such as DNA damage, p53 regulation, GSK3β activity 
and Aβ production and aggregation, Tau dynamic and aggregation and 
immunisation pathways (passive and active), but also how immunization against 
A𝛽 can indirectly reduce the level  of tau pathologies. Proctor et al., (2013) also 
included possible players, such as p53, GSK3β, and ROS, that have roles linking A𝛽 
and tau, as shown in Figure 1.1. This system is the case study that has been used 




Figure 1.3: Immunization in AD. Passive and active Immunization using 
antibodies and Glia to reduce the number of A𝜷 that indirectly reduces the 
number of tangles. 
 
1.4 Motivation and main research questions 
The importance of stochasticity in biological systems has gained greater 
acceptance because it has become very clear that noise in biology is the rule 
rather than the exception (McAdams & Arkin, 1999). Therefore, stochastic 
approaches are the best way to investigate the behaviour of biochemical systems. 
GSSA described in Chapter 2 is the first stochastic algorithm that was introduced 
by D.T. Gillespie more than 40 years ago (Gillespie, 1976). However, the time 
required for executing GSSA, especially when the biochemical system under study 
have many reactions, is very high.  Sequential running is also one of the main 
limitations of GSSA and its variants while concurrency is considered to be one of 
the main features of biochemical systems. Concurrency means that components 
of any biochemical systems have the ability to simultaneously collide each other. 
Different versions have been proposed to accelerate the GSSA, each version has 
its own advantages and disadvantages. These versions are described in Chapter 2. 
Therefore, the first question that we ask is: 
1- How could a single run of GSSA be accelerated and how could GSSA be 
extended to include the concurrency feature? 
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To answer the two parts of this question, Mapping Reduction method (MRM) is 
selected to be modified and combined with GSSA itself to not only accelerate the 
GSSA but also indirectly to include the concurrency feature by advancing the 
system with several reactions. This combination is discussed in Chapter 4 
(sections 4.1 and 4.2).  
2- What are the main advantages of MRM/GSSA over not only GSSA, but also 
one of the fastest version of GSSA (modified Tau-leap method)? 
To answer this question, immunization in AD is modelled by GSSA, MRM/GSSA 
and the modified Tau-leap method. These approaches are compared from 
different angles, results, CPU times and implementation. This comparison is 
discussed in Chapter 4 (section 4.5). 
As previously mentioned, Proctor et al. (2013), include possible players, such as 
p53 and GSK3β, to investigate the link between A𝛽 and tau and how these players 
participate to reduce the level of tangles when a patient with AD is immunized 
against A𝛽. Investigating the behaviour of these players in addition to other 
players in this system is a need to check how the system behaves in response 
parameters perturbation. Therefore, LSA and GSA using ODEs and MRM/GSSA are 
performed to achieve this purpose.   
At the level of LSA analysis, we aim to answer six questions. These questions are: 
1- What are maximum and minimum ranges of each parameter? 
2- What are the most important species in the system? 
3- What are the most important parameters that contribute most to the variation in the 
system?  
4- What are the most important parameters that specifically contribute most 
to the variation on the level of plaques and tangles? 
5- What are the most important pathways that are hugely affected when 
parameters are perturbed?  
6- What time are species showing the maximum sensitivity in response to 
parameters perturbation? 
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To answer these question, LAS using ODEs and MRM/GSSA is performed and each 
parameter in this system is perturbed by two values (50% and 200%) of its basal 
values, one at a time. The main players of the system are selected to be checked 
against parameters perturbation. These players are p53 (from p53 regulation), 
ATMA (from DAN damage activity), p53_GSK3β (from GSK3β activity) Aβ & 
plaques (from Aβ production and aggregation), tangles (from Tau dynamic and 
aggregation) and GliaA (from immunisation pathways (passive and active)).  
Each player is used to measure the sensitivity of its pathways against parameters 
perturbation to classify these pathways and reduce the complexity of the system 
by determining pathways that are not dramatically affected when parameters are 
perturbed.  LSA identifies the most important parameters that contribute most to 
the variation and group the parameters that contribute to the behaviour of 
plaques and Tangles. Sensitivity is computed at each time step, the time step for 
the maximum sensitivity value of each species is determined.         
The results of the LSA using ODEs and MRM/GSSA are discussed in Chapter 5.   
At the level of GSA, using ODEs and MRM/GSSA, we aim to answer two questions.  
1- How would changing a wide range of parameter values simultaneously drive the 
dynamic behaviour of the system?  
This question is answered by checking the behaviour of the system in response to 
perturbing all parameters at the same time to explore the effects of the 
interactions between parameters.  This helps to identify the key parameters that 
drive the dynamic behaviour of the system.    
2- Is there any difference between the results of GSA using ODEs or MRM/GSSA? 
Identifying the key parameters that drive the dynamic behaviour of the system 
using ODEs and MRM/GSSA separately helps to achieve this comparison.    
1.5 Objectives 
There are three major objectives in this study 
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(1) To not only accelerate a single run of GSSA but also to include the concurrency 
feature in order to increase its performance.    
To achieve this objective, we modified MRM to be suitable to be combined with 
GSSA. The MRM method is a programming model that uses 
a parallel  distributed algorithm on a cluster to run multiple processes 
simultaneously. The main benefit of the MPR is dividing the work across many 
processors and keeping as much data in memory as possible during processing.  
MRM employs 𝑘 worker threads to execute the same task at the same time. 
Therefore, we use MRM to run GSSA for the same system 𝑘 times (𝑘 is 
determined depending on the number of reactions that have the propensity 
function at greater than zero). The main two steps of this combination are 
election and selection. Each thread elects a reactions index, 𝑗, and a time step, 𝜏. 
The 𝑘 index is then analysed to select the eligible reactions. This combination not 
only allows us to accelerate GSSA, but also includes the concurrency feature by 
advancing the state of the system by several reactions within the calculated time 
step, τ. MRM and MRM/GSSA are described in detail in Chapter 4 (sections 4.1 
and 4.2).  
(2) To validate MRM/GSSA.  
The model of immunization in AD is modelled by MRM/GSSA, GSSA and the 
modified Tau-leap method. To validate MRM/GSSA, these three methods are 
compared at three different levels; results, performance and implementing 
difficulties.  
(3) To investigate the critical behaviour of main players in immunization in the AD model,  
LSA and GSA are performed not only using ODEs, but also MRM/GSSA.     
 To perform LSA using ODE models, we use a finite difference 
approximation (FDA) that is the most popular and simplest way to perform 
LSA (Saltelli, Chan, & Scott, 2000). To perform LSA using the MRM/GSSA 
model, we use the common random number (CRN) method (Rathinam, 
Sheppard, & Khammash, 2010) for sensitivity estimation. Positive 
correlations are obtained by using the CRN method for nominal and 
perturbed parameters in conjunction with MRM/GSSA.  The results of LAS 
are discussed in detail in Chapter 5.   
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 To perform GSA using ODEs and the MRM/GSSA model, we use Latin 
hypercube sampling (LHS) in combination with partial rank correlation 
coefficient analysis (PRCC) since it is shown to be efficient in assessing a 
model over a global parameter space (Saltelli et al., 2000). The PRCC 
method is a useful tool since it has the ability to monotonically relate the 
model outputs to the input parameters. Input-output scatter plots are used 
to examine the monotonic relationships between the inputs and outputs 
(Marino, Hogue, Ray, & Kirschner, 2008). The results of GSA are discussed 
in Chapter 6.  
LSA and GSA allow us to:  
 Quantify the uncertainty in the outputs by incorporating uncertainties into 
the modelling process. 
 Reduce model output uncertainty since sensitivity analysis has the ability to 
determine the parameters that contribute most to the variation. Therefore, 
experimental effort should be focussed on refining those parameters.    
 Identify the parameters that are most dominant with respect to the system 
output and suggest targets for intervention since it provides a method for 
systematically investigating the effects of perturbations.  
1.6 Thesis structure 
This thesis consists of seven chapters.  
In the current chapter, Chapter 1, we briefly give an introduction about different 
topics: AD, modelling approaches, sensitivity analysis techniques and 
immunization in AD. We also discuss the motivations and objectives of this thesis.    
Chapter 2 reviews in detail: (1) the deterministic and stochastic approaches; (2) 
the sensitivity analysis techniques (LAS and GSA); and (3) the existing 
computational approaches that have been used to investigate AD.  
Chapter 3 discusses the case study (immunizations in AD).  
Chapter 4 proposes MRM/GSSA for stochastically modelling biochemical systems. 
It also describes the LSA and GSA methods that are used to analyse the system. 
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We also validate the proposed method by comparing it with the GSSA and Tau-
leap methods. 
Chapter 5 discusses the results of LSA analysis using ODEs and MRM/GSSA and 
provides comparisons between them. 
Chapter 6 presents the results of GSA analysis using ODEs and MRM/GSSA. 
Chapter 7 summarizes the work and the contribution of this thesis and suggests future 





Numerous molecular processes (pathways) contributing to AD have already been 
elucidated. However, these processes have a daunting complexity and it was 
challenging to understand their integrated functions and the dynamic crosstalk 
between them. This complexity arises from the large number of interactions and 
the non-linear character of these processes (Lloret‐Villas et al., 2017).  To cope with 
this challenge, different types of modelling approaches and sensitivity analysis 
techniques have been proposed to gain a better understanding of biological 
systems at the system level. Modelling approaches are developed to explicitly 
predict and test the dynamic behaviour of biochemical pathways as a whole 
instead of their individual components (Toh & Allen-Vercoe, 2015; Ullah, Schmidt, 
Cho, & Wolkenhauer, 2006). Sensitivity analysis techniques are used to address the 
lack of precise parameter values, and incorporating the uncertainty of these 
parameters into the model helps to quantify the uncertainty in the output 
(Kiparissides et al., 2009; Kulasiri et al., 2017). This chapter reviews the most 
popular approaches and techniques for modelling and analysing the biochemical 
pathways, as well as a comprehensive review of mathematical models of AD.  
2.2 Modelling Approaches  
Two popular approaches for modelling and simulating biochemical pathways are 
deterministic and stochastic approaches. The deterministic approach (mainly ODEs) 
constructs a set of equations to describe the reactions in a biochemical pathway 
(Mellman & Misteli, 2003). Stochastic approaches involve the formation of a set of 
chemical master equations with probabilities as variables (Van Kampen, 1992). 
2.2.1 Deterministic modelling and simulation 
The deterministic approach (mainly ODEs) ignores all fluctuation events and 
regards variables as continuous concentrations rather than actual particle or 
molecular numbers (Bluman & Anco, 2002). Therefore, at any particular instant, 
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the state of the system is observed as a list of concentrations of molecules, and 
changes in these concentrations are assumed to occur by deterministic processes 
(Wilkinson, 2009). To represent a biological system using ODE models, two 
assumptions are made: (1) the molecular number is very large; and (2) reactions 
are very frequent. ODEs are equations in the form: 
𝐝(𝐲)
𝐝𝐭
= 𝐟(𝐤, 𝐘(𝐭)), 𝐘(𝟎) = 𝐘𝟎 
      𝟐. 𝟏 
Here 𝑌(𝑡) is the vector of variables, 𝑘 is the 𝑚-vector of system parameters, 𝑌0 are 
the initial values. ODEs have been widely studied for many years. Therefore, there 
are many accurate solvers available for analysing and numerically solving ODE 
models, such as one-step first-order methods (Euler method) (Shampine & Watts, 
1969), multistage methods (fourth order Runge-kutta method) (Hu, Hussaini, & 
Manthey, 1996), multistep methods and the Richardson extrapolation (Deuflhard, 
Hairer, & Zugck, 1987). For more details about these methods see (Hairer, Lubich, 
& Roche, 2006; Székely, 2014; Xing & Stern, 2010). 
Euler method (One step methods) 
This method is classified as the simplest ODE solver and its solution at each time 
steps depends on the solution of the previous step.  For example, the solution at 
step 𝑚+ 1  depends only on the solution at step 𝑚: 
𝑌𝑚+1
ℎ = 𝑌𝑚
ℎ + ℎ𝑓(𝑡 𝑚 , 𝑌𝑚 
ℎ ) 2.2 
𝒀𝑚
ℎ   is the approximate solution to Eq 2.1 at time step 𝑚 with step size ℎ and 𝑡𝑚 =
𝑚ℎ.  The Euler method takes only one step to get a single sample of the gradient of 
𝒇 for calculating the next step. Therefore, it is called a one-step, one-stage explicit 
solver. However, it is not often used because of its low accuracy. The local 
truncation error of this method, is the difference among the true solution and the 
numerical approximation of the Euler method: 
𝜀((𝑡𝑚+1 − 𝑡𝑚), ℎ) = 𝑌(𝑡𝑚+1) − 𝑌𝑚+1
ℎ =  𝑌(𝑡𝑚+1) − 𝑌𝑚
ℎ − ℎ𝑓( 𝑡𝑚, 𝑌𝑚
ℎ) 2.3 
                                                       
The method is considered to be consistent if and only if its local error tends to 




(𝜀((𝑡𝑚+1 − 𝑡𝑚), ℎ))
 
= 0 2.4 
  
Multistage and multistep methods 
The Euler method is simple and fast but it is not always a good solver of ODE 
models because of its low accuracy. According to (Székely, 2014), a higher accuracy 
is achieved by sampling the function 𝒀,  more times at each time step.  Two 
methods are used to do this sampling but they differently deal with the evaluating 
the function 𝒀; these methods are one-step multistage and multistep methods. For 
example, to find 𝒀𝒎+𝟏 one-step multistage method evaluates the function 𝒀 and its 
derivatives at several points between 𝒀𝒎 and 𝒀𝒎+𝟏 (such 
as 𝒀𝒎, 𝒀𝒎+𝒉/𝟐 , 𝒀𝒎+𝒉/𝟒, ………………… , 𝒆𝒕𝒄), while multistep method uses the 
solutions and derivatives of previous steps such as 𝒀𝒎−𝟏, 𝒀𝒎−𝟐………… . . 𝒆𝒕𝒄  
One-step multistage methods 
These methods are used to achieve greater accuracy than the Euler method. As 
stated before, one-step multistage methods evaluate the function 𝒀 and its 
derivatives at several points between 𝒀𝒎 and 𝒀𝒎+𝟏 (such as 
𝒀𝒎, 𝒀𝒎+𝒉/𝟐 , 𝒀𝒎+𝒉/𝟒, ………………… , 𝒆𝒕𝒄) (Humphries & Stuart, 1998). In other 
words, additional samples within the step are taken to achieve higher accuracy. 
The simplest multistage method is called the midpoint method. The general form of 
the midpoint method is similar to one step method (Eq (2.2)) but sampling of the 






ℎ + ℎ𝑓 ( 𝑡𝑚 + 
ℎ
2








Midpoint method is classified as the simplest member of the Runge-Kutta family of 
numerical solvers (Schwartz, 1996).  This group is considered to be an important  
member of multistage methods for achieving higher accuracy as the members of 
this group use extra samples within the current step (Munthe-Kaas, 1999). In this 
family, the most frequently used method is called fourth order Runge-kutta 
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method. Runge-kutta 4th order method (RK4) solves first order differential 
equation of the form: 
𝑑𝑦
𝑑𝑡
= 𝑓(𝑥, 𝑦), 𝑦(0) = 𝑦0 
2.6 
In this algorithm, four function evaluations are made, two intermediate evaluations 
on the gradient at two points around the midpoint and two other gradient 
evaluations at the start and the end of the step, respectively.  
𝑌𝑖+1 = 𝑌𝑖 +
1
6
(𝑘1 + 2 ∗ 𝑘2 + 2 ∗ 𝑘3 + 𝑘4) ∗ ℎ 
2.7 
 
where knowing the value 𝒀𝒊
  at 𝒙𝒊
 , the value of 𝒀𝒊+𝟏
  could be easily found at 𝒙𝒊+𝟏
  
and ℎ = 𝒙𝒊+𝟏
 − 𝒙𝒊
  (step size). 𝑘𝑗 is the gradient at the 4 points. RK4 algorithm 
performs well for different types of problems including non-smooth ones especially 
when it is combined with adaptive step size. It is  fast to run, as well as being 
accurate and easy to code (Press, 2007).  
To generate 𝑘𝑗 for Equation 2.7, this equation is equated to the first five terms of 
Taylor series that is used to represent a function as an infinite sum of terms 
calculated from the values of the function's derivatives at a single point.  
𝑦𝑖+1 = 𝑦𝑖 + 
𝑑𝑦
𝑑𝑥


















|𝑥𝑖𝑦𝑖  (𝑥𝑖+1 − 𝑥𝑖)
4 
2.8 
Knowing that  
𝒅𝒚
𝒅𝒙




𝑦𝑖+1 = 𝑦𝑖 +  𝑓(𝑥, 𝑦)ℎ + 
1
2!
𝑓(𝑥, 𝑦)′ℎ2  + 
1
3!





Equating Equations (2.8) and (2.9), one of the most popular solutions used for 
Equation (2.7) is obtained, where: 
𝑘1 =  𝑓(𝑥𝑖, 𝑦𝑖)  2.10 
𝑘2 =  𝑓(𝑥𝑖 + 
1
2
ℎ , 𝑦𝑖 +
1
 2
𝑘1ℎ )   2.11 
𝑘3 =  𝑓(𝑥𝑖 + 
1
2
ℎ , 𝑦𝑖 +
1
 2
𝑘2ℎ )   2.12 
𝑘4 =  𝑓(𝑥𝑖 + ℎ , 𝑦𝑖 + 𝑘3ℎ ) 2.13 
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Discarding the evaluations carried out at all previous steps at the next step is 
considered to be the main drawback of one-step multistage methods (Akrivis, 
Crouzeix, & Makridakis, 1999). 
(a)  Multistep methods  
Multisptep methods aruge that soultions to differential equations are more 
efficient if an algorithm stores the solutions that are already calculated at all 
previous steps and use these solutions in the next steps (Székely, 2014). 
According to (Székely, 2014) multistep methods are not only face some problems 
when the step size is varied, but also they do not have stability properties as one-
step methods.  
(b)  Richardson extrapolation 
Richardson extrapolation is a technique that is proposed to improve the order of 
accuracy of deterministic numerical methods when the structure of the error is 
known (Székely, 2014). The main idea of Richardson extrapolation is to perform 
numerical calculations using various values of step size. This is used for numerical 
calculation whose accuracy depends on unknown analytic function of the step size 
ℎ. The deterministic function 𝑌(𝑡) resulting from numerical solution using the same 
solver with different stepsizes at a given time 𝑇 = 𝑛ℎ is written as:  
𝑌(𝑇) =  𝑌𝑇 
ℎ +  𝜀(𝑇, ℎ) 2.14 
 
𝒀𝑻 
𝒉  is consdiered to be an estimattion to 𝑌(𝑇) at time 𝑇 using stepsize ℎ and 
𝞮(𝑻, 𝒉) is the (global) error of the approximate solution. 𝞮(𝑻, 𝒉) could be written in 
terms of powers of the stepsize ℎ for general numerical solver as:  





The 𝒆 𝒌𝟏 are constant vectors that depend on the final integration time 𝑇 and  𝒌𝟏 <
𝒌𝟐 < 𝒌𝟑……. in Eq (2.15) are known as the global error expansions in this method. 
Constructing a higher-order approximation is the main reason for the existence of 
such an expansion. Fundamentally, Richardson extrapolation employes polynomial 
extrapolation of approximations 𝒀𝑻
𝒉𝒒 , 𝒒 = 𝟏, 𝟐,… .. where 𝒒 can be any integer and 




Bulirsch-Stoer algorithm and Romberg integration are major practical applications 
of Richardson method. These methods are considered to be very powerful and 
accurate ODE solvers that rely on extrapolation within each step. 
 
Bulirsh-Stoer algorithm (Bulirsch & Stoer, 1966) is an accurate method for 
numerical solutions of ODEs. This algorithm is based on three different ideas: (i) 
Richardson extrapolation, (ii) using rational function extrapolation in Richardson-
type applications, (iii) using the modified midpoint method (MMP, Algorithm 2.1) 
to obtain high accuracy numerical soultions for ODE models with comparatively 
little computational effort. 
Bulirsh-Stoer algorithm argues that rational functions as fitting functions are 
superior to polynomial functions in Richardson extrapolation in numerical 
integration (Monroe, 2002). This is because rational functions have the ability to 
estimate functions with poles whereas polynomial functions uses higher-power 
terms in the denominator to account for nearby poles (Chambers, Quintana, 
Duncan, & Lissauer, 2002). In a complex plan, a polynomial functions are able to 
produce worthy results when the nearest pole is rather far outside of the circle 
around the known data points, while rational functions can have notably accurate 
results even in the presence of nearby poles (Fang et al., 2011). 
The modified midpoint method (MMP, Algorithm 2.1) is considered to be a second 
order method but the main advantage of MMP is requiring one derivative 
evaluation per subset (Gragg, 1965). The modified midpoint method subdivides 
each step size 𝒉 into (?̂?)  substeps of size ?̂?  where ?̂?= 𝒉/?̂? as shown in MMP 
Algorithm 2.1. The error expansion of the The modified midpoint method covers 
even powers only of ℎ̂. This results in fast convergence (Gragg, 1965). This makes 
MMP significantly useful to the Bulirsh-Stoer algorithm because the accuracy is 
increased by two different orders at a time step when the results of separate 
attempts cross the interval ℎ with increasing numbers of substep sizes are 
combined (Bowers, Dror, & Shaw, 2006).  
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Algorithm 2.1: Modified midpoint method (MMP) 
 
The Bulirsch-Store algorithm has the ability to adapt its order step-size for 
maximising not only its accuracy, but also its computational efficiency (Székely, 
2014).  






The composite trapezium rule is a common way to evaluate this integration with 
𝑃 =  
𝑏−𝑎
ℎ
  intervals. Then, the integral can be approximated as: 





+ ∑𝑓(𝑎 + 𝑝ℎ)
𝑃−1
𝑝=1
) + 𝑂(ℎ2) 
2.17 
Romberg integration repeats this evaluation using 2𝑃 intervals, 4𝑃 intervals, 
etc, and then extrapolate them to get more successively accurate solutions.  
However, ODE models are not able to address the role of noise, one of the major 
challenges in current biology, or the random switching between different states of 
the system as ODE models predict the average and continuous behaviour at the 
population level. Deterministic models argue that random events could be 
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averaged because, in many cases, these random events happen on a very small 
time scale while deterministic models focus on larger time scales  (Proctor & Gray, 
2008; Trewavas, 2006). 
2.2.2 Stochastic modelling and simulation (Discrete stochastic methods) 
It has become very clear that noise in biology is the rule rather than an exception 
(Sauer, 2012). Therefore, stochastic models have received a great deal of attention 
recently leading to many recent reviews (Burrage, Burrage, Leier, & Marquez-Lago, 
2017; Česka, Šafránek, Dražan, & Brim, 2014; Gillespie, 2007; Pischel, Sundmacher, 
& Flassig, 2017; Raser & O'shea, 2005). Stochastic models are widely used to model 
biological systems and are classified as small systems (<100 molecules for each 
species in a given system). The denotational semantics of stochastic models are 
through the definition of rules to describe how the modelled system moves from 
one state to the next state. Therefore, stochastic models have been used to 
describe the states of the modelled system by determining the initial state and the 
procedure to be applied to give a new system state (Fisher & Henzinger, 2007). 
GSSA and its extensions are the most popular approaches that have been used to 
stochastically investigate biochemical systems.   
The GSSA (a trajectory-based approach) is a technique used to generate individual 
realizations (Monte Carlo paths) from the full distribution given by the chemical 
master equation (CME) (Székely, 2014). The CME is an exact method that is used to 
enumerate all possible states for any stochastic system at any given time by 
tracking the behaviour of the system (Gillespie, 1992). 
Using GSSA, a PDF (probability density function) can be obtained from an infinite 
number of simulations and this PDF is identical to the true distribution of the 
system, as given by the CME (Haugh, 2004). However, the identical PDF to the true 
distribution is never reached but an accurate PDF that depends on the system or 
type of application could be achieved using a high number of repeats of the GSSA 
(Gillespie, 2007). The GSSA is used to generate a step-by-step trajectory of the 
system instead of following the time evolution of the probabilities of the CME. In 
each time step, the GSSA uses the current state of the system and determines what 
reaction will occur next and when it will occur. In the literature, there are several 
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implementation strategies that have been proposed for the GSSA. They are: (1) the 
direct method (Gillespie, 1977); (2) the first reaction method (Gillespie, 1977); (3) 
the next reaction method (Gibson & Bruck, 2000); (4) the optimized direct method 
(Cao, Li, & Petzold, 2004); (5) the sorted direct method (McCollum, Peterson, Cox, 
Simpson, & Samatova, 2006); (6) the logarithmic direct method (Madani et al., 
2006); and (7) the Tau-leap modified Poisson method (Cao, Gillespie, & Petzold, 
2006).  
 Direct method  
The direct method is a well-known technique that is used to stochastically model 
biochemical reactions and it is roughly equivalent to the CME. Assume a system 
involves 𝑁 molecular species (𝑆1, ………… , 𝑆𝑁), species are represented by 𝑋(𝑡) 
=(𝑋1(𝑡), ………… ,𝑋𝑁(𝑡)) (the state vector), where 𝑋𝑖(𝑡) is the number of 
molecules of 𝑆𝑖 at time 𝑡 and 𝑀 reactions channels (𝑅1, ………… , 𝑅𝑚). The GSSA 
steps along in time reaction-by-reaction, governed by the reaction probability (𝑎𝑗) 
(propensity function) and by the state change vector 𝑣𝑗 = (𝑣1𝑗 , … . , 𝑣𝑁). 𝑎𝑗(𝑥)𝑑𝑡 
gives the probability that one reaction will occur in the next time step. The steps of 





















Figure 2.1: Schematic of the direct method 
First reaction method  
The first reaction method (Gillespie, 1977) is theoretically equivalent to the direct 
method since they select just one reaction to be run. The main difference between 
them is that the first reaction method is much less efficient than the direct method 
since 𝑀 random numbers need to be generated to select just one reaction. 
Generating random numbers is computationally expensive (Cao & Samuels, 2009). 
The pseudo code of this method is given by Gillespie (1977). 
Next Reaction method  
In the next reaction method, remarkable progress has been made to the first 
reaction method to improve its efficiency. A dependent graph is used to record the 
influence of each reaction on the other reactions. This method employs a 
dependent graph to record the absolute time, 𝑡 +  𝜏𝑘, as the expected firing time 
for the 𝑅𝑘 reaction (the expected firing reaction). It aims to avoid unnecessary 
updates of the reactions that are not affected by the firing reactions in the current 
state (Cao & Samuels, 2009). The pseudo code for this method was given by Gibson 
Initialize the number of species (𝑆𝑖), the 
molecules (𝑛) for each species in the system, 
chemical reactions 𝑅𝑚 reaction rates (𝑘𝑗) and 
Set 𝑡 = 0. 
Increase the time step by the randomly 
generated time 𝒕.  
𝒕 = 𝒕 + 𝝉 
Update the molecule count based on the 
reaction that occurred. 
Calculate 𝑎𝑗 = ℎ𝑗 . 𝐾𝑗 for each reaction 𝑗 and 
𝑎0 = σ𝑎𝑗  where ℎ𝑗  is the number of distinct 
combinations of individual reactants for 
reaction 𝑗 
Number of reactions 
=0 OR the simulation 
time has been 
exceeded 
Generate two random numbers (𝑟1, 𝑟2) from 
a uniform distribution on (0; 1). Determine 
the next reaction to occur so that 
 σ𝑎𝑗−1 < 𝑟2. 𝑎0 ≤ σ𝑎𝑗  And time for that 








NO The simulation is 
completed 
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& Bruck (2000). According to Gibson and Bruck (2000), in the next reaction method, 
there are two different data structures that need to be created. These data 
structures are the dependency graph and the indexed priority queue.  
 The dependency graph is used to precisely determine what 𝑎𝑗 has to change 
once a reaction is executed. In this graph, reactions are symbolized as nodes 
and a directed edge connecting 𝑅𝑖 and 𝑅𝑗 if the execution of 𝑅𝑖 affects the 
reactants in 𝑅𝑗. The graph recalculates the minimal number of propensity 
functions. 
 The indexed priority queue (heap tree) is a data structure that is used to 
display ordered pairs in the form (𝑖, 𝜏𝑖), 𝑖 is the reaction channel index and 𝜏𝑖 
is the time for reaction, 𝑖. In the heap tree, each parent has a smaller 𝜏 than 
either of its leaves. Therefore, the minimum values stay at the top and the 
order is always vertical. Theoretically, for the  𝑚 reaction, this procedure 
takes at most 𝑙𝑛(𝑀) operations. In practice, there are usually a few 
reactions that occur frequently. Thus, the actual update takes fewer than 
𝑙𝑛(𝑀) operations. 
The next reaction method and the direct method have the same efficiency. The 
only difference between these two methods is that the next reaction method 
needs only one random number to be generated while the direct method needs 
two. However, the direct method is much easier to be implemented since there is 
no need to deal with different types of data structures (Cao & Samuels, 2009).   
Optimized Direct Method 
The optimized direct method adopts a dependent graph that is used in the next 
reaction method to be able to efficiently index the reactions. The main idea behind 
this method is that the frequent reactions are always indexed before the less 
frequent ones (Cao et al., 2004). However, the re-indexing technique used by this 
method needs many sample runs of the GSSA to collect information, and this  is not 
convenient in many applications (Cao & Samuels, 2009). More details about this 
method are given by Cao et al. (2004). 
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Sorted Direct Method 
The sorted direct method involves a bubble up sorting method that is proposed in 
order to dynamically adjust the index of reactions. In the simulation, every time 
when one reaction occurs, its reaction index decreases by one so that in the next 
step it is found more quickly. It is a less efficient than the optimized direct method 
but it is mainly used to reduce the average search depth (McCollum et al., 2006).  
Logarithmic direct method  
The logarithmic direct method uses a binary search method to determine which 
reaction is due to fire next. The search is totally independent on the ordering of the 
propensity functions for reactions  (Madani et al., 2006).   
The modified Tau- leaping method 
All versions of the GSSA need to create a state vector for all chemical reactions in 
any given chemical system at each time step. This process needs a long time 
because the effects of many reactions are computed at each time step. Therefore, 
the fastest version of the SSA is not fast enough especially when the system is 
large. In 2001, Gillespie proposed the Tau-leap method to speed up the stochastic 
simulation by leaping over many reactions at each time step by approximating the 
firing of each reaction as a Poisson random variable (Gillespie, 2001). However, the 
possibility that the population of some reactant species could be driven become 
negative is the main issue of this version since the Poisson random variable has the 
ability to have arbitrarily large sample values that cause one or more reactions to 
fire many times (Cao, Gillespie, & Petzold, 2005). A negative occurrence is avoided 
by replacing the Poisson random variable with a binomial random variable (Tian & 
Burrage, 2004).  Cao et al. (2005) also proposed a modified procedure of Tau-leap 
to not only avoid negative population, but also be easier to implement than the 
binomial procedure. In the modified Poisson tau-leap method, reactions that have 
propensity functions of more than zero are divided into two groups, critical and 
non-critical reactions. Let 𝐿𝑗 be the maximum number of permitted firings of 𝑅𝑗 
during 𝜏. A reaction is classified as a critical reaction if it is currently in the state of 
exhausting any of its reactants and 𝐿𝑗 is equal or less than some critical value, 𝑐𝑛. 
 25 
The value assigned to  𝑐𝑛 is discretionary but, typically, it should be between 2 and 
20. The modified Poisson tau-leap method ensures that no more than one critical 
reaction can occur in each single 𝜏 leap to make sure it is impossible for any critical 
reactions to produce negative population counts. The steps of the modified Poisson 
tau-leap method are summarized in Figure 2.2. For more details about the modified 









Figure 2.2: Schematic of the modified Poisson tau-leap method 
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2.3 Applications of sensitivity analysis (SA) in systems biology 
Sensitivity analysis, as a term, has a different meanings in different disciplines 
(Nestorov, 1999), and  was defined by Nestorov (1999) as:  
“The systematic investigation of the model responses to either 
perturbations of the model quantitative factors (e.g. inputs 
and/or parameters) or ii) variations in the model qualitative 
factors (e.g. structure, connectivity modules or sub models)." 
The investigation of quantitative factors has received the most work in SA because 
in complex mathematical and computational models, values of some parameters 
are estimated and not precisely known. Therefore, uncertainty in the values of 
these parameters produces uncertainty in the outputs of the model. Using SA 
techniques to understand and quantify this uncertainty is an important part of the 
development and use of these models (Saltelli, Tarantola, Campolongo, & Ratto, 
2004).  
As mentioned in Chapter 1, there are two main classes of SA: LSA and GSA. LSA is 
specifically used to pay attention to a specific set of nominal parameter values. 
Studying the impact of small perturbations on the outputs of the model is used to 
simplify the analysis and interpretation of the results (Castillo, Hadi, Conejo, & 
Fernández-Canteli, 2004). GSA addresses the behaviour of a model over a wide 
range of parameter values simultaneously. These ranges are not only based on an 
approximation of parameter values, but also the upper and lower boundaries might 
be used to specify them. Statistical methods are always used to sample the values 
of these parameters within specified domains of the parameter spaces (Saltelli et 
al., 2008). 
2.3.1 Local Sesntivity Analysis (LSA) 
when undertaking LSA for a general ODE model (Eq 2.1), A Taylor series expansion 
is used to express the effect of a small parameter change.   















 ∆𝐤𝐥∆𝐤𝐣 +⋯ 
 
 
     𝟐. 𝟏𝟖 
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The partial derivatives 
𝝏𝒙𝒊
𝝏𝒌𝒋
 (known as the first-order local sensitivity coefficients) 
form the sensitivity matrix. A sensitivity matrix 𝑺(𝒕) =  𝝏𝒙𝒊
𝝏𝒌𝒋
∗  𝒔𝒊𝒋(𝒕) is used to describe 
the effect of a small change in the 𝑗𝑡ℎ parameter around its nominal value on the 
𝑖𝑡ℎ output at time, 𝑡. However, 𝑆(𝑡) at each time point is needed to be numerically 
calculated; therefore, numerical methods must be used to do this calculation (Van 
Griensven et al., 2006). Table 2.1 lists some of LSA techniques that have been used 
to numerically calculate the sensitivity matrix and their advantages and 
disadvantages.   
Table 2.1: Advantages and disadvantages of some LSA techniques 
LSA techniques Advantages Disadvantages 
Indirect Method 
(De Pauw & 
Vanrolleghem, 
2003). 
 Simplest technique for 
calculating local sensitivities 
for a general ODE model. 
 No need any extra numerical 
machinery since it does not 
need more sophisticated 
methods to access to and 
modify of the model code, 
something that is not often 
desirable. 
 
 Using the finite difference 
approximation method to 
mathematically formulate the 
partial derivative (subtraction 
of nearly equal numbers) 
 Selection of the step size  
∆ 𝑘 (Perturbation value of 
parameter 𝑘) is implemented 
as the nominal parameter 
value, 𝑘,  that is multiplied by 
a user defined perturbation 
factor, 𝜀. Once the 
perturbation factor is chosen 
to be very small it will result in 
numerical instabilities. The 
perturbation factor should 
not be also chosen to be too 
large because the nonlinearity 
of the model will start to play 







Sturdza, & Alonso, 
2003) 
 Easy to be implemented. 
 Avoiding the subtraction of 
nearly equal numbers and 
therefore does not exhibit 
the accuracy problems 
associated with small step-
size. This is by using Taylor 
series expansion of a 
function in terms of complex 
variables.  
 Only the first order derivative 
accessible using the imaginary 
part of Taylor series expansion, 
while the second derivatives 
needs to be evaluated by the 
real part of Taylor series 
expansion (Abreu, Stich, & 
Morales, 2013).  
Feature Sensitivity 
Analysis (Saltelli et 
al., 2000) 
 More interested in the 
sensitivity of aspects of the 
output of biological systems 
rather than the sensitivity of 
the output at a given time. 
This is likely to be the case 
when biologists wish to 
answer questions about 
features of the biological 
systems output such as how 
does the period of an 
oscillatory solution vary with 
the model parameters? 
 In  some cases, a feature that 
needs to be analysed might 
not be present in all runs (for 
example only certain 
parameter values may 
generate oscillations in the 
output)  like what happened 
in (Ihekwaba et al., 2005) 
when they analysed of the 
NF − κB signalling pathway 
by using the feature 
sensitivity analysis. 
 
However, these methods have a number of limitations. These limitations are 
summarised as follows.  
 In biology the input values are always very uncertain and they cover large 
ranges that could not be investigated by local sensitivity methods (Marino et 
al., 2008). 
 Local sensitivity techniques change one parameter at each time step while 
all other parameters should remain fixed at their nominal values. In 
biological systems, the interactions between parameters are very important. 
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Therefore, changes to more than one parameter at each time step should be 
also considered (van Riel, 2006).  
Therefore, global sensitivity analysis methods are required to cope with these 
limitations. 
2.3.2 Global Senstivity Analysis (GSA) 
Recently, GSA methods have been applied to biological systems (Zielinski et al., 
2017). In this section, we discuss the application of a number of global methods to 
model biological systems.   
Sampling-based Methods 
Monte-Carlo (MC) methods are used to explore the mapping between uncertain 
model inputs and outputs. A general sampling based approach for a model with 𝑁 
inputs,  𝑥 = (𝑥1, 𝑥2, 𝑥3………… , 𝑥𝑁), involves five main steps (Saltelli et al., 2000) 














Figure 2.3: Five main steps that are involved by a general sampling approach to model a 
system with N inputs.  
Saltelli et al (2000) state that the output of any MC method is extremely sensitive 
to distributions; therefore, those distributions are probably the most important 
part of the sampling-based method. The definition of these distributions depends 
Step 1:  Define 𝑵 distributions 𝑫𝟏, 𝑫𝟐, ……… . , 𝑫𝒏 to characterize 
the uncertainties in the model inputs. 
Step 2:  Generate a sample of size  𝑴 (𝒙𝟏, 𝒙𝟐, ……… . , 𝒙𝒏 ) form 
the 𝑵 distributions that are defined in step 1. 
Step 3: Obtain a set of model outputs by evaluating the model for 
each element in the input sample 
Step 4: Quantify and display the uncertainty in the model 
outputs. 
Step 5: Explore the mapping between uncertain inputs and the 
output uncertainty. 
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not only on the purpose of the analysis, but also on the available knowledge about 
the input values. When there is enough information, specific distributions could be 
assigned for each input whether by using parametric fitting to known distributions 
or by using non-parametric density estimation techniques. With limited data on a 
particular parameter the minimum and maximum values of that parameter could 
be identified. The natural choice with the limitation of data is to assume a uniform 
distribution across this range. Uniform distributions are always used in biological 
modelling since the lack of information is always encountered. 
 
Random sampling is considered to be the simplest way to generate samples from 
the input distributions. However, computational cost is the main issue for random 
sampling since a large number of samples is required to be generated to ensure 
that the entire range of each input is sampled appropriately (Sumner, 2010).  
 
Latin hypercube sampling (LHS) was introduced by Mckay et al. in 1979 (McKay, 
Beckman, & Conover, 1979).  LHS is a sampling procedure shown to be more 
efficient than random sampling. In LHS, the range of each input is split into 𝑛 
intervals that have equal probability; then, one value from these intervals is 
selected randomly. These random values are combined in a random manner to 
generate 𝑛 samples (Kulasiri et al., 2017; Marino et al., 2008; Segovia-Juarez, 
Ganguli, & Kirschner, 2004). When the 𝑛 samples are generated, evaluating the 
model for each set of inputs and storing the results of each run is the next step of 
LHS. If the model outputs are scalar, assessing the overall uncertainty in the model 
output is performed by the mean values and variance. Plotting the probability 
density function (PDF) or cumulative distribution function (CDF) is used to obtain 
more information about the uncertainty in the model output. For time dependent 
model outputs, Helton and Davis (2000) suggest that the picture of the output 
uncertainty is obtained by plotting together the point-wise mean with some 
appropriate point-wise percentiles. Finally, exploring the effects of individual 
parameters on the model output is performed by examining scatter plots of the 
output against parameter values for each parameter (Kulasiri et al., 2017). The 
main steps of LHS are: 
1. Start out with a mathematical model of interest.   
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2. List all parameters in the model (i. e.M parameters). 
3. Identify the uncertain parameters in the parameter list.  
4.  Decide the sample size for the model analysis. The sample size is 
determined by the number of simulations that are intended to be run. 
Assume we decided to do 𝑁 simulations. Also, assume there are 𝐿 
uncertain parameters. Then the parameter space for the uncertain 
parameters is defined by 𝐿 dimensions. The choice for N should be at 
least k + 1 (Marino et al., 2008),  where K is the number of parameters.  
5. Each of the 𝐿 dimensions corresponds to an uncertain parameter and 
the length of each dimension is determined by the number of runs, 𝑁. 
Each of the 𝑁 input values is selected or determined by the LHS 
sampling method for each uncertain parameter. 
6. For each uncertain parameter, the LHS sampling method is 
implemented by specifying a probability density function (PDF). The 
variability in the probability density function could be used as a direct 
measure of the variability of the uncertain parameter. Each specified 
PDF is used not only to describe a range of possible values, but also the 
probability of occurrence of any specific value for the parameter.  
7.  Sampling values for each parameter is achieved by dividing the 
probability density function into 𝑁 non-overlapping equiprobable 
intervals.  This sampling is used to reflect the shape of the particular 
PDF. 
8. Each interval of each parameter is then randomly sampled. The 
frequency of the selection of possible values of each parameter is 
determined by the probability of occurrence in the PDF. Each 
parameter is sampled independently.  
Once step 8 is completed, each uncertain parameter will have 𝑁 values. These 
values should be stored in a  𝑁 ∗  𝐿 matrix. The values for each column in this 
matrix are random and they are not arranged in any particular order. Each column 
of this matrix has entry (𝑟𝑗, 𝑣𝑖), where1 ≤ 𝑖 ≤ 𝑘, 1 ≤ 𝑗 ≤ 𝑁. Therefore, each row in 
this matrix comprises 𝐾 random values that each correspond to a specific LHS 
parameter. 
 33 
LHS, in combination with Partial rank correlation coefficient analysis (PRCC) 
(LHS/PRCC), has been shown as a very useful procedure to perform a sensitivity 
analysis over a global parameter space with a minimum number of computer 
simulations. PRCC is a robust sensitivity method that is used to indicate not only 
nonlinear, but also the monotonic relationships between the LHS parameters 
(inputs), 𝒙𝒊 and outcomes (outputs), 𝒚 as long as little to no correlation exists 
between the inputs (Hamby, 1994). This is used to measure the strength of the 
relationship between two variables while controlling the effect of the other 
variables.  
LHS/PRCC is used to precisely indicate the degree of monotonicity between a 
specific input and the corresponding output variable to measure the strength of a 
relationship between two variables while controlling the effect of the other 
variables.  Therefore, only outcome measure having a monotonic relationship with 
the input variables should be chosen for this type of sensitivity analysis (De La 
Fuente, Bing, Hoeschele, & Mendes, 2004).   
Once the LHS parameter ranges are adjusted and generate a final version of sample 
LHS matrix, the 𝑘 values in each row of the sample matrix are used as input values 
for the numerical simulation of the model. Then, a frequency histogram and 
descriptive statistics, such as minimum, maximum, mean and variance, could be 
calculated for the outcome measures (Kulasiri et al., 2017).  PRCC is performed by: 
1- Rank the LHS matrix  
2- Rank the matrix for the outcome measure   
3- For each parameter in the LHS matrix and each outcome measure, 
there are two linear regression models are used 
 The first linear model is used to represent a ranked parameter in 
the sampled LHS matrix in terms of the other ranked parameters 
 The second linear model is used to represent the ranked outcome 
measures in terms of the other ranked parameter values.  
4- The PRCC value for that specific parameter is given by a Pearson 
correlation coefficient for the residuals from those two regression 
models.  
Using a sort routine 
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Variance Based Methods 
Variance-based methods are considered to be free model since they are not 
dependent on any assumption about the relationships between model inputs and 
outputs (Saltelli et al., 2000).  These methods are used to identify the amount of 
variation that is explained by the uncertainty in the parameters by partitioning the 
total output variance. These methods are used not only to quantify the relative 
importance of parameters that have the ability to drive system the output, but also 
to investigate the effects on the interactions between parameters.  
Two approaches are commonly used to calculate the variance-based sensitivity 
indices. These approaches are the Fourier amplitude sensitivity test (FAST) (Cukier, 
Levine, & Shuler, 1978) and its extended version (eFAST) (Saltelli, Tarantola, & 
Chan, 1999). These approaches are used to explore the uncertain parameters in the 
frequency space. eFAST was previously classified as the most efficient method that 
has been used to determine the main parameters in the model and their total 
effects. This was used by Marino et al. (2008) for applying global sensitivity analysis 
in systems biology (Marino et al., 2008). See (Sumner, 2010) for full description 
about  variance based methods.  
Sobol’s method is an alternative variance-based approach (Zi, 2011). This method is 
based on the decomposition of the variance of the output or system into terms 
that can be attributed to inputs. For example, if a system has two inputs and one 
output, one might find that 60% of the output variance is caused by the variance in 
the first input, 25% by the variance in the second input and 15% of the output 
variance because of interactions between these two inputs. These percentages are 
directly used as measures of sensitivity. See (Sobol, (1993), ((2001); Sumner (2010)) 
for more details about Sobol’s method. 
Screening Methods 
Screening methods are a class of sensitivity analysis approaches used with models 
containing large numbers of input factors. The main advantage of screen methods 
is their economy since they require a fewer number of runs than other methods 
(Yue, Brown, He, Jia, & Kell, 2008). However, they have the ability to provide only a 
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qualitative measure of importance; they can rank the parameters in order of their 
importance but the differences in importance are not quantified. There are 
different screening methods that have been proposed (Saltelli et al., 1999). Morris’ 
method (Cropp & Braddock, 2002) is classified in the literature as the most robust 
and effective screening method.  
By using the Morris method, an approximate global importance measure is 
provided by using the average and standard deviation of a number of local 
sensitivity measures. The Morris method is considered to be an efficient way to 
select the input points that are used to not only optimise coverage of the space, 
but also to minimise the number of evaluations required to calculate the 
elementary effects (Van Griensven et al., 2006). 
The low computational cost makes the Morris method an appropriate technique 
that has the ability to study complicated biological systems involving large number 
of parameters. The Morris method was used to study a model of circadian rhythm 
in a type of mould,  𝑁𝑒𝑢𝑟𝑜𝑠𝑝𝑟𝑎 (Jin, Peng, Liang, & Ma, 2008). It was also used to 
analyse the  𝑁𝐹 − 𝑘𝐵 pathway that already been analysed by local methods (Yue et 
al., 2006). Yue et al., (2008) found that the Morris method has the ability to identify 
additional important parameters whose interaction effects were not really 
captured by local sensitivity analysis methods (Yue et al., 2008).  
2.3.3 Sensitivity analysis of discrete stochastic chemical reaction networks 
With stochastic models, the quantification of the parameter sensitivities is a 
challenging task since each simulation has the ability to generate a different result. 
Therefore, if a parameter is modified and a change in behaviour is observed, it 
could not be known whether this change is from the parameter alteration or from 
the inherent randomness (Gunawan, Cao, Petzold, & Doyle, 2005). In the stochastic 
setting, computing a finite difference via Monte Carlo simulations is considered to 
be the simplest and commonest method for finite perturbation systems (Rathinam 
et al., 2010). Several estimators using a finite difference approximation have been 
proposed: Independent random number (IRN) (Ethier & Kurtz); Common random 
number (CRN) (Glynn & Iglehart, 1988); Common Reaction Path (CRP) (Rathinam et 
al., 2010) and Coupled Finite difference (CFD) (Anderson, 2012).  
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CRN in conjunction with MRM/GSSA is used for parametric sensitivity of 
immunization in AD model. CRN is the easiest and most common method to 
achieve variance reduction. Implementation of CRN is achieved by using the same 
stream of uniform random numbers. CRN in conjunction with MRM/GSSA is 
described in detail in Chapter 4 (Methodology chapter).  
2.4 Alzheimer’s disease models 
Molecular processes involved in Alzheimer’s is constructed in a comprehensive 
interaction map that was published in (Mizuno et al., 2012). Due to the 
complexity, this map is not able to provide a clear view of Alzheimer’s disease 
according to Mizuno et al. (2012) as it includes around 1347 molecules, 1070 
reactions and about 129 phenotypes. Mizuno et al. (2012) collected this 
information from 100 review articles on Alzheimer’s disease. However, the map is 
used to provide an overview of Alzheimer’s pathways overlaid with canonical 
pathway annotations, as shown in Figure 2.4.  
For better visualisation, a comprehensive interaction map for neurodegenerative 
diseases (including Alzheimer’s and Parkinson’s disease) was published in (Lloret‐
Villas et al., 2017).  Only the important mechanisms involved in these diseases are 
shown in this map. 
From the literature, we collected 31 mathematical models. These models are 
listed in Table 1 the Appendix A. These models have been developed over the last 
two decades to describe different aspects of Alzheimer’s disease. There are 14 
different aspects (or pathways) described by these models. These pathways are 
listed in Table 2.2.  
Some of the models as shown in Table 2.3 are exclusive models (models devoted 
to a single pathway), while others are shared models (models involving multiple 
pathways). APP breakdown, fibril organization and synaptic transmission are the 





Figure 2.4: Overview of Alzheimer’s pathways overlaid with canonical pathway annotations 
for an explanation of the Alzheimer’s interaction map by Minzuno et al (2012). These 
pathways include 1347 molecules, 1070 reactions and 129 phenotypes (Acknowledgement: 
This figure is Figure 1 in (Mizuno et al., 2012)). 
Table 2.2: Functional modules in AD.  
1 Intercellular signalling 8 Blood–brain barrier transport (BBB- 
transport) 
2 Energy metabolism 9 Protein degradation 
3 Oxidative metabolism 10 Fibril organization 
4 Inflammatory response 11 Tauopathy 
5 Apoptosis 12 APP breakdown 
6 Ion homoeostasis 13 Microtubule-based transport 
7 Synaptic transmission 14 genetics 
 
This might be because they are specifically aberrant in Alzheimer’s disease so they 
receive specific attention to be understandable (Lloret‐Villas et al., 2017). Empirical 
data from human cells are used by most of the models that have had their fibril 
organization aspects investigated. These models are relatively simple and small 
because the fibrillation mechanism in Alzheimer’s disease involves only a few 
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molecules (Lloret‐Villas et al., 2017). By analysing the shared models, we observed 
that there are varying degrees of association among the different pathways. For 
example, fibril organization has frequent associations with protein degradation and 
oxidative stress while other pathways, such as microtubule-based transport, are 
less studied in association with other pathways.  


































































































































































Intercellular signalling 2   2 2     1  1  1 
Energy metabolism  2  1  1 1 1  1  1   
Oxidative metabolism   3 2 3    1 3 2    
Inflammatory response 2 1 1 6 3  1 1  3 1 2  1 
Apoptosis 2  1 3 3     2 1 1  1 
Ion homoeostasis  1    3 1   1 1    
Synaptic transmission  1  1  1 7 1  1  3   
BBB transport  1  1   1 4  3  3   
Protein degradation   1      1 1 1    
Fibril organization 1 1 3 3 2 1 1 3 1 11 2 4  1 
Tauopathy   2 1 1    1 2 5    
APP breakdown 1 1  3 1  3 3  3  12  1 
Microtubule-based transport           1  1  
Genetics 1   1      1  1  3 
 
Our model collection includes models for Alzheimer’s pathways from 1996 to 2016. 
In Figure 2.5, we investigate the evolution of these models. Most of models were 
developed between 2012 and 2016 as there were 16 mathematical models to 
investigate Alzheimer’s processes. The periods from 2000 to 2003 and 2008 to 
2011 have six models each while the periods from 2004 to 2007 and 1996 to 1999 
have one and two models, respectively.  
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Figure 2.5: Evolution of Alzheimer’s models. This graph shows evolution of 
mathematical models that have been used to describe Alzheimer’s processes 
over 20 years in four-year increments. Most of models in the collection were 
proposed after 2012.  
 
Alzheimer’s pathways in our collection of models use different approaches, as 
shown in Table 2.3. Some pathways are modelled by using multiple approaches 
(hybrid models). Table 2.4 lists all approaches and their frequency in our collection 
of models. 
 
Table 2.4: Modelling approaches and their frequency in the collection of models. 
# Modelling Type Frequency 
1 Ordinary Differential Equations 15 
2 Hybrid models 7 
3 Partial Differential Equations 3 
4 Algebraic Equations 3 
5 Stochastic Models 2 
6 Rule-based Models 1 
 Total 31 
 
ODEs were the predominant technique used in the collection of models because 





This chapter is divided into three main sections.   
The first section focuses on deterministic and stochastic approaches that have been 
widely used to investigate, understand and model biochemical systems. It has been 
found that the deterministic approaches are used to describe the dominant 
physical processes and give the average behaviour of a given system. Deterministic 
models deterministically track the exact concentration of biological components 
through continuous representation of system dynamics over time. Stochastic 
approaches look at biological systems differentially from the deterministic 
approaches. The denotational semantics of stochastic models is by defining rules to 
describe how the modelled system moves from one state to another state. 
Stochastic approaches focus on the importance of the randomness and they have 
been used mainly to model small biological systems.  
In the second section we describe the most popular sensitivity analysis methods 
(LSA and GSA) that have been used to investigate the behaviour of biochemical 
system in response to parameters perturbation, one at a time, using LSA and over 
the space of parameters using GSA.  
Third part covers a historical review of mathematical models that are used to 
investigate aspects of Alzheimer’s disease over the last two decades. A collection of 




Case study- Immunisation in Alzheimer's disease 
3.1 Overview 
Alzheimer's disease (AD) is mainly characterized by the presence of two proteins 
and their aggregation relationship. These proteins are amyloid-beta (Aβ) and 
micro-tubular binding protein (tau) accompanied by glial cell activation, together 
with synaptic and neuronal losses (Proctor et al., 2013). It has been found that 
there is no effective treatment that could target the underlying neurodegeneration 
in AD in spite of many interventions tested. For instance, a phase 11a clinical trial 
of PBT2 (an experimental drug candidate) according to (Lannfelt et al., 2008) shows 
preliminary promising results though larger trails are needed. Also, based on 
promising experimental results and the amyloid cascade hypothesis (Schenk, 
Barbour, Dunn, & Gordon, 1999).   
Aβ immunotherapy in some clinical trials for animals shows that cognitive function 
deterioration has slowed down or deteriorating slowly (Hock et al., 2003); 
however, septic meningoencephalitis was developed in a small part of subjects that 
were treated with the first Aβ immunotherapy agent (AN1792) (Bayer et al., 2005). 
Therefore, the trial had to be halted. Different side effects that were unexpected by 
the pre-clinical animal models are classified to be the main problem. This 
demonstrates that animal models of Alzheimer's disease would not be able to 
replicate the complexity of the human disease (Jucker, 2010). In human clinical 
trials, unforeseen side effects are also considered to be the main reason to slow 
development of therapeutic interventions of AD (Nicoll et al., 2003).   
Neuropathological studies of patients with AD have shown that a decrease in Aβ-
plaques occurs if patients are immunised against Aβ (Boche, Denham, Holmes, & 
Nicoll, 2010). This observation has been  subsequently  confirmed in vivo by 
amyloid imaging (Rinne et al., 2010).  The techniques of how immunisation is used 
to clear Aβ are not fully understood but it seems that phagocytosis of Aβ by 
microglia and the solubilisation of Aβ by antibody binding are involved (Boche et 
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al., 2010; Maarouf et al., 2010; Nicoll et al., 2006; Nicoll et al., 2003; Zotova et al., 
2011).  
Due to these relapses, new approaches are highlighted as needed for pre-clinical 
testing of possible interventions. Modelling approaches and computer simulation 
are considered to be new approaches in the medical fields and their potential is 
being progressively recognised as a valuable complementary tool to gain better 
understanding of Alzheimer's disease (Proctor et al., 2013). 
Therefore, the system developed by Proctor et al. (2013) and described in this 
chapter is used to examine how plaques and tangles formation could be affected 
by immunising an AD patient against Aβ. Two sub-systems for immunisation against 
Aβ are included in this system (passive and active). Passive and active immunisation 
systems use antibodies and glia, respectively, to immunise against Aβ. An overview 
of the system is shown in Figure 3.1.  
Hint, all figures in this chapter are created using Visio 2016 tool.  
3.2 Reactions 
The system developed by Proctor et al (2013) has 112 reactions. The reactions and 
ODEs are listed in Tables 1 and 2 in the Appendices (B). 
3.3 Species 
The system developed by Proctor et al (2013) contains 69 species. Five species are 
set to be constant as they are not able to be changed by any reaction. The numbers 
of antibodies are initially zero but change to 50 on day 4. These species and their 
initial values are listed in Table 3 in the Appendices (B).  
3.4 Parameters 
The system developed by Proctor et al (2013) contains 73 global parameters. These 
parameters and their values are listed in Table 4 in the Appendices (B). 
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3.5 Events  
Each event in the model is initiated when its trigger condition switches from false 
to true. A delay function then postpones the effects of an event to a later time 
point. In This system, antibodies is initially zero and when the time reach 345600 
seconds (day #4), antibodies are added to the system and the value of antibodies is 
changed suddenly from 0 to 50.  
Trigger condition                       t ≥  345600 (day #4) 
Assignment                                 antibodies =  50 
 
 
Figure 3.1: Overview of immunization in AD. The system includes 112 reactions, 69 species, 
73 global parameters, simulation over a 12-day period and immunisation at day 4. It has 
seven main activities that are included in this system (DNA damage, p53 regulation, Gsk3 
activity, Aβ production and aggregation, tau dynamics and aggregation, and active and 
passive immunisation). 
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3.6 Sub-systems (activities) 
The model proposed by Proctor et al (2013) includes six main activities (or 
pathways). These pathways are DNA damage, p53 regulation, GSK3 activity, Aβ 
production and aggregation, tau dynamics and aggregation, and active and passive 
immunisation. Some assumptions are made by Proctor et al. (2013) when they built 
this model because the pathways involved in Aβ immunization are complex and 
many of the mechanisms are not fully known. These assumptions, below, are also 
shown in Figure 3.2:  
A. Aβ could cause harmful effects by motivating the production of Reactive Oxygen 
Species (ROS) that lead to further DNA damage. 
B. ROS increases DNA damage that results in increasing the production of p53, which 
leads to increased activity of GSK3β.  
C. Aβ can directly enhance the production of p53. 
D. Soluble Aβ has the ability to inhibit the proteasome that has detrimental effects on 
cells. 
E. The pool of soluble Aβ is decreased by plaques.  
However, these assumptions may not be in agreement with other points of view 
because there is controversy over the different mechanisms used to investigate Aβ 
immunisation.  
Figure 3.3 shows the activity of DNA damage pathway and GSK3b activity. DNA 
damage is the first initiator of the system. When stress happens, the system 
responds by increasing the activity of ATM that phosphorylates p53 and Mmd2 to 
break the binding relationships between them. When the level of p53 is elevated, 
binding relationship is established between p53 and GSK3β to increase the activity 
of both proteins; this leads to more phosphorylation of tau and Aβ to form tangles 







Figure 3.2: System activities. The DNA damage signal activates p53, and this 
causes phosphorylation of p53 and Mdm2 to prevent their binding, so p53 is no 
longer degraded. When the level of p53 is elevated, a binding relationship is 
established between p53 and GSK3β to increase the activity of both proteins. Tau 
then starts to aggregate and the production of Aβ is increased. In passive 
immunisation, antibodies reduce the levels of soluble Aβ and plaques. The active 
immunisation (microglia cells) used not only reduces the levels of plaques but 
also makes sure that antibodies are continually produced. However, microglia 
cells might also increases the production of ROS as shown in Figure 3.6. 
Figure 3.4 shows how phosphorylated and non-phosphorylated p53_GSK3β 
increase the activity of Aβ (known as Abeta). Aβ increases the production of an 
Abeta_Dimer that is used to increase the production of plaques. Aβ directly 
increases the production of p53_mRNA. Therefore, it can easily be seen that there 
is an indirect positive feedback relationship between p53 and Aβ since both of 
them indirectly increase the production of each other through other species. Table 




Figure 3.3: DNA damage and GSK3 activity. It displays that DNA damage through ATM 
activities of p53 and Mdm2 and breaks the binding relationship to elevate the level of p53. 
Unbound p53 establishes a binding relationship with GSK3β to increase its activity and that 
leads to more phosphorylation of tau and Aβ. Dashed lines from a species indicates the 
species is a modifier of the reaction. 
Table 3.1: Reactions for DNA damage pathway and GSK3b activity. Reaction numbers 
correspond to the numbers in the reaction table of the whole system (Table 1 in the 
Appendices (B)). 
# Reaction name Reaction Equation 
11 GSK3_p53 Binding 𝐆𝐒𝐊𝟑𝐛 + 𝐩𝟓𝟑
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑   
12 GSK3_p53 Release 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐫𝐞𝐥𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛+ 𝐩𝟓𝟑   
13 GSK3_p53_P Binding 𝐆𝐒𝐊𝟑𝐛 + 𝐩𝟓𝟑_𝐏
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏   
14 GSK3_p53_P Release 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛+ 𝐩𝟓𝟑_𝐏 
66 DNA damage 𝐈𝐑 
𝐤𝐝𝐚𝐦
→    𝐈𝐑 + 𝐝𝐚𝐦𝐃𝐍𝐀 
67 DNA repair 𝐝𝐚𝐦𝐃𝐍𝐀
𝐤𝐫𝐞𝐩𝐚𝐢𝐫
→     𝐒𝐢𝐧𝐤 
68 ATM activation 𝐝𝐚𝐦𝐃𝐍𝐀+ 𝐀𝐓𝐌𝐈
𝐤𝐚𝐜𝐭𝐀𝐓𝐌
→      𝐝𝐚𝐦𝐃𝐍𝐀 +𝐀𝐓𝐌𝐀 
69 p53 phosphorylation 𝐩𝟓𝟑 + 𝐀𝐓𝐌𝐀
𝐤𝐩𝐡𝐨𝐬𝐩𝟓𝟑
→       𝐩𝟓𝟑_𝐏 + 𝐀𝐓𝐌𝐀 
70 p53 dephosphorylation 𝐩𝟓𝟑_𝐏
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝟓𝟑
→         𝐩𝟓𝟑 
71 Mdm2 phosphorylation 𝐌𝐝𝐦𝟐+ 𝐀𝐓𝐌𝐀
𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐
→         𝐌𝐝𝐦𝟐_𝐏 + 𝐀𝐓𝐌𝐀 
72 Mdm2 dephosphorylation 𝐌𝐝𝐦𝟐_𝐏
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐 
73 Mdm2_P Ubiquitination 𝐌𝐝𝐦𝟐_𝐏 + 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐔𝐛
→        𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 + 𝐄𝟐 
87 ROS DNA damage 𝐑𝐎𝐒
𝐤𝐝𝐚𝐦𝐑𝐎𝐒
→       𝐑𝐎𝐒 + 𝐝𝐚𝐦𝐃𝐍𝐀 
112 ROS removal 𝐑𝐎𝐒
𝐤𝐫𝐞𝐦𝐑𝐎𝐒




Figure 3.4: Activity of Aβ (Abeta in the figure) production and aggregation. It 
shows that p53_GSK3β in the phosphorylated and non-phosphorylated form is 
used to increase the activity of Abeta that not only increases the activity of Aβ 
_Dimer to increase the activity of plaques, but also directly increases the activity 
of p53_mRNA. Dashed lines from a species indicate the species is a modifier of 
the reaction. 
Table 3.2: Reactions of Aβ (Abeta in in the Table) production and aggregation. 
Reaction numbers correspond to the numbers in the reaction table of the whole 
system (Table 1 in the Appendices (B)). 
# Reaction name Reaction Equation 
60 Abeta production1 𝐒𝐨𝐮𝐫𝐜𝐞 
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚
→         𝐀𝐛𝐞𝐭𝐚 
61 Abeta production2 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐
→          𝐀𝐛𝐞𝐭𝐚 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 
62 Abeta production3 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐
→          𝐀𝐛𝐞𝐭𝐚 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 
63 Proteasome Inhibition Abeta 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭
→        𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
64 Abeta Degradation 𝐀𝐛𝐞𝐭𝐚 
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐒𝐢𝐧𝐤 
65 p53 transcription Via Abeta 𝐀𝐛𝐞𝐭𝐚 
𝐤𝐬𝐲𝐧𝐩𝟓𝟑𝐦𝐑𝐍𝐀𝐀𝐛𝐞𝐭𝐚
→               𝐩𝟓𝟑_𝐦𝐑𝐍𝐀+ 𝐀𝐛𝐞𝐭𝐚 
84 Abeta ROS production1 𝐀𝐛𝐞𝐭𝐚
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚
→           𝐀𝐛𝐞𝐭𝐚 + 𝐑𝐎𝐒 
85 Plaque ROS production 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐏𝐥𝐚𝐪𝐮𝐞
→            𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 + 𝐑𝐎𝐒 
86 Agg Abeta ROS production2 𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚
→           𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝐑𝐎𝐒 
91 Abeta Aggregation1 𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚
𝐤𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 
92 Abeta Plaque Formation1 𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝐤𝐩𝐟
→  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
93 Abeta Plaque Growth 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐩𝐟,𝐤𝐩𝐠𝐡𝐚𝐥𝐟
→        𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
94 Abeta Disaggregation1 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚
→          𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚 
95 Abeta Disaggregation3 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟏
→           𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟏 
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Figure 3.5 shows the dynamics and aggregation of tau and how phosphorylated 
and non-phosphorylated p53_GSK3β increases the phosphorylation process of tau 
be continuously aggregated to produce tangles (NFT in Figure 3.5). Table 3.3 lists all 
reaction to achieve tau dynamic and aggregation. 
 
Figure 3.5: Tau dynamics and aggregation. It shows how all forms of GSK3β have 
the ability to increase the double phosphorylation process of tau to be 
aggregated to increase the production of tangles (NFT). Dashed lines from a 
species indicate the species is a modifier of the reaction. 
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Table 3.3: Reactions of tau dynamic and aggregation. Reaction numbers correspond to the 
numbers in the reaction table of the whole system (Table 1 in the appendices (B)). 
# Reaction name Reaction Equation 
41 Tau_MT binding 𝐓𝐚𝐮   
𝐤𝐛𝐢𝐧𝐌𝐓𝐓𝐚𝐮
→        𝐌𝐓_𝐓𝐚𝐮 
42 Tau_MT release 𝐌𝐓_𝐓𝐚𝐮   
𝐤𝐫𝐞𝐥𝐌𝐓𝐓𝐚𝐮
→        𝐓𝐚𝐮 
43 Tau phosphorylation1 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟏 
44 Tau phosphorylation2 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟏   
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟐 
45 Tau phosphorylation3 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟏 
46 Tau phosphorylation4 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟏  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟐 
47 Tau phosphorylation5 𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛
→             𝐆𝐒𝐊𝟑𝐛+ 𝐓𝐚𝐮_𝐏𝟏 
48 Tau phosphorylation6 𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮_𝐏𝟏 
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛
→             𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮_𝐏𝟐 
49 Tau dephosphorylation1 𝐓𝐚𝐮_𝐏𝟐+ 𝐏𝐏𝟏  
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮
→          𝐓𝐚𝐮_𝐏𝟏+ 𝐏𝐏𝟏  
50 Tau dephosphorylation2 𝐓𝐚𝐮_𝐏𝟏+ 𝐏𝐏𝟏   
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮
→          𝐓𝐚𝐮 + 𝐏𝐏𝟏 
51 Tau_P1 Aggregation1 𝟐 ∗ 𝐓𝐚𝐮_𝐏𝟏  
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
52 Tau_P1 Aggregation2 𝐓𝐚𝐮_𝐏𝟏+ 𝐀𝐠𝐠𝐓𝐚𝐮  
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
53 Tau_P2 Aggregation1 𝟐 ∗ 𝐓𝐚𝐮_𝐏𝟐 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
54 Tau_P2 Aggregation2 𝐓𝐚𝐮_𝐏𝟐+ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
55 Tau Aggregation1 𝟐 ∗  𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮
→      𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
56 Tau Aggregation2 𝐓𝐚𝐮 +  𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮
→      𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
57 Tangle Formation1 𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫
→      𝟐 ∗ 𝐍𝐅𝐓  
58 Tangle Formation2 𝐍𝐅𝐓 + 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫
→      𝟐 ∗ 𝐍𝐅𝐓 
59 Proteasome Inhibition Agg Tau 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭
→        𝐀𝐠𝐠𝐓𝐚𝐮 _𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
88 Tau Synthesis 𝐒𝐨𝐮𝐫𝐜𝐞
𝐤𝐬𝐲𝐧𝐓𝐚𝐮
→      𝐓𝐚𝐮 
89 Tau Proteasome Binding 𝐓𝐚𝐮 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐛𝐢𝐧𝐓𝐚𝐮𝐏𝐫𝐨𝐭
→         𝐓𝐚𝐮_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
90 Tau 20SProteasome Degradation 𝐓𝐚𝐮_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐝𝐞𝐠𝐓𝐚𝐮𝟐𝟎𝐒𝐏𝐫𝐨𝐭
→            𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
Glia is found in three different forms, inactive form (GliaI), partially active form 
(GliaM1 and GliaM2), or fully active form (GliaA). Initially, all glia are inactive. They 
are partially activated by immunotherapy and fully activated by antibodies. The 
fully active form of glia have the ability to bind to plaques for degradation. 
However, this binding relationship could generate ROS that increases DNA damage.   
Figures 3.6 and 3.7 show their active and passive immunisation activities, 
respectively, and the reactions needed. Figure 3.6 shows how glia species need 
three different reactions and one modifier to be changed to be fully active and how 
they targets plaques to be degraded.  This shows how antibodies (antiAb in the 3.6) 
take a part in the activation process of glia.  Figure 3.7 displays how antibodies 
target not only soluble Aβ and the Aβ dimer for degradation, but also the plaques 
to be disaggregated and then target them to be degraded. It also shows that 
antibodies could be degraded to mimic diffusion from the cells.  
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Figure 3.6: Active immunisation. It shows how the status of the glia is changed to 
be fully active through three different reactions and one modifier to target 
plaques to be degraded. Dashed lines from a species indicate the species is a 
modifier of the reaction. 
Table 3.4: Reactions of active immunisation. Reaction numbers correspond to the numbers 
in the reaction table of the whole system (Table 1 in the appendices (B)). 
# Reaction name Reaction Equation 
101 Glia Activation Step1 𝐆𝐥𝐢𝐚𝐈 +  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏
→       𝐆𝐥𝐢𝐚𝐌𝟏 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
102 Glia Activation Step2 𝐆𝐥𝐢𝐚𝐌𝟏+  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏
→       𝐆𝐥𝐢𝐚𝐌𝟐 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
103 Glia Activation Step3 𝐆𝐥𝐢𝐚𝐌𝟐+  𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐀 + 𝐚𝐧𝐭𝐢𝐀𝐛 
104 Glia Inactivation Step1 𝐆𝐥𝐢𝐚𝐀
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐌𝟐 
105 Glia Inactivation Step2 𝐆𝐥𝐢𝐚𝐌𝟐
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐌𝟏 
106 Glia Inactivation Step3 𝐆𝐥𝐢𝐚𝐌𝟏
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐈 
107 Abeta Binding To Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮 +  𝐆𝐥𝐢𝐚𝐀
𝐤𝐛𝐢𝐧𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→          𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀 
108 Abeta Release From Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐫𝐞𝐥𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→          𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮+  𝐆𝐥𝐢𝐚𝐀 
109 Abeta Plaque Clearance By Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→           𝐆𝐥𝐢𝐚𝐀 + 𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 
110 ROS generation By Glia 𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐆𝐥𝐢𝐚





Figure 3.7: Passive immunisation. Antibodies (antiAb) are added to the system at 
day 4 and they are considered to be a species that has the ability to have 
reactions with other species. Antibodies target Aβ and Aβ_dimers (Abeta Dimer 
in the Figure) to be degraded and plaques to be disaggregated and then 
degraded. Antibodies also could be degraded to mimic diffusion from the cell. 
Dashed lines from a species indicates the species is a modifier of the reaction. 
Table 3.5: Reactions for passive immunisation. Reaction numbers correspond to the 
numbers in the reaction table of the whole system (Table 1 in the Appendices (B)). 
# Reaction name Reaction Equation 
96 Abeta Disaggregation4 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟐
→           𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐚𝐧𝐭𝐢𝐀𝐛
+  𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟐 
97 Abeta_antiAb Binding 𝐀𝐛𝐞𝐭𝐚 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛
→          𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛 
98 AbetaDimer_antiAb Binding 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛
→          𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛   
99 Abeta_antiAb Degradation 𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐚𝐧𝐭𝐢𝐀𝐛   
100 AbetaDimer antiAb Degradation 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐚𝐧𝐭𝐢𝐀𝐛 
111 antiAb Removal 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐧𝐭𝐢𝐀𝐛
→         𝐒𝐢𝐧𝐤 
110 ROS generation By Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐆𝐥𝐢𝐚





This chapter covers immunization in AD model (case study in this research). It 
describes all pathways that are involved to examine the relationship between Aβ 
and tau. Six biochemical pathways form this system. These pathways as described 
previously are DNA damage, p53 regulation, GSK3β activity, Aβ production and 
aggregation, tau dynamics and aggregation, and active and passive immunisation. 
The first four pathways are involved in the examination process while active and 
passive immunization pathways show how antibodies reduce the activity of Aβ and 
p53- GSK3β by reducing the level of ROS. 
In response to immunization at day #4, the model predicts that: (1) the level of 
plaques is inhabited only at day # 4 while it starts to increase again from day # 5 to 
the end of the simulation, (2) the pool of soluble Aβ is reduced only by a small 
amount during day # 4 and then one day after immunization, Aβ starts to rise 
again, (3) the activity of p53-GSK3β reduced since antibodies target ROS to be 
reduced which results  decreasing in the level of p53 and prevent its binding with 
GSK3β and (4) the levels of phospho-tau is instantly reduced after the addition of 
antibodies and, thereafter, remained at the appropriate constant levels. This is 
because the level of ROS is reduced after the clearance of plaques. The reduction in 
the level of phospho-tau agrees with neuropathological data. 
It has been found that it is more appropriate to use a stochastic approach to model 
this system because: 
1- Many of the mechanisms involved in protein aggregation are inherently 
random. For example, Proctor et al. (2013) mentioned that the fully active 
form of glia has the ability to bind to plaques for degradation and they said 
that the binding relationship might result in more ROS.  
2- The number of molecules involved in many of reactions in this systems are 
small. Therefore, stochastic approaches are more appropriate to deal with a 




Methods and Algorithms 
This chapter covers all methods and algorithms that are used to stochastically 
model and investigate immunisation in AD.      
4.1 Mapping Reduction Method (MRM) 
MRM is an implementation tool that is used to process large data sets on a single 
multi-processor computer (using threads or processors) (Dean & Ghemawat, 2008), 
a cluster (Barroso, Dean, & Holzle, 2003), or a grid (Bent, Thain, Arpaci-Dusseau, 
Arpaci-Dusseau, & Livny, 2004). The MRM is also defined as a framework that is 
used for parallel problems to be processed across large datasets using a large 
number of nodes that work together and are seen as a single system. Each node 
performs the same task and is controlled and scheduled by software (Dean & 
Ghemawat, 2008; Lämmel, 2008).  
A single multi-processor computer is able to employ multiple threads or processors 
to work in a parallel manner on the same machine (Dean & Ghemawat, 2010). A 
computer cluster is composed of a set of loosely, or tightly, connected computers 
on the same local network and using the same hardware. A computer grid is also a 
set of connected computers but these computers are not only shared over 
geographically distributed systems, but also use heterogeneous hardware (Mann, 
Trasatti, Carlozzi, Ywoskus, & McGrath, 2003).  
Implementing MRM using a single machine is less complex than using a cluster or a 
grid because the input data is split only among worker threads that all reside on the 
same machine and typically use the same data store (Lattanzi, Moseley, Suri, & 
Vassilvitskii, 2011). 
Additional complexity is added into the process when multiple computers are used 
to run MRM because the input data have to be split among all computers within 
the cluster using a master node (McKenna et al., 2010). Another challenge for using 
a cluster is that different physical memories on different machines have to be used 
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to save data from the reduction method (Lv et al., 2010). In other words, more 
routing needs to be done to get all reduction results to reside on one physical 
machine. A cluster is needed to implement MRM especially when the input and 
output data are too large to fit into the memory of a single computer (Ferreira 
Cordeiro et al., 2011).   
Many programming platforms support thread-safe objects that are easily used to 
produce mapping reduction style programs (Guzev, 2008). Visual Studio (mainly C# 
paradigm) has a good ability to support this process since there are many features 
and classes used to successfully achieve mapping reduction processing (Groot & 
Kitsuregawa, 2010).  
In a computer system, a thread pool is a software pattern used to achieve 
concurrency of execution in a computer program (Sturm, 2011). Multiple threads 
are maintained by the thread pool to complete  different tasks in a concurrently 
executed manner (Benton, Cardelli, & Fournet, 2002). Maintaining a pool of 
threads not only increases the performance of the whole system, but also avoids 
latency in its execution. The size of a thread pool depends on the number of tasks 
needing to be completed in a concurrent manner. The main advantage of creating a 
thread pool over creating a thread for each task is that thread creation and 
destruction overheads are restricted to the initial creation of the pool. This may 
increase the performance level since creating and terminating threads is an 
expensive process in terms of time  (Loidl, 2012).  MRM is combined with GSSA to 
increase the performance of GSSA for generating a single realization by selecting 
multiple reactions at each time step.  
4.2 MRM with GSSA 
The GSSA and its variants have the ability to advance the state of the system under 
study by executing one reaction at a time. In cases where the system under study 
involves a large number of reactions, the simulation of this system becomes 
prohibitively expensive. Also, the GSSA and its variants totally ignore the 
concurrency feature that needs to be taken into consideration in modelling 
biochemical systems. The computational intractability of the GSSA has been 
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addressed in different ways (Cao et al., 2006; Gibson & Bruck, 2000; Gillespie, 
1977; Madani et al., 2006; McCollum et al., 2006) , as described in Chapter 2.  
Here, we propose a novel variant of the GSSA to not only address its computational 
intractability, but also include a concurrency feature by using MRM on a single 
multiprocessor computer to advance the system by several reactions. Here, we are 
not accelerating GSSA using a collection of threads to be executed synchronously to 
generate multiple independent trajectories, instead, we target a single run to be 
accelerated by advancing the system through several reactions at each time step.  
MRM/GSSA is divided into four steps. These steps are initialization, election 
(mapping), selection (reduction), and updating the system. These steps are 
summarized as follow.  
Initialization step  
1- Create a thread pool that contains 𝑇 numbers of threads,  
𝐓 =  𝐓𝐡𝐞 𝐧𝐮𝐦𝐛𝐞𝐫 𝐨𝐟  𝐫𝐞𝐚𝐜𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐲𝐬𝐭𝐞𝐦 
The number of threads in the thread pool is set to be equal to the number of 
reactions for two reasons.  
 All reactions in the system might have the ability to run together. 
 Creating and terminating threads as needed is considered to be an 
expensive process in terms of time.    
 
2-  Initialize the biochemical system - 
 The number of species (𝑆𝑖) 
 The molecules (𝑛)  for each species in the system 
 Chemical reactions 𝑅𝑚 
 Reaction rates (𝑘𝑗) 
 Set 𝑡 = 0. 
 Calculate the propensity function for each reaction aj = hj. Kj 
 
3- Create Election_index_array and Election_time_step_array to store the 
indexes and time steps, respectively that return from threads.   
   
4- Create Selection_index_array and Selection_time_step_array to store the 
indexes and time steps, respectively, after the selection step.     
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Election step  
1- Elect M threads to run GSSA  
𝐌 = 𝐓𝐡𝐞 𝐧𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐫𝐞𝐚𝐜𝐭𝐢𝐨𝐧𝐬 𝐭𝐡𝐚𝐭 𝐡𝐚𝐯𝐞 𝐩𝐫𝐨𝐩𝐞𝐧𝐬𝐢𝐭𝐲 𝐟𝐮𝐜𝐧𝐭𝐢𝐨𝐧𝐬 > 𝟎  
2- Each thread returns an index and a time step.   
3- Store the index of the next 𝑀 reactions to occur in the Election_index_array 
and 𝑀 time steps in the Election_time_step_array.  
Selection step  
1- Test the eligibility of each reaction as follows: 
 If all reaction indexes in the Election_index_array are different, all 
reactions are eligible for the selection step.  
A. Transfer the next 𝑀 reactions from the Election_index_array to the 
Selection_index_array 
B. Transfer 𝑀 time steps from the Election_time_step_array to the 
Selection_time_step_array 
 If some reaction indexes are the same (for example, 𝐿 threads return the 
same index, 𝑗).  
 Transfer all the different indexes (𝑀 − 𝐿) next reactions to 
occur from the Election_index_array to the 
Selection_index_array 
 Transfer time steps for all different indexes from the 
Election_time_step_array to the Selection_time_step_array 
 Check the number of molecules for each species in reaction 𝑗 
 If the number of molecules for each participant species in reaction 𝑗 is 
enough to run reaction 𝑗 𝐿 times, reaction 𝑗 is eligible for the selection 
step 𝐿 times. So, 
 Transfer the  𝐿 reaction 𝑗 from the Election_index_array to the 
Selection_index_array 
 Transfer the 𝐿 time steps for reaction 𝑗 from 
Election_time_step_array to the Selection_time_step_array 
  Else 
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 Set 𝑥= the number of molecules for a species in reaction 𝑗 that has 
the smallest number of molecules. 
 Number 𝑗 of eligible for the selection step =  𝑥 − 𝐿 
 Select indexes of 𝑗 that have a large time step.  
 Update the Selection_index_array. 
 Update the Selection_time_step_array. 
Updating the system 
1- Update the number of molecules 
 Update the molecules in the number of species in all the next reactions to 
occur in the Selection_index_array 
2- Update the time of the system 
 If Selection_time_step_array. length =1 
 𝐭 = 𝐭 + 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧_𝐭𝐢𝐦𝐞_𝐬𝐭𝐞𝐩_𝐚𝐫𝐫𝐚𝐲[𝟎] 
 If Selection_time_step_array. length =2 
 𝐭 = 𝐭 + 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧_𝐭𝐢𝐦𝐞_𝐬𝐭𝐞𝐩_𝐚𝐫𝐫𝐚𝐲[𝟎] +  𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧_𝐭𝐢𝐦𝐞_𝐬𝐭𝐞𝐩_𝐚𝐫𝐫𝐚𝐲[𝟏]  
 If Selection_time_step_array. length > 2 
 𝐭 = 𝐭 + 𝐓𝐡𝐞 𝐥𝐚𝐫𝐠𝐞𝐬𝐭 𝐭𝐡𝐫𝐞𝐞 𝐭𝐢𝐦𝐞 𝐬𝐭𝐞𝐩𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧_𝐭𝐢𝐦𝐞_𝐬𝐭𝐞𝐩_𝐚𝐫𝐫𝐚𝐲   
Figure 4.2 provides an illustration of the proposed method (MRM/GSSA). Algorithm 











Figure 4.1: Schematic of MRM/GSSA.  
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Algorithm 4.1: MRM/GSSA 
DEF initialization step (𝐓𝐏, 𝐒𝐢, 𝐧,  𝐑𝐣, 𝐊𝐣, 𝐭, 𝛕, 𝐚𝐣,𝐕𝐚𝐣 𝐄𝐈𝐀,𝐄𝐓𝐀,𝐒𝐈𝐀,𝐒𝐓𝐀) 
 
 𝐓𝐏: 𝐓𝐡𝐫𝐞𝐚𝐝𝐬 𝐩𝐨𝐨𝐥 (𝐓 𝐭𝐡𝐫𝐞𝐚𝐝𝐬) 
 𝐒𝐢: 𝐒𝐩𝐞𝐜𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐲𝐬𝐭𝐞𝐦 [𝐚𝐫𝐫𝐚𝐲 𝐨𝐟 𝐝𝐨𝐮𝐛𝐥𝐞 ] 
 𝐧:𝐍𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐥𝐥𝐦𝐨𝐞𝐥𝐜𝐮𝐞𝐬 𝐨𝐟 𝐞𝐚𝐜𝐡 𝐬𝐩𝐞𝐜𝐢𝐞𝐬[𝐚𝐫𝐫𝐚𝐲 𝐨𝐟 𝐝𝐨𝐮𝐛𝐥𝐞 ]  
  𝐑𝐣: 𝐑𝐞𝐚𝐜𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐲𝐬𝐭𝐞𝐦 [𝐚𝐫𝐫𝐚𝐲 𝐨𝐟 𝐝𝐨𝐮𝐛𝐥𝐞 [𝐓]]  
 𝐊𝐣: 𝐑𝐞𝐚𝐜𝐭𝐢𝐨𝐧𝐬 𝐫𝐚𝐭𝐞𝐬  [𝐚𝐫𝐫𝐚𝐲 𝐨𝐟 𝐝𝐨𝐮𝐛𝐥𝐞]  
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4.2.1 Test and validation of MRM/GSSA 
In order to not only test, but also verify the quality of MRM/GSSA, it is used to 
model the immunisation in AD model that is described in Chapter 3.  It has been 
found that MRM/GSSA is a useful way to model biochemical systems when number 
of reactions with propensity functions greater than zero are quite large. This allows 
MRM/GSSA to employ large numbers of threads to run GSSA. Therefore, the 
chance for multiple reactions to be eligible for the selection step is high. 
MRM/GSSA is compared with GSSA and the modified tau-leap method from 
different angles, results in term of stochasticity, and performance in term of CPU 
time and implementation difficulties. The result of this comparison is discussed in 
section 4.5. MRM/GSSA is used with LSA and GSA to stochastically investigate the 
behaviour of the immunisation in AD model in response to parameters 
perturbation. LSA and GSA discussed in Chapter 5 and 6.    
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4.3 LSA 
In this research, LSA is performed to deterministically and stochastically investigate 
the behaviour of the most important players in the system (immunization in AD) 
against parameter perturbations, one-at-a time, using ODEs and MRM/GSSA.  
The finite difference approximation method is used to compute the sensitivity 
analysis of the ODE and MRM/GSSA models, these methods are shown in Figures 
4.3 and 4.4, respectively, and the result of the LSA using the ODE and MRM/GSSA 














Figure 4.2: Steps of the finite difference method for calculating LSA using ODE models 
In Figure 4.3 we show how the finite difference method is stochastically used to 
estimate the sensitivity of the parameters using MRM/GSSA in conjunction with the 
Common Random Number (CRN). The implementation of CRN to compute the 
While N > 0  
N is the number 
of parameters 
𝐑𝐮𝐧 𝐭𝐡𝐞 𝐬𝐲𝐬𝐭𝐞𝐦 𝐰𝐢𝐭𝐡 𝐛𝐚𝐬𝐞 𝐯𝐚𝐥𝐮𝐞 𝐨𝐟 𝐩𝐚𝐫𝐚𝐦𝐞𝐭𝐞𝐫 𝐍 to find 𝐗(𝐓, 𝐜𝟎) 
(X is the species, c is the value of the parameter) 
 
𝐑𝐮𝐧 𝐭𝐡𝐞 𝐬𝐲𝐬𝐭𝐞𝐦  to find 𝐗(𝐓, 𝐜𝟎 + 𝒉) (X is the Species, c is the value of 
the parameter h is the perturbed factor 
Compute sensitivity for ith trajectory    𝐙𝐢 =
 (𝐄(𝐟(𝐗(𝐓, 𝐜𝟎 + 𝐡))) − 𝐄(𝐟(𝐗(𝐓, 𝐜𝟎)))/𝐡); 
 
Compute sample mean and sample standard 
deviation of  𝐙𝐢|𝐢 = 𝟏,……… . , 𝐍 
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sensitivity with MRM/GSSA is achieved by using the same stream of uniform 
random numbers that need to be generated for selecting the next reaction and 
time step from each thread at each step. CRN in conjunction with MRM/GSSA 
reseeds the random number generator prior to computing 𝑋(𝑇, 𝑐0 + ℎ) with the 















Figure 4.3: Steps of the finite difference method for calculating LSA using MRM/GSSA 
The seed function is employed to ensure that the random numbers used when 
parameters are not perturbed are also used when parameters perturbed are  
(Rathinam et al., 2010). 
𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐫𝐚𝐧𝐝𝐨𝐦 𝐬𝐞𝐞𝐝: 𝐰 = 𝐭𝐢𝐦𝐞 (𝐍𝐮𝐥𝐥) 
While N > 0  
N is the number of 
parameters 
 𝐬𝐞𝐞𝐝: 𝐰 
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(X is the Species, c is the value of the parameter) 
𝐑𝐮𝐧 𝐌𝐑𝐌/𝐆𝐒𝐒𝐀 𝐰 to find 𝐗(𝐓, 𝐜𝟎 + 𝒉) (X is the species, c is 
the value of the parameter h is the perturbed factor 
Compute sensitivity for ith trajectory    𝐙𝐢 =
 (𝐄(𝐟(𝐗(𝐓, 𝐜𝟎 + 𝐡))) − 𝐄(𝐟(𝐗(𝐓, 𝐜𝟎)))/𝐡); 
Compute sample mean and sample 
standard deviation of  𝐙𝐢|𝐢 = 𝟏,……… . , 𝐍 
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4.4 GSA (LHS/PRCC) 
LHS/PRCC is used in this research to assess not only the ODEs model of 
immunisation in AD, but also the MRM/GSSA over a global parameter space. See 
Chapter 2 for more details about LHS/PRCC. Several functions are implemented to 
perform GSA and interpret the results with LHS/PRCC. Figure 4.5 shows all these 
functions and how these functions are connected to each other. Table 4.1 shows 
the function names and their descriptions. 
 
Figure 4.4: LHS/PRCC diagram. 
 
To investigate the behaviour of a biochemical system using LHS/PRCC tool, as 
shown in Figure 4.4, there are different functions needed to be performed.  
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The main function calls four different sub functions to generate output to be used 
by PRCC analysis. System setting is used to define: (1) species and their initial 
values; (2) parameters and their baseline values; (3) time span of the simulation; (4) 
events; and (5) minimum and maximum values of each parameter for generating 
the LHS matrix. LHS matrix generator is used to generate the LHS parameters using 
the minimum and maximum values of each parameter. Assume a system includes 
𝑀 parameters. A probability distribution is assigned to each parameter. Each 
distribution is divided into 𝑁 equiprobable regions, where 𝑁 the required number 
of samples, and these regions are then sampled with no replacement. Thus the 
parameter space for the LHS parameters has a dimension of length 𝑀 with each 
dimension specifying an uncertain parameter vector of length 𝑁. Solver runs the 
simulation using the LHS parameters combination. Ranking function is used to rank 
the LHS matrix and then the matrix for the outcome measure using a sort routine. 
The monotonic relationship between the outcome measure and the LHS 
parameters is verified by picking separately each parameter’s row form the LHS 
matrix and run simulations using its values from that row and the baseline values 
for all other parameters. This results in 𝑀 simulations for this monotonicity test for 
each parameter.  
If the monotonic relationship is verified, output is used by PRCC analysis to 
measure the strength of the relationship between the LHS parameters and 
outcomes. PRCC is used to classify the most important parameters that contribute 
most uncertainty to model predications. If non-monotonic regions exist over the 
whole interval for any of the LHS parameters, we consider truncating the range and 
looking at each truncated separately.   
These steps are described using an example form immunization in AD model in Chapter 6. 
Results of LHS/PRCC for immunization in AD are also shown in Chapter 6.  
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4.5 An Analogy for MRM/GSSA and the Modified Tau-leap Method 
In this research, immunization in AD model is modelled using four different 
approaches. These approaches are ODEs, GSSA, MRM/GSSA and the modified tau-
leap method. The purpose of using ODEs is to be used with LSA and GSA (the 
results are presented in Chapters 5 and 6, respectively).  
To validate MRM/GSSA, it is compared with GSSA and the modified tau-leap 
method. The main difference between GSSA and the other two approaches is that 
GSSA advances the state of the system by executing one reaction at a time while 
MRM/GSSA and the modified tau-leap method advance the system state by several 
reactions within a calculated time step, 𝜏. Therefore, these two methods are 
mainly used to accelerate a single run of GSSA and explicitly include the 
concurrency feature.   
However, MRM/GSSA and the modified tau-leap are different not only from 
assumptions that allow the system state to be advanced by several reactions, but 
also from the way of calculating the time step, 𝜏. These two approaches are 
compared in this section from different angles, with the results in term of 
stochasticity depending on the GSSA results, performance in term of CPU time, 
reliability and implementation difficulties.  
4.5.1 Results 
Noise (known stochasticity or randomness) is one of the main biochemical systems 
features needed to be represented when these systems are stochastically modelled 
for better understanding of the behaviour of biochemical systems. Thus, when 
MRM/GSSA is developed, the stochastic feature is taken into consideration to be 
represented even we advance the system by several reaction at calculated time 
step, 𝜏. In this research we verified that MRM/GSSA has more ability to represent 
the stochasticity feature than the modified tau leap method by comparing their 
results with GSSA.  
Figure 4.5 (A) shows the average behaviour of p53 from 200 runs from GSSA (red 
line), MRM/GSSA (blue line) and the modified tau-leap method, where 𝑛 is chosen 
to be 10, (black line). The value of 𝑛 is an integer, but it might be anywhere 
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between 2 and 20. The value of  𝑛 is used to determine the number of reactions 
that classified to be critical reactions.  
At day # 4 (vertical line in Figure 4.5), the values of mean for p53 from MRM/GSSA, 
GSSA and the modified tau-leap method are 124.5423, 117.0693 and 111.8416, 
respectively. To check how each approach represents the stochasticity, the 
standard deviation (σ) is calculated at day #4 to measure how other values are 
spread around the mean µ for all approaches. It has been found that GSSA is more 
able to represent stochasticity feature than MRM/GSSA and the modified tau-leap 
method. MRM/GSSA shows that the values of the data set of p53 at day #4 are 
more widely spread than the modified tau-leap method since MRM/GSSA 
demonstrates larger standard deviation than the modified tau-leap as shown in 
Table 4.1.  
Table 4.1: The mean and the standard deviation from MRM/GSSA, GSSA and the modified 
tau leap method for p53 at day #4. 
 MRM/GSSA GSSA The modified tau-leap method 
Mean (µ) 124.5 117.0 111.8 
standard deviation (σ) 53.8 58.0 31.5 
 
Table 4.1 shows that MRM/GSSA has the ability to represent more variance than 
the modified tau-leap method since the standard deviation of the mean at day # 4 
is 53.8 while it is 31.5 from the modified tau-leap method. Figure 4.6 shows mean 
and (+/- 1 S.D.) of 200 run at day # 4 for p53 from all MRM/GSSA, GSSA and the 








Figure 4.5: Average of 200 runs for p53 from MRM/GSSA, GSSA and the modified 
tau-leap method. GSSA advances the system by only one reaction at each time 
step while MRM/GSSA and the modified tau-leap method advance the system by 
several reactions. MRM/GSSA and the modified tau leap method show good 
representation of the behaviour of p53 comparing to GSSA even they advance the 
system by several reactions. At day # 4, vertical line, we compare between 
MRM/GSSA and the modified tau leap method in term of stochasticity depending 
the GSSA result. Results shown in Table 4.1.    
 
 
Figure 4.6: Mean of data (200 runs) at day #4 for p53 from MRM/GSSA, GSSA and 
the modified tau-leap method. Approaches name are labelled under columns, 
values of mean are shown in the red rectangle in each column. It could be clearly 
seen that MRM/GSSA shows better representing of variance than the modified 
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4.5.2 Performance and Reliability  
In MRM/GSSA, all reaction channels 𝑅𝑗 for which 𝑎𝑗(𝑥) > 0  that are eligible for the 
selected step are saved in a list. The system state is advanced by executing all these 
reactions where each reaction is executed just once.  
In the modified tau-leap method, reaction channels, 𝑅𝑗, for which 𝑎𝑗(𝑥) > 0 are 
classified into two different types, critical and non-critical reactions. Critical 
reactions: namely, those reaction channels for which 𝐿𝑗 ≤ 𝑛 (𝐿𝑗 is the maximum 
number of permitted firings of 𝑅𝑗 and 𝑛 is an integer value, but it might be 
anywhere between 2 and 20). The system state is advanced by executing a 
maximum of one reaction channel from the critical reactions list and all reaction 
channels from non-critical reactions’ list. Each reaction channel in the non-critical 
reaction is executed 𝑘 times (𝑘 is a sample of the Poisson random variable).   
We use GSSA, MRM/GSSA and the modified tau-leap method to run the 
immunization in AD model to produce just one realization of the system for 10 
times. The value of 𝑛 in the modified tau-leap method is chosen to be 2, 10 and 20 
respectively.  
As shown in Table 4.2 (excluding rows 6 and 9) MRM/GSSA and the modified tau-
leap method are much faster than GSSA at all the 10 times. It could be clearly seen 
that both of them need less than half of the time required by GSSA. Therefore, 
MRM/GSSA and the modified tau-leap method show good performance in term of 
time comparing to GSSA.  
The modified tau-leap method shows better performance than MRM/GSSA but 
they still comparable in terms of time since it has been found that the modified 
tau-leap method only needs around 92% of the time required by MRM/GSSA.  
Reliability is also another measure that needs to be taken into consideration for 
using the modified tau-leap method and MRM/GSSA. As shown in Table 4.2 (rows 6 
and 9), when the modified tau-leap method assigns 2 for 𝑛, it went through a 
deadlock situation. The deadlock situation here means that the simulation went 
through an infinite loop. It happened because at each iteration, at least one 
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reaction should be located in the critical reaction list to avoid dividing by zero (step 
5 in Figure 2.2 Chapter 2, compulsory step).  
Therefore, the reliability of the modified tau-leap method is less MRM/GSSA 
because there is no way to determine the value of 𝑛, the value of 𝑛 is arbitrary 
chosen between 2 and 20. To avoid a deadlock situation that could happened, the 
system under study should be manually analysed before modelling to determine 𝑛 
that suites the system. This results more time needed to produce results for the 
modified tau-leap method. Also, the modified tau leap method has no way to 
dynamically changing the value of 𝑛 depending on the state of the system, 𝑛 sets to 
the constant over the whole simulation time (Cazzaniga, Pescini, Besozzi, & Mauri, 
2006).  
Table 4.2: CPU time. GSSA, MRM/GSSA and the modified tau-leap method (n=2, 10 and 
20). The average CPU time for MRM/GSSA and the modified tau-leap method is less than 
half of that for the GSSA. 
# GSSA MRM/GSSA The modified Tau-leap method 
𝒏 
2 10 20 
1 11m.23s.233ms 4m.55s.22ms 3m.41s.123ms 3m.23s.234ms 3m.41s.231ms 
2 10m.55s.723ms 5m.01s.766ms 3m.52s.231ms 4m.17s.119ms 3m.17s.111ms 
3 12m.42s.341ms 4m.22s.211ms 4m.12s.564ms 3m.55s.861ms 3m.51s.389ms 
4 11m.45s.22ms 5m.14s.2ms 3m.23s.333ms 2m.13s.345ms 3m.37s.258ms 
5 9m.59s.721ms 4m.57s.123ms 4m.01s.786ms 3m.22s.12ms 3m.58s.121ms 
6 12m.1s.113ms 3m.59s.704ms Deadlock 3m.56s.312ms 4m.01s.456ms 
7 12m.15s.517ms 5m.44s.1ms 3m.22s.129ms 4m.12s.763ms 3m.49s.721ms 
8 11m.12s.122ms 3m.59s.517ms 3m.45s.342ms 3m.11s.179ms 3m.23s.345ms 
9 11m.51s.21ms 4m.52s.311ms Deadlock 4m.02s.812ms 3m.55s.765ms 
10 10m.56s.221ms 5m.10s.221ms 3m.55s.12ms 3m.29s.119ms 3m.39s.234ms 
AVG 11m.36s.303ms 4m.38s.288ms 3m.35s.417ms 3m.49s.378ms 3m.27s.512ms 
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4.5.3 Implementation 
Visual Studio (C# 2017) is used to implement all approaches used in this research to 
model immunization in AD. The structure of the code for GSSA, MRM/GSSA and the 
modified tau leap method is divided into three parts, as shown in Figure 4.7.  
 
Figure 4.7: General structure of coding an algorithm. The system needs to be initialized 
before the implementation step updates the system   
Initializing and updating the system in both algorithms are the same since both are 
used to model the system. During the implementation, it is found that MRM/GSSA 
is much easier to implement than the modified tau-leap method for different 
reasons. 
1- Only three steps are needed to be implemented in MRM/GSSA (election, 
selection and calculating the time step). In the modified tau-leap method, 
eight steps are needed to be implemented. These steps are shown in Figure 
2.2.  
2- Only one summation mathematical equation needs to be calculated to 
compute time step, 𝜏, while the modified tau-leap method needs three 
mathematical equations and a logical expression to calculate the final value 
of 𝜏. The complexity of the code is increased when there are many 
mathematical equations.  
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3- Dividing reactions into critical and non-critical is like dealing with a black box 
because at each iteration, the status of these reactions could be changed 
from critical to non-critical or vice versa depending on the state of the 
system. This increases the complexity of the code because each reaction 
needs to be checked at each iteration.  
4- Reject, accept and undo are used in the modified tau-leap method, these 
concepts are not particularly easy to implement.   
5- The whole structure of MRM/GSSA is undertaken by coding 3313 lines in C# 
while 10338 lines are needed to implement the whole structure of the 
modified tau-leap method.   
4.6 Specifications 
The basic information about the computer that has been used to run all 
approaches and algorithms is listed in Table 4.3. 
Table 4.3: Computer specifications. 
Windows edition 10 
Processor Intel(R) Core(TM) i5-6300U CPU@2.40GHz  2.50 GHz 
Installed memory (RAM) 8.00 GB 
System type 64-bit Operating System, x64-based processor 
Programming language .Net (C# 2017) 
 
4.7 Summary  
This chapter covers the MRM/GSSA that is used to model immunization in AD 
model. It also described algorithms that are used to stochastically and 
deterministically perform LSA. The finite approximation method is used to 
deterministically perform LSA using ODEs and stochastically using MRM/GSSA in 
conjunction with CRN.   
LHS/PRCC is described in this chapter since it is used to stochastically and 
deterministically investigate the behaviour of the model in response to parameters 
perturbation one-at-a time and over the space of the parameters, respectively.  
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Results of LSA and GSA are discussed in Chapters 5 and 6, respectively.  
This chapter also describes how MRM is combined with GSSA to accelerate a single 
run of GSSA by advancing the system with several reactions at each time step and 
explicitly include the concurrency feature. The combination of MRM with GSSA is 
validated by comparing it with not only GSSA, but also the modified tau leap 






Local Sensitivity Analysis of Immunization in an AD model 
5.1 Overview 
In order to examine the behaviour of immunisation in AD model against parameter 
perturbation, LSA is performed using not only ODEs, but also MRM/GSSA. In other 
words, the behaviour of the system is deterministically and stochastically 
investigated in response to parameters perturbation. All parameters in this system 
are perturbed to 50% and 200% of their basal values, one at a time to:  
1- Determine the maximum and minimum ranges for each parameter. 
2- Identify the most important parameters that contribute most of the 
variation. 
3- Categorize the most important parameters that target the level of plaques 
and tangles to be changed since these species highly contribute to AD.   
4- Identifying pathways that are not dramatically affected when parameters 
are perturbed. 
5- Classify the most sensitive species in the system. LSA focuses on the main 
species in the system to be classified since this system has 69 species and it 
is hard to track the behaviour of all these species in response to parameter 
perturbations. The main species that are selected and their pathways are 
listed in Table 5.1.   
6- Determine when a species is more sensitive to a parameter’s perturbation.   
The minimum value of parameters perturbation is chosen to be 50% of their basal 
value because parameters value are going to be very small if they are taken less 
than 50%. Table 5.2 lists all parameters in the system, their description, their basal 





Table 5.1: Selected species and their pathways.  
Species Pathway 
p53 p53 regulation 
ATMA DAN damage pathway 
p53_GSK3β GSK3β activity 
Aβ Aβ production and aggregation 
plaques Aβ production and aggregation 
tangles tau dynamics and aggregation 
GliaA immunisation pathway 
 
The species in Table 5.1 are selected to be investigated in response to parameters 
perturbation for different reasons. Firstly, Aβ, plaques and tangles are selected 
since they are considered to be the most important species that contribute AD. 
Secondly, Proctor et al., (2013) classified p53, ATMA and p53_GSK3β to be the main 
species respectively in p53 regulation, DAN damage pathway and GSK3β activity. 
p53 regulation, DAN damage pathway and GSK3β activity are classified to be the 
key pathways involved in the mechanisms that link Aβ and tau. GliaA is the main 
species that is used in the immunization pathway. Also, it has been found that 
these species take a prat of 52 reactions (around half reactions of the system), 
therefore, they have the most contribution of the behaviour of the system.  











1 kactATM  ATMactivation 0.0001 5.00E-05 0.0002 
2 kactDUBMdm2  p53Deubiquitination3 1.00E-07 5.00E-08 2.00E-07 
3 kactDUBp53  Mdm2PDeubiquitination4 1.00E-07 5.00E-08 2.00E-07 
4 kactDUBProtp53   0.0001 5.00E-05 0.0002 
5 kactglia1  GliaActivationStep1 6.00E-07 3.00E-07 1.20E-06 
6 kactglia2  GliaActivationStep3 6.00E-07 3.00E-07 1.20E-06 
7 kaggAbeta Abetaaggregation1 3.00E-06 1.50E-06 6.00E-06 
8 kaggTau  Tauaggregation1 1.00E-08 5.00E-09 2.00E-08 
9 kaggTauP1  TauP1Aggregation1 1.00E-08 5.00E-09 2.00E-08 
10 kaggTauP2  TauP2Aggregation1 1.00E-07 5.00E-08 2.00E-07 
11 kbinAbantiAb  Abeta_antiAbBinding 1.00E-06 5.00E-07 2.00E-06 
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12 kbinAbetaGlia  AbetaBindingToGlia 1.00E-05 5.00E-06 2.00E-05 
13 kbinE1Ub  E1UbBinding 0.0002 0.0001 0.0004 
14 kbinE2Ub  E2UbBinding 0.001 0.0005 0.002 
15 kbinGSK3bp53  GSK3p53Binding 2.00E-06 1.00E-06 4.00E-06 
16 kbinMdm2p53  p53Mdm2Binding 0.001155 0.000578 0.00231 
17 kbinMTTau  TauMTbinding 0.1 0.05 0.2 
18 kbinProt  Mdm2ProteasomeBinding1 2.00E-06 1.00E-06 4.00E-06 
19 kbinTauProt  TauProteasomeBinding 1.93E-07 9.63E-08 3.85E-07 
20 kdam  DNAdamage 0.08 0.04 0.16 
21 kdamROS  ROSDNAdamage 1.00E-05 5.00E-06 2.00E-05 
22 kdegAbeta  AbetaDegredation 1.50E-05 7.50E-06 3.00E-05 
23 kdegAbetaGlia Abeta_antiAbDegredation 0.005 0.0025 0.01 
24 kdegAntiAb  antiAbRemoval 2.75E-06 1.38E-06 5.50E-06 
25 kdegMdm2  Mdm2Degradation 0.01 0.005 0.02 
26 kdegMdm2mRNA  Mdm2mRNADegradation 0.0005 0.00025 0.001 
27 kdegp53  p53Degradation 0.005 0.0025 0.01 
28 kdegp53mRNA  p53mRNADegradation 0.0001 5.00E-05 0.0002 
29 kdegTau20SProt  Tau20SProteasomeDegradation 0.01 0.005 0.02 
30 kdephosMdm2  Mdm2dephosphorylation 0.5 0.25 1 
31 kdephosp53  p53dephosphorylation 0.5 0.25 1 
32 kdephospTau  Taudephosphorylation2 0.01 0.005 0.02 
33 kdisaggAbeta  AbetaDisaggregation1 1.00E-06 5.00E-07 2.00E-06 
34 kdisaggAbeta1  AbetaDisaggregation3 0.0002 0.0001 0.0004 
35 kdisaggAbeta2 AbetaDisaggregation4 1.00E-06 5.00E-07 2.00E-06 
36 kgenROSAbeta AggAbetaROSproduction2 2.00E-05 1.00E-05 4.00E-05 
37 kgenROSGlia  ROSgenerationByGlia 1.00E-05 5.00E-06 2.00E-05 
38 kgenROSPlaque  PlaqueROSproduction 1.00E-05 5.00E-06 2.00E-05 
39 kinactATM  ATMinactivation 0.0005 0.00025 0.001 
40 kinactglia1  GliaInactivationStep1 5.00E-06 2.50E-06 1.00E-05 
41 kinactglia2   GliaInactivationStep3 5.00E-06 2.50E-06 1.00E-05 
42 kinhibprot  ProteasomeInhibitionAggTau 1.00E-07 5.00E-08 2.00E-07 
43 kMdm2PolyUb  p53Polyubiquitination 0.00456 0.00228 0.00912 
44 kMdm2PUb  Mdm2PUbiquitination 6.84E-06 3.42E-06 1.37E-05 
45 kMdm2Ub  Mdm2Ubiquitination 4.56E-06 2.28E-06 9.12E-06 
46 kp53PolyUb  Mdm2polyUbiquitination1 0.01 0.005 0.02 
47 kp53Ub  p53Monoubiquitination 5.00E-05 2.50E-05 0.0001 
48 kpf  AbetaPlaqueFormation 0.2 0.1 0.4 
49 kpg  AbetaPlaqueGrowth 0.15 0.075 0.3 
50 kpghalf  AbetaPlaqueGrowth1 10 5 20 
51 kphosMdm2  Mdm2phosphorylation 2 1 4 
52 kphosMdm2GSK3b  Mdm2GSK3phosphorylation1 0.005 0.0025 0.01 
53 kphosMdm2GSK3bp53  Mdm2GSK3phosphorylation2 0.5 0.25 1 
54 kphosp53  p53phosphorylation 0.0002 0.0001 0.0004 
55 kphosTauGSK3b Tauphosphorylation6 0.0002 0.0001 0.0004 
56 kphospTauGSK3bp53  Tauphosphorylation4 0.1 0.05 0.2 
57 kprodAbeta  Abetaproduction1 1.86E-05 9.30E-06 3.72E-05 
58 kprodAbeta2  Abetaproduction2 1.86E-05 9.30E-06 3.72E-05 
59 kproteff  Extra parameter is used in 
different degradation reactions 
1 0.5 2 
60 krelAbPGlia  AbetaReleaseFromGlia 5.00E-05 2.50E-05 0.0001 
61 krelGSK3bp53  p53GSK3bRelease 0.002 0.001 0.004 
62 krelMdm2p53  p53Mdm2Release 1.16E-05 5.78E-06 2.31E-05 
63 krelMTTau  TauMTrelease 0.0001 5.00E-05 0.0002 
64 kremROS  ROSremoval 7.00E-05 3.50E-05 0.00014 
65 krepair  DNArepair 2.00E-05 1.00E-05 4.00E-05 
66 ksynMdm2  Mdm2Synthesis 0.000495 0.000248 0.000595 
67 ksynMdm2mRNA  Mdm2mRNASynthesis1 0.0005 0.00025 0.001 
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68 ksynMdm2mRNAGSK3bp53  Mdm2mRNASynthesis3 0.0007 0.00035 0.0014 
69 ksynp53  p53Synthesis 0.007 0.0035 0.014 
70 ksynp53mRNA  p53mRNASynthesis 0.001 0.0005 0.002 
71 ksynp53mRNAAbeta  p53transcriptionViaAbeta 1.00E-05 5.00E-06 2.00E-05 
72 ksynTau  TauSynthesis 8.00E-05 4.00E-05 0.00016 
73  ktangfor TangleFormation1 0.001 0.0005 0.002 
 
5.2 ODEs and MRM/GSSA Results for the Selected Species 
According to Proctor et al., (2013), the behaviour of this model is&supported 
by&neuropathological observations in Alzheimer&patients&immunised against 
Aβ.  Figures 5.1 A and B show, respectively, the behaviour of the selected species 
from ODEs and MRM/GSSA when the parameters are not perturbed. Part B shows 
the average behaviour of 200 realizations produced by MRM/GSSA for all selected 
species. 
To assume a species is highly sensitive to a parameter’s perturbation, a dramatic 
change should happen in its behaviour by increasing or decreasing to an 
unpredictable level. Levels of all the selected species are tracked when 
parameters are perturbed (one at a time) to examine how these species 
















    
   
Figure 5.1: Behaviour of selected species from ODEs (A) and average of 200 
realizations using MRM/GSSA (B). ODEs and MRM/GSSA show that the level 
ATAM (2 in A and B) increases in response to DNA damage. ATMA 
phosphorylates p53 (1 in A and B) to prevent its binding with Mdm2, and p53 is 
no longer degraded. p53 is elevated and binds to GSK3β to increase the level of 
p53_ GSK3β (3 in A and B). p53_GSK3β continuously phosphorylates Aβ (4 in A 
and B) and tau, which results in more production of plaques (5 in A and B) and 
tangles (6 in A and B), respectively.  At day #4, the system is immunized by 
adding antibodies, which results in a dramatic increase in the level of GliaA (7 in 
A and B) and a slight decrease in the level of p53, ATMA, p53_ GSK3β, Aβ, 
totally cleared plaques and a small inhibition in the level of tangles. 
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5.3 LSA Results 
To deterministically and stochastically perform LSA, we use the algorithms shown 
in Figures 4.3 and 4.4 to quantify the influence each parameter’s perturbation had 
on the selected species. The sensitivity of each of the selected species in response 
to each parameter perturbation is computed at each time step. Assume that 𝑁 
time steps is needed to run the simulation. Therefore, 𝑁 sensitivity values (𝑆𝑉) 
are produced for each species in response to any parameter perturbation over 
the time series of the system. Therefore, a list contains 𝑁 sensitivity 
values,   𝑆𝑉𝑙𝑖𝑠𝑡 = (𝑆𝑉1, 𝑆𝑉2, 𝑆𝑉3, ……………𝑆𝑉𝑁).We use this list to generate 
three different values. These values are  average (μ),
standard deviation σ and  Max.  
1- μ =  σ 𝑆𝑉𝑖/𝑁
𝑁
𝑖=1 . It is used to display the average sensitivity on the behaviour of any 
of the selected species in response to any parameter perturbation.   
2- σ =  √
1
𝑁
σ (𝑆𝑉𝑖 − 𝜇)
2𝑁
𝑖=1  . It is used to quantify how much the members of 
𝑆𝑉𝑙𝑖𝑠𝑡 differ from μ.  
3- Max = MAX(𝑆𝑉1, 𝑆𝑉2, 𝑆𝑉3, ……………𝑆𝑉𝑁). It is used to identify the maximum 
member of 𝑆𝑉𝑙𝑖𝑠𝑡 (the minus sign indicates a decreasing status). We also find the 
exact time (Time days) for Max to determine exactly when the maximum sensitivity 
of a species in response to a parameter happened. We use Max and (Time days) to 
determine the good time for observing a species in response to a parameter 
perturbation.  
Parameters are divided into three groups (A, B and C). Group A includes all 
parameters that have no effect on the behaviour of a selected species when 
parameters are perturbed. Group B consists of parameters that have minor effect 
on the behaviour of a selected species when parameters are perturbed. Group C 
lists all parameters that dramatically change the behaviour of the selected species 
when parameters are perturbed.   
Results of LSA using ODEs and MRM/GSSA are generated using visual studio (C# 
2017). All 3D figures that are used to show the maximum sensitivity of the 
selected species are drawn using a statistical package produced and distributed 
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by NCSS. Figures that are used to show μ and σ of 𝑆𝑉𝑙𝑖𝑠𝑡 are created using Excel 
tool 2016.  
μ, σ, Max, and  Time (second) for each species in response to all parameters 
using ODEs and MRM/GSSA are listed in Tables 1 and 2 in the Appendices C.  
5.3.1 Results of LSA for p53, ATMA, p53_ GSK3β and Aβ 
LSA using ODEs and MRM/GSSA demonstrates that the behaviour of p53, ATMA, 
p53_GSK3β and Aβ are not dramatically changed when parameters are perturbed 
to 50% and 200% of their basal values, one at a time.  
Using ODEs to perform LSA shows that p53, ATMA and p53_ GSK3β are slightly 
changed in response to 28 parameters while Aβ is altered in response to only 24 
parameters. Performing LSA using MRM/GSSA demonstrate that the behaviour of 
p53 is altered in response to 66 parameters when the parameters are perturbed 
to 50% of their basal values while 71 parameters change its behaviour when they 
perturbed to 200% of their basal values. Therefore, p53 is more sensitive for 
increasing the rates of parameters. Whereas, ATMA, p53_ GSK3β and Aβ are 
sensitive to 71 parameters when the list of parameters in the system adjusted to 
50% and 200% of their basal values.  
Thus, LSA using ODEs and MRM/GSSA demonstrates that p53, ATMA, p53_ GSK3β 
and Aβ are not highly contributing to the overall behaviour of the system in 
response to parameters perturbation. Therefore, minimum and maximum ranges 
of parameters for these species could be less and greater than 50% and 200% of 
their basal values, respectively. The results of LSA using ODEs and MRM/GSSS for 
p53, ATMA, p53_ GSK3β and Aβ are summarized in Table 5.3.  
LSA using ODEs indicates that days # 4 and 5 of the simulation time are the most 
important days to observe the behaviour of p53, ATMA, p53_ GSK3β and Aβ 
because the maximum sensitivity of these species in response to parameters 
perturbation is recoded in these two days.  
Using MRM/GSSA to perform LSA shows that the maximum sensitivity of p53, 
ATMA, p53_ GSK3β and Aβ is recorded over the whole period of the system. The 
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maximum sensitivity of these species is recorded over the whole period of the 
system because these species are targeted to be altered to more parameters 
specific to different pathways that are activated at different times.  Therefore, 
observing the maximum changed on the behaviour of these species when LSA 
uses MRM/GSSA should be done over the whole period of the system.  
For simplicity we just show figures for p53 and Aβ to display how the maximum 
sensitivity is demonstrated using ODEs and MRM/GSSA. Figures 5.2 (A and B) and 
5.3 (A and B) show Max and Time (days) of p53 in response to parameters 
perturbation when parameters are perturbed to 50% and 200% of their basal 
values using ODEs and MRM/GSSA, respectively while Figures 5.4 (A and B) and 
5.5 (A and B) show same for Aβ.   
Because p53, ATMA and p53_GSK3β are not hugely contribute to the whole 
system since they are not dramatically changed in response to parameters 
perturbation, we conclude that also pathways included these species are not 
hugely affect the behaviour of the whole the system. Therefore, we identify that 
p53 regulation, DNA damage pathway and GSK3β activity are not dramatically 
changed in response to parameters perturbation.  Aβ has no ability to contribute 
the overall behaviour of the system since minor changes happened to its 
behaviour in response to parameters perturbation but its pathway is identified as 
an important pathway in the system because plaques are dramatically changed in 
response to parameters perturbation. The results LSA for plaques are described in 








Table 5.3:   Summary of LSA results using ODEs and MRM/GSSA for p53, ATMA, p53_ 
GSK3β and Aβ. Groups A, B and C, respectively, contain parameters that have no effect, 
minor effects and major effects on the behaviour of these species. 
Parameters are perturbed to 
50% of their basal values.   
LSA Using ODEs LSA Using MRM/GSSA 
Is p53 very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 7 66 0 
Is ATMA very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 2 71 0 
Is p53_GSK3β very sensitive to 
parameters perturbations?? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 2 71 0 
Is Aβ very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 2 71 0 
Minimum ranges of parameters 50% or less 50% or less 
Parameters are perturbed to 
200% of their basal values.   
LSA Using ODEs LSA Using MRM/GSSA 
Is p53 very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 2 71 0 
Is ATMA very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28 0 2 71 0 
Is p53_GSK3β very sensitive to 
parameters perturbations?? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28  2 71 0 
Is Aβ very sensitive to parameters 
perturbations? 
NO NO 
Number of parameters in each group Group A Group B Group C Group A Group B Group C 
45 28  2 71 0 












Figure 5.2: Maximum sensitivity and it’s time for p53 when parameters are 
adjusted to 50% of their basal values using ODEs (A) and MRM/GSSA (B),  
respectively.  A shows that p53 using ODEs to perform LSA recodes its maximum 
sensitivity in response to parameters perturbation in the early stage of the 
system, mainly from day #4 to day #6. B shows that p53 records its maximum 
sensitivity over the whole period of the system when MRM/GSSA is used in 
response to parameters perturbation.      
 
(A) Maxiumum senstivity of p53 and its time in resposne to paramater pertubation using ODEs when 
parameters are pertubed to 50% basal values. 
(B) Maxiumum senstivity of p53 and its time in resposne to paramater pertubation using MRM/GSSA when 






Figure 5.3: Maximum sensitivity and it’s time for p53 when parameters are adjusted to 200% 
of their basal values using ODEs (A) and MRM/GSSA (B),  respectively.  A shows that p53 
using ODEs to perform LSA recodes its maximum sensitivity in response to parameters 
perturbation in the early stage of the system, mainly from day #4 to day #6. B shows that 
p53 records its maximum sensitivity over the whole period of the system when MRM/GSSA 
is used in response to parameters perturbation.      
 
A. Maxiumum senstivity of p53 and its time in resposne to paramater pertubation using ODEs when 
parameters are pertubed to 200% basal values. 
B. Maxiumum senstivity of p53 and its time in resposne to paramater pertubation using MRM/GSSA 






Figure 5.4: Maximum sensitivity and it’s time for Aβ when parameters are adjusted to 50% 
of their basal values using ODEs (A) and MRM/GSSA (B),  respectively.  A shows that Aβ using 
ODEs to perform LSA recodes its maximum sensitivity in response to parameters 
perturbation in the early stage of the system, mainly from day #4 to day #6. B shows that 
p53 records its maximum sensitivity over the whole period of the system when MRM/GSSA 
is used in response to parameters perturbation.      
 
 
A. Maxiumum senstivity of Aβ and its time in resposne to paramater pertubation using ODEs when 
parameters are pertubed to 50% basal values. 
B. Maxiumum senstivity of Aβ and its time in resposne to paramater pertubation using MRM/GSSA when 






Figure 5.5: Maximum sensitivity and it’s time for Aβ when parameters are adjusted to 200% 
of their basal values using ODEs (A) and MRM/GSSA (B),  respectively.  A shows that Aβ using 
ODEs to perform LSA recodes its maximum sensitivity in response to parameters 
perturbation in the early stage of the system, mainly from day #4 to day #6. B shows that 
p53 records its maximum sensitivity over the whole period of the system when MRM/GSSA 
is used in response to parameters perturbation.      
 
A. Maxiumum senstivity of Aβ and its time in resposne to paramater pertubation using ODEs when parameters are 
pertubed to 200% basal values. 
B. Maxiumum senstivity of Aβ and its time in resposne to paramater pertubation using MRM/GSSA when parameters 
are pertubed to 200% basal values. 
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Figures 5.6 (A and B) and 5.7 (A and B) show µ and σ of 𝑆𝑉𝑙𝑖𝑠𝑡 for p53 in response 
to parameters perturbation when parameters are perturbed to 50% and 200% of 




Figure 5.6:  µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation using ODEs 
when parameters are perturbed to 50% (A) and 200% (B) of their basal values. The 
parameter indexes correspond to the indexes in Table 5.1. All parameters have minor effects 
on the behaviour of p53. When parameters are perturbed to 50% (A), 13 parameters 
decrease the level of p53 while 16 parameters decrease its level when parameters are 
perturbed to 200%. In A when parameters are perturbed to 50% of their basal value, 
parameters 16 and 30 (indicated in A) have the same effect on the level of p53 while 
parameter 67 (indicated in A) has the major effect on the behaviour of p53. B shows that 44 
and 51 (indicated in B) have the same effect on the level of p53. Parameters 26 (indicated in 
B) has the major effect on the behaviour of p53. Therefore, it could be clearly seen that 
parameters specific to Mdm2 are the most important parameters that affect p53 when LSA 
uses ODEs.   
B. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation using ODEs when parameters are perturbed to 
50% of their basal values. 
B. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation using ODEs when parameters are perturbed to 





Figure 5.7: µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation 
using MRM/GSSA when parameters are perturbed to 50% (A) and 200% (B) of 
their basal values. The parameter indexes correspond to the indexes in Table 
5.1. All parameters have minor effects on the behaviour of p53. In A, it is clearly 
seen that parameters # 49, 50, 58 and 66 (indicated in A) have the major effects 
on the behaviour of p53 when parameters are perturbed to 50% of their basal 
value.  Parameters # 49, 50, 69 and 74 (indicated in A) have the major effects on 
the behaviour of p53 when parameters are perturbed to 50% of their basal 
value. When parameters are perturbed to 50% and 200% of their basal values, 
p53 is more sensitive to parameter specific to Aβ.  
 
A. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation using MRM/GSSA when parameters are 
perturbed to 50% of their basal values. 
B. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for p53 in response to parameters perturbation using MRM/GSSA when parameters are 
perturbed to 200% of their basal values. 
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It has been found that ATMA and p53_GSK3β are more sensitive to KinactATM (1 
in Table 5.2) when LSA uses ODEs and parameters are perturbed to 50% and 
200%. LSA using MRM/GSSA demonstrates that ATMA and p53_GSK3β are more 
sensitive parameters specific to p53 and Mdm2 such as ksynp53, kbinE2Ub, 
ksynMdm2 (69, 14 and 66 in Table 5.2) when parameters are perturbed to 50% of 
their basal values. Parameter specific to Aβ such as kpg and KprodAbeta2 and 
Kpghalf (49, 50 and 58 in Table 5.2) have more effects than others on the 
behaviour of ATMA and p53_GSK3β when parameters are perturbed to 200%.   
Aβ is more sensitive to KrelGSK3bp53 specific p53_GSK3b (61 in Table 5.2) using 
ODEs and MRM/GSSA when parameters are perturbed to 50% of their basal 
values. KprodAbeta2 specific to Aβ (58 in Table 5.2) is the more effectiveness 
parameter on the behaviour of Aβ using ODEs and MRM/GSSA when parameters 
are perturbed to 200% of their basal values. Figures 5.8 (A, and B), 5.9 (A and B) 
show µ and σ of 𝑆𝑉𝑙𝑖𝑠𝑡 for Aβ in response to parameters perturbation when 
parameters respectively are perturbed to 50% and 200% of their basal values 
using ODEs and MRM/GSSA, respectively 
It is really interesting to find that KrelGSK3bp53 and KprodAbeta2 is the most 
effective parameter on the behaviour of Aβ using respectively ODEs and 
MRM/GSSA when parameters are perturbed to 50% and 200% of their basal 


















Figure 5.8: µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using 
ODEs when parameters are perturbed to 50% (A) and 200% (B) of their basal 
values. The parameter indexes correspond to the indexes in Table 5.1. All 
parameters have minor effects on the behaviour of p53. KrelGSK3bp53 (61 in 
Table 5.1) is the most effectives parameter on the behaviour of Aβ when 
parameters are perturbed to 50% of their basal values using ODEs. KprodAbeat2 
has the largest effects on the behaviour of Aβ using ODEs when parameters are 






A. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using ODEs when parameters are perturbed 
to 50% of their basal values. 
B. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using ODEs when parameters are perturbed 







Figure 5.9: µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using 
MRM/GSSA when parameters are perturbed to 50% (A) and 200% (B) of their 
basal values. The parameter indexes correspond to the indexes in Table 5.1. All 
parameters have minor effects on the behaviour of p53. KrelGSK3bp53 (61 in 
Table 5.1) is the most effectives parameter on the behaviour of Aβ when 
parameters are perturbed to 50% of their basal values using MRM/GSSA. 
KprodAbeat2 has the largest effects on the behaviour of Aβ using MRM/GSSA 







B. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using MRM/GSSA when parameters are 
perturbed to 200% of their basal values. 
A. µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for Aβ in response to parameters perturbation using MRM/GSSA when parameters are 
perturbed to 200% of their basal values. 
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5.3.2 Results of LSA for plaques 
LSA using ODEs shows that the behaviour of plaques is changed in response to 26 
parameters when the list of parameters are perturbed to 50% and 200% of their 
basal values. When MRM/GSSA is used to perform LSA, plaques are sensitive to 
71 parameters.  Day #4 is the day that the species of plaques shows it maximum 
sensitivity using ODEs as shown in Figures 5.10 (A and B). From day # 4 to the end 
of the simulation, plaques show their maximum sensitivity in response to 
parameter perturbation when MRM/GSSA is used to perform LSA as shown in 
Figure 5.11 (A and B).  
Plaques are classified to be one of the most important species of the system since 
it is dramatically changed in response to parameters perturbation using ODEs and 
MRM/GSSA.  
LSA using ODEs shows that plaques are hugely affected by parameters specific 
p53_GSK3β and Aβ when parameters are perturbed to 50% and 200% of their 
basal values as shown in Table 5.4. LSA using MRM/GSSA shows that the 
behaviour of plaques could be dramatically changed in response to more 
parameters than ODEs do and these parameters are specific to different species 
in the system as shown in Table 5.5.  
Therefore, plaques are classified to be very important species that contribute to 
the overall behaviour of the system and all parameters listed in Tables 5.4 and 5.5 
are identified to be the most important parameters that contribute most to the 
variation of plaques. 
Here we just show µ and σ of 𝑆𝑉𝑙𝑖𝑠𝑡 for plaques in response to parameters 
perturbation when parameters are perturbed to 50% and 200% of their basal 
values respectively using ODEs as shown in Figures 5.12 (A and B). Parameters in 
Tables 5.4 are indicated in Figure5.12. Parameters listed in Table 5.5 contribute   







Figure 5.10: Maximum sensitivity and it’s time for plaques when parameters are altered to 
50% (A) and 200% (B)  of their basal values using ODEs,  respectively.  A and B show that 
plaques using ODEs to perform LSA recode their maximum sensitivity in response to 
parameters perturbation at Day #4. Therefore, LSA using ODEs demonstrates that plaques 
should be observed only at day #4 in response to parameters perturbation. 
 
 
B. Maxiumum senstivity of plaques and its time in resposne to paramater pertubation using ODEs when parameters 
are pertubed to 50% basal values. 
A. Maxiumum senstivity of plaques and its time in resposne to paramater pertubation using ODEs when parameters 






Figure 5.11: Maximum sensitivity and it’s time for plaques when parameters are altered to 
50% (A) and 200% (B)  of their basal values using MRM/GSSA,  respectively. A and B show 
that plaques using MRM/GSSA to perform LSA recode their maximum sensitivity in response 
to parameters perturbation from Day #4 to the end of the simulation. 
 
 
A. Maxiumum senstivity of plaques and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 50% basal values. 
B. Maxiumum senstivity of plaques and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 200% basal values. 
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Table 5.4: Parameters hugely affected the behaviour of plaques. LSA uses ODEs 
50% 200% 
Index Name Status Index Name Status 
15 kbinGSK3bp53  15 kbinGSK3bp53  
58 kprodAbeta2  34 kdisaggAbeta1  
61 krelGSK3bp53  50 kpghalf  
   58 kprodAbeta2  
   61 krelGSK3bp53  
 Table 5.5: Parameters hugely affected the behaviour of plaques. LSA uses MRM/GSSA 
50% 200% 
Index Name Status Index Name Status 
15 kbinGSK3bp53  14 kbinE2Ub  
25 kdegMdm2  32 kdephospTau  
26 kdegMdm2mRNA  34 kdisaggAbeta1  
36 kgenROSAbeta  47 kp53Ub  
45 kMdm2Ub  49 kpg  
50 kpghalf  50 kpghalf  
69 ksynp53  51 kphosMdm2  
73 ktangfor  53 kphosMdm2GSK3bp53  
   55 kphospTauGSK3b  
   63 krelMTTau  
   68 ksynMdm2mRNAGSK3bp53  
   70 ksynp53mRNA 
ksynp53mRNAAbeta 
 
   71 ksynp53 RNAAbeta  
 
Tables 5.4 and 5.5 show that plaques are more sensitive for increasing the rates 
of parameters using both approaches since more parameters affect the behaviour 
of plaques when parameters are perturbed to 200% of their basal values.       
Parameters are specific to p53_GSK3β and Aβ are the most effectiveness 
parameters on the behaviour of plaques when LSA uses ODEs while parameters 
that are specific different species in the system dramatically affect the behaviour 
of plaques when LSA uses MRM/GSSA as shown Table 5.5.    
The results of LSA for plaques using ODEs and MRM/GSSA are summarized in 







Figure 5.12: µ and σ of 𝑺𝑽𝒍𝒊𝒔𝒕 for plaques in response to parameters 
perturbation using ODEs when parameters are perturbed to 50% (A) and 200% 
(B) respectively of their basal values. The parameter indexes correspond to the 
indexes in Table 5.2. Parameters indicated in A and B are majorly affected the 
behaviour of plaques while others have only minor effect on the behaviour of 
plaques. KbinGSK3bp53, kprodAbeta2 and krelGSK3bp53 (15, 58 and 61 in Table 
5.2) are the most important parameter that affect the behaviour of plaques 




Table 5.6: Summary of LSA results using ODEs and MRM/GSSA for plaques. Groups A, B 
and C, respectively, contain parameters that have no effect, minor effects and major 
effects on the behaviour of these species. 
Parameters are perturbed 
to 50% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Are plaques very sensitive to 
perturbations? 
YES YES 
Number of parameters in each group 
affecting plaques 
Group A Group B Group C Group A Group B Group C 
45 25 3 2 63 8 
Are plaques production and aggregation 
contributing highly to the overall system?  
YES YES 
Minimum ranges  Group A Group B Group C Group A Group B Group C 
<= 50% > 50% <= 50% > 50% 
Parameters are perturbed 
to 200% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Are plaques very sensitive to 
perturbations? 
YES YES 
Number of parameters in each group 
affecting plaques 
Group A Group B Group C Group A Group B Group C 
45 23 5 2 57 14 
Are plaques production and aggregation 
contributing highly to the overall system? 
YES YES 
Maximum ranges   Group A Group B Group C Group A Group B Group C 
>=200%  < 200% >=200% < 200% 
 
LSA using ODEs and MRM/GSSA demonstrates that plaques are more sensitive to 
increase the rates of parameters as shown in Table 5.6. Three parameters 
dramatically change the behaviour of plaques when LSA uses ODEs and 
parameters are perturbed to 50% of their basal values while 8 parameters affect 
the plaques level when ODEs are used to perform LSA and parameters are 
perturbed to 200% of their basal values.  Five and 14 parameters dramatically 
changed the behaviour of plaques when LSA uses MRM/GSSA and parameters are 
perturbed to 50% and 200% of their basal values.  
5.3.3 LSA for Tangles 
We select tangles from the pathway of tau dynamics and aggregation as the main 
species since they highly contribute to AD. The level of tangles according to 
Proctor et al., (2013) is initially zero and increases slightly until it reaches around 
18 molecules at the end of the simulation. Proctor et al., (2013) predicts that 
immunisation results in small inhibitions to the level of tangles. In this section we 
show how parameter perturbations using ODEs and MRM/GSSA could change its 
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behaviour and determine the most important parameters that affect behaviour of 
tangles.  
1- Tangles are sensitive to 28 parameters when LSA uses ODEs and 71 
parameters affect the behaviour of tangles when LSA uses MRM/GSSA.  
2- The last day for observing immunization in AD (day #12) recodes the 
maximum sensitivity on the level of tangles in ODE and MRM/GSSA when 
the parameters are perturbed to 50% and 200% of their basal values, as 
shown in Figures 5.12(A and B) and 5.13 (A and B).  
Therefore, observing the behaviour of tangles in response to parameters 
perturbation should be done on the last day of the system using ODEs and 
MRM/GSSA.  
Parameters that dramatically change the behaviour of tangles using ODEs and 
MRM/GSSA are listed in Tables 5.7 and 5.8. Tables 5.7 shows that tangles are 
more sensitive to decrease the rate of parameters when ODEs are used to 
perform LSA while same number of parameters affects the behaviour of tangles 
when parameters are perturbed to 50% and 200% of their basal values using 
MRM/GSSA as shown in Table 5.8. Table 5.8 shows that tangles are sensitive to 
more parameters when LSA uses MRM/GSSA.  
Results of LSA using ODEs for tangles in response to parameter perturbation 
demonstrates that tangles are hugely affected by parameters that are specific to 
Mdm2. Parameters specific to different species dramatically change the 
behaviour of tangles when LSA uses MRM/GSSA.  










Figure 5.12: Maximum sensitivity and it’s time for plaques when parameters are 
altered to 50% (A) and 200% (B) of their basal values using ODEs. A and B show 
that tangles using ODEs to perform LSA recode their maximum sensitivity in 
response to parameters perturbation at Day #12. Therefore, ODEs demonstrates 
that tangles should be observed only at the last day of the in response to 
parameters perturbation.   
 
A. Maxiumum senstivity of tangles and its time in resposne to paramater pertubation using ODEs when parameters 
are pertubed to 50% basal values. 
B. Maxiumum senstivity of tangles and its time in resposne to paramater pertubation using ODEs when parameters 






Figure 5.13: Maximum sensitivity and it’s time for plaques when parameters are 
altered to 50% (A) and 200% (B) of their basal values using MRM/GSSA. A and B 
show that tangles using MRM/GSSA to perform LSA recode their maximum 
sensitivity in response to parameters perturbation at Day #12.  
 
 
A. Maxiumum senstivity of tangles and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 50% basal values. 
B. Maxiumum senstivity of tangles and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 200% basal values. 
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Table 5.7: Parameters are hugely affected by the behaviour of tangles. LSA uses ODEs 
50% 200% 
Index Name Status Index Name Status 
15 kbinGSK3bp53  15 kbinGSK3bp53  
16 kbinMdm2p53  26 kdegMdm2mRNA  
17 kbinMTTau  44 kMdm2PUb  
26 kdegMdm2mRNA  51 kphosMdm2  
28 kdegp53mRNA  69 ksynp53  
30 kdephosMdm2  70 ksynp53mRNA  
32 kdephospTau     
44 kMdm2PUb     
51 kphosMdm2     
61 krelGSK3bp53     
66 ksynMdm2     
Table 5.8: Parameters are hugely affected the behaviour of plaques. LSA uses MRM/GSSA 
50% 200% 
Index Name Status Index Name Status 
15 kbinGSK3bp53  15 kbinGSK3bp53  
21 kdamROS  26 kdegMdm2mRNA  
25 kdegMdm2  44 kMdm2PUb  
26 kdegMdm2mRNA  49 kpg  
32 kdephospTau  50 kpghalf  
36 kgenROSAbeta  51 kphosMdm2  
40 kinactglia1  56 kphospTauGSK3bp53  
44 kMdm2PUb  57 kprodAbeta  
49 kpg  58 kprodAbeta2  
50 kpghalf  61 krelGSK3bp53  
61 krelGSK3bp53  62 krelMdm2p53  
66 ksynMdm2  63 krelMTTau  
70 ksynp53mRNA  69 ksynp53  
73 ktangfor  73 ktangfor  
Therefore, tangles are classified as a very important species that contribute to the 
overall behaviour of the system and all parameters listed in Tables 5.7 and 5.8 are 







Table 5.9: Summary of LSA results for tangles using ODEs and MRM/GSSA. Groups A, B 
and C contain parameters, respectively, that have no effect, minor effects and major 
effects on the behaviour of the tangles. 
Parameters are perturbed 
to 50% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Are tangles very sensitive to 
perturbations? 
YES YES 
Number of parameters in each group 
affecting tangles 
Group A Group B Group C Group A Group B Group C 
44 17 11 2 57 14 
Are tangles production and aggregation 
contributing highly to the overall system?  
YES YES 
Minimum ranges  Group A Group B Group C Group A Group B Group C 
<= 50% > 50% <= 50% > 50% 
Parameters are perturbed 
to 200% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Are tangles very sensitive to 
perturbations? 
YES YES 
Number of parameters in each group 
affecting tangles 
Group A Group B Group C Group A Group B Group C 
44 22 6 2 57 14 
Are tangles production and aggregation 
contributing highly to the overall system? 
YES YES 
Maximum ranges   Group A Group B Group C Group A Group B Group C 
>=200%  < 200% >=200% < 200% 
5.3.4 LSA for GliaA 
According to Proctor et al., (2013), glia are activated by adding antibodies to the 
system. GliaA is selected to be the main species in the immunization pathway 
because it targets the plaques to be degraded.  
GliaA is sensitive to 28 parameters when LSA uses ODEs and 71 parameters to 
affect the behaviour of GliaA when LSA uses MRM/GSSA. GliaA as shown in 
Figures 5.14 (A and B) and 5.15 (A and B) records its maximum sensitivity from 
day # 4 until the end of the simulation using ODEs and MRM/GSSA when 












Figure 5.14: Maximum sensitivity and it’s time for GliaA when parameters are 
altered to 50% (A) and 200% (B) of their basal values using ODEs. A and B show 
that GliaA using ODEs to perform LSA recodes its maximum sensitivity in 
response to parameters perturbation from day #4 to the end of the simulation.  
 
A. Maxiumum senstivity of GliaA and its time in resposne to paramater pertubation using ODEs when parameters 
are pertubed to 50% basal values. 
B. Maxiumum senstivity of GliaA and its time in resposne to paramater pertubation using ODEs when parameters 






Figure 5.15: Maximum sensitivity and it’s time for GliaA when parameters are 
altered to 50% (A) and 200% (B) of their basal values using MRM/GSSA. A and B 
show that GliaA using MRM/GSSA to perform LSA recodes its maximum 
sensitivity in response to parameters perturbation from day #4 to the end of the 
simulation. 
 
A. Maxiumum senstivity of GliaA and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 50% basal values. 
B. Maxiumum senstivity of GliaA and its time in resposne to paramater pertubation using MRM/GSSA when 
parameters are pertubed to 200% basal values. 
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When parameters are perturbed to 50% of their basal values, LSA using ODEs 
shows that that only two parameters significantly change the behaviour of GliaA. 
These parameters are kbinGSK3bp53 and kprodAbeta2 (15 and 58 in Table 5.2). 
These two parameters kept the level of GliaA at nearly zero for the whole time of 
the system. Whereas, GliaA is dramatically decreased in response to 6 parameters 
listed in Table 5.10 when LSA uses MRM/GSSA.    
When parameters are perturbed to 200% of their basal values, LSA using ODEs 
shows that 6 parameters shown in Table 5.11 significantly change the behaviour 
of GliaA. These parameters also kept the level of GliaA is nearly zero for the whole 
time of the system. Whereas, 13 parameters are kept the level GliaA is zero listed 
in Table 5.12 when LSA uses MRM/GSSA.    
Table 5.10: Parameters decreased the level of GliaA to around zero when LSA uses 
MRM/GSSA and parameters are perturbed to 50% of their basal value.   








Table 5.11: Parameters dramatically decrease the level of GliaA when LSA uses 
ODEs and parameters are perturbed to 200% of their basal value  
 
  Parameter 
index 
Parameter name   Parameter 
index 
Parameter name 
16 kbinMdm2p53 34 kdisaggAbeta1 
28 kdegp53mRNA 50 kpghalf 













Table 5.12: Parameters dramatically decrease the level of GliaA when LSA uses 















It has been found that GliaA is more sensitive for increasing the rate of 
parameters since more parameters affects its behaviour when parameters are 
perturbed to 200% of their basal values. Parameters specific to p53 and Mdm2 
are more affected than others on the behaviour of GliaA when LSA uses ODEs and 
MRM/GSSA.  
Table 5.13: Summary of LSA results for tangles using ODEs and MRM/GSSA. Groups A, B 
and C contain parameters, respectively, that have no effect, minor effects and major 
effects on the behaviour of GliaA.  
Parameters are perturbed 
to 50% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Is GliaA very sensitive to perturbations? YES YES 
Number of parameters in each group 
affecting tangles 
Group A Group B Group C Group A Group B Group C 
44 26 2 2 65 6 
Is GliaA production and aggregation 
contributing highly to the overall system?  
YES YES 
Minimum ranges  Group A Group B Group C Group A Group B Group C 
<= 50% > 50% <= 50% > 50% 
Parameters are perturbed 
to 200% of their basal 
values.   
LSA Using ODEs LSA Using MRM/GSSA 
Is GliaA very sensitive to perturbations? YES YES 
Number of parameters in each group 
affecting tangles 
Group A Group B Group C Group A Group B Group C 
44 22 6 2 58 13 
Is GliaA production and aggregation 
contributing highly to the overall system? 
YES YES 
Maximum ranges   Group A Group B Group C Group A Group B Group C 
>=200%  < 200% >=200% < 200% 
  
 















Therefore, LSA using ODEs and MRM/GSSA demonstrates that GliaA is one of the 
most important species that contributes to the overall behaviour of the system 
when parameters are perturbed to 50% and 200% of their basal values. 
KbinGSK3bp53 and kprodAbeta2 and parameters listed in Tables 5.10, 5.11 and 
5.12 are identified to be the most important parameters that contribute most to 
the variation. 
5.4 Summary 
LSA using ODEs and MRM/GSSA classifies that: 
1-  The behaviour of p53, ATMA and p53_GSK3β are not dramatically changed 
in response to parameter perturbations whether parameters are perturbed 
to 50% or 200% of their basal values. As a result of this classification, we 
identify that p53 regulation, the DNA damage pathway and GSK3β activity 
have no effect on the overall behaviour of the system.  
2- The differences between ODEs and MRM/GSSA are the number of 
parameters that affect the behaviour of these species and time for the 
maximum sensitivity of these species.  
3- LSA using ODEs shows that p53 is more sensitive to parameters that are 
specific to Mdm2 while when LSA uses MRM/GSS, parameters specific to Aβ 
are more effectiveness on the behaviour of p53. ATMA and p53_GSK3β are 
more sensitive to KinactATM (1 in Table 5.1) when LSA uses ODEs and 
parameters are perturbed to 50% and 200%.  
4- LSA using MRM/GSSA demonstrates that ATMA and p53_GSK3β are more 
sensitive parameters specific to p53 and Mdm2 such as ksynp53, kbinE2Ub, 
ksynMdm2 (69, 14 and 66 in Table 5.1) when parameters are perturbed to 
50% of their basal values. Parameter specific to Aβ such as kpg and 
KprodAbeta2 and Kpghalf (49, 50 and 58 in Table 5.1) have more effects than 
others on the behaviour of ATMA and p53_GSK3β when parameters are 
perturbed to 200%.   
5- Aβ is also not dramatically changed in response to parameters perturbation 
and it doesn’t contribute to the overall behaviour of the system. However, 
Aβ production and aggregation is classified as an important pathway since 
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plaques are dramatically changed in response to parameters perturbation 
using ODEs and MRM/GSSA. It was really interesting to find that 
KrelGSK3bp53 and KprodAbeta2 is the most effectiveness parameter on the 
behaviour of Aβ using respectively ODEs and MRM/GSSA when parameters 
are perturbed to 50% and 200% of their basal values, respectively.  
6- LSA using ODEs and MRM/GSSA classifies that the behaviour of plaques, 
tangles and GliaA are not dramatically changed in response to parameter 
perturbations weather parameters are perturbed to 50% or 200% of their 
basal values. As a result of this classification, we identify that Aβ production 
and aggregation, tau dynamics and aggregation, and the immunisation 
pathway hugely affect the overall behaviour of the system. The only 
difference between ODEs and MRM/GSSA is that the number of parameters 
that affect the behaviour of plaques, tangles and GliaA.  
7- Parameters are specific to p53_GSK3β and Aβ are the most effectiveness 
parameters on the behaviour of plaques when LSA uses ODEs while 
parameters that are specific different species in the system dramatically 
affect the behaviour of plaques when LSA uses MRM/GSSA. LSA using ODEs 
for tangles in response to parameter perturbation demonstrates that tangles 
are hugely affected by parameters that are specific to Mdm2 when 
parameters are perturbed to 50% of their basal value. In general, tangles are 
hugely affected by parameters that are specific to Mdm2, p53, Aβ tau and 
p53_GSK3β.  GliaA is affected by parameters specific to different species in 
the system.  
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Chapter 6 
Latin Hypercube Sampling and Partial Rank Correlation Coefficient 
(LHS/PRCC) Analysis Applied to Immunization in an AD Model 
6.1 Overview  
Chapter 5 discussed the results of LSA using ODEs and MRM/GSSA. However, LSA 
only considers changes to one parameter at a time while all the other parameters 
remain fixed at their base values. LSA methods do not accurately assess 
uncertainty and sensitivity in biochemical systems. GSA techniques, therefore, are 
needed to demonstrate how a multi-dimensional parameter space can be studied 
to accurately assess uncertainty and sensitivity in biochemical systems.  
The combination of LHS and PRCC makes a powerful tool that employs a 
minimum number of computer simulations for uncertainty analysis to explore the 
entire parameter space of a model. The main goal of this tool is to identify key 
parameters whose uncertainties contribute to prediction imprecision and rank 
these parameters by their importance in contributing to the imprecision. 
Specifically, LHS/PRCC provides a measure of monotonicity between the LHS 
parameters and the outcomes measured after the removal of the linear effect of 
the LHS parameters (inputs), 𝑥𝑖, and the output measure (outputs), 𝑦.  
Therefore, this tool is used to deterministically and stochastically using ODEs and 
MRM/GSSA to: (1) explore the entire parameter space of immunization in the AD 
model and measure the monotonicity between model’s parameters and the 
outcome; and (2) rank all parameters in this model.  
Here, we assess the effect of uncertainty and sensitivity on the behaviour of the 
main players used in Chapter 5 (p53, ATMA, p53_GSK3β, plaques, tangles and 
GliaA) using LHS/PRCC at three different time points (days #4, #8 and # 12). These 
time points are chosen because we want to assess how the system behaves in 
response to perturbations on the day of immunization and after immunization.  
The LHS matrix and simulation results for the selected species in response to a 
combination of the LHS parameters are generated for both approaches (ODEs and 
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MRM/GSSA) using visual studio (C# platform). Ranking the LHS matrix and the 
results of the selected species are achieved by developing a C# program.  Data 
produced after the ranking process was statistically analysed using the IBM SPSS 
statistics tool.    
6.2 Performing the LHS 
For immunization in the AD model, 73 LHS parameters, as shown in Table 5.1, are 
identified. Probability distributions are assigned to the parameters, the intervals 
in the distribution are divided into 100 equiprobable regions, and these intervals 
are then sampled without replacement. Thus, the parameter space for the LHS 
parameters has a dimension of length 73 with each dimension specifying an 
uncertain parameter vector of length 100. Fifty per cent and 200% are 
determined to be minimum and maximum values for each of the 73 parameters.  
A sample LHS matrix/table for parameter immunization in the AD model is 
illustrated in Figure 6.1. Note that for this matrix, each column has an entry 
(𝑃𝑖 , 𝑆𝑗) and the 𝑗th sampled random value of the 𝑖th parameter, where 1 ≤ 𝑗 ≤
𝑘, 1 ≤ 𝑖 ≤ 𝑁. Each row in the table contains 𝑘 samples corresponding to a 
specific LHS parameter. 
  𝑆1 𝑆2 𝑆3 𝑆4 𝑆5 𝑆6 𝑆7 ...... 
kactATM 𝑃1 
0.000101 5.23E-08 1.30E-07 0.000156 6.26E-07 7.75E-07 5.17E-06 
...... 
kactDUBMdm2 𝑃2 
0.000192 6.44E-08 8.63E-08 8.59E-05 3.46E-07 7.02E-07 4.44E-06 
...... 
kactDUBp53 𝑃3 
0.000138 7.95E-08 1.50E-07 5.91E-05 6.83E-07 9.84E-07 4.95E-06 
...... 
kactDUBProtp53 𝑃4 
0.000179 1.91E-07 1.09E-07 8.48E-05 4.71E-07 3.73E-07 3.41E-06 
...... 
kactglia1 𝑃5 
7.47E-05 1.48E-07 1.23E-07 7.93E-05 7.75E-07 5.15E-07 3.11E-06 
...... 
Kactglia2 𝑃6 
6.46E-05 6.74E-08 1.04E-07 0.000104 9.24E-07 7.99E-07 4.67E-06 
...... 
kaggAbeta 𝑃7 
0.000169 1.93E-07 1.72E-07 0.000146 4.10E-07 7.10E-07 1.94E-06 
...... 
kaggTau 𝑃8 
0.000142 8.31E-08 1.00E-07 0.000144 1.18E-06 6.58E-07 2.96E-06 
...... 
. . . . . . . . . ...... 
. . . . . . . . . ...... 
 
Figure 6.1: Sample LHS matrix/table 
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6.3 Interpreting the Monotonicity Plots 
As discussed in Chapters 2 and 3, PRCC measures the strength of the relationship 
between two variables while the effect of the other variables is controlled. This is 
achieved by indicating the degree of monotonicity between a specific input 
variable and outputs. Only output measures having a monotonic relationship with 
the input variables should be chosen for this LHS/RPCC.  
Consequently, we verify that there is a monotonic relationship between the 
values of the selected species and the LHS parameters at the level of ODEs and 
MRM/GSSA. To investigate the level of monotonicity for the LHS test parameter, 
kactATM (𝑃1) in Figure 1 and p53; as an example, we pick its row from the LHS 
matrix and run simulations using its values from that row and the baseline values 
for all other parameters. This results in 𝑀 simulations for this monotonicity test. 
Figure 6.2 (A and B) shows that monotonicity exists between kactATM and p53 




Figure 6.2: Sample monotonicity plot of kactATM for p53 using ODEs (A) and MRM/GSSA 




Monotonicity plots of each parameter in the LHS for each of the selected species 
are shown in the next sections. Note, PRCC values and p-values for all parameters 
for each species are shown in Appendix D. Here we just show the PRCC values for 
parameters that have the strongest correlation with the selected species.     
6.4 Handling the PRCC steps 
Once the LHS parameter ranges are adjusted and the final version of the LHS 
matrix is generated, PRCC analysis is able to be used. All the 𝑘 values in each 
column in the LHS matrix are used as input values for the numerical simulation of 
the model. The non-parametric partial rank correlation coefficients are then used 
to determine the most sensitive parameters. How parameter values are selected 
per run is demonstrated in Figure 6.3. 
 
 
  𝑺𝟏 𝑺𝟐 𝑺𝟑 ......  
kactATM 𝑷𝟏 0.000101 5.23E-08 1.30E-07 ...... 𝑷𝟏,𝒌 
kactDUBMdm2 𝑷𝟐 0.000192 6.44E-08 8.63E-08 ...... 𝑷𝟐,𝒌 
kactDUBp53 𝑷𝟑 0.000138 7.95E-08 1.50E-07 ...... 𝑷𝟑,𝒌 
kactDUBProtp53 𝑷𝟒 0.000179 1.91E-07 1.09E-07 ...... 𝑷𝟒,𝒌 
. . . . . ...... . 
. . . . . ...... . 






Figure 6.3: How parameter values are selected per run 
𝒇(𝟎. 𝟎𝟎𝟎𝟏𝟎𝟏, 𝟓. 𝟐𝟑𝐄 − 𝟎𝟖, 𝟏. 𝟑𝟎𝐄 − 𝟎𝟕,… . 𝑷𝟏,𝒌) 
𝒇(𝟎. 𝟎𝟎𝟎𝟏𝟗𝟐, 𝟔. 𝟒𝟒𝐄 − 𝟎𝟖, 𝟖. 𝟔𝟑𝐄 − 𝟎𝟖,… . 𝑷𝟐,𝒌) 
𝒇(𝟎. 𝟎𝟎𝟎𝟏𝟑𝟖, 𝟕. 𝟗𝟓𝐄 − 𝟎𝟖, 𝟏. 𝟏. 𝟓𝟎𝐄 − 𝟎𝟕,… . . 𝑷𝟑,𝒌) 
𝒇(𝟎. 𝟎𝟎𝟎𝟏𝟕𝟗, 𝟏. 𝟗𝟏𝐄 − 𝟎𝟕, 𝟏. 𝟎𝟗𝐄 − 𝟎𝟕,… . . 𝑷𝟒,𝒌) 
. 
. 
𝒇(𝑷𝑵,𝟏, 𝟏.𝑷𝑵,𝟐,𝑷𝑵,𝟑, … . .𝑷𝑵,𝒌) 
The 𝑁 ∗ 𝐾 LHS 
matrix for 𝑁 




The 𝐾 ∗ 1 LHS 
matrix produced 
after 𝐾  simulations.   
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PRCC is used to answer the question about which parameters contribute most 
uncertainty to model predications. A parametric procedure is applied to the rank 
the data instead of the data themselves.  The ranking is undertaken simply by 
arranging the values of our data in order and then assigning the largest values to 
be 1 and the next largest value to be 2, etc. The transformation usually results in 
uniform residuals for the transformed variables. 
Hence, to perform PRCC, we first rank the LHS matrix and then the matrix for the 
outcome measure using a sort routine. For each parameter and each outcome 
measure, two linear regression models are found, the first representing the 
ranked parameter in terms of the other ranked parameter values, and the second, 
representing the ranked outcome measures in terms of the other ranked 
parameter values. A Pearson correlation coefficient (PCC) for the residuals from 
those two regression models gives the PRCC value for that specific parameter (see 
Equations (1) and (2) in (Marino et al., 2008)). The PRCC steps using 
kbinGSK3bp53 as a parameter of interest, and p53 at day #8 as an example, are 
illustrated in Figure 6.3.  
A Pearson correlation coefficient for the residuals from those two regression 
models gives the PRCC value for that specific parameter. To assess the level of 
uncertainty the LHS parameter contributes to the model, a partial rank correlation 
analysis equips us with PRCC and the corresponding p-values. Parameters with a 
large PRCC (<-0.5 or >0.5) with correspondingly small p-values are the most 
important parameters that contribute uncertainty to the model.  
The next seven sections show the level of uncertainty from the LHS parameters 
on the behaviour of the selected species (p53, ATMA, GSK3β, Aβ, plaques, tangles 






1) Before ranking 
  𝑺𝟏 𝑺𝟐 𝑺𝟑 ...... 𝑺𝒌 
kactATM 𝑷𝟏 0.000101 5.23E-08 1.30E-07 ...... 𝑷𝟏,𝒌 
kactDUBMdm2 𝑷𝟐 0.000192 6.44E-08 8.63E-08 ...... 𝑷𝟐,𝒌 
kactDUBp53 𝑷𝟑 0.000138 7.95E-08 1.50E-07 ...... 𝑷𝟑,𝒌 
kbinGSK3bp53 𝑷𝟒 0.000162 1.29E-07 1.62E-07 ...... 𝑷𝟏𝟓,𝒌 
. . . . . ...... . 
. . . . . ...... . 
. . 𝑷𝑵,𝟏 𝑷𝑵,𝟐 𝑷𝑵,𝟑 ...... 𝑷𝑵,𝒌 
 
       
𝑨𝒓𝒂𝒏𝒌𝒆𝒅 = 35 71 70 . . 
37 71 70 . . 
34 68 70 . . 
37 67 71 . . 
. . . . . 
. . . . . 










Figure 6.4: An Illustration of the PRCC steps. KbinGSK3bp53 is the parameter of interest 
and p53 at day #8 is an example. LHS and the outcome matrix are ranked, then multiple 
linear regressions on each of the ranked columns in each matrix are performed. Residuals 




























LHS matrix p53 at day #8 
Multiple Liner Regression of each column of  
𝑨𝒓𝒂𝒏𝒌𝒆𝒅 
Multiple Liner Regression of 
each column of  
𝑩𝒓𝒂𝒏𝒌𝒆𝒅 
Obtain Residuals, 𝑅𝑨𝒓𝒂𝒏𝒌𝒆𝒅, from regression  
𝑨𝒓𝒂𝒏𝒌𝒆𝒅 
Obtain Residuals, 𝑅𝑩𝒓𝒂𝒏𝒌𝒆𝒅, 




6.5 Results of LHS/PRCC for p53 
The plots in Figure 6.5 show the behaviour of p53 over 12 days corresponding to 
the parameter combinations of the LHS scheme using ODEs (A) and MRM/GSSA 
(B). Vertical lines (red lines in the plots) indicate the time points where we 
calculate the level of uncertainty from the LHS parameters (days #4, #8 and #12).     
 
Figure 6.5: Behaviour of p53 over 12 days corresponding to the parameter combinations 
of the LHS scheme using ODEs (A) and MRM/GSSA (B). Days 4, 8 and 12, indicated by the 
vertical lines (red lines), are used as time points to compute the level of uncertainty from 
the LHS parameters on the behaviour of p53. The behaviour of p53 is not dramatically 
changed in response to the combination of LHS parameters using ODEs and MRM/GSSA.   
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To measure the strength of the relationship between p53 and each parameter in 
the LHS matrix, we first verify that a monotonic relationship exists between p53 
and the LHS parameters. Figures 6.6 and 6.7 verify that a monotonic relationship 
exists between p53 and the LHS parameters using ODEs and MRM/GSSA, 
respectively.   
 
Figure 6.6: Monotonicity plots of all parameters in the LHS matrix for p53 using 
ODEs at times t = 4, 8 and 12 (days). Numbers shown in the plots correspond to 





Figure 6.7: Monotonicity plots of all parameters in the LHS matrix for p53 using 
MRM/GSSA at times t = 4, 8 and 12 (days). Numbers shown above the figures 






PRCC analysis using ODEs and MRM/GSSA shows that none of the parameters in 
the LHS matrix has a strong correlation with p53 at all time points. Tables 6.1 and 
6.2 list the sub-sets of parameters from ODEs and MRM/GSSA that have the 
largest correlation with p53. The output from PRCC analysis for all parameters is 
listed in Table 1 in Appendix D.   
Table 6.1: Output from PRCC analysis for p53 using ODEs 
 
Index Parameter name At day # 4 
PRCC 
21 kdamROS 0.204 
39 kinactATM 0.210 
Index Parameter name At day # 8 
PRCC 
15 kbinGSK3bp53 -0.305 
35 kdisaggAbeta2 0.277 
Index Parameter name At day # 12 
PRCC 
   16 kbinMdm2p53 -0.387 
14 kbinE2Ub 0.226 
 
Table 6.2: Output from PRCC analysis for p53 using MRM/GSSA 
 
Index Parameter name At day # 4 
PRCC 
16 kbinMdm2p53 -0.411 
64 kremROS 0.230 
Index Parameter name At day # 8 
PRCC 
11 kbinAbantiAb 0.407 
71 ksynp53mRNAAbeta 0.219 
Index Parameter name At day # 12 
PRCC 
 36 kgenROSAbeta -0.247 
16 kbinMdm2p53 -0.371 
 
Figure 6.8 (A and B) shows the PRCC output for three test parameters from each 
method. In A, we show the PRCC output for kinactATM, kbinGSK3bp53 and 
kbinMdm2p53 when PRCC uses ODEs. In B, we show the PRCC output when it 
uses MRM/GSSA for kbinMdm2p53, kbinAbantiAb and kbinMdm2p53. Note that 
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in the plots, the 𝑦-axis corresponds to the regression coefficients for p53 while 






Figure 6.8: PRCC plots for p53 using ODEs (A) and MRM/GSSA (B).  A and B show 
the plots of the parameters that have the largest correlation with p53 using 
ODEs and MRM/GSSA. The values of PRCC and their time points are shown in 
brackets above the plots. PRCC analysis using ODEs demonstrates that 
kbinMdm2p53 (16 in Table 5.2) is the most important parameter that affects the 
behaviour of p53. In addition to kbinMdm2p53, PRCC illustrates that 
kbinAbantiAb (11 in Table 5.2) is also important for p53 at day #8 using 




(0.204, day #4) (-0.305, day #8) 
(-0.371, day #12) 
(-0.411, day #4) (0.407, day# 8) 
(-0.307, day # 12) 
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6.6 Results of LHS/PRCC for ATMA 
ATMA is the second species that we are interested in checking its behaviour over 
the parameter space of the mode. Figure 6.9 A and B shows the behaviour of 
ATMA using the 100 values in the LHS matrix from ODEs and MRM/GSSA 
respectively, over 12 days.  
 
Figure 6.9: Behaviour of ATMA over 12 days corresponding to the parameter combinations 
of the LHS scheme using ODEs (A) and MRM/GSSA (B). Days 4, 8 and 12 are indicated by 
the vertical lines (red lines) used as time points to compute the level of uncertainty from 
the LHS parameters on the behaviour of ATMA. The behaviour of ATMA does not change 
very much in response to the combination of the LHS parameters using ODEs and 
MRM/GSSA.   
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In Figure 6.10 we verify that there is a monotonic relationship between ATMA and 
all parameters in the LHS matrix when PRCC uses ODEs, while Figure 6.11 verifies 
that a monotonic relationship exists between ATMA and all parameters when 
RPCC uses MRM/GSSA.  
 
Figure 6.10: Monotonicity plots of all parameters in the LHS matrix for ATMA 
using ODEs at times t = 4, 8 and 12 (days). Numbers shown in the figures 




Figure 6.11: Monotonicity plots of all parameters in the LHS matrix for ATMA 
using MRM/GSSA at times t = 4, 8 and 12 (days). Numbers shown above the 
figures correspond to the parameter indexes in Table 6.1.  
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The results of PRCC analysis using ODEs shows that only kbinMdm2p53 (16 in 
Table 5.2) has a strong correlation with ATMA at all the time points selected, 
while ksynp53mRNAAbeta (71 in Table 5.2) shows a strong correlation with ATMA 
at day #12 when PRCC uses MRM/GSSA. Tables 6.1 and 6.2 show the two most 
effective parameters at each time point on the behaviour of ATMA using ODEs 
and MRM/GSSA, respectively.     
Table 6.3: Output from PRCC analysis for ATM using ODEs 
 
Index Parameter name At day # 4 
PRCC 
16 kbinMdm2p53 -0.501 
13 kbinE1Ub 0.228 
Index Parameter name At day # 8 
PRCC 
16 kbinMdm2p53 -0.508 
13 kbinE1Ub 0.218 
Index Parameter name At day # 12 
PRCC 
 16 kbinMdm2p53 -0.560 
13 kbinE1Ub 0.223 
 
Table 6.4: Output from PRCC analysis for ATM using MRM/GSSA 
Index Parameter name At day # 4 
PRCC 
5 Kactglia1 -0.231 
29 KdegTau20Port 0.221 
Index Parameter name At day # 8 
PRCC 
45 KMdm2Ub -0.293 
72 ksynTau 0.219 
Index Parameter name At day # 12 
PRCC 
 36 Kdegp53mRNA 0.402 
71 Ksynp53mRNAAbeta 0.502 
 
Using ODEs, kbinMdm2p53 is the strongest parameter that affects the behaviour 
of ATMA over the whole period of the system, while Ksynp53mRNAAbeta is the 
only parameter that strongly affects the behaviour of ATMA when PRCC uses 
MRM/GSSA.  
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Figure 6.12 (A and B) shows the PRCC outputs from ODEs and MRM/GSSA. In A, 
we show the PRCC output only for kbinMdm2p53 at days #4 and #12 because this 
is the only parameter that has a strong correlation with ATMA. In B, we show the 
PRCC output for Kactglia1 at day #4, KMdm2Ub at day #8, and 









Figure 6.12: PRCC plots for ATMA using ODEs (A) and MRM/GSSA (B).  (A) Shows 
plots of kbinMdm2p53 at days #4, #8 and #12 since it has the strongest 
correlation with ATAM. (B) Shows the plots of kactglia, kMdm2Ub and 
Ksynp53mRNAAbeta (5, 45 and 71 in Table 5.1). RPCC using MRM/GSSA shows 
that ATMA is only affected by Ksynp53mRNAAbeta while kactglia and 
kMdm2Ub have minor effects the behaviour of ATMA.  The values of PRCC and 
time point are shown in brackets above the plots. 
(-0.501, day #4) (--0.508, day #8) 
(-0.560, day #12) 
(-0.231, day #4) (-0.293, day #8) 




6.7 Results of LHS/PRCC for p53_GSK3β 
p53_GSK3β is the main player in GSK3β activity and is considered to be one of the 
most important species in the system since it activates not only the activity of Aβ 
production and aggregation but also tau dynamics and aggregation, as shown in 
Figure 3.2. Therefore, it has been chosen to be analysed using LHS/PRCC. Figure 
6.13 (A and B) shows the behaviour of p53_GSK3β using the 100 values in the LHS 
matrix from ODEs and MRM/GSSA, respectively, over 12 days.  
 
Figure 6.13: Behaviour of p53_GSK3β over 12 days corresponding to the parameter 
combinations of the LHS scheme using ODEs (A) and MRM/GSSA (B). Days 4, 8 and 12, 
indicated by the vertical lines (red lines), are used as time points to compute the level of 
uncertainty from the LHS parameters on the behaviour of p53_GSK3β. ODEs illustrate that 
the level of p53_GSK3β decreases when the rates of the parameters in the LHS matrix  
decrease while its level increases in response to the increasing rates of these parameters. 
MRM/GSSA shows a different time point for p53_GSK3β to start increasing in response to 
the parameter combinations in the LHS matrix.  
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The monotonic relationship between p53_GSK3β and the parameters in the LHS 
matrix is verified using ODEs and MRM/GSSA.  Figures 6.14 and 6.15 show the 
monotonicity plots of all LHS parameters and p53_GSK3β at days #4, #8 and #12.  
 
Figure 6.14: Monotonicity plots of all parameters in the LHS matrix for 
p53_GSK3β using ODEs at times t = 4, 8 and 12 (days). The plots show that there 
is a monotonic relationship between the LHS parameters and p53_GSK3β. 





Figure 6.15: Monotonicity plots of all parameters in the LHS matrix for 
p53_GSK3β using MRM/GSSA at times t = 4, 8 and 12 (days). Numbers shown 
above the figures correspond to the parameter indexes in Table 5.2. The plots 
show that there is a monotonic relationship between the LHS parameters and 
p53_GSK3β. 
 127 
PRCC analysis using ODEs shows that there are three parameters that have a 
strong correlation with p53_GSK3β and all these parameters have this strong 
correlation at day #4. These parameters are kbindMdam2p53, KbinGSk3p53 and 
KbinE2Ub (16, 15 and 14 in Table 5.2). The PRCC values and p-values for these 
parameters are shown in Table 6.5.  
Table 6.5: Sub-set of parameters for which PRCC>0.5 and p<0.05 against p53_GSk3β at 
day #4 when PRCC uses ODEs  
 
Index Parameter name PRCC p-value 
16 kbinMdm2p53 -0.592 0.00112 
15 kbinGSK3bp53 0.671 4.2E-05 
14 kbinE2Ub 0.620 0.0016705 
 
Figure 6.16 shows the PRCC plots for p53_GSK3β using ODEs. KbinMdm2p53, 
KbinGSk3bp53 and KbinE2Ub have an important influence on the behaviour of 
p53_GSK3β.  
PRCC analysis using MRM/GSSA demonstrates that only two parameters have an 
important influence on the behaviour of p53_GSK3β at day #4. These parameters 
are KbinMdm2p53 and KsynMdm2 (16 and 66 in Table 5.2). PRCC using ODEs and 
MRM/GSSA illustrates that KbinMdm2p53 is the most important parameter that 
influences the behaviour of p53_GSK3β. The PRCC values and p-values for 
kbinMdm2p53 and KsynMdm2 are listed in Table 6.6. Figure 6.17 shows PRCC 
plots for p53_GSK3β using MRM/GSSA.  
Table 6.6: Sub-set of parameters for which PRCC>0.5 and p<0.05 against p53_GSk3β at 
day #4 when PRCC uses MRM/GSSA  
 
Index Parameter name PRCC p-value 
16 kbinMdm2p53 -0.588 0.001032 
66 KsynMdm2 0.504 0.00424 
 
 128 





Figure 6.16: PRCC Plots for p53_GSK3β using ODEs. KbinMdm2p53, KbinGSk3bp53 and 
KbinE2Ub have an important influence on the behaviour of p53_GSK3β. PRCC values and 
p-values are shown in brackets above the plots. The 𝒚-axis corresponds to the regression 










Figure 6.17: PRCC plots for p53_GSK3β using MRM/GSSA for ksynMdm2 and 
KbinMdm2p53. The 𝒚-axis corresponds to the regression coefficients for p53_GSK3β while 
the 𝒙-axis represents regression coefficients parameters. PRCC values and p-values are 
shown in brackets above the plots. The 𝒚-axis corresponds to the regression coefficients 





6.8 Results of LHS/PRCC for Aβ 
Aβ is selected to investigate the space of the parameters in the model because of 
its importance as it is one of the most important species that contributes to AD, 
as described in Chapter 2. Figure 6.18 (A and B) shows the behaviour of Aβ in 
response to parameter combinations in the LHS matrix using ODEs and 
MRM/GSSA.  
 
Figure 6.18: Behaviour of Aβ over 12 days corresponding to the parameter combinations 
of the LHS scheme using ODEs (A) and MRM/GSSA (B). Days 4, 8 and 12, indicated by the 
vertical lines (red lines), are used as time points to compute the level of uncertainty from 
the LHS parameters on the behaviour of Aβ.  More variance is shown in the behaviour of 
Aβ when MRM/GSSA is used, as shown in B while ODEs in A shows that Aβ has the same 
pattern in response to parameters in the LHS matrix    
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Before using PRCC analysis we verify that a monotonic relationship exists 
between Aβ and all parameters in the matrix using ODEs and MRM/GSSA at all-
time points (days #4, #8 and #12). Figures 6.19 and 6.20 show that a monotonic 
relationship exists between Aβ and all LHS parameters when ODEs and 
MRM/GSSA are used, respectively. 
 
Figure 6.19: Monotonicity plots of all parameters in the LHS matrix for Aβ using 
ODEs at times t = 4, 8 and 12 (days). Plots show that there is a monotonic 
relationship between the LHS parameters and Aβ. Numbers shown in the figures 




Figure 6.20: Monotonicity plots of all parameters in the LHS matrix for Aβ using 
MRM/GSSA at times t = 4, 8 and 12 (days). Plots show that there is a monotonic 
relationship between the LHS parameters and Aβ. Numbers shown in the figures 




PRCC analysis using ODEs and MRM/GSSA shows that KbinMdm2p53 and 
ksynMdm2 (16 and 66 in Table 5.2) at day #8 are the most important parameters 
that influence the behaviour of Aβ. Both these parameters have strong 
correlations with Aβ. Table 6.7 lists the PRCC values and p-values for these 
parameters using both approaches. Figure 6.21 (A and B) displays the PRCC plots 
for KbinMdm2p53 and ksynMdm2 using ODEs in A and MRM/GSSA in B.  
Table 6.7: Sub-set of parameters for which PRCC>0.5 and p<0.05 against Aβ at day#8 
when PRCC uses ODEs and MRM/GSSA  
Index Parameter ODEs MRM/GSSA 
PRCC p-value PRCC p-value 
16 KbinMdm2p53 -0.7446 2.48E-05 -0.7006 2.48E-05 




Figure 6.21: PRCC plots for Aβ using ODEs and MRM/GSSA for KbinMdm2p53 and 
ksynMdm2. The 𝒚-axis corresponds to the regression coefficients for Aβ while the 𝒙-axis 
represents the regression coefficients of the parameters. PRCC values and p-values are 
labelled above the plots and listed in Table 6.7. KbinMdm2p53 and ksynMdm2 are the 




(-0.7446, 2.48E-05) 0.7211, 3.66E-06) 
(--0.7006, 2.48E-05) 00.7911, 8.31E-05) 
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6.9 Results of LHS/PRCC for plaques 
The plots in Figure 6.22 show the behaviour of plaques over 12 days 
corresponding to the parameter combinations of the LHS scheme using ODEs (A) 
and MRM/GSSA (B). The vertical lines in A and B indicate the time points we used 
to calculate the level of uncertainty from the LHS parameters (days #4, #8 and 
#12). One hundred runs are plotted using ODEs and MRM/GSSA.   
 
Figure 6.22: Behaviour of plaques over 12 days. A and B show the behaviour of plaques 
corresponding to the parameter combinations in the LHS scheme using ODEs and 
MRM/GSSA. Days 4, 8 and 12, indicated by the vertical lines (red lines), are used as time 
points to compute the level of uncertainty from the LHS parameters on the behaviour of 
plaques. It can be clearly seen that plaques are more sensitive to the parameter 
combinations of the LHS scheme in the first four days (from time zero to four 
(immunization day). 
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We show in Figures 6.23 and 6.24 that there is a monotonic relationship between 
the plaques and the parameters in the LHS matrix using ODEs and MRM/GSSA. 
We then, investigate the parameters in the LHS matrix to classify the most 
important parameters that have strongest correlation with plaques. 
 
Figure 6.23: Monotonicity plots of all parameters in the LHS matrix for plaques 
using ODEs at times t = 4, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and plaques. Only one line 
is clearly seen in all plots (day #4) because plaques are only sensitive before 
immunization. The immunization is totally clear of plaques from the system 
even when the parameters are perturbed. Numbers shown in the figures 
correspond to the parameter indexes in Table 5.2. 
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Figure 6.24: Monotonicity plots of all parameters in the LHS matrix for plaques 
using MRM/GSSA at times t = 4, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and the plaques. As shown 
in Figure 6.22, the plaques show variance after immunization (day #4). The level 
of plaques reaches around 30 molecules in response to parameter 
perturbations. Numbers shown in the figures correspond to the parameter 
indexes in Table 5.2. 
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PRCC analysis using ODEs shows that kbinMdm2p53 and ksynMdm2 (16 and 66 in 
Table 5.2) are the most important parameters that have strong correlations with 
plaques at day #4. Table 6.8 lists the PRCC values and p-values for these 
parameters. Figure 6.25 displays the PRCC plots of these parameters with 
plaques. PRCC analysis using MRM/GSSA demonstrates that kdegTau20Sport and 
kbinMdm2p53 (29 and 16 in Table 5.2) are the most important parameters that 
have the most influence on the behaviour of the plaques. Table 6.9 lists the PRCC 
and p-values for kdegTau20Sport and kbinMdm2p53. Figure 6.25 displays the 
PRCC plots for these parameters. Note, in Figures 6.25 and 6.26, the 𝑦-axis 
corresponds to the regression coefficients for plaques while the 𝑥-axis represents 
regression coefficients parameters 
 
Table 6.8: Sub-set of parameters for which PRCC>0.5 and p<0.05 against plaques at day 
#8 when PRCC uses ODEs  
 
Index Parameter ODEs 
PRCC p-value 
16 KbinMdm2p53 -0.5786 1.01E-03 
66 ksynMdm2 0.6235 4.68E-04 
 
Table 6.9: Sub-set of parameters for which PRCC>0.5 and p<0.05 against plaques at day 
#8 when PRCC uses MRM/GSSA  
 
Index Parameter MRM/GSSA 
PRCC p-value 
29 kdegTau20Sport 0.501 0.00066 






Figure 6.25: PRCC plots for plaques using ODEs. KbinMdm2p53 and ksynMdm2 
are the most important parameters that affect the behaviour of plaques. The 
PRCC and p-values are labelled above plots and listed in Table 6.8; the 




Figure 6.26: PRCC plots for plaques using MRM/GSSA. KdegTau20Sport and 
KbinMdm2p53 are the most important parameters that affect the behaviour of 
plaques. PRCC values and p-values are labelled above the plots and listed in 







6.10 Results of LHS/PRCC for tangles 
Tangles are important contributors to AD. Therefore, the behaviour of tangles is 
investigated over the space of the parameters in the system. The plots in Figure 
6.27 show the behaviour of tangles over 12 days corresponding to the parameter 
combinations of the LHS scheme using ODEs (A) and MRM/GSSA (B). The vertical 
lines in A and B indicate the time points we use to calculate the level of 
uncertainty of the LHS parameters (days #4, #8 and #12).  Figures 6.28 and 6.29 
verify the monotonic relationship between the tangles and LHS parameters using 
ODEs and MRM/GSSA.   
 
Figure 6.27: Behaviour of the tangles over 12 days. A and B show the behaviour of plaques 
corresponding to the parameter combinations of the LHS scheme using ODEs and 
MRM/GSSA. Days 4, 8 and 12, indicated by the vertical lines (red lines), are used as time 
points to compute the level of uncertainty from LHS parameters on the behaviour of 




Figure 6.28: Monotonicity plots of all parameters in the LHS matrix for tangles 
using ODEs at times t = 4, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and the plaques. Numbers 





Figure 6.29: Monotonicity plots of all parameters in the LHS matrix for tangles 
using MRM/GSSA at times t = 4, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and plaques. Numbers 




PRCC analysis using ODEs shows that KbinMdm2p53 (16) is the only parameter 
that has a strong correlation with tangles at day #12. The PRCC value is -0.6102 
and the p-value is 2.64E-0.5. The PRCC plot for kbinMdm2p53 is shown in Figure 
6.30. PRCC analysis using MRM/GSSA demonstrates that kgenROSGila, 
ksynMdm2, KbinMdm2p53 and kbinE2UB (37, 66, 16 and 14 in Table 5.2) have 
strong correlations with tangles. Table 6.9 lists the PRCC values and p-values of 
these parameters and Figure 6.31 displays the PRCC plots for these parameters. 
 
 
Figure 6.30: PRCC plots for tangles using ODEs. KbinMdm2p53 is the most 
important parameter that affects the behaviour of the tangles. PRCC and p-
values are labelled above the plot.  
 
Table 6.10: Sub-set of parameters for which PRCC>0.5 and p<0.05 against tangles at day 
#12 when PRCC uses MRM/GSSA  
 
Index Parameter MRM/GSSA 
PRCC p-value 
37 kgenROSGila -0.6057 0.00033 
66 ksynMdm2 0.6073 1.98E-005 
16 KbinMdm2p53 0.6493 2.93E-006 









Figure 6.31: PRCC plots for tangles using MRM/GSSA. KgenROSGila, ksynMdm2, 
KbinMdm2p53 and kbinE2UB are the most important parameters that affect the 
behaviour of the tangles. The PRCC value and p-values are labelled above the 
figures and are also listed in Table 6.9. The 𝒚-axis corresponds to the regression 







6.11 Results of LHS/PRCC for GilaA 
 
In Figure 6.32, we show the behaviour of GilaA in response to the parameter 
combinations of the LHS scheme over 12 days. Part A shows the behaviour of 
GilaA from ODEs while the results of MRM/GSSA are represented in Part B. Figure 
6.32 (A and B) contains vertical lines (red lines); these lines indicate the time 
points where we calculate the level of uncertainty in the behaviour of GilaA from 
the LHS parameters.  
 
Figure 6.32: Behaviour of GilaA over 12 days. A and B, respectively, show the behaviour of 
GilaA corresponding to the parameter combinations of the LHS scheme using ODEs and 
MRM/GSSA. Days 4.2, 8 and 12, indicated by the vertical lines (red lines), are used as time 
points to compute the level of uncertainty from the LHS parameters on the behaviour of 
GilaA. For GilaA, we use day #4.2 to calculate the sensitivity because at day #4, the level of 
GilaA is zero and it starts to increase in response to antibodies that are added to the system 
at day #4. Therefore, we use the closest point after day #4 to check the behaviour of GilaA 
over the space of parameters in the system.      
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Verifying the monotonic relationship between GilaA and the LHS parameters is 
the first step to be achieved before using PRCC analysis. Figures 6.33 and 6.34 
show how the monotonic relationship between GilaA and parameters in the LHS 
matrix is verified using ODEs and MRM/GSSA, respectively.     
 
Figure 6.33: Monotonicity plots of all parameters in the LHS matrix for GilaA 
using ODEs at times t = 4.2, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and GilaA. Numbers 






Figure 6.34: Monotonicity plots of all parameters in the LHS matrix for GilaA 
using ODEs at times t = 4.2, 8 and 12 (days). The plots show that there is a 
monotonic relationship between the LHS parameters and GilaA. Numbers 




PRCC analysis using ODEs demonstrates that none of the parameters have strong 
correlations with GliaA while the analysis using MRM/GSSA indicates that there 
are three parameters that have strong correlations with GilaA at day #4.2. These 
parameters are KdegAbetaGlia, ksynMdm2 and ktangfor (23, 66 and 73 in Table 
5.2). This table lists PRCC values and p-values for these parameters. Figure 6.35 
displays the PRCC plots for GilaA in response to these parameters.  
Table 6.11: Sub-set of parameters for which PRCC>0.5 and p<0.05 against GilaA at day 
#4.2 when PRCC uses MRM/GSSA  
 
Index Parameter MRM/GSSA 
PRCC p-value 
23 KdegAbetaGlia -0.503 0.00041 
66 ksynMdm2 0.543 0.00023 








Figure 6.35: PRCC plots for GilaA using MRM/GSSA. KdegAbetaGlia, ksynMdm2, 
ktangfor are the most important parameters that affect the behaviour of GilaA 
at day #4.2. The PRCC value and p-values are listed in Table 6.10. The 𝒚-axis 
corresponds to the regression coefficients for Aβ while the 𝒙-axis represents the 







This chapter discusses the results of LHS/PRCC using ODEs and MRM/GSSA for the 
selected species in immunization in the AD model. In the first four sections we 
described, using an example from the system, how to generate the LHS matrix 
and how to rank the values in this matrix. We also described how the monotonic 
relationship is verified between the LHS parameters and the outcome measures 
using an example. It was found that all species selected to be investigated have a 
monotonic relationship with the LHS parameters using ODEs and MRM/GSSA.   
We also show using an example from the system how all steps of PRCC are 
handled and how PRCC values for a specific parameter are calculated using 
Pearson correlation coefficient (PCC) for the residuals from the two regression 
models that representing the ranked parameter in terms of the other ranked 
parameter values and the ranked outcome measures in terms of the other ranked 
parameter values.  
Then, we discuss LHS/PRCC results for all of the selected species. PRCC 
demonstrated that: 
1- p53 has no strong correlation with the LHS parameters when PRCC uses 
ODEs and MRM/GSSA. 
2- ATMA has a strong correlation with kbinMdm2p53 at all-time points (days 
#4, #8 and #12) when PRCC uses ODEs, while ATMA has a strong 
correlation with Ksynp53mRNAAbeta only at day #12 when PRCC uses 
MRM/GSSA. 
3- p53_GSk3β has strong correlation using ODES with kbinMdm2p53, 
kbinGSK3bp53 and kbinE2Ub at day #4 while only KbinMdm2p53 and 
ksynMdm2 at day #4 have strong correlation with p53_GSk3β when PRCC 
uses MRM/GSSA.  
4-  Aβ is very sensitive after immunization at day #8 in response to 
kbinMdm2p53 and ksynMdm2 when PRCC uses ODEs and MRM/GSSA.  
5-  Plaques are only sensitive at day #4 for kbinMdm2p53 and ksynMdm2 
when PRCC uses ODEs and kdegTau20Sport and kbinMdm2p53 when it 
uses MRM/GSSA.  
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6- Tangles are very sensitive in the last day of the system only to 
KbinMdm2p53 when ODEs are used, while kgenROSGila, ksynMdm2, 
KbinMdm2p53 and kbinE2UB have strong correlations with tangles when 
MRM/GSSA are used in PRCC analysis.  
7- GliaA is not sensitive to any of the LHS parameters when ODEs are used 
while it is very sensitive to KdegAbetaGlia, ksynMdm2 and ktangfor when 
MRM/GSAA is used.  
It was really interesting to find that parameters specific to p53 and Mdm2 
(KbinMdm2p53 and ksynMdm2) ranked so highly since these parameters have 
strong correlations with most of the selected species under study using ODEs and 
MRM/GSSA. This is because increasing the binding of Mdm2 and p53 and 
increasing the synthesis of Mdm2 prevents binding of GSK3β to p53 and decrease 
the activity of GSK3β.  It was also interesting to find that parameters specific to 
p53 regulation pathway (KbinMdm2p53, ksynMdm2, kbinE2UB and 
Ksynp53mRNAAbeta) are the most important parameters in the system.   
Most of the selected species are more sensitive in response to the LHS 
parameters at day #4. Therefore, immunization day is classified to be the most 
important day in the system that need to be taken into account to observe the 











Conclusion and Future Directions 
In this thesis, an immunization in AD model is modelled and its behaviour is 
investigated in response to parameters perturbation, one at a time and over the 
global space of parameters using LSA and GSA, respectively. This model is 
deterministically and stochastically modelled using ODEs GSSA, MRM/GSSA and 
the modified tau-leap method. The finite difference approximation method is 
used to locally investigate the behaviour of the system in response to parameters 
perturbation, one at a time, using ODEs and MRM/GSSA. LHS/PRCC is used to 
assess the behaviour of the system over global parameters space using also ODEs 
and MRM/GSSA. In this chapter, we give a general overview of our work and 
conclusions, summarise the major contribution and suggest several future 
directions that can follow this work.  
7.1 Overview of the study and conclusions 
The first object of this research is to not only accelerate a single run of GSSA but 
also include the concurrency feature in order to increase the performance of 
GSSA (Chapter 4). To accomplish this target, we modified MRM to be suitable to 
be combined with GSSA. The MRM method is a programming model that uses 
a parallel  distributed algorithms on a cluster to run multiple processes 
simultaneously. We employ 𝑘 threads to run 𝑘 copies of GSSA for the same 
system. These threads elect 𝑘 reactions and these 𝑘 reactions go through a 
selection step to check their eligibility to be executed, where 𝑘 is equal to the 
number of reactions that have propensity function more than zero. The value of 𝑘 
is dynamically changed depending on the status of the system.      
The second objective is to validate MRM/GSSA also in Chapter 3 by comparing it 
with GSSA and the modified tau leap method. Immunization in AD model is 
modelled using these three approaches to achieve this validation in terms of 
results (stochasticity), performance (CPU time), reliability and implementation. In 
term of results, MRM/GSSA is more able to represent the stochasticity feature 
than the modified tau-leap method. We use all three approaches to produce 200 
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realizations and display the mean of these 200 runs. We use standard deviation to 
check how the set of data from these 200 realizations spread around its mean. 
GSSA shows the largest standard deviation and MRM/GSSA show larger standard 
deviation than the modified tau-leap method.  In term of time, MRM/GSSA shows 
better performance than GSSA. MRM/GSSA also is comparable with the modified 
tau leap method. MRM/GSSA needs half time that is required by GSSA and a 
round 110% of time required by the modified tau leap method. However, 
MRM/GSSA is more reliable than the modified tau leap method that needs to deal 
with a critical value (𝑛 number of critical reactions). The value of 𝑛 needs to be 
carefully determined depending on the status of the system. Therefore, an 
advance analysis of the system under required prior modelling step. Also, 
MRM/GSSA is much easier to be implemented than the modified tau leap 
method.  
Conclusion: MRM/GSSA is not only able to include the stochastic feature more 
than the modified tau-leap method, but also more reliable and much easier to be 
implemented than the modified tau-leap method.  
The third objective is to deterministically and stochastically investigate the critical 
behaviour of main species in immunization in the AD model.  p53, ATMA, 
p53_GSK3β, Aβ, plaques, tangles and GliaA are selected to be the main species of 
the system.  Investigating the critical behaviour of main species is achieved using 
LSA and GSA. To perform LSA using ODEs we use a finite difference 
approximation. To stochastically perform LSA, we use MRM/GSSA in conjunction 
with common random number (CRN) method. We use LHS/PRCC to analyse the 
global sensitivities of the parameters of the system and predict the most 
vulnerable target the main species of the system.   
LSA using ODEs and MRM/GSSA shows that the behaviour of p53, ATMA, 
p53_GSK3β and Aβ are not dramatically changed in response to parameter 
perturbations. LSA using ODEs shows that only 28 parameters can change the 
behaviour of p53, ATMA and p53_GSK3β and 24 parameters to change the 
behaviour of Aβ. LSA using MRM/GSS demonstrates that 66 and 71 parameters 
adjust the behaviour of p53, ATMA and p53_GSK3β when parameters are 
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perturbed to 50% and 200% of their basal values, respectively. Aβ is changed in 
response to 71 parameters when LSA uses MRM/GSSA.  Using ODEs to perform 
the sensitivity analysis show that p53, ATMA, p53_GSK3β and Aβ are more 
sensitive to their parameters in the early stages of the system. MRM/GSSA to 
perform the sensitivity analysis shows that p53, ATMA, p53_GSK3β and Aβ are 
sensitive over the whole period of the system.  
Conclusion: performing LSA using ODEs and MRM/GSSA shows that p53, ATMA, 
p53_GSK3β and Aβ are not highly contributing to the overall behaviour of the 
system. The only difference between ODEs and MRM/GSSA is that the number of 
parameters that change the behaviour of these species.   
LSA sensitivity analysis using ODEs and MRN/GSSA demonstrates that plaques, 
tangles and GliaA are very sensitive species in response to parameters 
perturbation one at a time since they dramatically changed in response to some 
parameters adjustments. LSA using ODEs and MRM/GSSA shows that there are 28 
and 71 parameters adjust the behaviour of tangles, respectively. Conclusion: 
plaques, tangles and GliaA are highly contributing the overall behaviour of the 
system and more parameters affected the level of plaques when LSA uses 
MRM/GSSA.    
Plaques level is significantly changed in response to 2 and 8 parameters when 
parameters are adjusted to 50% using ODEs and MRM/GSSA, respectively. 
Whereas, 5 and 13 parameters are dramatically changed plaques behaviour when 
parameters are perturbed to 200% using ODEs and MRM/GSSA. Conclusion: 
plagues are more sensitive for increasing the rates of parameters using both 
approaches.  
LSA using ODEs shows that tangles are significantly changed in response to 11 
parameters using ODEs when parameters are perturbed to 50% of their basal 
values while only 6 parameters dramatically changed tangles behaviour when 
parameters are adjusted to 200% of their basal values. Using MRM/GSSA to 
perform the sensitivity analysis show same parameters (14 parameters) are 
dramatically changed the behaviour of tangles when parameters are perturbed to 
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50% and 200% of their basal value. Conclusion: tangles are more sensitive for 
decreasing parameters rate using ODEs.  
The level of GliaA is significantly changed in response to 2 and 6 parameters when 
parameters are adjusted to 50% using ODEs and MRM/GSSA, respectively. 
Whereas, 6 and 13 parameters are dramatically changed the behaviour of GliaA 
when parameters are perturbed to 200% using ODEs and MRM/GSSA. Conclusion: 
GliaA is more sensitive for increasing the rates of parameters using both 
approaches.  
GSA using LHS/PRCC (Chapter 6) demonstrates that parameters specific to p53 
and Mdm2 (KbinMdm2p53 and ksynMdm2) ranked so highly since these 
parameters affect the behaviour of most of the selected species under study 
using ODEs and MRM/GSSA. This is because increasing the binding of Mdm2 and 
p53 and increasing the syntheses of Mdm2 prevent binding of GSK3β to p53 and 
lower the activity of GSK3β.  It was also interesting to find that parameters 
specific to p53 regulation pathway (KbinMdm2p53, ksynMdm2, kbinE2UB and 
Ksynp53mRNAAbeta) are the most important parameters in the system.  
Conclusion: parameters specific to p53 regulation are the most important 
parameters that highly contribute to the variation.  
7.2 Contributions 
The major contributions of this thesis are:  
 
1- Developiving MRM/GSSA to accelerate a single run of GSSA. 
2- Validating MRM/GSSA by comparing it with not only GSSA itself, but also 
the modified tau-leap method and verifying that MRM/GSSA needs only 
half time required by GSSA and it is commparable with the modified tau-
leap method.  MRM/GSSA is not only more able to represent variance, but 
also more reliable to be used for any biochemical system than the modified 
tau-leap method.  
3- Using ODEs and MRM/GSSA to perform LSA and GSA to: 
 Determine the maximum and minimum ranges of each parameter in 
immunization in AD model. 
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 Classify the most important species in the model 
 Classify the most important parameters that contribute to the overall 
behaviour of the system not only when parameters are perturbed one 
at a time, but also over the space of parameters.  
 Identify pathways that are not dramatically changed when parameters 
are perturbed. 
7.3 Future Directions 
We suggest several future direction that can follow the current work: 
1. Developing a tool that is based on MRM/GSSA to not only model 
biochemical system, but also stochastically perform LSA and GSA. 
  
2. Proposing a dynamic way to change the value of 𝑛 in the modified tau-leap 
method depending on the dynmaic status of the system.  
 
3. At the level of LSA: 
 Investigate the behaviour of all species in response to 
parameters pertubation since all species are important in the 
system while we just investiged the behaviour of seven species in 
this parameters.  
 For those parameters that dramatically changed the behaviour of 
the selected species, reducing the ranges of minimum and 
maximum to determine the exact ranges of these parameters. 
 
4. Investigating the behaviour of more species in response to parameters 
perturbation over the global space of parameters would be the future 






Alzheimer’s disease Models  
Table A.1: Mathematical models of AD. Table A.1 lists collection of mathematical 
models that have been proposed to model different concepts of AD. Table A.1 
includes:   
1- Title of the publication  
2- Reference 
3- Study nature  
4- Modelling Type 
5- Pathways involved  













Table A. 1: Mathmatical Models of AD 
ID 
 









1 Alzheimer’s disease: a 
mathematical model for 
onset and progression 
(Bertsch, Franchi, 
Marcello, Tesi, & 
Tosin, 2016) 
Modelling  Integro differential 
equations; PDE 
APP breakdown, fibril 
organization, BBB 
transport 
Transport and diffusion of Aβ 
along with the random onset of 
Alzheimer’s disease 
2 The zinc dyshomeostasis 
hypothesis of Alzheimer’s 
disease 








Role of zinc in beta-amyloid 
aggregation and memory 
formation 
3 A mathematical model of 
the impact of novel 
treatments on the A beta 
burden in the Alzheimer’s 
brain 
(Craft, Wein, & 
Selkoe, 2002) 
Modelling Ordinary Differential 
Equations 
Fibril organization Kinetics of Aβ levels in the brain, 
cerebrospinal fluid and plasma 
5 The choline-leakage 
hypothesis for the 
loss of acetylcholine in 
Alzheimer’s disease 
(Ehrenstein, Galdzicki, 












feedback:  Aβ-dependent 
leakage of choline and ACh-
dependent production of Aβ 
 
6 A positive-feedback model 
for the loss of acetylcholine 
in Alzheimer’s disease 
(Ehrenstein, Galdzicki, 











Two component positive 
feedback: Aβ-mediated 
apoptosis decreases ACh and 
low ACh favours APP processing 
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7 Effect of beta-amyloid block 
of the fast-inactivating K+ 
channel on intracellular Ca2+ 
and excitability in a 
modelled neuron. 
(Good & Murphy, 
1996) 






Interplay between Aβ, ion 
homoeostasis and neuron 
excitability 
 
8 Cerebral amyloid-beta 
proteostasis is regulated by 
the membrane transport 
protein, ABCC1, in mice. 






APP breakdown, BBB 
transport 
 
Processes regulating the 
production and removal of Aβ 
aggregates 
 
9 Mathematical models of 













Dynamics of MT-based-Tau 
protein transport in 
degenerating axons 
 
10 Of mice and maths: a 
systems biology model for 
Alzheimer’s disease 
(Kyrtsos, 2011) Experiment + 
modelling 
 










Interplay between APP, Aß and 
cholesterol processing in the 
brain 
 
11 Studying the role of ApoE in 
Alzheimer’s disease 
pathogenesis using a 
systems biology model 

















                                                          
1 SORLA is an endocytosis and sorting receptor 
12 Modelling the role of the 
glymphatic pathway and 
cerebral blood vessel 
properties in Alzheimer’s 
disease pathogenesis 









Aβ dynamics regulated by brain 
vasculature, glymphatic system 
kinetics and age 
 
13 Multi-compartmental 
modelling of SORLA1’s 
influence on amyloidogenic 
processing in Alzheimer’s 
disease 
(Lao, Schmidt, 










Effects of SORLA on APP 
processing 
 
14 Chemotactic signalling, 
microglia, and Alzheimer’s 
disease senile plaques: is 











Microglia chemotaxis in 
response to a combination of 
chemoattractant and 
chemorepellents 
15 Mathematical model of 











AD evolution with respect to 
ApoE gene variability 
 
16 A mathematical model of 
aging-related and cortisol 
induced hippocampal 
dysfunction 







Effects of elevated plasma 




17 Interplay between alpha-, 
beta- and gamma-secretases 
determines biphasic 
amyloid-beta protein level 
in the presence of a gamma-
secretase inhibitor 
(Ortega, Stott, Visser, 









Interplay between α-, β-, and γ-
secretases on Aβ dynamics in 
presence of a γ-secretase 
inhibitor 
 
18 A mathematical model of 
the kinetics of beta-amyloid 
fibril growth from the 
denatured state.  










Fibril formation process of Aβ 
 
19 GSK3 and p53 — is there a 
link in Alzheimer’s disease? 









Role of GSK3 and p53 in Aβ 
aggregation dynamics 
 
20 Aggregation, impaired 
degradation and 
immunization targeting of 
amyloid-beta dimers in 












Aβ turnover and its aggregation 
kinetics along with the effect of 
immunization against Aβ dimers 
 
21 Investigating interventions 
in Alzheimer’s disease with 
computer simulation 
models. 










Effectiveness of passive and 
active immunisation against Aβ 
in phosphorylated tau, tangles 
and Aβ plaques 
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22 Mathematical modelling for 
the pathogenesis of 
Alzheimer’s disease. 









Cross-talk among distinct states 
of microglia, astroglia, and 
neurons 
 
23 Differences in amyloid-beta 
clearance across mouse and 
human 
blood-brain barrier models: 
kinetic analysis and 
mechanistic modelling. 






Fibril organization, BBB 
transport 
 
Uptake, efflux and degradation 
of Aβ 
 
24 Computational modelling of 
the effects of amyloid-beta 
on release 
probability at hippocampal 
synapses. 
(Romani et al., 2013) Experiment + 
modelling 
 
 Synaptic transmission 
 
Role of Aβ on synaptic currents 
 
25 Electrostimulation to reduce 
synaptic scaling driven 
progression of Alzheimer’s 
disease. 








Effect of electrostimulation on 




modelling of SORLA’s 
influence on amyloidogenic 
processing in Alzheimer’s 
disease. 






















27 Modulators of gamma-
secretase activity can 
facilitate the toxic side-
effects and pathogenesis of 
Alzheimer’s disease. 








Modulation of γ-secretase 
activity by the biphasic inhibitor, 
DAPT 
 
28 Altered intrinsic excitability 
of hippocampal CA1 
pyramidal neurons in aged 
PDAPP mice 










Effect of altered Aβ levels on 
action potential of aged neurons 
 
29 Modelling of calcium 
dynamics in brain energy 
metabolism and Alzheimer’s 
disease 
(Tiveci, Akın, Çakır, 








Ion homoeostasis, energy 
metabolism 
 
Dynamics of calcium ion in 
membrane ionic currents, 
glycolysis, mitochondrial activity 
and exchanges through the 
blood-brain barrier 
 
30 Are improper kinetic models 
hampering drug 
development? 






Kinetic model of the drug action 
of DAPT on gamma-secretase. 
31 Vulnerabilities in the tau 
network and the role of 
ultrasensitive points in tau 
pathophysiology 









Aggregation process of 3R and 





Appendix B includes four Tables and one Figure. 
 Table B.1 lists all reactions of the system (Names, Equations and Kinetic 
laws) 
 Table B. 2 includes the set of ODEs 
 Table B. 3 contains all species with their initial values.  
 Table B.4 consists of parameters, their description and their initial values.  
 Figure B.1 displays p53 regulation and its reaction.  
 Table B.5 lists reactions that are included in p53 regulation. Reaction 
numbers correspond to the numbers in Table 1 
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Table B. 1: Reactions of the system 
# Reaction name Reaction Equation Kinetic law 
1 p53_mRNA_Synthesis 𝐒𝐨𝐮𝐫𝐜𝐞 
𝐤𝐬𝐲𝐧𝐩𝟓𝟑𝐦𝐑𝐍𝐀
→           𝐩𝟓𝟑_𝐦𝐑𝐍𝐀 𝐯𝟏 =  𝐤𝐬𝐲𝐧𝐩𝟓𝟑𝐦𝐑𝐍𝐀 ∗  𝐒𝐨𝐮𝐫𝐜𝐞 
2 p53_mRNA_Degradation 𝐩𝟓𝟑_𝐦𝐑𝐍𝐀
𝐤𝐝𝐞𝐠𝐩𝟓𝟑𝐦𝐑𝐍𝐀
→           𝐬𝐢𝐧𝐤 𝐯𝟐 =  𝐤𝐝𝐞𝐠𝐩𝟓𝟑𝐦𝐑𝐍𝐀 ∗  𝐩𝟓𝟑𝐦𝐑𝐍𝐀 
3 Mdm2Synthesis 𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀
𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐
→        𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀+𝐌𝐝𝐦𝟐 𝐯𝟑 =  𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀 
4 Mdm2mRNASynthesis1 𝐩𝟓𝟑
𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀 
→             𝐩𝟓𝟑 +  𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀 𝐯𝟒 =  𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀 ∗  𝐩𝟓𝟑 
5 Mdm2mRNASynthesis2 𝐩𝟓𝟑_𝐏
𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀 
→             𝐩𝟓𝟑_𝐏 +𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀+  𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀𝐬𝐲𝐧     𝐯𝟓 =  𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀 ∗  𝐩𝟓𝟑_𝐏 
6 Mdm2mRNASynthesis3 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                     𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 +  𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀     𝐯𝟔 =  𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 
7 Mdm2 mRNA Synthesis4 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                     𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 +  𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀 𝐯𝟕 = 𝐤𝐬𝐲𝐧𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗  𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏  
8 Mdm2mRNADegradation 𝐌𝐝𝐦𝟐 𝐦𝐑𝐍𝐀
𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀
→             𝐒𝐢𝐧𝐤 +𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀𝐝𝐞𝐠 𝐯𝟖 =  𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐𝐦𝐑𝐍𝐀 ∗  𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀 
9 p53_Mdm2 Binding 𝐌𝐝𝐦𝟐+  𝐩𝟓𝟑
𝐤𝐛𝐢𝐧𝐌𝐝𝐦𝟐𝐩𝟓𝟑 
→           𝐌𝐝𝐦𝟐_𝐩𝟓𝟑   𝐯𝟗 =  𝐤𝐛𝐢𝐧𝐌𝐝𝐦𝟐𝐩𝟓𝟑 ∗  𝐩𝟓𝟑 ∗ 𝐌𝐝𝐦𝟐 
10 p53_Mdm2 Release 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑
𝐤𝐫𝐞𝐥𝐌𝐝𝐦𝟐𝐩𝟓𝟑 
→           𝐌𝐝𝐦𝟐+ 𝐩𝟓𝟑 𝐯𝟏𝟎 =  𝐤𝐫𝐞𝐥𝐌𝐝𝐦𝟐𝐩𝟓𝟑 ∗  𝐩𝟓𝟑 _𝐌𝐝𝐦𝟐 
11 GSK3_p53 Binding 𝐆𝐒𝐊𝟑𝐛 + 𝐩𝟓𝟑
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑   𝐯𝟏𝟏 = 𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛 ∗ 𝐩𝟓𝟑 
12 GSK3_p53 Release 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐫𝐞𝐥𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛+ 𝐩𝟓𝟑   𝐯𝟏𝟐 = 𝐤𝐫𝐞𝐥𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 
13 GSK3_p53_P Binding 𝐆𝐒𝐊𝟑𝐛 + 𝐩𝟓𝟑_𝐏
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏   𝐯𝟏𝟑 = 𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛 ∗ 𝐩𝟓𝟑_𝐏 
14 GSK3_p53_P Release 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐛𝐢𝐧𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→           𝐆𝐒𝐊𝟑𝐛+ 𝐩𝟓𝟑_𝐏 𝐯𝟏𝟒 = 𝐤𝐫𝐞𝐥𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 
15 E1_Ub Binding 𝐄𝟏 + 𝐔𝐛 + 𝐀𝐓𝐏
𝐤𝐛𝐢𝐧𝐄𝟏𝐔𝐛
→       𝐄𝟏_𝐔𝐛+ 𝐀𝐌𝐏   𝐯𝟏𝟓 =
𝐤𝐛𝐢𝐧𝐄𝟏𝐔𝐛 ∗ 𝐄𝟏 ∗ 𝐔𝐛 ∗ 𝐀𝐓𝐏
𝟓𝟎𝟎𝟎 + 𝐀𝐓𝐏
 
16 E2_Ub Binding 𝐄𝟐 + 𝐄𝟏_𝐔𝐛
𝐤𝐛𝐢𝐧𝐄𝟐𝐔𝐛
→       𝐄𝟐_𝐔𝐛+ 𝐄𝟏 𝐯𝟏𝟔 = 𝐤𝐛𝐢𝐧𝐄𝟐𝐔𝐛 ∗ 𝐄𝟐 ∗  𝐄𝟏_𝐔𝐛 
17 Mdm2_Ubiquitination 𝐌𝐝𝐦𝟐+ 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐔𝐛
→       𝐌𝐝𝐦𝟐_𝐔𝐛 + 𝐄𝟐 𝐯𝟏𝟕 = 𝐤𝐌𝐝𝐦𝟐𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐 ∗ 𝐄𝟐_𝐔𝐛 
18 Mdm2 poly Ubiquitination1 𝐌𝐝𝐦𝟐_𝐔𝐛 + 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐔𝐛𝟐 + 𝐄𝟐 𝐯𝟏𝟖 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛 ∗  𝐄𝟐_𝐔𝐛 
19 Mdm2 poly Ubiquitination2 𝐌𝐝𝐦𝟐_𝐔𝐛𝟐+ 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐔𝐛𝟑 + 𝐄𝟐 𝐯𝟏𝟗 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟐 ∗ 𝐄𝟐_𝐔𝐛 
20 Mdm2 poly Ubiquitination3 𝐌𝐝𝐦𝟐_𝐔𝐛𝟑+ 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐔𝐛𝟒 + 𝐄𝟐 𝐯𝟐𝟎 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟑 ∗  𝐄𝟐_𝐔𝐛 
21 Mdm2 Deubiquitination4 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒+𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐 𝐔𝐛𝟑+𝐌𝐝𝐦𝟐𝐃𝐔𝐁 +𝐔𝐛 𝐯𝟐𝟏 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒 ∗  𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
22 Mdm2 Deubiquitination3 𝐌𝐝𝐦𝟐_𝐔𝐛𝟑+𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐔𝐛𝟐+𝐌𝐝𝐦𝟐𝐃𝐔𝐁 +𝐔𝐛 𝐯𝟐𝟐 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟑 ∗ 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
23 Mdm2 Deubiquitination2 𝐌𝐝𝐦𝟐_𝐔𝐛𝟐+𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐔𝐛 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁 +𝐔𝐛 𝐯𝟐𝟑 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟐 ∗  𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
24 Mdm2 Deubiquitination1 𝐌𝐝𝐦𝟐_𝐔𝐛 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐+𝐌𝐝𝐦𝟐𝐃𝐔𝐁 +𝐔𝐛 𝐯𝟐𝟒 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛 ∗  𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
25 Mdm2_Proteasome Binding1 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒+ 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭
→      𝐌𝐝𝐦𝟐_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟐𝟓 = 𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭 ∗ 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒 ∗  𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
26 Mdm2 Degradation 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐∗𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟
→               𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝟒𝐔𝐛 𝐯𝟐𝟔 = 𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐 ∗ 𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟 ∗  𝐌𝐝𝐦𝟐_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
27 p53 Synthesis 𝐩𝟓𝟑𝐦𝐑𝐍𝐀
𝐤𝐬𝐲𝐧𝐩𝟓𝟑
→      𝐩𝟓𝟑 +   𝐩𝟓𝟑𝐦𝐑𝐍𝐀 + 𝐩𝟓𝟑𝐬𝐲𝐧 𝐯𝟐𝟕 =  𝐤𝐬𝐲𝐧𝐩𝟓𝟑 ∗ 𝐩𝟓𝟑𝐦𝐑𝐍𝐀 
28 p53 Monoubiquitination 𝐄𝟐_𝐔𝐛+𝐌𝐝𝐦𝟐_𝐩𝟓𝟑  
𝐤𝐩𝟓𝟑𝐔𝐛
→     𝐌𝐝𝐦𝟐 𝐩𝟓𝟑 𝐔𝐛 +   𝐄𝟐   𝐯𝟐𝟖 =  𝐤𝐩𝟓𝟑𝐔𝐛 ∗ 𝐄𝟐_𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑 
29 p53 Polyubiquitination1 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 + 𝐄𝟐_𝐔𝐛  
𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟐+ 𝐄𝟐 𝐯𝟐𝟗 =  𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 ∗  𝐄𝟐_𝐔𝐛 
 165 
30 p53 Polyubiquitination2 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟐+ 𝐄𝟐_𝐔𝐛 
𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑+ 𝐄𝟐   𝐯𝟑𝟎 =  𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟐 ∗ 𝐄𝟐_𝐔𝐛 
31 p53 Polyubiquitination3 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑+ 𝐄𝟐_𝐔𝐛 
𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒+ 𝐄𝟐   𝐯𝟑𝟏 =  𝐤𝐩𝟓𝟑𝐏𝐨𝐥𝐲𝐔𝐛 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑 ∗ 𝐄𝟐_𝐔𝐛 
32 p53 Deubiqutination4 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒+ 𝐩𝟓𝟑𝐃𝐔𝐁  
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑 + 𝐩𝟓𝟑𝐃𝐔𝐁+ 𝐔𝐛 𝐯𝟑𝟐 =  𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒 ∗  𝐩𝟓𝟑𝐃𝐔𝐁 
33 p53 Deubiquitination3 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑+ 𝐩𝟓𝟑𝐃𝐔𝐁  
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 
→         𝐌𝐝𝐦𝟐_𝐩𝟓_ 𝐔𝐛𝟐 + 𝐩𝟓𝟑𝐃𝐁 + 𝐔𝐛 𝐯𝟑𝟑 =  𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 ∗ 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑 ∗ 𝐩𝟓𝟑𝐃𝐔𝐁 
34 p53 Deubiquitination2 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟐+ 𝐩𝟓𝟑𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 + 𝐩𝟓𝟑𝐃𝐔𝐁 + 𝐔𝐛 𝐯𝟑𝟒 =  𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 ∗ 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟐 ∗ 𝐩𝟓𝟑𝐃𝐔𝐁 
35 p53 Deubiquitination1 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 + 𝐩𝟓𝟑𝐃𝐔𝐁   
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 
→         𝐌𝐝𝐦𝟐_𝐩𝟓𝟑 + 𝐩𝟓𝟑𝐃𝐔𝐁 + 𝐔𝐛 𝐯𝟑𝟓 =  𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐩𝟓𝟑 ∗ 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 ∗  𝐩𝟓𝟑𝐃𝐔𝐁 
36 Mdm2_GSK3 phosphorylation1 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒+ 𝐆𝐒𝐊𝟑𝐛  
𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛 
→              𝐌𝐝𝐦𝟐_𝐏𝟏_𝐩𝟓𝟑_𝐔𝐛𝟒 + 𝐆𝐒𝐊𝟑𝐛 𝐯𝟑𝟔 = 𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒 ∗ 𝐆𝐒𝐊𝟑𝐛 
37 Mdm2 GSK3 phosphorylation2 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                 𝐌𝐝𝐦𝟐_𝐏𝟏_𝐩𝟓𝟑_𝐔𝐛𝟒 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑                                                                                                                        𝐯𝟑𝟕 = 𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 
38 Mdm2 GSK3 phosphorylation3 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒+ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                 𝐌𝐝𝐦𝟐_𝐏𝟏_𝐩𝟓𝟑_𝐔𝐛𝟒 +   𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐩                                                                                                                              𝐯𝟑𝟖 = 𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗  𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒
∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 
39 p53_Proteasome Binding1 𝐌𝐝𝐦𝟐_𝐏_𝐩𝟓𝟑_𝐔𝐛𝟒 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭
→      𝐩𝟓𝟑_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 +𝐌𝐝𝐦𝟐 𝐯𝟑𝟗 = 𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐩𝟓𝟑_𝐔𝐛𝟒 ∗  𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
40 Degradation p53_Ub4 𝐩𝟓𝟑_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝐀𝐓𝐏
𝐤𝐝𝐞𝐠𝐩𝟓𝟑∗𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟
→             𝟒𝐔𝐛 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+  𝐀𝐃𝐏 𝐯𝟒𝟎 =   
𝐤𝐝𝐞𝐠𝐩𝟓𝟑 ∗  𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟 ∗  𝐩𝟓𝟑_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 ∗ 𝐀𝐓𝐏
𝟓𝟎𝟎𝟎 +  𝐀𝐓𝐏
 
41 Tau_MT binding 𝐓𝐚𝐮   
𝐤𝐛𝐢𝐧𝐌𝐓𝐓𝐚𝐮
→        𝐌𝐓_𝐓𝐚𝐮 𝐯𝟒𝟏 = 𝐤𝐛𝐢𝐧𝐌𝐓𝐓𝐚𝐮 ∗ 𝐓𝐚𝐮 
42 Tau_MT release 𝐌𝐓_𝐓𝐚𝐮   
𝐤𝐫𝐞𝐥𝐌𝐓𝐓𝐚𝐮
→        𝐓𝐚𝐮 𝐯𝟒𝟐 = 𝐤𝐫𝐞𝐥𝐌𝐓𝐓𝐚𝐮 ∗ 𝐌𝐓_𝐓𝐚𝐮 
43 Tau phosphorylation1 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟏 𝐯𝟒𝟑 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗  𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 ∗ 𝐓𝐚𝐮 
44 Tau phosphorylation2 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟏   
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 + 𝐓𝐚𝐮_𝐏𝟐 𝐯𝟒𝟒 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 ∗ 𝐓𝐚𝐮_𝐏 
45 Tau phosphorylation3 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟏 𝐯𝟒𝟓 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 ∗ 𝐓𝐚𝐮 
46 Tau phosphorylation4 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟏  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑
→                𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 + 𝐓𝐚𝐮_𝐏𝟐 𝐯𝟒𝟔 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛𝐩𝟓𝟑 ∗  𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 ∗ 𝐓𝐚𝐮_𝐏𝟏 
47 Tau phosphorylation5 𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮  
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛
→             𝐆𝐒𝐊𝟑𝐛+ 𝐓𝐚𝐮_𝐏𝟏 𝐯𝟒𝟕 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛 ∗   𝐆𝐒𝐊𝟑𝐛 ∗ 𝐓𝐚𝐮 
48 Tau phosphorylation6 𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮_𝐏𝟏 
𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛
→             𝐆𝐒𝐊𝟑𝐛 + 𝐓𝐚𝐮_𝐏𝟐 𝐯𝟒𝟖 = 𝐤𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮𝐆𝐒𝐊𝟑𝐛 ∗ 𝐆𝐒𝐊𝟑𝐛 ∗ 𝐓𝐚𝐮_𝐏𝟏 
49 Tau dephosphorylation1 𝐓𝐚𝐮_𝐏𝟐+ 𝐏𝐏𝟏  
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮
→          𝐓𝐚𝐮_𝐏𝟏+ 𝐏𝐏𝟏  𝐯𝟒𝟗 = 𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮 ∗  𝐏𝐏𝟏 ∗ 𝐓𝐚𝐮_𝐏𝟐 
50 Tau dephosphorylation2 𝐓𝐚𝐮_𝐏𝟏+ 𝐏𝐏𝟏   
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮
→          𝐓𝐚𝐮 + 𝐏𝐏𝟏 𝐯𝟓𝟎 = 𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝐓𝐚𝐮 ∗  𝐏𝐏𝟏 ∗ 𝐓𝐚𝐮_𝐏𝟏 
51 Tau_P1 Aggregation1 𝟐 ∗ 𝐓𝐚𝐮_𝐏𝟏  
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟏 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏 ∗  𝐓𝐚𝐮_𝐏𝟏 
𝟐  ∗ 𝟎. 𝟓 
52 Tau_P1 Aggregation2 𝐓𝐚𝐮_𝐏𝟏+ 𝐀𝐠𝐠𝐓𝐚𝐮  
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟐 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟏 ∗  𝐓𝐚𝐮_𝐏𝟏 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
53 Tau_P2 Aggregation1 𝟐 ∗ 𝐓𝐚𝐮_𝐏𝟐 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟑 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐 ∗  𝐓𝐚𝐮_𝐏𝟐 
𝟐  ∗ 𝟎. 𝟓 
54 Tau_P2 Aggregation2 𝐓𝐚𝐮_𝐏𝟐+ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐
→        𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟒 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮𝐏𝟐 ∗  𝐓𝐚𝐮_𝐏𝟐 
𝟐  ∗ 𝟎. 𝟓 
55 Tau Aggregation1 𝟐 ∗  𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮
→      𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟓 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮 ∗  𝐓𝐚𝐮 
𝟐  ∗ 𝟎. 𝟓 
56 Tau Aggregation2 𝐓𝐚𝐮 +  𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐚𝐠𝐠𝐓𝐚𝐮
→      𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 𝐯𝟓𝟔 = 𝐤𝐚𝐠𝐠𝐓𝐚𝐮 ∗  𝐓𝐚𝐮 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
57 Tangle Formation1 𝟐 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫
→      𝟐 ∗ 𝐍𝐅𝐓  𝐯𝟓𝟕 = 𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫 ∗  𝐀𝐠𝐠𝐓𝐚𝐮  
𝟐  ∗ 𝟎. 𝟓 
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58 Tangle Formation2 𝐍𝐅𝐓 + 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫
→      𝟐 ∗ 𝐍𝐅𝐓 𝐯𝟓𝟖 = 𝐤𝐭𝐚𝐧𝐠𝐟𝐨𝐫 ∗  𝐀𝐠𝐠𝐓𝐚𝐮 ∗ 𝐍𝐅𝐓 
59 Proteasome Inhibition Agg Tau 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝐀𝐠𝐠𝐓𝐚𝐮 
𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭
→        𝐀𝐠𝐠𝐓𝐚𝐮 _𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟓𝟗 = 𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭 ∗ 𝐀𝐠𝐠𝐓𝐚𝐮 ∗ 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
60 Abeta production1 𝐒𝐨𝐮𝐫𝐜𝐞 
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚
→         𝐀𝐛𝐞𝐭𝐚 𝐯𝟔𝟎 = 𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚 ∗ 𝐒𝐨𝐮𝐫𝐜𝐞 
61 Abeta production2 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐
→          𝐀𝐛𝐞𝐭𝐚 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 𝐯𝟔𝟏 = 𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 
62 Abeta production3 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏
𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐
→          𝐀𝐛𝐞𝐭𝐚 + 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 𝐯𝟔𝟐 = 𝐤𝐩𝐫𝐨𝐝𝐀𝐛𝐞𝐭𝐚𝟐 ∗ 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 
63 Proteasome Inhibition Abeta 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭
→        𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟔𝟑 = 𝐤𝐢𝐧𝐡𝐢𝐛𝐩𝐫𝐨𝐭 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 ∗ 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
64 Abeta Degradation 𝐀𝐛𝐞𝐭𝐚 
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐒𝐢𝐧𝐤 𝐯𝟔𝟒 = 𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚 
65 p53 transcription Via Abeta 𝐀𝐛𝐞𝐭𝐚 
𝐤𝐬𝐲𝐧𝐩𝟓𝟑𝐦𝐑𝐍𝐀𝐀𝐛𝐞𝐭𝐚
→               𝐩𝟓𝟑_𝐦𝐑𝐍𝐀+ 𝐀𝐛𝐞𝐭𝐚 𝐯𝟔𝟓 = 𝐤𝐬𝐲𝐧𝐩𝟓𝟑𝐦𝐑𝐍𝐀𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚 
66 DNA damage 𝐈𝐑 
𝐤𝐝𝐚𝐦
→    𝐈𝐑 + 𝐝𝐚𝐦𝐃𝐍𝐀 𝐯𝟔𝟔 = 𝐤𝐝𝐚𝐦 ∗ 𝐈𝐑 
67 DNA repair 𝐝𝐚𝐦𝐃𝐍𝐀
𝐤𝐫𝐞𝐩𝐚𝐢𝐫
→     𝐒𝐢𝐧𝐤 𝐯𝟔𝟕 = 𝐤𝐫𝐞𝐩𝐚𝐢𝐫 ∗ 𝐝𝐚𝐦𝐃𝐍𝐀 
68 ATM activation 𝐝𝐚𝐦𝐃𝐍𝐀+ 𝐀𝐓𝐌𝐈
𝐤𝐚𝐜𝐭𝐀𝐓𝐌
→      𝐝𝐚𝐦𝐃𝐍𝐀 +𝐀𝐓𝐌𝐀 𝐯𝟔𝟖 = 𝐤𝐚𝐜𝐭𝐀𝐓𝐌 ∗ 𝐝𝐚𝐦𝐃𝐍𝐀 ∗ 𝐀𝐓𝐌𝐈 
69 p53 phosphorylation 𝐩𝟓𝟑 + 𝐀𝐓𝐌𝐀
𝐤𝐩𝐡𝐨𝐬𝐩𝟓𝟑
→       𝐩𝟓𝟑_𝐏 + 𝐀𝐓𝐌𝐀 𝐯𝟔𝟗 = 𝐤𝐩𝐡𝐨𝐬𝐩𝟓𝟑 ∗ 𝐩𝟓𝟑 ∗ 𝐀𝐓𝐌𝐀 
70 p53 dephosphorylation 𝐩𝟓𝟑_𝐏
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝟓𝟑
→         𝐩𝟓𝟑 𝐯𝟕𝟎 = 𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐩𝟓𝟑 ∗ 𝐩𝟓𝟑_𝐏 
71 Mdm2 phosphorylation 𝐌𝐝𝐦𝟐+ 𝐀𝐓𝐌𝐀
𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐
→         𝐌𝐝𝐦𝟐_𝐏 + 𝐀𝐓𝐌𝐀 𝐯𝟕𝟏 = 𝐤𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐 ∗ 𝐀𝐓𝐌𝐀 
72 Mdm2 dephosphorylation 𝐌𝐝𝐦𝟐_𝐏
𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐 𝐯𝟕𝟐 = 𝐤𝐝𝐞𝐩𝐡𝐨𝐬𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏 
73 Mdm2_P Ubiquitination 𝐌𝐝𝐦𝟐_𝐏 + 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐔𝐛
→        𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 + 𝐄𝟐 𝐯𝟕𝟑 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐏 ∗ 𝐄𝟐_𝐔𝐛 
74 Mdm2_P polyUbiquitination1 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛+ 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 + 𝐄𝟐 𝐯𝟕𝟒 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 ∗ 𝐄𝟐_𝐔𝐛 
75 Mdm2_P polyUbiquitination2 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 + 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 + 𝐄𝟐 𝐯𝟕𝟓 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 ∗ 𝐄𝟐_𝐔𝐛 
76 Mdm2_PpolyUbiquitination3 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 + 𝐄𝟐_𝐔𝐛
𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 + 𝐄𝟐 𝐯𝟕𝟔 = 𝐤𝐌𝐝𝐦𝟐𝐏𝐨𝐥𝐲𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 ∗ 𝐄𝟐_𝐔𝐛 
77 Mdm2_P Deubiquitination4 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁 + 𝐔𝐛 𝐯𝟕𝟕 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 ∗ 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
78 Mdm2_P Deubiquitination3 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁+𝐔𝐛 𝐯𝟕𝟖 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 ∗ 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
79 Mdm2_P Deubiquitination2 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁+ 𝐔𝐛 𝐯𝟕𝟗 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 ∗ 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
80 Mdm2_P Deubiquitination1 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛+𝐌𝐝𝐦𝟐𝐃𝐔𝐁
𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐
→           𝐌𝐝𝐦𝟐_𝐏 +𝐌𝐝𝐦𝟐𝐃𝐔𝐁+ 𝐔𝐛 𝐯𝟖𝟎 = 𝐤𝐚𝐜𝐭𝐃𝐔𝐁𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 ∗ 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 
81 Mdm2_P_Proteasome Binding1 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭
→      𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟖𝟏 = 𝐤𝐛𝐢𝐧𝐏𝐫𝐨𝐭 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 ∗ 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
82 Mdm2_P Degradation 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐∗𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟
→               𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝟒 ∗ 𝐔𝐛 𝐯𝟖𝟐 = 𝐤𝐝𝐞𝐠𝐌𝐝𝐦𝟐 ∗ 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 ∗ 𝐤𝐩𝐫𝐨𝐭𝐞𝐟𝐟 
83 ATM Inactivation 𝐀𝐓𝐌𝐀
𝐤𝐢𝐧𝐚𝐜𝐭𝐀𝐓𝐌
→        𝐀𝐓𝐌𝐈 𝐯𝟖𝟑 = 𝐤𝐢𝐧𝐚𝐜𝐭𝐀𝐓𝐌 ∗ 𝐀𝐓𝐌𝐀 
84 Abeta ROS production1 𝐀𝐛𝐞𝐭𝐚
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚
→           𝐀𝐛𝐞𝐭𝐚 + 𝐑𝐎𝐒 𝐯𝟖𝟒 = 𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚 
85 Plaque ROS production 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐏𝐥𝐚𝐪𝐮𝐞
→            𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 + 𝐑𝐎𝐒 𝐯𝟖𝟓 = 𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐏𝐥𝐚𝐪𝐮𝐞 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
86 Agg Abeta ROS production2 𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚
→           𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞+ 𝐑𝐎𝐒 𝐯𝟖𝟔 = 𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
87 ROS DNA damage 𝐑𝐎𝐒
𝐤𝐝𝐚𝐦𝐑𝐎𝐒
→       𝐑𝐎𝐒 + 𝐝𝐚𝐦𝐃𝐍𝐀 𝐯𝟖𝟕 = 𝐤𝐝𝐚𝐦𝐑𝐎𝐒 ∗ 𝐑𝐎𝐒 
 167 
88 Tau Synthesis 𝐒𝐨𝐮𝐫𝐜𝐞
𝐤𝐬𝐲𝐧𝐓𝐚𝐮
→      𝐓𝐚𝐮 𝐯𝟖𝟖 = 𝐤𝐬𝐲𝐧𝐓𝐚𝐮 ∗ 𝐒𝐨𝐮𝐫𝐜𝐞 
89 Tau Proteasome Binding 𝐓𝐚𝐮 + 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞
𝐤𝐛𝐢𝐧𝐓𝐚𝐮𝐏𝐫𝐨𝐭
→         𝐓𝐚𝐮_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟖𝟗 = 𝐤𝐛𝐢𝐧𝐓𝐚𝐮𝐏𝐫𝐨𝐭 ∗ 𝐓𝐚𝐮 ∗ 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 




→            𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 𝐯𝟗𝟎 = 𝐤𝐝𝐞𝐠𝐓𝐚𝐮𝟐𝟎𝐒𝐏𝐫𝐨𝐭 ∗ 𝐓𝐚𝐮_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 
91 Abeta Aggregation1 𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚
𝐤𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 𝐯𝟗𝟏 = 𝐤𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚
𝟐 ∗ 𝟎. 𝟓 
92 Abeta Plaque Formation1 𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝐤𝐩𝐟
→  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 𝐯𝟗𝟐 = 𝐤𝐩𝐟 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝟐 ∗ 𝟎. 𝟓 
93 Abeta Plaque Growth 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐩𝐟,𝐤𝐩𝐠𝐡𝐚𝐥𝐟
→        𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 𝐯𝟗𝟑 =
𝐤𝐩𝐟 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝐤𝐩𝐠𝐡𝐚𝐥𝐟𝟐 +𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞𝟐
 
94 Abeta Disaggregation1 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚
→          𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚 𝐯𝟗𝟒 = 𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 
95 Abeta Disaggregation3 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟏
→           𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟏 𝐯𝟗𝟓 = 𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟏 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
96 Abeta Disaggregation4 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟐
→           𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐚𝐧𝐭𝐢𝐀𝐛 +  𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟐 𝐯𝟗𝟔 = 𝐤𝐝𝐢𝐬𝐚𝐠𝐠𝐀𝐛𝐞𝐭𝐚𝟐 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 ∗ 𝐚𝐧𝐭𝐢𝐀𝐛 
97 Abeta_antiAb Binding 𝐀𝐛𝐞𝐭𝐚 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛
→          𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛 𝐯𝟗𝟕 = 𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛 ∗ 𝐀𝐛𝐞𝐭𝐚 ∗ 𝐚𝐧𝐭𝐢𝐀𝐛 
98 AbetaDimer_antiAb Binding 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 + 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛
→          𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛   𝐯𝟗𝟖 = 𝐤𝐛𝐢𝐧𝐀𝐛𝐚𝐧𝐭𝐢𝐀𝐛 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 ∗ 𝐚𝐧𝐭𝐢𝐀𝐛 
99 Abeta_antiAb Degredation 𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐚𝐧𝐭𝐢𝐀𝐛   𝐯𝟗𝟗 = 𝟏𝟎 ∗ 𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛 
100 AbetaDimer antiAb Degredation 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚
→        𝐚𝐧𝐭𝐢𝐀𝐛 𝐯𝟏𝟎𝟎 = 𝟏𝟎 ∗ 𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛 
101 Glia Activation Step1 𝐆𝐥𝐢𝐚𝐈 +  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏
→       𝐆𝐥𝐢𝐚𝐌𝟏 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 𝐯𝟏𝟎𝟏 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏 ∗ 𝐆𝐥𝐢𝐚𝐈 ∗  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
102 Glia Activation Step2 𝐆𝐥𝐢𝐚𝐌𝟏+  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏
→       𝐆𝐥𝐢𝐚𝐌𝟐 + 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 𝐯𝟏𝟎𝟐 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏 ∗ 𝐆𝐥𝐢𝐚𝐌𝟏 ∗  𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞 
103 Glia Activation Step3 𝐆𝐥𝐢𝐚𝐌𝟐+  𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐀 + 𝐚𝐧𝐭𝐢𝐀𝐛 𝐯𝟏𝟎𝟑 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐 ∗ 𝐆𝐥𝐢𝐚𝐌𝟐 ∗  𝐚𝐧𝐭𝐢𝐀𝐛 
104 Glia Inactivation Step1 𝐆𝐥𝐢𝐚𝐀
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐌𝟐 𝐯𝟏𝟎𝟒 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟏 ∗ 𝐆𝐥𝐢𝐚𝐀 
105 Glia Inactivation Step2 𝐆𝐥𝐢𝐚𝐌𝟐
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐌𝟏 𝐯𝟏𝟎𝟓 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐 ∗ 𝐆𝐥𝐢𝐚𝐌𝟐 
106 Glia Inactivation Step3 𝐆𝐥𝐢𝐚𝐌𝟏
𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐
→       𝐆𝐥𝐢𝐚𝐈 𝐯𝟏𝟎𝟔 = 𝐤𝐚𝐜𝐭𝐠𝐥𝐢𝐚𝟐 ∗ 𝐆𝐥𝐢𝐚𝐌𝟏 
107 Abeta Binding To Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮 +  𝐆𝐥𝐢𝐚𝐀
𝐤𝐛𝐢𝐧𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→          𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀 𝐯𝟏𝟎𝟕 = 𝐤𝐛𝐢𝐧𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮 ∗ 𝐆𝐥𝐢𝐚𝐀 
108 Abeta Release From Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐫𝐞𝐥𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→          𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮+  𝐆𝐥𝐢𝐚𝐀 𝐯𝟏𝟎𝟖 = 𝐤𝐫𝐞𝐥𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞_𝐆𝐥𝐢𝐚𝐀 
109 Abeta Plaque Clearance By Glia 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚
→           𝐆𝐥𝐢𝐚𝐀 + 𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 𝐯𝟏𝟎𝟗 = 𝐤𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞_𝐆𝐥𝐢𝐚𝐀 
110 ROS generation By Glia 𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀
𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐆𝐥𝐢𝐚
→         𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮_𝐆𝐥𝐢𝐚𝐀 + 𝐑𝐎𝐒 𝐯𝟏𝟏𝟎 = 𝐤𝐠𝐞𝐧𝐑𝐎𝐒𝐆𝐥𝐢𝐚 ∗ 𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞_𝐆𝐥𝐢𝐚𝐀 
111 antiAb Removal 𝐚𝐧𝐭𝐢𝐀𝐛
𝐤𝐝𝐞𝐠𝐀𝐧𝐭𝐢𝐀𝐛
→         𝐒𝐢𝐧𝐤 𝐯𝟏𝟏𝟏 = 𝐤𝐝𝐞𝐠𝐀𝐧𝐭𝐢𝐀𝐛 ∗ 𝐚𝐧𝐭𝐢𝐀𝐛 
112 ROS removal 𝐑𝐎𝐒
𝐤𝐫𝐞𝐦𝐑𝐎𝐒













𝐌𝐝𝐦𝟐 =  𝐯𝟑 +  𝐯𝟏𝟎 +  𝐯𝟐𝟒 +  𝐯𝟑𝟗 +  𝐯𝟕𝟐 −  𝐯𝟗 −  𝐯𝟏𝟕 −  𝐯𝟕𝟏 1 𝐩𝟓𝟑 =  𝐯𝟒 +  𝐯𝟏𝟎 +  𝐯𝟏𝟐 +  𝐯𝟐𝟕 +  𝐯𝟕𝟎 −  𝐯𝟒 −  𝐯𝟗 −  𝐯𝟏𝟏 −  𝐯𝟔𝟗 2 
𝐌𝐝𝐦𝟐_𝐩𝟓𝟑 =  𝐯𝟗 +  𝐯𝟑𝟓 −  𝐯𝟏𝟎 −  𝐯𝟐𝟖 3 𝐌𝐝𝐦𝟐_𝐦𝐑𝐍𝐀 =  𝐯𝟑 +  𝐯𝟒 +  𝐯𝟓 +  𝐯𝟔 +  𝐯𝟕 −  𝐯𝟑 −  𝐯𝟖 4 
𝐩𝟓𝟑_𝐦𝐑𝐍𝐀 =  𝐯𝟏 +  𝐯𝟐𝟕 +  𝐯𝟔𝟓 −  𝐯𝟐 −  𝐯𝟐𝟕 5 𝐀𝐓𝐌𝐀 =  𝐯𝟔𝟖 +  𝐯𝟔𝟗 +  𝐯𝟕𝟏 −  𝐯𝟔𝟗 −  𝐯𝟕𝟏 −  𝐯𝟖𝟑 6 
𝐀𝐓𝐌𝐈 =  𝐯𝟖𝟑 −  𝐯𝟔𝟖 7 𝐩𝟓𝟑_𝐏 =  𝐯𝟓 +  𝐯𝟏𝟒 +  𝐯𝟔𝟗 −  𝐯𝟓 −  𝐯𝟏𝟑 −  𝐯𝟕𝟎 8 
𝐌𝐝𝐦𝟐_𝐏 =  𝐯𝟕𝟏 +  𝐯𝟖𝟎 −  𝐯𝟕𝟐 −  𝐯𝟕𝟑 9 𝐈𝐑 =  𝐯𝟔𝟔 −  𝐯𝟔𝟔 10 
𝐑𝐎𝐒 =  𝐯𝟖𝟒 +  𝐯𝟖𝟓 +  𝐯𝟖𝟔 +  𝐯𝟖𝟕 +  𝐯𝟏𝟏𝟎 −  𝐯𝟖𝟕 −  𝐯𝟏𝟏𝟐 11 𝐝𝐚𝐦𝐃𝐍𝐀 =  𝐯𝟔𝟔 +  𝐯𝟔𝟖 +  𝐯𝟖𝟕 −  𝐯𝟔𝟕 −  𝐯𝟔𝟖 12 
𝐄𝟏 =  𝐯𝟏𝟔 −  𝐯𝟏𝟓 13 𝐄𝟐 =  𝐯𝟏𝟕 +  𝐯𝟏𝟖 +  𝐯𝟏𝟗 +  𝐯𝟐𝟎 +  𝐯𝟐𝟖 +  𝐯𝟐𝟗 +  𝐯𝟑𝟎 +  𝐯𝟑𝟏 +  𝐯𝟕𝟑 +  𝐯𝟕𝟒 +  𝐯𝟕𝟓 
+  𝐯𝟕𝟔 −  𝐯𝟏𝟔 
14 
𝐄𝟏_𝐔𝐛 =  𝐯𝟏𝟓 −  𝐯𝟏𝟔 15 𝐄𝟐_𝐔𝐛 =  𝐯𝟏𝟔 −  𝐯𝟏𝟕 −  𝐯𝟏𝟖 −  𝐯𝟏𝟗 −  𝐯𝟐𝟎 −  𝐯𝟐𝟖 −  𝐯𝟐𝟗 −  𝐯𝟑𝟎 −  𝐯𝟑𝟏 −  𝐯𝟕𝟑 
−  𝐯𝟕𝟒 −  𝐯𝟕𝟓 −  𝐯𝟕𝟔 
16 
𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦 =  𝐯𝟐𝟔 +  𝐯𝟒𝟎 +  𝐯𝟖𝟐 +  𝐯𝟗𝟎 −  𝐯𝟐𝟓 −  𝐯𝟑𝟗 −  𝐯𝟓𝟗 −  𝐯𝟔𝟑 −  𝐯𝟖𝟏 −  𝐯𝟖𝟗 17 𝐔𝐛 =  𝐯𝟐𝟏 +  𝐯𝟐𝟐 +  𝐯𝟐𝟑 +  𝐯𝟐𝟒 +  𝟒 ∗ 𝐯𝟐𝟔 +  𝐯𝟑𝟐 +  𝐯𝟑𝟑 +  𝐯𝟑𝟒 +  𝐯𝟑𝟓 +  𝟒 ∗ 𝐯𝟒𝟎 
+  𝐯𝟕𝟕 +  𝐯𝟕𝟖 +  𝐯𝟕𝟗 +  𝐯𝟖𝟎 +  𝟒 ∗ 𝐯𝟖𝟐 −  𝐯𝟏𝟓 
18 
𝐩𝟓𝟑𝐃𝐔𝐁 =  𝐯𝟑𝟐 +  𝐯𝟑𝟑 +  𝐯𝟑𝟒 +  𝐯𝟑𝟓 −  𝐯𝟑𝟐 −  𝐯𝟑𝟑 −  𝐯𝟑𝟒 −  𝐯𝟑𝟓 19 𝐌𝐝𝐦𝟐𝐃𝐔𝐁 =  𝐯𝟐𝟏 +  𝐯𝟐𝟐 +  𝐯𝟐𝟑 +  𝐯𝟐𝟒 +  𝐯𝟕𝟕 +  𝐯𝟕𝟖 +  𝐯𝟕𝟗 +  𝐯𝟖𝟎 −  𝐯𝟐𝟏 
−  𝐯𝟐𝟐 −  𝐯𝟐𝟑 −  𝐯𝟐𝟒 −  𝐯𝟕𝟕 −  𝐯𝟕𝟖 −  𝐯𝟕𝟗 −  𝐯𝟖𝟎 
20 
𝐃𝐔𝐁 =  𝟎 21 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛 =  𝐯𝟐𝟖 +  𝐯𝟑𝟒 −  𝐯𝟐𝟗 −  𝐯𝟑𝟓 22 
𝐌𝐝𝐦𝟐_𝐩𝟓𝟑 𝐔𝐛 = 𝐯𝟐𝟗 +  𝐯𝟑𝟑 −  𝐯𝟑𝟎 −  𝐯𝟑𝟒 
 
23 𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟑 =  𝐯𝟑𝟎 +  𝐯𝟑𝟐 −  𝐯𝟑𝟏 −  𝐯𝟑𝟑 24 
𝐌𝐝𝐦𝟐_𝐩𝟓𝟑_𝐔𝐛𝟒 =  𝐯𝟑𝟏 −  𝐯𝟑𝟐 −  𝐯𝟑𝟔 −  𝐯𝟑𝟕 −  𝐯𝟑𝟖 
 
25 𝐌𝐝𝐦𝟐_𝐏𝟏_𝐩𝟓𝟑_𝐔𝐛𝟒 =  𝐯𝟑𝟔 +  𝐯𝟑𝟕 +  𝐯𝟑𝟖 −  𝐯𝟑𝟗 
 
26 
𝐌𝐝𝐦𝟐_𝐔𝐛 =  𝐯𝟏𝟕 +  𝐯𝟐𝟑 −  𝐯𝟏𝟖 −  𝐯𝟐𝟒 27 𝐌𝐝𝐦𝟐_𝐔𝐛𝟐 =  𝐯𝟏𝟖 +  𝐯𝟐𝟐 −  𝐯𝟏𝟗 −  𝐯𝟐𝟑 28 
𝐌𝐝𝐦𝟐_𝐔𝐛𝟑 =  𝐯𝟏𝟗 +  𝐯𝟐𝟏 −  𝐯𝟐𝟎 −  𝐯𝟐𝟐 29 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒 =  𝐯𝟐𝟎 −  𝐯𝟐𝟏 −  𝐯𝟐𝟓 30 
𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛 =  𝐯𝟕𝟑 +  𝐯𝟕𝟗 −  𝐯𝟕𝟒 −  𝐯𝟖𝟎 
 
31 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟐 =  𝐯𝟕𝟒 +  𝐯𝟕𝟖 −  𝐯𝟕𝟓 −  𝐯𝟕𝟗 32 
𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟑 =  𝐯𝟕𝟓 +  𝐯𝟕𝟕 −  𝐯𝟕𝟔 −  𝐯𝟕𝟖 33 𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 =  𝐯𝟕𝟔 −  𝐯𝟕𝟕 −  𝐯𝟖𝟏 34 
𝐩𝟓𝟑_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 =  𝐯𝟑𝟗 −  𝐯𝟒𝟎 35 𝐌𝐝𝐦𝟐_𝐔𝐛𝟒_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 =  𝐯𝟐𝟓 −  𝐯𝟐𝟔 36 
𝐌𝐝𝐦𝟐_𝐏_𝐔𝐛𝟒 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 =  𝐯𝟖𝟏 −  𝐯𝟖𝟐 
 
37 𝐆𝐒𝐊𝟑𝐛 =  𝐯𝟏𝟐 +  𝐯𝟏𝟒 +  𝐯𝟑𝟔 +  𝐯𝟒𝟕 +  𝐯𝟒𝟖 −  𝐯𝟏𝟏 −  𝐯𝟏𝟑 −  𝐯𝟑𝟔 −  𝐯𝟒𝟕 −  𝐯𝟒𝟖 38 
 169 
𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑 =  𝐯𝟔 +  𝐯𝟏𝟏 +  𝐯𝟑𝟕 +  𝐯𝟒𝟑 +  𝐯𝟒𝟒 +  𝐯𝟔𝟏 −  𝐯𝟔 −  𝐯𝟏𝟐 −  𝐯𝟑𝟕 −  
𝐯𝟒𝟑 −  𝐯𝟒𝟒 −  𝐯𝟔𝟏 
39 𝐆𝐒𝐊𝟑𝐛_𝐩𝟓𝟑_𝐏 =    𝐯𝟕 +  𝐯𝟏𝟑  +  𝐯𝟑𝟖 +  𝐯𝟒𝟓 +  𝐯𝟒𝟔 +  𝐯𝟔𝟐 −  𝐯𝟕 − 𝐯𝟏𝟒 − 𝐯𝟑𝟖
−  𝐯𝟒𝟓 −  𝐯𝟒𝟔 −  𝐯𝟔𝟐 
40 
𝐀𝐛𝐞𝐭𝐚 =  𝐯𝟔𝟎 +  𝐯𝟔𝟏 +  𝐯𝟔𝟐 +  𝐯𝟔𝟓 +  𝐯𝟖𝟒 + 𝟐 ∗ 𝐯𝟗𝟒 −  𝐯𝟔𝟒 −  𝐯𝟔𝟓 −  𝐯𝟖𝟒 − 𝟐 ∗ 𝐯𝟗𝟏 
−  𝐯𝟗𝟕 
41 𝐀𝐠𝐠𝐀𝐛𝐞𝐭𝐚_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 =  𝐯𝟔𝟑 +  𝐯𝟖𝟔 −  𝐯𝟖𝟔 42 
𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪 =  𝐯𝟖𝟓 +  𝐯𝟗𝟐 +  𝟐 ∗ 𝐯𝟗𝟑 +  𝐯𝟏𝟎𝟏 +  𝐯𝟏𝟎𝟐 +  𝐯𝟏𝟎𝟖 −  𝐯𝟖𝟓 −  𝐯𝟗𝟑    
−  𝐯𝟗𝟓 −  𝐯𝟗𝟔 −  𝐯𝟏𝟎𝟏 −  𝐯𝟏𝟎𝟐 −  𝐯𝟏𝟎𝟕 
43 𝐓𝐚𝐮 =  𝐯𝟒𝟐 +  𝐯𝟓𝟎 +  𝐯𝟖𝟖 −  𝐯𝟒𝟏 −  𝐯𝟒𝟑 −  𝐯𝟒𝟓 −  𝐯𝟒𝟕 −  𝟐 ∗ 𝐯𝟓𝟓 −  𝐯𝟓𝟔 −  𝐯𝟖𝟗 
 
44 
𝐓𝐚𝐮_𝐏𝟏 =  𝐯𝟒𝟑 +  𝐯𝟒𝟓 +  𝐯𝟒𝟕 +  𝐯𝟒𝟗 −  𝐯𝟒𝟒 −  𝐯𝟒𝟔 −  𝐯𝟒𝟖 −  𝐯𝟓𝟎 −  𝟐 ∗  𝐯𝟓𝟏 
−  𝐯𝟓𝟐 
45 𝐓𝐚𝐮_𝐏𝟐 =  𝐯𝟒𝟒 +  𝐯𝟒𝟔 +  𝐯𝟒𝟖 −  𝐯𝟒𝟗 −  𝟐 ∗  𝐯𝟓𝟑 −  𝐯𝟓𝟒 46 
𝐌𝐓_𝐓𝐚𝐮 =  𝐯𝟒𝟏 −  𝐯𝟒𝟐 47 𝐀𝐠𝐠𝐓𝐚𝐮 =  𝟐 ∗ 𝐯𝟓𝟏 +  𝟐 ∗ 𝐯𝟓𝟐 +  𝟐 ∗ 𝐯𝟓𝟑 +  𝟐 ∗ 𝐯𝟓𝟒 +  𝟐 ∗ 𝐯𝟓𝟓 +  𝟐 ∗ 𝐯𝟓𝟔 
−  𝐯𝟓𝟐 −  𝐯𝟓𝟒 −  𝐯𝟓𝟔 −  𝟐 ∗ 𝐯𝟓𝟕 −  𝐯𝟓𝟖 −  𝐯𝟓𝟗 
48 
𝐀𝐠𝐠𝐓𝐚𝐮_𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞 =  𝐯𝟓𝟗 49 𝐏𝐫𝐨𝐭𝐞𝐚𝐬𝐨𝐦𝐞_𝐓𝐚𝐮 =  𝐯𝟖𝟗 −  𝐯𝟗𝟎 
 
50 
𝐏𝐏𝟏 =  𝐯𝟒𝟗 +  𝐯𝟓𝟎 −  𝐯𝟒𝟗 −  𝐯𝟓𝟎 51 𝐍𝐅𝐓 =  𝟐 ∗ 𝐯𝟓𝟕 +  𝟐 ∗ 𝐯𝟓𝟖 −  𝐯𝟓𝟖 52 
𝐀𝐓𝐏 =  𝟎 53 𝐀𝐃𝐏 =  𝟎 54 
𝐀𝐌𝐏 =  𝟎 55 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫 =  𝐯𝟗𝟏 +  𝐯𝟗𝟓 +  𝐯𝟗𝟔 −  𝐯𝟔𝟑 −  𝟐 ∗  𝐯𝟗𝟐 −  𝐯𝟗𝟑 −  𝐯𝟗𝟒 −  𝐯𝟗𝟖 56 
𝐀𝐛𝐞𝐭𝐚𝐏𝐥𝐚𝐪𝐮𝐞_𝐆𝐥𝐢𝐚𝐀 =  𝐯𝟏𝟎𝟕 +  𝐯𝟏𝟏𝟎 −  𝐯𝟏𝟎𝟖 −  𝐯𝟏𝟎𝟗 −  𝐯𝟏𝟏𝟎 57 𝐆𝐥𝐢𝐚𝐈 =  𝐯𝟏𝟎𝟔 −  𝐯𝟏𝟎𝟏 58 
𝐆𝐥𝐢𝐚𝐌𝟏 =  𝐯𝟏𝟎𝟏 +  𝐯𝟏𝟎𝟓 −  𝐯𝟏𝟎𝟐 −  𝐯𝟏𝟎𝟔 
 
59 𝐆𝐥𝐢𝐚𝐌𝟐 =  𝐯𝟏𝟎𝟐 +  𝐯𝟏𝟎𝟒 −  𝐯𝟏𝟎𝟑 −  𝐯𝟏𝟎𝟓 60 
𝐆𝐥𝐢𝐚𝐀 =  𝐯𝟏𝟎𝟑 +  𝐯𝟏𝟎𝟖 +  𝐯𝟏𝟎𝟗 −  𝐯𝟏𝟎𝟒 −  𝐯𝟏𝟎𝟕 61 𝐚𝐧𝐭𝐢𝐀𝐛 =  𝐯𝟗𝟔 +  𝐯𝟗𝟗 +  𝐯𝟏𝟎𝟎 +  𝐯𝟏𝟎𝟑 −  𝐯𝟗𝟔 −  𝐯𝟗𝟕 −  𝐯𝟗𝟖 −  𝐯𝟏𝟎𝟑 −  𝐯𝟏𝟏𝟏 
 
62 
𝐀𝐛𝐞𝐭𝐚_𝐚𝐧𝐭𝐢𝐀𝐛 =  𝐯𝟗𝟕 −  𝐯𝟗𝟗 63 𝐀𝐛𝐞𝐭𝐚𝐃𝐢𝐦𝐞𝐫_𝐚𝐧𝐭𝐢𝐀𝐛 =  𝐯𝟗𝟖 −  𝐯𝟏𝟎𝟎 64 
𝐝𝐞𝐠𝐀𝐛𝐞𝐭𝐚𝐆𝐥𝐢𝐚 =  𝐯𝟏𝟎𝟗 65 𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟏 =  𝐯𝟗𝟓 
 
66 
𝐝𝐢𝐬𝐚𝐠𝐠𝐏𝐥𝐚𝐪𝐮𝐞𝟐 =  𝐯𝟗𝟔 67 𝐒𝐨𝐮𝐫𝐜𝐞 =  𝟎 68 













Table B.3: Species of the system 
Name  Initial value  Description Name  Initial value  Description 
Mdm2 5.0 E3 ubiquitin-protein ligase Mdm2 (Unbound 
Mdm2 protein) 
Proteasome 500.0 A large multisubunit complex catalyzes protein 
degradation 
p53 5.0 Cellular tumor antigen p53 (Unbound p53 
protein) 
Ub 4000.0 Polyubiquitin-B exists either covalently attached to 
another protein, or free (unanchored). 
Mdm2_p53 95.0 Mdm2/p53 complex p53DUB 200.0 Deubiquitinating enzyme for p53 
Mdm2_mRNA 10.0 Mdm2 messenger RNA Mdm2DUB 200.0 Deubiquitinating enzyme for Mdm2 
p53_mRNA 10.0 p53 messenger RNA DUB 200.0 Ubiquitin carboxyl-terminal hydrolase DUB controls 
levels of cellular ubiquitin through processing of 
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ubiquitin precursors and ubiquitinated proteins. 
Thiol protease that recognizes and hydrolyzes a 
peptide bond at the C-terminal glycine of either 
ubiquitin or RUB1. Preferentially cleaves ubiquitin 
from peptides and small adducts 
ATMA 0.0 Serine-protein kinase ATM (Active ATM) Mdm2_p53_Ub 0.0 Monoubiquitinated p53 
ATMI 200.0 Inactive ATM Mdm2_p53_Ub2 0.0 Polyubiquitinated p53 
p53_P 0.0 Phosphorylated p53 Mdm2_p53_Ub3 0.0 Polyubiquitinated p53 
Mdm2_P 0.0 Phosphorylated Mdm2 Mdm2_p53_Ub4 0.0 Polyubiquitinated p53 
IR 0.0 IR Ionizing radiation Mdm2_P1_p53_Ub4 0.0 Phosphorylated Mdm2 bound to p53 
ROS 0.0 Reactive Oxygen Species: Molecules or ions 
formed by the incomplete one-electron 
reduction of oxygen.  
Mdm2_Ub 0.0 Monoubiquitinated Mdm2 
damDNA 0.0 Deoxyribonucleic acid Mdm2_Ub2 0.0 Polyubiquitinated Mdm2 
E1 100.0 Ubiquitin/SUMO-activating enzyme E1: alters 
the function, location or trafficking of a protein  
Mdm2_Ub3 0.0 Polyubiquitinated Mdm2 
E2 100.0 Ubiquitin-conjugating enzymes: catalyse the 
covalent attachment of ubiquitin to target 
proteins 
Mdm2_Ub4 0.0 Polyubiquitinated Mdm2 
E1_Ub 0.0 E1 bound by Ub Mdm2_P_Ub 0.0 Monoubiquitinated phospho-Mdm2 
E2_Ub 0.0 E2 bound by Ub Mdm2_P_Ub2 0.0 Polyubiquitinated phospho-Mdm2  
Mdm2_P_Ub3 0.0 Polyubiquitinated phospho-Mdm2 Mdm2_Ub4_Proteasome 0.0 Mdm2 bound to proteasome 
Mdm2_P_Ub4 0.0 Polyubiquitinated phospho-Mdm2 Mdm2_P_Ub4-
Proteasome 
0.0 Mdm2 bound to proteasome 
p53_Ub4_Proteasome 0.0 p53 bound to proteasome GSK3b 500.0 Glycogen synthase kinase-3 beta. Constitutively 
active protein kinase that acts as a negative 
regulator in the hormonal control of glucose 
homeostasis.  
GSK3β _p53 0.0 GSK3β bound to p53 AMP (constant) 1000.0 Adenosine monophosphate 
GSK3β _p53_P 0.0 GSK3β bound to phosphorylated p53 AbetaDimer 0.0  
Abeta 0.0 Amyloid-beta A4 protein  AbetaPlaque_GliaA 0.0  
AggAbeta-
Proteasome 
0.0 AggAbeta bound to the proteasome GliaI 100.0 Inactive Glia. 
AbetaPlaque 0.0 Aβ plaque GliaP1 0.0 Partially active Glia 1 
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Tau 0.0 Microtubule-associated protein Tau GliaP2 0.0 Partially active Glia 2 
Tau_P1 0.0 tau phosphorylated by GSK3β at one site GliaA 0.0 Glia active 
Tau_P2 0.0 tau phosphorylated by GSK3β at two sites antiAb 0.0 Antibody against amyloid-beta 
MT_Tau 100.0 tau bound to the microtubule  50.0 𝒕 ≥ 𝟑𝟒𝟓𝟔𝟎𝟎 
AggTau 0.0 small aggregate of tau Abeta_antiAb 0.0 Abeta monomer bound to antibody 
AggTau_Proteasome 0.0 AggTau bound to proteasome AbetaDimer_antiAb 0.0 Abeta dimer bound to antibody 
Proteasome_Tau 0.0 Tau bound to proteasome degAbetaGlia 0.0  
PP1 50.0 Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit is essential for cell 
division. 
disaggPlaque1 0.0  
NFT 0.0 tau neurofibrillary tangle disaggPlaque2 0.0  
ATP (constant) 10000.0 Adenosine triphosphate Source (constant) 1.0 An empty set: it is often used to represent the 
source of a creation process.  
ADP (constant) 1000.0 Adenosine diphosphate: A purine ribonucleoside 
5'-diphosphate having adenine as the 
nucleobase 
Sink (constant) 1.0 An empty set: it is often used to represent the result 






Table B.4: Parameters of the system 
Rate constant (𝐤𝐬) Description value Rate constant (𝐤𝐬) Description value 
ksynp53mRNA p53mRNASynthesis 0.001 kMdm2Ub Mdm2Ubiquitination 4.56 *10-6 
kdegp53mRNA p53mRNADegradation 10-4 kMdm2PUb Mdm2PUbiquitination 6.84 *10-6 
ksynMdm2mRNA Mdm2mRNASynthesis1 5.10-4 kMdm2PolyUb Mdm2polyUbiquitination1 0.005 
kdegMdm2mRNA Mdm2mRNADegradation 5.10-4 kdam DNAdamage 0.080 
ksynMdm2mRNAGSK3bp53 Mdm2mRNASynthesis3 7 * 10-4 krepair DNArepair 2 * 10-5 
ksynp53 p53Synthesis 0.007 kactATM ATMactivation 10-4 
kdegp53 p53Degradation 0.005 kinactATM ATMinactivation 5 * 10-4 
kbinMdm2p53 p53Mdm2Binding 0.001 kphosp53 p53phosphorylation 2 * 10-4 
krelMdm2p53 p53Mdm2Release 1.155 *10-5 kdephosp53 p53dephosphorylation 0.500 
kbinGSK3bp53 GSK3p53Binding 2 * 10-6 kphosMdm2 Mdm2phosphorylation 2.000 
krelGSK3bp53 GSK3p53Release 0.002 kdephosMdm2 Mdm2dephosphorylation 0.500 
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ksynMdm2 Mdm2Synthesis 4.95 * 10-4 kphosMdm2GSK3b Mdm2GSK3phosphorylation1 0.005 
kdegMdm2 Mdm2Degradation 0.010 kphosMdm2GSK3bp53 Mdm2GSK3phosphorylation2 0.500 
kbinE1Ub E1UbBinding 2 * 10-4 kphospTauGSK3bp53 Tauphosphorylation4 0.100 
kbinE2Ub  E2UbBinding 0.001 kphospTauGSK3b Tauphosphorylation6 2 * 10-4 
kp53Ub p53Monoubiquitination 5 * 10-5 kdephospTau Taudephosphorylation2 0.010 
kp53PolyUb p53Polyubiquitination 0.010 kbinMTTau TauMTbinding 0.100 
kbinProt Mdm2ProteasomeBinding1 2 * 10-6 krelMTTau TauMTrelease 10-4 
kactDUBp53 p53Deubiquitination3 10-7 ksynTau TauSynthesis 8 * 10-5 
kactDUBMdm2 Mdm2PDeubiquitination4 10-7 kbinTauProt TauProteasomeBinding 1.925 *10-7 
kproteff Extra parameter is used in different 
degradation reactions 
1.000 kdegTau20SProt Tau20SProteasomeDegradation 0.010 
kremROS ROSremoval 7 * 10-5 kaggTau Tauaggregation1 10-8 
kprodAbeta Abetaproduction1 1.86 *10-5 kaggTauP1 auP1Aggregation1 10-8 
kprodAbeta2 Abetaproduction2 1.86 *10-5 kaggTauP2 TauP2Aggregation1 10-7 
kdegAbeta AbetaDegredation 1.5 *10-5 ktangfor TangleFormation1 0.001 
kaggAbeta Abetaaggregation1 3 *10-6 kinhibprot ProteasomeInhibitionAggTau 10-7 
kdisaggAbeta AbetaDisaggregation1 10-6 ksynp53mRNAAbeta p53transcriptionViaAbeta 10-7 
kdisaggAbeta1 AbetaDisaggregation3 2 *10-4 kdamROS ROSDNAdamage 10-5 
kdisaggAbeta2 AbetaDisaggregation4 10-6 kgenROSAbeta AggAbetaROSproduction2 2*10-5 
kdegAbetaGlia Abeta_antiAbDegredation 0.005 kgenROSPlaque PlaqueROSproduction 10-5 
kpf AbetaPlaqueFormation 0.200 kgenROSGlia ROSgenerationByGlia 10-5 
kpg AbetaPlaqueGrowth 0.150 kinactglia2  GliaInactivationStep3 5 *10-6 
kpghalf AbetaPlaqueGrowth1 10.000 kbinAbetaGlia AbetaBindingToGlia 10-5 
kactglia1 GliaActivationStep1 6 *10-7 krelAbetaGlia AbetaReleaseFromGlia 5 *10-5 
kactglia2 GliaActivationStep3 6 *10-7 kdegAntiAb antiAbRemoval 2.75 *10-6 




Figure 1: p53 regulation. This graph shows how p53 and Mdm2 are produced and degrade. Both of them are degraded using proteasome system but 
p53 should bind to Mdm2 to be degraded (middle part of the graph). On the left top side, the graph shows how the species of p53_mRNA produced, 
degrade and how it is considered as another pathway to increase the unbound p53 in the systems. The species of p53_mRNA is indirectly increased 
as a result of the DNA damage since Aβ (increased through GSK3b when there is a damage) increases the production of p53_mRNA. On the right top 
side, the graph shows how p53, p53_P, p53_GSK3b and (p53_GSK3b)_P are used to be a modifier to increase the production of Mdm2_mRNA. On 
the left bottom side, the graph shows how E1 (Ubiquitin/SUMO-activating enzymes) binds with Ub (Polyubiquitin-B) to E1_Ub and later E1 is replaced 
by E2 (Ubiquitin-conjugating enzymes) to produce E2_Ub that is used for degradation process as shown in the graph. Dashed lines from a species 
indicates the species is a modifier of the reaction. 
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Appendix C includes Tables C.1 and C.2. In Table C.1, we list the results of LSA 




TableC.1: LSA results using ODEs 
 
Species  p53 ATMA GSK3b_p53 Aβ Plaques Tangles GliaA 
Parameters P.V 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 
1. kactATM 𝜇 -34.35 31.89 -31.26 38.59 -14.16 12.31 -2.661 2.157 -3.207 2.86 -5.529 7.658 -11.13 3.526 
𝜎 9.085 6.747 11.72 10.48 3.50 2.58 0.622 0.515 6.820 5.19 3.982 5.258 8.789 2.768 
Max -47.85 41.34 -51.84 51.67 -19.12 16.02 -3.556 3.103 -20.29 15.08 -12.70 17.06 -23.57 7.407 
Time 281253 177972 329193 214557 272604 167652 268794 101238 276054 212670 1036800 1036800 444993 446820 
2. kactDUBMdm2 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
3. kactDUBp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
4. kactDUBProtp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
5. kactglia1 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 -10.05 6.309 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 7.930 4.948 
Max 0 0 0 0 0 0 0 0 0 0 0 0 -21.25 13.22 
Time             445746 446370 
6. Kactglia2 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 -7.115 7.135 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 5.250 5.210 
Max 0 0 0 0 0 0 0 0 0 0 0 0 -15.11 16.27 
Time             394071 369540 
7. kaggAbeta  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
               
8. kaggTau 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
9. kaggTauP1 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Time               
10. kaggTauP2 𝜇 0 0 0 0 0 0 0 0 0 0 -3.742 6.613 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 2.701 4.601 0 0 
Max 0 0 0 0 0 0 0 0 0 0 -8.635 14.51 0 0 






𝜇 3.085 -5.54 2.847 -4.98 1.226 -2.233 1.050 -1.694 0 0 0 0 0 0 
𝜎 2.513 4.49 2.368 4.092 1.004 1.827 0.849 1.293 0 0 0 0 0 0 
Max 6.65 -11.65 6.149 -10.30 2.667 -4.759 2.287 -3.194 0 0 0 0 0 0 
Time 565974 595521 567300 598410 567234 595905 381069 378612       
12. kbinAbetaGlia 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
13. kbinE1Ub 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
14. kbinE2Ub 𝜇 -5.403 2.764 -3.158 3.095 -2.158 1.095 0 0 -1.117 0.6018 0 0 0 0 
𝜎 1.815 0.932 0.782 0.746 0.682 0.346 0 0 0.793 0.4246 0 0 0 0 
Max -8.328 4.268 -2.146 8.994 -3.146 1.594 0 0 -2.502 1.337 0 0 0 0 
Time 347937 347487 338525 339038 348525 349038   1036780 1036790     
15. kbinGSK3bp53 𝜇 -14.57 2.595 -22.15 19.25 -26.21 40.95 -5.178 6.077 -5.407 7.059 -7.351 29.20 -22.87 5.568 
𝜎 8.848 3.866 12.18 7.145 6.957 8.858 1.179 1.137 11.96 12.22 5.383 18.26 18.08 4.325 
Max -34.48 12.851 -51.43 34.36 -37.25 50.03 -7.101 7.360 -43.77 33.69 -17.19 57.44 -48.41 11.46 
Time 350583 180801 359379 213141 349458 230649 345582 200985 345600 223155 1036800 1036800 448092 454383 
16. kbinMdm2p53 𝜇 62.95 -41.89 12.50 -13.44 23.66 -17.42 3.710 -3.258 4.336 -3.759 16.01 -6.223 4.606 -14.24 
𝜎 15.51 11.64 4.946 7.175 5.200 4.507 0.706 0.730 7.738 8.196 10.57 4.496 3.599 11.25 
Max 81.53 -60.48 23.12 -29.82 29.33 -24.17 4.561 -4.408 21.51 6.162 33.36 -14.32 9.579 -30.18 
Time 268470 325509 223923 306858 235170 311250 210189 300108 231708 364842 1036800 1036800 451998 444831 
17. kbinMTTau 𝜇 0 0 0 0 0 0 0 0 0 0 12.19 -5.379 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 8.263 3.909 0 0 
Max 0 0 0 0 0 0 0 0 0 0 25.79 -12.51 0 0 
Time           1036800 1036800   
18. kbinProt 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
19. kbinTauProt 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Time               
20. kdam 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
21. kdamROS 𝜇 -34.36 31.89 -31.26 38.59 -14.16 12.31 -2.66 2.16 -3.21 2.86 -5.53 7.66 -11.13 3.53 
𝜎 9.086 6.747 11.72 10.48 3.503 2.579 0.622 0.515 6.820 5.195 3.982 5.258 8.789 2.768 
Max -47.85 41.34 -51.84 51.67 -19.12 16.02 -3.56 3.10 -20.29 15.08 -12.70 17.06 -23.57 7.41 
Time 281253 177972 329265 214557 272604 167652 268794 101238 276150 212496 1036800 1036800 445053 446820 
22. kdegAbeta 𝜇 10.21 -10.12 9.10 -8.92 4.01 -8.92 4.48 -3.59 0 0 2.10 -1.80 0 0 
𝜎 3.407 3.225 3.272 3.041 1.336 3.041 1.649 1.124 0 0 1.592 1.379 0 0 
Max 13.93 -13.26 12.90 -12.05 5.44 -12.05 7.02 -5.20 0 0 5.38 -4.63 0 0 
Time 1036640 1036550 1036800 1036790 1036800 1036790 345594 345582   1036800 1036790   
23. kdegAbetaGlia 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
24. kdegAntiAb 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
25. kdegMdm2 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
26. kdegMdm2mRNA 𝜇 -42.82 66.23 -13.67 12.81 -17.81 24.79 -3.33 3.85 -3.79 4.38 -6.30 16.93 -14.42 4.66 
𝜎 12.257 17.183 7.282 4.976 4.778 5.788 0.783 0.785 8.267 7.838 4.565 11.208 11.393 3.638 
Max -61.97 86.49 -30.16 23.10 -24.76 30.75 -4.52 4.72 -25.06 21.76 -14.55 35.24 -30.55 9.68 
Time 331983 289122 309192 227061 316494 247779 304401 218409 292026 236790 1036800 1036800 444888 451929 
27. kdegp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
28. kdegp53mRNA 𝜇 -42.82 66.23 -13.67 12.81 -17.81 24.79 -3.33 3.85 -3.79 4.38 -6.30 16.93 -14.42 4.66 
𝜎 12.257 17.183 7.282 4.976 4.778 5.788 0.783 0.785 8.267 7.838 4.565 11.208 11.393 3.638 
Max -61.97 86.49 -30.16 23.10 -24.76 30.75 -4.52 4.72 -25.06 21.76 -14.55 35.24 -30.55 9.68 
Time 331983 289122 309192 227061 316494 247779 304401 218409 292026 236790 1036800 1036800 444888 451929 
29. kdegTau20SProt 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
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30. kdephosMdm2 𝜇 61.974 -41.287 12.081 -13.005 23.281 -17.145 3.630 -3.183 4.135 -3.655 15.784 -6.182 4.534 -13.63 
𝜎 16.226 11.963 4.828 6.998 5.544 4.672 0.782 0.785 7.434 7.920 10.499 4.472 3.542 10.77 
Max 80.603 -59.632 22.037 -28.712 28.904 -23.809 4.476 -4.333 20.686 -23.868 33.070 -14.249 9.426 -28.90 
Time 278106 326274 228534 305481 242070 311115 216123 299103 236964 289572 1036800 1036800 451443 445254 
31. kdephosp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
32. kdephospTau 𝜇 0 0 0 0 0 0 0 0 0 0 34.404 -7.156 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 21.859 5.256 0 0 
Max 0 0 0 0 0 0 0 0 0 0 67.761 -16.870 0 0 
Time           1036800 1036800   
33. kdisaggAbeta 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
34. kdisaggAbeta1 𝜇 4.888 -9.844 4.827 -9.565 1.931 -3.938 1.316 -2.301 1.639 -3.001 1.142 -2.177 2.022 -10.02 
𝜎 1.756 4.488 2.236 5.634 0.662 1.703 0.301 0.613 3.046 6.342 0.741 1.422 1.547 7.913 
Max 8.840 -20.158 9.709 -22.470 3.445 -7.859 1.741 -3.391 8.582 -18.722 2.304 -4.326 4.091 -21.21 
Time 216906 270186 237822 288456 212193 265518 216075 272304 240267 275985 1036800 1036780 476580 447498 
35. kdisaggAbeta2 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
36. kgenROSAbeta 𝜇 -30.627 28.992 -27.988 34.275 -12.608 11.258 -2.378 1.985 -2.969 2.619 -4.836 6.474 -9.784 3.261 
𝜎 7.588 7.159 9.086 9.412 3.041 2.834 0.602 0.567 6.276 4.778 3.541 4.695 7.730 2.561 
Max -41.290 37.284 -42.318 42.567 -16.685 14.952 -3.149 3.060 -18.854 14.231 -11.561 15.516 -20.75 6.873 
Time 242751 148149 270192 185523 237501 122079 237288 98832 264465 205047 1036800 1036800 444531 445506 
37. kgenROSGlia 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
38. kgenROSPlaque 𝜇 -3.165 4.768 -3.723 5.985 -1.231 1.823 0 0 0 0 0 0 0 0 
𝜎 4.017 5.526 5.070 7.625 1.534 2.059 0 0 0 0 0 0 0 0 
Max -12.526 15.871 -16.574 23.115 -4.719 5.789 0 0 0 0 0 0 0 0 
Time 353844 347358 359337 357699 356268 347268         
39. kinactATM 𝜇 31.34 -34.140 38.06 -31.122 12.088 -14.06 2.108 -2.64 2.680 -3.15 7.537 -5.51 3.415 -10.82 
𝜎 6.963 9.107 10.65 11.664 2.639 3.518 0.498 0.622 4.893 6.674 5.237 3.971 2.679 8.546 
Max 39.91 -47.23 50.26 -51.28 15.43 -18.87 2.83 -3.51 14.16 -19.83 16.93 -12.67 7.17 -22.92 
Time 183405 280470 219969 329517 173385 271425 115635 268401 217392 275832 1036800 1036800 447441 444993 
𝜇 0 0 0 0 0 0 0 0 0 0 0 0 6.171 -7.02 
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40. kinactglia1 𝜎 0 0 0 0 0 0 0 0 0 0 0 0 5.394 5.591 
Max 0 0 0 0 0 0 0 0 0 0 0 0 13.76 -12.95 
Time             1036760 780846 
41. kinactglia2 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 6.520 -7.98 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 4.894 5.929 
Max 0 0 0 0 0 0 0 0 0 0 0 0 11.03 -13.81 
Time             797667 579348 
42. kinhibprot 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
43. kMdm2PolyUb 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
44. kMdm2PUb 𝜇 -41.118 61.75 -12.871 11.98 -17.069 23.19 -3.162 3.61 -3.608 4.07 -6.169 15.72 -13.373 4.51 
𝜎 12.031 16.377 6.889 4.768 4.708 5.613 0.793 0.792 7.797 7.334 4.466 10.492 10.566 3.522 
Max -59.21 80.28 -28.23 21.69 -23.63 28.74 -4.30 4.44 -23.46 20.41 -14.23 33.02 -28.33 9.37 
Time 326907 284235 304800 229758 311487 245631 298704 219036 289533 238710 1036800 1036800 444993 451731 
45. kMdm2Ub 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
46. kp53PolyUb 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
47. kp53Ub 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
48. kpf 𝜇 0 0 0 0 0 0 0 0 1.795 -1.81 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 3.772 3.903 0 0 0 0 
Max 0 0 0 0 0 0 0 0 14.77 -13.59 0 0 0 0 
Time         345756 345600     
49. kpg 𝜇 -3.104 2.30 -3.736 2.92 -1.199 0.88 0 0 -3.435 3.41 -1.122 0.88 -13.679 4.90 
𝜎 5.482 3.562 6.723 4.633 2.107 1.350 0 0 7.880 7.158 0.702 0.537 10.870 3.889 
Max -15.46 9.28 -19.98 13.31 -5.85 3.41 0 0 -25.99 29.19 -1.77 1.38 -29.28 10.44 
Time 339624 355254 352941 358794 330063 357303   345600 345831 571725 576147 444378 445506 
𝜇 1.656 -4.57 1.965 -5.40 0.641 -1.78 0 0 1.870 -4.70 0.574 -1.64 2.537 -21.79 
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50. kpghalf 𝜎 2.655 9.023 3.146 10.757 1.029 3.497 0 0 3.455 11.676 0.305 1.060 2.007 17.368 
Max 8.53 -26.93 9.81 -33.75 3.34 -10.32 0 0 10.40 -42.48 0.82 -2.70 5.39 -46.78 
Time 207129 358854 221706 360150 204762 360306   183114 345600 546396 568584 444774 446586 
51. kphosMdm2 𝜇 -41.31 62.11 -13.01 12.10 -17.15 23.33 -3.185 3.64 -3.658 4.14 -6.185 15.82 -13.656 4.54 
𝜎 11.97 16.258 7.006 4.835 4.676 5.555 0.785 0.784 7.928 7.448 4.474 10.522 10.791 3.545 
Max -59.68 80.77 -28.74 22.07 -23.83 28.96 -4.34 4.48 -23.89 20.72 -14.26 33.14 -28.94 9.43 
Time 326274 278373 305709 228528 311658 241953 298878 216435 289575 237087 1036800 1036800 445023 451422 
52. kphosMdm2GSK3b 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
53. kphosMdm2GSK3bp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
54. kphosp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
55. kphospTauGSK3b 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
56. kphospTauGSK3bp53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
57. kprodAbeta 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
58. kprodAbeta2 𝜇 -28.858 28.30 -26.034 27.86 -11.805 10.97 -6.151 9.66 -5.579 11.00 -5.173 6.98 -23.04 6.32 
𝜎 10.761 7.386 12.933 9.526 4.163 2.756 1.389 1.837 12.099 18.48 3.632 4.526 18.20 4.859 
Max -51.04 43.67 -56.20 47.07 -20.01 16.81 -8.28 11.53 -44.51 50.37 -11.10 14.51 -48.72 12.76 
Time 349659 183744 359514 204696 350250 176646 345597 202983 345600 218892 1036800 1036800 448242 460059 
59. kproteff 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
60. krelAbetaGlia 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
61. krelGSK3bp53 𝜇 2.505 -14.53 19.139 -22.13 40.851 -26.20 6.057 -5.17 6.990 -5.41 29.135 -7.35 5.559 -22.87 
𝜎 3.757 8.848 7.091 12.180 8.962 6.971 1.151 1.182 12.121 11.957 18.260 5.383 4.318 18.079 
Max 12.56 -34.45 34.03 -51.40 49.89 -37.25 7.33 -7.10 33.42 -43.77 57.40 -17.19 11.44 -48.41 
Time 181275 350583 214329 359379 232335 349644 202716 345597 224340 345600 1036800 1036800 454743 448092 
62. krelMdm2p53 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
63. krelMTTau 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
64. kremROS 𝜇 29.289 -33.008 35.918 -30.380 11.267 -13.570 1.940 -2.521 1.948 -2.804 6.996 -5.372 2.834 -9.101 
𝜎 8.013 9.214 11.532 11.322 3.017 3.603 0.509 0.633 3.598 5.840 5.184 3.912 2.217 7.181 
Max 35.161 -43.405 46.275 -47.836 13.511 -17.312 2.280 -3.212 10.324 -17.231 16.415 -12.480 5.918 -19.24 
Time 475563 276084 431373 332922 496650 265425 553347 260556 236898 275760 1036800 1036800 447549 445746 
65. krepair 𝜇 27.018 -31.175 33.279 -28.98 10.38 -12.79 1.771 -2.351 1.179 -2.050 6.240 -5.068 1.960 -5.865 
𝜎 10.757 10.127 13.912 10.98 4.119 4.098 0.695 0.733 2.166 4.123 5.131 3.799 1.523 4.613 
Max 39.035 -43.773 48.566 -44.64 15.06 -17.90 2.549 -3.141 6.257 -12.124 15.784 -12.077 4.055 -12.32 
Time 522477 434118 491286 403461 530289 441357 551970 467745 264393 281952 1036800 1036800 446370 446451 
66. ksynMdm2 𝜇 66.55 -43.078 12.952 -13.88 24.91 -17.92 3.879 -3.35 4.466 -3.853 17.01 -6.322 4.689 -14.79 
𝜎 16.95 12.135 5.058 7.436 5.684 4.715 0.770 0.768 7.974 8.443 11.21 4.573 3.662 11.69 
Max 86.89 -62.550 23.571 -30.866 30.95 -25.01 4.764 -4.567 22.131 -25.65 35.31 -14.570 9.742 -31.36 
Time 281985 331008 225297 310458 243270 316686 215322 305361 234120 292248 1036800 1036800 451713 444831 
67. ksynMdm2mRNA 𝜇 32.13 -31.46 7.033 -9.427 12.41 -12.94 2.015 -2.356 2.294 -2.718 7.727 -5.176 3.235 -8.725 
𝜎 8.611 8.790 2.893 4.730 3.020 3.361 0.426 0.535 4.231 5.639 5.278 3.718 2.536 6.888 
Max 43.16 -44.58 13.02 -19.806 15.84 -17.604 2.525 -3.136 11.82 -16.51 16.66 -11.83 6.765 -18.46 
Time 303597 316701 238794 285615 264360 296766 233442 280677 247236 277563 1036800 1036800 449835 446094 
68. ksynMdm2mRNAGSK3bp53 𝜇 17.35 -22.851 4.100 -6.549 6.807 -9.317 1.133 -1.667 1.323 -1.940 3.929 -4.045 2.144 -5.446 
𝜎 4.459 6.213 1.763 3.175 1.594 2.344 0.235 0.368 2.475 3.919 2.719 2.889 1.684 4.296 
Max 22.97 -31.693 7.883 -13.472 8.659 -12.43 1.429 -2.185 6.960 -11.32 8.626 -9.194 4.500 -11.50 
Time 275169 299355 241620 273165 248913 280344 227931 264141 246306 268428 1036800 1036800 448497 446325 
69. ksynp53 𝜇 -41.32 60.993 -13.29 13.06 -17.173 23.08 -3.22 3.714 -3.746 4.763 -6.176 15.425 -14.15 4.697 
𝜎 11.23 12.221 7.121 5.501 4.323 3.932 0.691 0.552 8.164 8.337 4.454 9.937 11.18 3.674 
Max -59.71 78.827 -29.65 25.79 -23.862 31.55 -4.349 4.862 -24.68 23.261 -14.18 31.61 -30.01 9.790 
Time 322761 234786 305643 210717 309147 2934 299487 72684 288234 2145 1036800 1036800 444597 451167 
70. ksynp53mRNA 𝜇 -36.61 52.03 -11.46 11.00 -15.14 19.80 -2.808 3.175 -3.281 3.878 -5.727 13.022 -11.52 4.312 
𝜎 9.705 11.59 5.944 4.581 3.712 3.869 0.596 0.543 6.976 6.920 4.124 8.626 9.100 3.374 
Max -51.22 66.56 -24.90 21.33 -20.40 24.48 -3.692 3.914 -20.74 19.323 -13.11 27.300 -24.40 8.992 
Time 306234 244245 293031 220365 292770 220002 282657 201135 279051 224874 1036800 1036800 445542 450477 
𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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71. ksynp53mRNAAbeta 𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
72. ksynTau 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time               
73. ktangfor 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 












Table C.2: LSA results using MRM/GSSA 
Species   p53  ATMA GSK3b_p53 Aβ Plaques Tangles GliaA 
Parameters P.V 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 50% 200% 
1. kactATM 𝜇 -21.62 31.73 -25.22 34.34 -8.780 11.411 -1.48 2.98 0.148 1.717 -6.228 3.948 2.738 -0.700 
𝜎 47.33 58.31 31.48 35.36 20.83 24.07 4.81 5.406 2.277 4.261 4.865 3.447 3.360 3.368 
Max -168 281 -102 151 -86 112 -16 24 13 22 -16 12 13 -11 
Time 868600 937100 871500 142200 869300 422200 425500 426000 266100 274700 922800 956100 371600 356700 
2. kactDUBMdm
2 
𝜇 2.42 -25.06 -2.62 -20.68 1.303 -10.236 -0.23 -2.43 3.235 0.990 -1.227 -5.215 0.188 2.202 
𝜎 54.83 64.52 38.74 40.73 23.56 28.18 4.880 6.454 6.019 4.052 4.524 7.713 4.420 4.531 
Max 176 -194 -111 -106 87 -91 -18 -18 21 22 -10 -20 10 17 
Time 29400 968700 833100 867200 28400 718200 533100 741500 119200 254700 1017900 1017900 743100 413500 
3. kactDUBp53 𝜇 -6.67 26.35 -3.67 -28.19 -3.308 -14.18 -1.15 -3.83 -3.854 -5.734 -8.558 -6.025 -6.616 -22.54 
𝜎 63.44 55.51 49.56 49.05 26.98 30.58 5.930 6.546 7.361 16.554 6.708 5.009 7.310 19.471 
Max -183 218 -116 -143 -84 -92 -19 -25 -26 -64 -22 -18 -25 -55 
Time 1003900 343100 210400 340800 204300 267700 118900 256600 331300 345500 922800 731400 642900 427800 
4. kactDUBProtp
53 
𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
5. kactglia1 𝜇 36.86 23.09 0.17 -5.02 1.145 -4.264 0.10 -1.62 0.619 0.150 3.745 -4.845 -3.906 5.889 
𝜎 67.18 84.68 28.16 27.76 20.48 19.40 4.421 5.170 3.162 3.098 2.617 4.802 3.844 5.817 
Max 257 232 106 -93 70 -65 14 -17 18 19 10 -16 -16 18 
Time 328800 326700 1006700 847600 937800 994700 224900 810400 255700 354400 488300 1017900 427800 423900 
6. Kactglia2 𝜇 35.04 44.37 2.32 9.82 0.718 4.293 -0.22 -0.46 0.474 -0.251 -1.161 -3.570 -7.631 11.640 
𝜎 65.51 65.04 30.79 36.13 17.64 21.93 4.604 4.553 2.786 1.449 3.580 4.947 9.055 9.958 
Max 204 204 117 146 60 100 -15 -15 27 -18 -8 -14 -28 29 
Time 248600 248600 617200 1010400 645800 936500 494000 811800 358900 357400 922800 761400 639400 882000 








































































































 8. kaggTau 𝜇 -2.03 0.46 -3.29 -4.66 -0.946 0.067 -0.79 0.26 -0.802 -0.650 -7.120 2.835 -3.882 -0.650 
𝜎 31.95 46.24 21.21 32.39 22.02 20.87 4.862 4.975 2.599 2.516 6.788 2.346 3.952 3.587 
Max -162 122 -89 -94 -84 66 -17 17 -11 -15 -18 6 -16 -10 
Time 970400 924600 519600 340900 510600 936500 533100 107600 349500 349500 761400 225800 407100 872700 
9. kaggTauP1 𝜇 0 9.23 0 11.47 0 3.834 0 2.98 0 1.717 0 3.948 0 -0.700 
𝜎 0 36.48 0 27.10 0 16.01 0 5.406 0 4.261 0 3.447 0 3.368 
Max 0 186 0 112 0 86 0 24 0 22 0 12 0 -11 
Time 0 936400 0 572100 0 936200 0 940400 0 274700 0 956100 0 356700 
10. kaggTauP2 𝜇 -2.49 0.24 -4.29 -4.66 -0.946 0.067 -0.79 0.26 -0.802 -0.650 -7.120 2.835 -3.882 -0.650 
𝜎 51.95 48.24 31.21 30.39 22.02 20.87 4.862 4.975 2.599 2.516 6.788 2.346 3.952 3.587 
Max -162 144 -89 -92 -84 66 -17 17 -11 -15 -18 6 -16 -10 






𝜇 -0.71 5.15 0.84 4.58 -0.399 2.199 0.21 -1.39 0.031 -0.127 -3.250 0.127 0.766 -0.100 
𝜎 49.91 49.26 35.34 36.48 21.82 20.71 4.817 4.979 0.947 0.844 4.545 2.491 3.304 3.117 
Max -179 -209 107 146 -79 74 18 -19 11 -8 -12 8 13 10 
Time 588900 669300 937600 969600 482200 970300 786900 425500 353300 357700 761400 572000 371500 607300 
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12. kbinAbetaGlia 𝜇 12.01 -18.28 12.24 -12.49 5.079 -7.953 0.94 -2.19 0.531 -0.356 -3.906 -4.022 2.547 -5.597 
𝜎 44.28 55.58 32.34 38.98 18.61 23.82 4.355 4.919 2.427 1.424 6.085 6.410 4.186 4.975 
Max 172 -184 122 130 80 96 21 -18 21 -17 4 -16 17 -16 
Time 971400 837200 936100 1009200 972000 971100 941700 766000 355800 355000 430600 1017900 593200 784600 
13. kbinE1Ub 𝜇 -3.35 -8.06 -0.79 -9.14 -1.464 -3.983 -1.54 -0.55 -3.293 1.927 -0.447 -3.200 -4.537 -4.177 
𝜎 53.40 55.84 37.87 30.48 23.20 23.57 5.599 6.193 6.728 4.419 4.188 4.886 4.150 4.047 
Max 183 -210 114 -94 82 -100 18 24 -27 17 -8 -14 -14 -14 
Time 970500 669300 1001100 671800 970200 669900 933700 312200 219100 202300 761400 1017900 499100 897200 
14. kbinE2Ub 𝜇 -11.03 -3.13 -0.17 0.29 -4.940 -2.506 -1.65 -1.04 -0.478 -5.122 -3.171 -8.491 -1.059 -22.451 
𝜎 55.94 81.38 38.42 60.88 23.98 33.91 5.508 7.644 3.620 16.982 4.205 6.388 2.729 18.269 
Max -200 -199 121 139 -87 100 21 -23 -24 -63 -12 -20 -10 -54 
Time 153900 241600 1008700 935000 154500 937300 943300 256600 345700 339200 922800 922800 669000 468000 
15. kbinGSK3bp53 𝜇 9.94 -1.84 -6.51 18.01 -20.549 36.432 -4.35 4.72 -4.793 3.525 -9.253 23.725 -16.010 2.769 
𝜎 63.76 49.11 42.66 36.33 22.66 30.89 5.187 6.374 11.646 9.164 8.950 15.107 12.379 4.794 
Max 190 146 -116 118 -85 121 -19 24 -47 35 -25 47 -39 20 
Time 1012600 969200 210400 617000 424800 1012500 496300 197500 339200 255200 1017900 1024300 400000 424800 
16. kbinMdm2p53 𝜇 59.32 -42.20 12.67 -7.77 21.932 -17.710 3.18 -3.30 3.825 -5.669 10.117 -9.955 6.089 -15.791 
𝜎 78.53 53.83 42.89 48.78 31.40 23.71 6.009 5.907 7.986 11.593 6.102 8.836 5.759 12.766 
Max 306 -204 135 145 128 -91 25 20 32 -39 24 -26 21 -39 
Time 1006300 154000 936700 970400 970600 154500 972900 971200 255900 338400 1014600 1017900 601500 498800 
17. kbinMTTau 𝜇 -10.21 19.13 -2.65 21.85 -5.332 7.164 -1.00 0.91 -4.540 0.470 1.121 -7.206 -11.922 0.416 
𝜎 71.40 52.70 49.35 26.95 30.12 22.84 7.339 5.242 10.000 2.528 5.284 5.475 9.328 3.721 
Max -239 236 -124 118 -106 97 -20 21 -33 10 16 -16 -35 14 
Time 425900 1006500 420700 1006100 428700 1009800 256600 783200 324100 248700 1004800 731400 395000 424200 
18. kbinProt 𝜇 12.24 17.08 10.09 -9.56 4.536 -2.115 1.62 -0.49 -0.684 -2.087 -0.055 -0.866 -3.617 -6.090 
𝜎 55.45 47.96 40.37 38.07 23.40 24.18 5.423 5.135 2.716 4.517 3.755 1.967 4.042 5.417 
Max 246 188 125 -92 108 82 18 -16 -11 -21 -9 -8 -14 -18 
Time 1000200 1000200 967600 847600 1000600 620000 971200 118900 339200 346400 761300 761400 672200 786800 
19. kbinTauProt 𝜇 -3.71 -23.51 -5.86 -22.34 -4.129 -12.091 -0.49 -3.30 -2.577 -5.126 -6.005 -3.947 -2.925 -21.598 
𝜎 60.99 51.77 53.10 45.37 29.38 28.71 5.906 6.505 5.382 14.773 5.188 4.464 3.954 16.706 
Max -255 -208 -136 -123 -103 -91 -17 -20 -22 -49 -14 -12 -14 -49 
Time 488700 488700 265400 255200 479600 154500 492700 254800 346100 289300 684900 922800 874400 394900 
20. kdam 𝜇 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
𝜎 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Max 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Time 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
21. kdamROS 𝜇 -50.63 36.46 -44.95 36.75 -23.571 12.09 -4.97 1.76 -5.030 2.651 -9.691 5.586 -19.15 5.352 
𝜎 63.10 54.44 39.89 24.52 26.66 19.32 6.027 4.924 11.342 5.513 8.036 4.424 14.618 5.669 
Max -209 201 -140 112 -93 98 -21 20 -50 25 -24 14 -45 24 
Time 918900 170600 328300 1011400 325400 988200 811700 237100 345400 255900 1017900 475900 501000 601500 
22. kdegAbeta 𝜇 -3.30 -35.67 15.49 -17.50 5.353 -8.937 5.22 -4.49 -0.731 -3.605 4.636 -8.261 -4.008 -11.945 
𝜎 46.71 50.15 32.59 38.77 23.37 25.30 6.051 5.753 3.818 8.933 3.113 8.119 5.359 9.977 
Max -162 -242 125 -111 93 -72 25 -20 -16 -30 10 -22 -18 -29 
Time 557400 942800 1007800 265200 1012800 134300 1012000 179600 163800 219400 721900 904700 619900 463800 
23. kdegAbetaGlia 𝜇 24.08 19.12 23.56 11.61 7.723 5.700 1.33 0.60 -0.033 -0.089 -0.719 -0.896 -0.802 -0.732 
𝜎 48.89 51.81 33.45 28.20 19.84 19.67 4.591 4.424 1.046 0.857 3.521 1.413 3.260 3.230 
Max 175 175 152 110 96 85 22 16 -10 -10 -9 -6 -13 -9 
Time 203000 -189 936700 615000 970600 939900 786600 940300 350500 350800 731400 704800 466200 384700 
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24. kdegAntiAb 𝜇 12.91 10.27 6.92 6.15 3.171 2.143 -0.07 0.828 -0.107 0.217 -0.921 0.975 1.566 -6.450 
𝜎 54.67 55.40 33.09 29.85 19.14 20.08 4.600 4.378 0.820 1.235 2.631 2.899 4.079 5.580 
Max 200 192 124 111 92 87 -16 16 -7 16 -10 8 13 -17 
Time 561600 903300 1005100 1009000 1010900 1000000 766100 470000 351900 353300 761400 474700 616900 499000 
25. kdegMdm2 𝜇 -28.79 8.36 -25.20 -0.40 -14.126 0.80 -4.17 -0.25 -6.289 -1.177 -9.387 3.689 -23.610 -0.974 
𝜎 58.28 60.01 46.84 39.58 29.87 25.8928
6 
6.241 5.280 16.643 3.894 7.400 3.775 18.677 3.975 
Max -223 183 -142 -98 -95 87 -21 -16 -62 -14 -22 12 -54 -17 
Time 347900 510700 340800 844500 346400 1010500 256600 766000 346400 215200 761400 547400 400600 1034300 
26. kdegMdm2mR
NA 
𝜇 -59.92 80.74 -38.83 17.76 -27.80 27.82 -6.20 4.650 -6.661 5.214 -9.932 20.057 -24.95 3.672 
𝜎 54.67 64.33 46.29 37.47 27.24 25.92 5.838 5.773 16.949 9.849 8.801 13.516 20.508 6.263 
Max -253 318 -138 133 -105 113 -22 27 -65 39 -26 40 -58 25 
Time 488700 561100 265400 943000 426900 1009100 425500 622600 339200 256400 1017900 1013200 499000 436700 
27. kdegp53 𝜇 -0.44 -20.67 2.44 -20.49 -2.429 -10.821 -0.57 -2.46 -3.464 -3.042 -4.843 -1.702 -10.24 -1.837 
𝜎 51.03 62.21 39.79 47.80 24.48 29.39 5.525 6.118 7.034 6.002 6.947 4.593 7.924 3.670 
Max -187 -220 139 -123 -88 -104 -18 -20 -23 -26 -18 -13 -23 -15 
Time 604700 488700 971700 420700 154500 424800 531700 271300 201500 339200 922800 761400 410700 467200 
28. kdegp53mRNA 𝜇 80.33 -27.72 25.84 -6.36 27.81 -13.15 4.483 -2.18 6.419 -2.230 4.994 -11.130 5.517 -4.159 
𝜎 59.16 52.53 35.48 36.95 24.04 20.96 5.217 4.942 11.844 4.755 5.397 9.302 5.251 4.615 
Max 260 -202 127 -109 112 -88 20 -21 46 -27 15 -26 21 -17 
Time 556800 604700 1003600 328300 1010400 423600 470000 425500 270900 346700 1000400 922800 604400 483900 
29. kdegTau20SPr
ot 
𝜇 6.59 7.03 -1.60 2.06 0.97 0.96 0.089 0.357 -0.819 -0.635 -3.561 -5.499 -4.858 1.407 
𝜎 48.74 55.71 39.91 38.82 22.19 24.62 5.614 5.769 2.761 1.958 4.195 6.429 4.458 4.494 
Max 168 171 -98 126 92 85 18 18 -14 -10 -12 -16 -15 15 
Time 172300 310200 847600 1004800 936200 961900 968800 965400 346300 219100 761400 761400 460200 429000 
30. kdephosMdm
2 
𝜇 55.96 79.15 -0.45 4.47 19.23 -11.260 2.706 -2.02 2.856 -2.298 6.597 -9.090 -5.488 -4.283 
𝜎 63.64 52.53 37.97 32.60 25.88 20.38 5.854 4.670 5.298 4.603 5.501 8.275 5.305 4.596 
Max 227 243 -81 106 118 -93 30 -17 24 -18 16 -25 -16 -19 
Time 1004300 1028000 682500 941600 1005000 425800 970000 425500 236800 304300 488500 1017900 467200 679300 
31. kdephosp53 𝜇 15.39 17.12 -12.15 -9.41 -5.214 -4.613 -1.28 -1.29 2.456 -2.768 0.784 -0.076 7.257 -6.609 
𝜎 45.94 59.01 35.75 45.08 24.84 28.22 6.005 7.058 5.394 6.905 4.576 3.386 6.155 6.205 
Max 153 166 -105 -116 -99 -88 -19 -24 25 -31 10 -4 20 -21 
Time 398900 393600 271700 210400 669900 239900 684200 256600 250900 339200 510800 262800 563000 400600 
32. kdephospTau 𝜇 4.69 16.43 -11.65 -10.67 -10.322 -5.065 -2.67 -1.66 -4.461 -5.530 8.439 -11.383 -6.296 -18.746 
𝜎 57.69 53.01 58.51 47.52 32.14 25.66 6.897 5.918 8.713 13.904 12.491 9.672 5.720 15.345 
Max 155 152 -139 -143 -105 -100 -22 -22 -31 -52 40 -28 -19 -46 
Time 740500 458800 349400 340800 424800 325400 425500 271300 219100 339200 1009900 1017900 394800 400600 
33. kdisaggAbeta 𝜇 34.34 19.41 6.62 -2.68 2.44 -3.611 -0.29 -0.88 -1.794 0.007 -3.363 -5.183 -3.566 -0.926 
𝜎 45.54 45.59 43.28 24.85 23.66 18.05 5.246 4.120 3.945 1.154 2.416 5.697 4.495 3.455 
Max 184 149 114 -95 80 -81 -16 -20 -18 16 -10 -16 -17 -10 
Time 593200 371000 934600 521100 940600 510600 255300 533100 275000 353100 761400 1017900 414300 389200 
34. kdisaggAbeta1 𝜇 4.39 12.45 -18.06 -11.75 -10.359 -6.844 -2.57 -1.38 -3.289 -6.011 -6.656 -8.325 -4.992 -22.057 
𝜎 57.97 58.48 35.05 55.79 25.46 31.24 5.736 6.535 6.816 15.584 5.417 6.351 4.914 19.118 
Max 157 206 -119 -143 -87 -99 -18 -22 -24 -60 -18 -18 -17 -56 
Time 399700 1028400 856700 340800 868600 325400 881600 336300 219100 345400 1017900 761400 871000 458300 
35. kdisaggAbeta2 𝜇 41.05 38.50 12.10 12.04 5.27 4.06 0.483 0.417 0.017 0.011 1.575 -1.147 2.220 -2.846 
𝜎 44.23 41.81 28.71 39.70 19.28 20.89 4.432 4.522 0.846 0.866 3.817 4.007 3.480 4.679 
Max 206 149 105 146 72 88 19 14 6 6 12 -10 14 -14 
Time 426100 348400 937700 1006000 944600 1003600 944300 924500 356600 353300 493900 761400 977900 1035100 
 188 
36. kgenROSAbeta 𝜇 -47.26 59.83 -52.52 36.96 -32.79 12.05 -7.73 2.782 -5.501 2.578 -11.35 7.575 -25.533 -3.156 
𝜎 52.49 40.24 48.01 32.79 32.43 21.81 7.469 4.877 18.209 5.418 9.646 4.061 20.791 4.118 
Max -171 195 -143 150 -103 86 -24 19 -66 23 -28 14 -58 -15 
Time 779400 367200 340800 941200 428800 984300 256600 325500 345400 270300 922800 500900 499000 875200 
37. kgenROSGlia 𝜇 22.65 41.12 -1.52 10.34 -2.350 5.38 -0.67 1.065 -0.090 0.071 -0.236 1.394 -1.501 -4.185 
𝜎 48.31 42.19 32.83 24.29 20.02 18.22 4.734 4.509 0.747 0.915 2.634 2.684 2.892 5.695 
Max 157 182 -99 80 -74 75 -19 19 -6 6 -4 6 -10 -17 
Time 398900 426400 750200 658000 753400 962600 767700 940000 357900 366100 684900 429200 871000 871000 
38. kgenROSPlaqu
e 
𝜇 24.44 38.36 -5.41 10.22 -1.456 3.93 -0.69 -0.07 -1.085 -2.924 -7.333 -3.167 2.553 -5.829 
𝜎 41.73 47.95 41.35 41.84 24.02 24.32 5.075 5.205 3.184 6.237 5.415 3.893 3.671 5.153 
Max 196 212 -104 124 -81 89 -19 -18 -18 -24 -16 -14 15 -23 
Time 636100 1028600 420700 999000 424800 999900 271300 534300 339600 345700 761400 761400 370100 400600 
39. kinactATM 𝝁 64.18 0.79 40.90 -24.34 13.69 -11.29 2.515 -2.33 1.805 -2.465 1.582 -11.158 4.297 -7.859 
𝝈 44.44 43.69 39.74 35.80 23.45 22.57 5.411 5.703 4.921 5.307 3.502 9.341 5.770 6.614 
Max 211 149 179 -102 122 -82 24 -18 21 -23 13 -26 24 -24 
Time 302500 125800 1008800 252700 1000500 674500 968900 531700 250000 324500 663000 1017900 604000 400600 
40. kinactglia1 𝜇 -3.48 9.22 -28.17 -13.19 -13.708 -8.104 -3.68 -2.48 -3.715 0.087 -8.384 -3.072 4.773 -9.601 
𝜎 53.97 55.72 50.80 50.75 31.35 30.40 5.980 6.081 7.228 2.274 7.671 6.035 4.605 8.039 
Max -159 172 -139 -125 -105 -107 -22 -22 -29 10 -22 -14 18 -25 
Time 829200 552600 357900 417700 426900 428700 425500 766000 339200 255700 922800 904700 429000 871000 
41. kinactglia2 𝜇 0 51.39 0 18.56 0 8.88 0 2.544 0 1.057 0 1.621 0 -11.339 
𝜎 0 42.89 0 33.80 0 20.03 0 4.938 0 1.914 0 2.951 0 9.851 
Max 0 197 0 130 0 86 0 22 0 10 0 10 0 -30 
Time 0 445400 0 931000 0 971600 0 974300 0 352600 0 994700 0 782000 
42. kinhibprot 𝜇 5.03 44.42 -19.85 15.02 -9.822 6.52 -3.05 -0.07 -0.195 -0.710 -3.592 0.125 -1.118 -0.691 
𝜎 47.83 46.07 29.99 40.63 21.52 22.30 5.520 5.533 2.078 3.419 4.789 2.553 3.136 3.398 
Max 120 227 -121 127 -105 88 -20 -18 -12 -18 -14 8 -14 -14 
Time 287200 497100 426900 1011800 426900 1008000 766000 274700 346700 350500 1017900 1005300 406500 382100 
43. kMdm2PolyUb 𝜇 24.13 25.48 -6.04 1.53 -2.101 -1.327 -0.51 -0.91 -3.469 -3.880 -0.867 -4.042 -10.229 -7.548 
𝜎 52.24 51.29 46.28 46.37 27.76 26.86 6.052 5.709 7.574 7.922 2.604 3.170 8.225 6.196 
Max 209 169 -111 118 -88 -92 -17 -17 -32 -32 -8 -10 -25 -22 
Time 187300 1023800 360500 929600 154500 384600 430200 248400 346400 345900 704800 575900 458300 394800 
44. kMdm2PUb 𝜇 -4.70 97.93 -2.60 10.28 -13.605 25.62 -2.42 3.300 -1.449 7.956 -7.515 17.198 -2.204 3.946 
𝜎 38.63 62.57 40.13 36.58 24.14 25.40 5.775 6.097 3.624 15.571 8.182 8.936 4.259 4.875 
Max -132 290 -113 108 -103 111 -21 22 -21 56 -22 27 -16 21 
Time 518600 191100 463700 943400 479600 972000 531700 106100 350800 202300 922800 472200 404500 424800 
45. kMdm2Ub 𝜇 7.34 7.69 -13.70 -11.26 -9.538 -8.944 -3.34 -2.11 -5.205 -4.918 -3.983 -7.553 -22.143 -23.092 
𝜎 67.73 59.86 57.01 54.81 33.29 30.66 8.014 6.915 17.663 17.516 3.274 6.006 18.861 18.449 
Max 181 189 -138 -138 -102 -93 -24 -22 -65 -63 -12 -16 -58 -54 
Time 1030800 1013500 265400 265400 478800 267700 256600 256600 345400 339200 1017900 731400 499000 405900 
46. kp53PolyUb 𝜇 19.29 16.97 -6.37 -6.16 -4.185 -4.591 -2.48 -0.68 -5.582 -2.909 -7.664 -7.690 -15.972 -9.812 
𝜎 59.76 48.08 43.51 29.20 28.55 20.71 6.475 4.921 13.227 6.244 6.582 6.123 12.419 7.520 
Max 183 158 -116 -83 -89 -73 -21 -19 -45 -22 -20 -20 -37 -22 
Time 727400 257900 210400 265700 249100 134300 254800 118900 279100 206400 922800 1017900 400600 391700 
47. kp53Ub 𝜇 7.75 16.95 -18.08 -7.41 -4.591 -5.397 -1.22 -2.01 -2.333 -5.694 -9.896 2.602 -0.573 -19.873 
𝜎 47.77 67.78 37.63 50.94 20.71 31.71 5.434 7.585 4.838 16.936 7.743 4.253 2.939 16.254 
Max 136 233 -108 -138 -73 -93 -22 -24 -18 -60 -20 10 -7 -55 
Time 907300 551200 360800 265400 134300 267700 533100 256600 346800 338400 704800 665700 390400 405900 
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48. kpf 𝜇 32.14 16.79 6.70 -2.94 0.99 -4.715 -0.06 -1.42 -0.149 -2.642 -0.595 -2.151 0.500 -4.137 
𝜎 49.47 48.06 24.07 40.11 20.85 25.07 5.147 5.715 4.542 5.280 3.242 3.950 4.618 4.143 
Max 190 168 89 -96 66 -99 -19 -19 -19 -20 -6 -12 18 -15 
Time 553000 922700 936900 572300 617400 669900 118900 118900 168200 346500 761400 731400 601500 357000 
49. kpg 𝜇 164.05 177.53 18.30 31.21 47.58 51.67 6.977 7.292 4.453 18.451 29.742 39.358 1.369 5.862 
𝜎 66.43 76.82 30.29 40.81 27.17 29.33 5.593 6.566 8.672 31.509 13.196 22.390 3.418 8.465 
Max 368 366 116 139 130 144 27 24 32 95 44 74 14 25 
Time 390100 194600 969100 1009700 1000500 1012400 72000 654100 126800 337000 890000 1015100 439500 598900 
50. kpghalf 𝜇 179.02 156.19 29.94 17.14 52.38 44.88 7.834 6.118 11.100 10.453 27.617 24.530 6.780 2.177 
𝜎 68.60 76.00 32.03 41.29 25.84 34.94 6.318 6.582 18.184 17.113 17.239 14.525 6.328 3.385 
Max 421 357 125 112 130 147 26 33 55 55 61 46 22 15 
Time 390100 550700 928800 940800 968300 969100 974000 300000 255700 315600 1011500 978000 593200 442800 
51. kphosMdm2 𝜇 12.00 162.91 -13.25 16.65 -6.674 47.72 -1.57 6.751 -5.331 11.802 -7.003 29.745 -15.408 1.681 
𝜎 51.86 63.98 42.36 30.88 27.23 24.96 6.513 6.086 12.247 19.300 5.530 16.208 11.744 4.890 
Max 159 344 -138 117 -95 130 -19 26 -43 60 -16 50 -34 17 
Time 911700 370800 265400 971700 267700 940000 256600 933800 324400 254700 922800 1006400 501500 420700 
52. kphosMdm2G
SK3b 
𝜇 62.33 92.19 0.99 16.50 12.34 24.23 1.511 4.365 -3.282 5.652 3.490 9.476 -8.015 -0.404 
𝜎 72.04 51.39 44.09 33.01 31.01 23.58 6.738 5.256 7.641 9.493 4.074 7.326 6.878 6.680 
Max 279 261 117 118 107 110 21 26 -28 33 15 23 -23 -17 
Time 686900 740100 971200 942900 1009300 938000 941200 786300 218900 179700 1010100 861200 400000 871300 
53. kphosMdm2G
SK3bp53 
𝜇 57.85 47.70 -7.00 -5.30 10.15 5.63 1.629 -0.57 1.277 -5.282 3.000 0.560 1.689 -18.885 
𝜎 66.47 82.84 38.61 49.79 30.86 36.53 6.487 8.188 4.880 14.876 3.451 3.504 3.455 15.079 
Max 224 252 -110 -138 121 99 26 -23 21 -50 10 8 15 -46 
Time 810900 908400 463700 265400 1003300 939800 976800 271300 274700 298800 433300 485200 424800 502100 
54. kphosp53 𝜇 79.80 85.78 12.01 13.45 19.21 21.40 2.516 3.561 2.532 6.822 6.374 14.045 4.064 2.635 
𝜎 66.81 48.00 39.88 40.83 28.56 25.60 5.969 5.898 5.903 11.526 5.105 7.688 5.070 5.366 
Max 275 231 145 148 119 104 23 25 26 36 16 26 24 20 
Time 398700 296100 1010000 1008600 999800 932300 965600 938100 254700 248700 416500 982800 429000 441900 
55. kphospTauGSK
3b 
𝜇 59.83 42.66 -2.46 -12.42 11.57 4.37 1.082 -1.01 0.991 -5.748 7.012 1.095 -1.259 -19.060 
𝜎 62.02 77.89 40.11 47.11 30.17 34.61 6.129 7.325 3.023 16.514 6.172 3.215 5.084 15.582 
Max 225 231 -96 -138 109 103 21 -19 14 -58 22 8 -14 -50 
Time 1029000 424600 733800 265400 970700 1007300 991800 248400 249200 324100 1010800 861800 1032600 394800 
56. kphospTauGSK
3bp53 
𝜇 91.50 65.06 15.94 0.70 23.52 13.72 3.731 1.549 5.308 -1.132 -6.712 42.605 -1.286 -3.617 
𝜎 53.67 62.67 25.51 33.43 21.36 25.33 5.267 5.423 9.538 4.528 6.884 27.180 2.989 4.404 
Max 268 256 90 102 93 93 21 18 32 -19 -18 72 -10 -17 
Time 685800 497600 146500 971600 812400 558600 134700 396500 179700 183100 761400 656000 498300 412400 
57. kprodAbeta 𝜇 62.11 94.05 -4.51 23.01 12.81 24.34 2.595 3.202 4.373 4.041 6.548 15.938 1.605 1.137 
𝜎 57.47 61.40 38.39 39.34 25.51 27.32 5.470 5.009 8.351 7.738 3.838 8.349 4.453 4.744 
Max 287 298 -99 143 96 122 24 20 30 32 14 35 19 15 
Time 344700 845400 841000 969300 1011300 971300 1036500 357200 211400 254700 500500 1033000 374200 431600 
58. kprodAbeta2 𝜇 26.57 80.32 -36.92 11.54 -4.832 19.25 -6.27 10.907 -2.427 6.062 8.410 11.078 -1.085 5.114 
𝜎 118.12 69.00 39.75 41.18 46.20 30.71 6.941 9.180 4.196 15.714 7.295 9.690 4.089 5.379 
Max 368 260 82 144 -104 114 -23 33 -17 66 22 36 -13 24 
Time 367100 985100 1020100 937400 479600 936000 533100 787200 280700 311900 412700 1002700 1032400 601500 
59. kproteff 𝜇 92.93 66.81 20.04 -0.20 24.01 14.31 3.675 1.915 3.824 0.429 9.466 -1.581 0.791 -0.875 
𝜎 49.02 58.10 36.64 38.54 23.33 26.24 5.750 5.917 7.338 3.431 7.933 3.852 5.278 4.069 
Max 240 268 122 -129 119 109 26 26 30 18 25 -11 18 -14 
Time 380800 1030600 937400 844500 939900 969500 944200 941700 212900 230700 990200 761400 601500 923200 
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60. krelAbetaGlia 𝜇 62.42 56.59 1.12 -2.10 12.30 9.76 1.190 1.506 -3.232 -3.036 11.089 6.312 -6.493 -6.871 
𝜎 66.32 70.55 46.15 41.15 30.50 31.14 5.856 6.871 7.274 7.368 9.214 4.368 6.053 5.709 
Max 264 249 136 -118 104 99 18 22 -28 -28 32 14 -21 -19 
Time 947300 396100 941100 274600 932500 971000 933100 971500 219100 219100 993300 454200 406700 499000 
61. krelGSK3bp53 𝜇 46.62 67.35 2.05 -10.58 48.98 -14.370 6.814 -2.91 7.347 -4.334 37.492 -11.379 2.232 -11.229 
𝜎 56.70 60.10 39.59 38.08 40.95 21.56 7.402 4.815 13.017 8.881 21.424 9.667 4.758 8.745 
Max 202 275 124 -95 174 -92 30 -17 47 -38 70 -28 17 -26 
Time 435900 498300 937800 712700 930300 718200 931800 533600 278600 346500 980300 1017900 376900 540200 
62. krelMdm2p53 𝜇 37.17 70.30 -14.32 6.44 2.13 15.27 0.039 1.923 1.850 3.098 3.391 13.024 0.882 -1.071 
𝜎 72.16 71.44 38.25 46.62 33.48 31.02 7.204 6.829 5.022 6.102 4.647 9.915 3.549 4.002 
Max 230 286 -97 140 97 120 19 20 25 24 14 28 14 -12 
Time 812000 985100 742500 1002300 1012700 970200 245500 142700 297500 199200 491300 492400 604700 871000 
63. krelMTTau 𝜇 74.74 43.67 2.15 -11.25 17.75 4.38 3.261 -0.76 5.546 -5.202 -7.294 14.325 -5.085 -21.071 
𝜎 59.77 82.59 39.89 52.33 27.33 36.36 5.840 7.662 9.415 17.148 6.458 17.085 4.959 17.949 
Max 256 248 115 -138 104 97 20 -22 35 -62 -18 43 -18 -55 
Time 1023300 596600 1010700 265400 1007300 937500 1003800 256600 150900 345700 904700 1015400 485100 407200 
64. kremROS 𝜇 104.62 42.97 33.86 -20.63 27.69 5.47 4.089 1.518 2.789 -0.986 12.363 2.768 5.736 4.155 
𝜎 58.59 58.49 41.76 35.11 25.96 25.39 5.832 5.522 6.451 2.723 9.702 4.541 5.757 5.330 
Max 264 225 162 -127 127 107 25 18 25 -13 40 14 22 23 
Time 1013600 425100 969900 274800 971900 970900 971800 787100 274700 222600 1012000 527000 601700 603400 
65. krepair 𝜇 115.29 37.44 39.89 -19.98 32.18 2.42 4.472 0.020 5.259 1.890 10.852 7.256 -0.161 1.219 
𝜎 51.41 73.13 31.23 34.30 22.82 32.82 5.095 6.525 8.767 4.010 7.812 5.887 2.738 4.597 
Max 269 268 148 -109 113 95 23 21 36 16 24 18 -11 18 
Time 549700 396400 1004700 477900 1005000 67700 911400 73800 255700 103600 899400 408500 362600 601500 
66. ksynMdm2 𝜇 177.46 -0.58 22.55 -19.78 51.30 -12.008 7.378 -2.52 6.034 1.955 33.946 -8.768 5.423 1.054 
𝜎 82.50 58.76 31.31 46.55 28.93 28.14 6.258 6.543 11.727 5.971 20.732 7.937 5.521 3.881 
Max 406 -170 119 -129 147 -87 28 -21 44 22 64 -24 21 14 
Time 385300 829200 1010600 844500 986600 837400 971000 861400 254700 254700 939800 1017900 601700 616200 
67. ksynMdm2mR
NA 
𝜇 86.41 31.46 -8.41 2.06 20.84 1.53 2.713 0.305 7.185 -2.457 8.515 0.645 2.156 -3.264 
𝜎 85.71 48.84 41.56 41.96 34.90 25.46 7.200 4.972 13.137 5.775 5.556 2.980 4.318 3.944 
Max 305 177 -129 120 122 89 28 17 42 -23 22 -6 19 -14 
Time 1013300 889100 844500 938100 1011900 935300 138100 933100 249000 288700 1022900 761400 598900 394800 
68. ksynMdm2mR
NAGSK3bp53 
𝜇 103.48 0.40 14.91 -28.57 27.40 -12.016 3.875 -3.44 3.271 -6.087 6.341 -8.697 -0.575 -21.451 
𝜎 68.41 66.03 35.10 46.44 28.06 30.83 5.419 7.059 8.248 17.268 5.354 6.439 7.452 17.187 
Max 288 182 134 -143 124 -99 23 -24 34 -66 18 -20 -18 -56 
Time 475600 1013600 935300 340800 1006500 325400 556500 274700 254700 345400 1009900 761400 921000 410600 
69. ksynp53 𝜇 6.34 110.76 -10.36 3.74 -9.408 28.98 -3.26 4.098 -5.345 3.660 -4.260 18.353 -21.538 2.214 
𝜎 59.43 80.55 59.33 39.35 32.45 30.32 7.532 6.347 15.882 8.076 2.850 12.142 17.804 5.730 
Max 136 411 -138 136 -103 133 -23 25 -54 35 -11 42 -50 20 
Time 626900 641100 265400 1011100 424800 980500 254800 981800 339200 256300 922800 984400 405000 601500 
70. ksynp53mRNA 𝜇 0.36 -4.25 -1.29 -40.07 -11.164 -14.754 -1.98 -3.98 -2.787 -5.502 -7.728 -0.266 -2.861 -24.152 
𝜎 36.07 75.12 43.81 51.52 21.77 36.77 5.433 7.373 5.836 17.590 8.504 4.580 4.649 19.478 
Max 113 -162 -128 -143 -82 -95 -20 -23 -29 -66 -22 -8 -17 -57 
Time 595800 309800 844500 340800 837400 346400 860300 271400 350600 345400 922800 704800 493400 410600 
71. ksynp53mRNA
Abeta 
𝜇 39.30 5.37 11.49 -22.54 4.29 -10.028 0.702 -2.37 3.086 -5.861 1.429 -9.313 2.274 -19.930 
𝜎 42.76 63.77 36.90 51.63 22.85 32.60 5.326 7.441 5.968 17.291 2.425 7.543 4.276 18.555 
Max 189 211 134 -143 85 -99 17 -23 24 -66 6 -22 15 -57 
Time 397400 924700 931000 340800 934200 325400 924500 336300 255700 345400 644700 761400 424900 410600 
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72. ksynTau 𝜇 20.04 -49.60 -4.42 -55.48 -3.384 -33.591 -0.05 -8.09 -0.899 -2.146 -4.740 -8.712 2.264 -5.666 
𝜎 49.68 47.74 36.79 36.37 24.69 26.60 5.969 6.814 2.907 5.170 6.938 9.123 3.682 5.143 
Max 173 -171 -99 -143 -90 -105 -17 -23 -19 -25 -18 -24 15 -18 
Time 370600 829200 750200 340800 669900 426900 271300 766000 339200 345400 1017900 922800 596600 871000 
ktangfor 𝜇 158.03 177.51 13.76 24.83 45.46 51.67 7.165 7.705 11.020 11.308 29.323 22.189 6.161 2.309 
𝜎 75.89 69.06 32.15 30.26 25.19 26.22 5.390 6.135 19.691 18.683 16.417 11.318 5.868 4.343 
Max 379 353 93 106 128 128 26 27 62 61 58 42 23 19 




Appendix D GSA Results 
This appendix includes results of LHS/PRCC for all the selected species in response to all parameters.  
 Table D.1 includes LHS/PRCC results for p53 in response to the LHS parameters using ODEs.  
 Table D.2 includes LHS/PRCC results for p53 in response to the LHS parameters using 
MRM/GSSA.  
 Table D.3 includes LHS/PRCC results for ATMA in response to the LHS parameters using ODEs.  
 Table D.4 includes LHS/PRCC results for ATMA in response to the LHS parameters using 
MRM/GSSA.  
 Table D.5 includes LHS/PRCC results for p53_GSK3β in response to the LHS parameters using 
ODEs.  
 Table D.6 includes LHS/PRCC results for p53_GSK3β in response to the LHS parameters using 
MRM/GSSA.  
 Table D.7 includes LHS/PRCC results for Aβ in response to the LHS parameters using ODEs.  
 Table D.8 includes LHS/PRCC results for Aβ in response to the LHS parameters using 
MRM/GSSA.  
 Table D.9 includes LHS/PRCC results for plaques in response to the LHS parameters using ODEs.  
 Table D.10 includes LHS/PRCC results for plaques in response to the LHS parameters using 
MRM/GSSA.  
 Table D.11 includes LHS/PRCC results for tangles in response to the LHS parameters using 
ODEs.  
 Table D.12 includes LHS/PRCC results for tangles in response to the LHS parameters using 
MRM/GSSA.  
 Table D.13 includes LHS/PRCC results for GilaA in response to the LHS parameters using ODEs.  























































1 kactATM 0.109 0.276 -0.106 0.290 -0.027 0.785 38 kgenROSPlaque 0.120 0.231 -0.071 0.480 -0.086 0.391 
2 kactDUBMdm2 0.004 0.968 0.073 0.463 0.004 0.965 39 kinactATM 0.210 0.034 -0.092 0.356 -0.008 0.939 
3 kactDUBp53 -0.066 0.512 0.088 0.377 0.010 0.922 40 kinactglia1 -0.168 0.090 0.210 0.034 -0.094 0.346 
4 kactDUBProtp53 -0.099 0.320 -0.169 0.090 0.049 0.623 41 kinactglia2 -0.035 0.725 -0.001 0.993 0.026 0.798 
5 kactglia1 0.025 0.805 -0.016 0.869 -0.057 0.569 42 kinhibprot 0.091 0.364 -0.057 0.566 -0.038 0.705 
6 Kactglia2 0.028 0.782 -0.020 0.842 -0.118 0.236 43 kMdm2PolyUb 0.069 0.491 -0.244 0.014 0.026 0.799 
7 kaggAbeta -0.047 0.636 0.072 0.471 0.098 0.327 44 kMdm2PUb 0.013 0.895 -0.123 0.220 -0.139 0.163 
8 kaggTau 0.064 0.523 0.016 0.870 0.239 0.016 45 kMdm2Ub 0.018 0.858 0.023 0.820 -0.045 0.653 
9 kaggTauP1 -0.041 0.679 -0.016 0.870 -0.239 0.016 46 kp53PolyUb 0.027 0.790 0.192 0.053 -0.086 0.388 
10 kaggTauP2 0.062 0.537 -0.052 0.605 0.027 0.787 47 kp53Ub -0.033 0.743 -0.159 0.110 -0.048 0.634 
11 kbinAbantiAb 0.088 0.381 -0.161 0.107 0.152 0.127 48 kpf 0.242 0.014 -0.007 0.945 0.048 0.631 
12 kbinAbetaGlia -0.311 0.001 0.024 0.807 -0.069 0.492 49 kpg -0.136 0.173 -0.048 0.635 0.006 0.953 
13 kbinE1Ub 0.146 0.142 -0.080 0.425 -0.070 0.485 50 kpghalf 0.254 0.010 0.021 0.836 0.133 0.181 
14 kbinE2Ub 0.089 0.376 -0.052 0.605 0.226 0.023 51 kphosMdm2 -0.173 0.082 -0.051 0.609 0.046 0.647 
15 kbinGSK3bp53 0.044 0.661 -0.225 0.023 -0.087 0.385 52 kphosMdm2GSK3b -0.017 0.866 -0.175 0.079 -0.123 0.218 
16 kbinMdm2p53 -0.070 0.483 0.027 0.784 -0.287 0.003 53 kphosMdm2GSK3bp53 0.020 0.842 0.050 0.619 -0.021 0.837 
17 kbinMTTau -0.036 0.718 -0.060 0.548 0.050 0.615 54 kphosp53 -0.058 0.559 0.002 0.983 0.113 0.260 
18 kbinProt -0.045 0.654 0.062 0.537 -0.002 0.981 55 kphospTauGSK3b -0.002 0.986 0.050 0.618 0.117 0.240 
19 kbinTauProt 0.076 0.446 -0.074 0.457 -0.013 0.898 56 kphospTauGSK3bp53 0.043 0.666 0.038 0.704 -0.159 0.110 
20 kdam -0.182 0.067 0.134 0.180 0.045 0.655 57 kprodAbeta -0.019 0.852 0.045 0.654 -0.029 0.773 
21 kdamROS 0.204 0.039 0.170 0.088 0.051 0.609 58 kprodAbeta2 -0.020 0.843 -0.009 0.927 -0.052 0.603 
22 kdegAbeta -0.025 0.806 0.035 0.728 -0.086 0.389 59 kproteff 0.137 0.169 0.005 0.959 -0.019 0.849 
23 kdegAbetaGlia 0.011 0.910 -0.053 0.599 -0.031 0.756 60 krelAbetaGlia -0.137 0.169 -0.128 0.200 0.073 0.467 
24 kdegAntiAb -0.060 0.552 -0.032 0.751 0.108 0.278 61 krelGSK3bp53 0.087 0.386 0.137 0.171 0.120 0.229 
25 kdegMdm2 0.069 0.489 0.107 0.284 -0.088 0.378 62 krelMdm2p53 0.038 0.703 -0.046 0.645 -0.014 0.890 
26 kdegMdm2mRNA -0.044 0.660 -0.072 0.474 0.034 0.735 63 krelMTTau -0.049 0.626 -0.146 0.144 -0.139 0.163 
27 kdegp53 -0.028 0.782 0.132 0.186 0.010 0.921 64 kremROS 0.041 0.679 -0.016 0.871 0.108 0.281 
28 kdegp53mRNA -0.127 0.203 -0.178 0.074 -0.095 0.343 65 krepair 0.164 0.099 0.012 0.902 0.028 0.783 
29 kdegTau20SProt -0.186 0.061 0.051 0.609 0.182 0.067 66 ksynMdm2 -0.004 0.967 -0.003 0.977 0.292 0.003 
30 kdephosMdm2 -0.045 0.653 -0.008 0.939 0.054 0.588 67 ksynMdm2mRNA -0.162 0.104 0.133 0.182 -0.156 0.118 
31 kdephosp53 -0.058 0.561 -0.059 0.554 -0.019 0.847 68 ksynMdm2mRNAGSK3bp
53 
-0.031 0.758 0.024 0.809 -0.038 0.708 
32 kdephospTau 0.001 0.996 0.069 0.489 0.005 0.959 69 ksynp53 0.075 0.453 -0.101 0.311 0.069 0.490 
33 kdisaggAbeta 0.049 0.625 -0.005 0.959 -0.072 0.469 70 ksynp53mRNA -0.043 0.671 -0.009 0.926 0.044 0.658 
34 kdisaggAbeta1 0.114 0.254 -0.164 0.099 -0.116 0.247 71 ksynp53mRNAAbeta 0.124 0.216 -0.171 0.085 0.176 0.076 
35 kdisaggAbeta2 -0.114 0.254 0.277 0.005 0.119 0.234 72 ksynTau 0.063 0.532 -0.119 0.233 0.095 0.342 
36 kgenROSAbeta -0.051 0.609 0.060 0.548 -0.082 0.413 73 ktangfor -0.45 0.651 -0.36 0.751 -0.003 0.979 
37 kgenROSGlia -0.118 0.237 -0.083 0.407 0.199 0.045         
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1 kactATM -0.174 0.081 -0.119 0.234 0.026 0.792 38 kgenROSPlaque -0.088 0.376 -0.067 0.503 0.068 0.499 
2 kactDUBMdm2 -0.011 0.910 0.127 0.202 0.060 0.548 39 kinactATM -0.003 0.973 -0.095 0.345 0.032 0.753 
3 kactDUBp53 0.058 0.566 0.069 0.493 -0.041 0.685 40 kinactglia1 -0.017 0.864 -0.051 0.608 -0.065 0.515 
4 kactDUBProtp53 0.020 0.844 0.002 0.982 0.048 0.630 41 kinactglia2 -0.157 0.116 0.035 0.730 0.046 0.644 
5 kactglia1 -0.174 0.081 -0.079 0.429 0.089 0.371 42 kinhibprot 0.007 0.945 -0.041 0.686 -0.027 0.785 
6 Kactglia2 -0.063 0.531 -0.156 0.117 -0.118 0.237 43 kMdm2PolyUb 0.028 0.778 -0.070 0.485 -0.071 0.476 
7 kaggAbeta -0.037 0.709 -0.028 0.780 0.153 0.124 44 kMdm2PUb -0.134 0.179 0.023 0.821 -0.092 0.358 
8 kaggTau 0.167 0.094 0.081 0.419 0.114 0.253 45 kMdm2Ub 0.066 0.508 0.046 0.649 -0.076 0.447 
9 kaggTauP1 -0.167 0.094 -0.081 0.419 -0.114 0.253 46 kp53PolyUb -0.153 0.124 -0.010 0.923 -0.131 0.188 
10 kaggTauP2 -0.047 0.642 -0.154 0.123 0.068 0.499 47 kp53Ub 0.083 0.406 -0.058 0.562 0.130 0.194 
11 kbinAbantiAb 0.157 0.114 0.247 0.012 0.059 0.558 48 kpf -0.120 0.230 -0.004 0.965 -0.156 0.117 
12 kbinAbetaGlia -0.054 0.590 -0.017 0.864 0.063 0.532 49 kpg 0.067 0.501 -0.050 0.619 0.131 0.188 
13 kbinE1Ub -0.023 0.817 -0.064 0.525 -0.014 0.889 50 kpghalf 0.144 0.148 0.141 0.157 0.155 0.120 
14 kbinE2Ub 0.168 0.091 0.098 0.329 0.038 0.703 51 kphosMdm2 -0.078 0.436 0.018 0.856 0.010 0.922 
15 kbinGSK3bp53 -0.048 0.635 -0.079 0.430 -0.147 0.142 52 kphosMdm2GSK3b -0.168 0.092 -0.037 0.715 -0.029 0.771 
16 kbinMdm2p53 -0.265 0.007 -0.018 0.854 -0.271 0.006 53 kphosMdm2GSK3bp53 -0.045 0.653 -0.054 0.591 0.126 0.206 
17 kbinMTTau -0.003 0.979 0.103 0.303 0.024 0.807 54 kphosp53 -0.022 0.828 0.169 0.089 0.037 0.713 
18 kbinProt -0.024 0.810 0.091 0.361 -0.100 0.318 55 kphospTauGSK3b -0.007 0.945 -0.039 0.698 0.069 0.488 
19 kbinTauProt 0.003 0.979 -0.029 0.769 -0.090 0.366 56 kphospTauGSK3bp53 -0.042 0.677 -0.082 0.413 -0.054 0.588 
20 kdam 0.058 0.561 -0.038 0.704 0.075 0.453 57 kprodAbeta 0.023 0.817 0.039 0.697 -0.129 0.195 
21 kdamROS -0.140 0.162 -0.005 0.959 -0.079 0.433 58 kprodAbeta2 0.011 0.912 -0.098 0.328 0.023 0.822 
22 kdegAbeta -0.007 0.942 0.004 0.967 0.060 0.548 59 kproteff -0.098 0.328 0.092 0.356 -0.080 0.425 
23 kdegAbetaGlia -0.003 0.972 -0.044 0.659 0.039 0.697 60 krelAbetaGlia -0.027 0.785 0.067 0.506 0.154 0.123 
24 kdegAntiAb 0.085 0.395 -0.048 0.630 0.077 0.441 61 krelGSK3bp53 0.134 0.178 0.095 0.341 0.070 0.485 
25 kdegMdm2 0.013 0.895 0.005 0.959 0.013 0.899 62 krelMdm2p53 0.161 0.106 0.035 0.730 -0.010 0.924 
26 kdegMdm2mRNA 0.086 0.393 -0.035 0.729 -0.022 0.828 63 krelMTTau -0.051 0.612 -0.083 0.404 -0.079 0.431 
27 kdegp53 0.110 0.270 0.000 0.997 0.026 0.794 64 kremROS 0.230 0.020 0.070 0.486 0.051 0.612 
28 kdegp53mRNA -0.024 0.808 0.008 0.935 -0.048 0.629 65 krepair 0.038 0.701 -0.150 0.134 0.050 0.618 
29 kdegTau20SProt 0.177 0.074 0.153 0.125 0.165 0.098 66 ksynMdm2 0.298 0.002 0.004 0.969 0.127 0.202 
30 kdephosMdm2 0.145 0.145 0.030 0.763 0.004 0.968 67 ksynMdm2mRNA -0.111 0.265 0.005 0.959 -0.143 0.152 
31 kdephosp53 0.034 0.738 0.000 0.998 -0.063 0.529 68 ksynMdm2mRNAGSK3bp
53 
-0.119 0.235 0.168 0.091 0.144 0.149 
32 kdephospTau -0.072 0.475 -0.075 0.454 -0.026 0.799 69 ksynp53 -0.009 0.929 0.041 0.682 -0.062 0.539 
33 kdisaggAbeta -0.055 0.586 0.042 0.676 0.043 0.667 70 ksynp53mRNA -0.008 0.936 -0.137 0.171 0.063 0.531 
34 kdisaggAbeta1 -0.015 0.883 0.109 0.277 -0.095 0.344 71 ksynp53mRNAAbeta 0.080 0.425 0.219 0.027 0.090 0.368 
35 kdisaggAbeta2 0.121 0.227 -0.044 0.660 0.109 0.274 72 ksynTau 0.080 0.424 0.097 0.332 -0.082 0.414 
36 kgenROSAbeta -0.043 0.669 -0.109 0.275 -0.247 0.012 73 ktangfor -0.132 0.184 -0.114 0.253 0.038 0.708 
37 kgenROSGlia 0.134 0.178 0.020 0.840 0.088 0.381         
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1 kactATM -0.005 0.964 -0.040 0.690 -0.041 0.682 38 kgenROSPlaque -0.081 0.421 -0.096 0.339 -0.090 0.369 
2 kactDUBMdm2 0.030 0.768 0.003 0.976 0.005 0.959 39 kinactATM -0.008 0.938 -0.016 0.873 -0.018 0.859 
3 kactDUBp53 0.017 0.864 0.045 0.657 0.045 0.652 40 kinactglia1 -0.093 0.351 -0.065 0.519 -0.066 0.508 
4 kactDUBProtp53 0.047 0.640 0.037 0.713 0.040 0.687 41 kinactglia2 0.023 0.819 0.001 0.995 0.003 0.977 
5 kactglia1 -0.028 0.781 -0.076 0.447 -0.075 0.452 42 kinhibprot -0.058 0.560 -0.036 0.720 -0.038 0.707 
6 Kactglia2 -0.162 0.103 -0.147 0.140 -0.142 0.155 43 kMdm2PolyUb 0.029 0.770 0.017 0.869 0.016 0.875 
7 kaggAbeta 0.097 0.332 0.098 0.328 0.100 0.318 44 kMdm2PUb -0.131 0.188 -0.123 0.219 -0.124 0.213 
8 kaggTau 0.240 0.015 0.223 0.024 0.222 0.025 45 kMdm2Ub -0.047 0.640 -0.072 0.470 -0.073 0.465 
9 kaggTauP1 -0.240 0.015 -0.223 0.024 -0.222 0.025 46 kp53PolyUb -0.096 0.337 -0.104 0.297 -0.109 0.276 
10 kaggTauP2 0.013 0.900 -0.014 0.887 -0.011 0.912 47 kp53Ub -0.093 0.355 -0.043 0.671 -0.041 0.680 
11 kbinAbantiAb 0.167 0.093 0.172 0.084 0.173 0.082 48 kpf 0.056 0.575 0.014 0.888 0.015 0.878 
12 kbinAbetaGlia -0.062 0.538 -0.065 0.517 -0.068 0.499 49 kpg -0.001 0.988 0.049 0.628 0.050 0.618 
13 kbinE1Ub 0.228 0.021 0.218 0.027 0.223 0.025 50 kpghalf 0.133 0.181 0.140 0.160 0.137 0.170 
14 kbinE2Ub -0.060 0.551 -0.074 0.459 -0.070 0.485 51 kphosMdm2 0.046 0.647 0.040 0.687 0.043 0.667 
15 kbinGSK3bp53 -0.110 0.270 -0.080 0.424 -0.084 0.401 52 kphosMdm2GSK3b -0.121 0.227 -0.099 0.320 -0.097 0.334 
16 kbinMdm2p53 -0.501 0.002 -0.508 0.009 -0.560 0.008 53 kphosMdm2GSK3bp53 -0.061 0.541 -0.037 0.715 -0.037 0.715 
17 kbinMTTau 0.062 0.538 0.019 0.848 0.014 0.886 54 kphosp53 0.080 0.423 0.103 0.302 0.109 0.274 
18 kbinProt 0.009 0.929 -0.006 0.954 -0.005 0.960 55 kphospTauGSK3b 0.134 0.180 0.140 0.161 0.138 0.168 
19 kbinTauProt -0.008 0.935 -0.005 0.958 -0.012 0.903 56 kphospTauGSK3bp53 -0.179 0.071 -0.152 0.127 -0.151 0.130 
20 kdam 0.074 0.462 0.055 0.581 0.058 0.561 57 kprodAbeta -0.045 0.655 0.003 0.976 0.003 0.974 
21 kdamROS 0.042 0.674 0.040 0.686 0.038 0.703 58 kprodAbeta2 -0.052 0.602 -0.040 0.691 -0.040 0.690 
22 kdegAbeta -0.084 0.404 -0.037 0.711 -0.037 0.715 59 kproteff 0.001 0.993 0.008 0.935 0.014 0.889 
23 kdegAbetaGlia -0.043 0.670 -0.053 0.594 -0.050 0.617 60 krelAbetaGlia 0.097 0.331 0.075 0.453 0.073 0.465 
24 kdegAntiAb 0.115 0.251 0.109 0.277 0.115 0.250 61 krelGSK3bp53 0.121 0.226 0.118 0.239 0.117 0.242 
25 kdegMdm2 -0.090 0.366 -0.077 0.444 -0.079 0.433 62 krelMdm2p53 0.016 0.870 -0.033 0.743 -0.037 0.711 
26 kdegMdm2mRNA 0.054 0.588 0.045 0.651 0.041 0.681 63 krelMTTau -0.164 0.099 -0.166 0.096 -0.166 0.095 
27 kdegp53 0.009 0.925 0.038 0.702 0.037 0.716 64 kremROS 0.139 0.164 0.121 0.225 0.123 0.219 
28 kdegp53mRNA -0.093 0.352 -0.082 0.414 -0.077 0.439 65 krepair 0.063 0.529 0.008 0.932 0.006 0.954 
29 kdegTau20SProt 0.199 0.045 0.199 0.045 0.198 0.046 66 ksynMdm2 0.285 0.004 0.269 0.006 0.268 0.006 
30 kdephosMdm2 0.086 0.388 0.007 0.945 0.008 0.938 67 ksynMdm2mRNA -0.134 0.179 -0.152 0.127 -0.147 0.139 
31 kdephosp53 -0.044 0.658 0.032 0.753 0.025 0.805 68 ksynMdm2mRNAGSK3bp5
3 
-0.043 0.669 -0.032 0.750 -0.035 0.725 
32 kdephospTau -0.002 0.987 0.004 0.971 0.007 0.944 69 ksynp53 0.079 0.430 0.033 0.744 0.033 0.739 
33 kdisaggAbeta -0.073 0.463 -0.063 0.528 -0.071 0.478 70 ksynp53mRNA 0.047 0.642 0.026 0.796 0.025 0.802 
34 kdisaggAbeta1 -0.122 0.222 -0.114 0.255 -0.115 0.248 71 ksynp53mRNAAbeta 0.139 0.163 0.174 0.081 0.175 0.078 
35 kdisaggAbeta2 0.105 0.292 0.131 0.190 0.133 0.184 72 ksynTau 0.076 0.449 0.122 0.221 0.112 0.261 
36 kgenROSAbeta -0.116 0.247 -0.072 0.472 -0.069 0.488 73 ktangfor -0.042 0.672 -0.046 0.649 -0.044 0.660 


















































1 kactATM -0.037 0.709 -0.016 0.871 0.093 0.351 38 kgenROSPlaque -0.105 0.292 -0.100 0.317 0.011 0.915 
2 kactDUBMdm2 0.039 0.700 0.086 0.390 -0.057 0.568 39 kinactATM -0.124 0.215 -0.126 0.205 0.010 0.918 
3 kactDUBp53 -0.038 0.702 0.010 0.917 -0.044 0.663 40 kinactglia1 -0.192 0.053 0.014 0.887 -0.067 0.506 
4 kactDUBProtp53 0.068 0.498 -0.072 0.472 0.067 0.503 41 kinactglia2 -0.065 0.517 -0.013 0.894 0.094 0.349 
5 kactglia1 -0.231 0.019 -0.032 0.752 0.141 0.156 42 kinhibprot 0.002 0.986 0.142 0.153 0.020 0.839 
6 Kactglia2 0.064 0.526 -0.148 0.137 -0.148 0.139 43 kMdm2PolyUb -0.008 0.937 0.032 0.747 0.012 0.906 
7 kaggAbeta 0.030 0.767 -0.169 0.089 0.023 0.818 44 kMdm2PUb -0.028 0.777 0.084 0.401 -0.086 0.388 
8 kaggTau 0.173 0.081 0.064 0.521 0.143 0.151 45 kMdm2Ub -0.021 0.837 -0.293 0.014 -0.034 0.734 
9 kaggTauP1 -0.173 0.081 -0.064 0.521 -0.143 0.151 46 kp53PolyUb -0.132 0.185 -0.059 0.556 -0.180 0.070 
10 kaggTauP2 -0.023 0.822 -0.070 0.482 0.133 0.181 47 kp53Ub -0.107 0.286 -0.012 0.905 0.045 0.653 
11 kbinAbantiAb 0.106 0.287 0.050 0.616 0.123 0.217 48 kpf -0.024 0.812 -0.067 0.503 -0.079 0.433 
12 kbinAbetaGlia 0.056 0.577 -0.111 0.265 -0.022 0.824 49 kpg 0.045 0.654 0.179 0.072 0.064 0.523 
13 kbinE1Ub -0.071 0.481 -0.162 0.103 -0.076 0.446 50 kpghalf 0.150 0.132 0.137 0.169 0.128 0.199 
14 kbinE2Ub 0.094 0.347 0.002 0.986 0.117 0.241 51 kphosMdm2 -0.157 0.115 0.078 0.439 0.081 0.420 
15 kbinGSK3bp53 -0.113 0.258 -0.093 0.351 -0.172 0.083 52 kphosMdm2GSK3b -0.137 0.169 0.003 0.974 -0.137 0.169 
16 kbinMdm2p53 -0.139 0.165 -0.034 0.737 -0.069 0.490 53 kphosMdm2GSK3bp53 0.036 0.717 0.168 0.091 0.030 0.768 
17 kbinMTTau 0.025 0.802 -0.094 0.346 -0.030 0.765 54 kphosp53 0.050 0.619 -0.036 0.716 0.025 0.801 
18 kbinProt 0.069 0.493 0.065 0.518 -0.004 0.969 55 kphospTauGSK3b 0.032 0.746 0.023 0.818 0.106 0.290 
19 kbinTauProt 0.021 0.838 -0.199 0.044 -0.052 0.603 56 kphospTauGSK3bp53 -0.120 0.228 -0.035 0.728 -0.128 0.201 
20 kdam 0.063 0.532 -0.044 0.660 0.197 0.047 57 kprodAbeta 0.143 0.151 0.109 0.275 -0.098 0.328 
21 kdamROS -0.063 0.531 -0.119 0.233 -0.015 0.879 58 kprodAbeta2 -0.027 0.786 -0.190 0.056 -0.070 0.482 
22 kdegAbeta -0.059 0.558 0.012 0.906 0.056 0.575 59 kproteff 0.023 0.820 -0.069 0.488 -0.071 0.475 
23 kdegAbetaGlia 0.076 0.450 -0.006 0.955 -0.111 0.269 60 krelAbetaGlia 0.002 0.983 -0.046 0.644 0.156 0.118 
24 kdegAntiAb 0.093 0.354 0.055 0.583 0.087 0.387 61 krelGSK3bp53 0.089 0.374 0.192 0.054 0.148 0.136 
25 kdegMdm2 -0.011 0.915 0.072 0.475 -0.006 0.953 62 krelMdm2p53 0.109 0.274 0.032 0.749 0.045 0.654 
26 kdegMdm2mRNA 0.030 0.768 -0.008 0.939 -0.083 0.407 63 krelMTTau -0.032 0.749 0.039 0.696 -0.006 0.952 
27 kdegp53 0.091 0.361 -0.038 0.707 0.067 0.507 64 kremROS 0.174 0.079 -0.091 0.364 -0.058 0.562 
28 kdegp53mRNA -0.168 0.091 0.024 0.814 -0.216 0.029 65 krepair 0.074 0.459 -0.209 0.035 -0.067 0.504 
29 kdegTau20SProt 0.221 0.025 -0.046 0.644 0.199 0.045 66 ksynMdm2 0.265 0.007 -0.034 0.737 0.071 0.478 
30 kdephosMdm2 0.073 0.465 -0.058 0.564 -0.092 0.356 67 ksynMdm2mRNA -0.069 0.489 0.108 0.278 -0.083 0.408 
31 kdephosp53 -0.065 0.518 -0.005 0.962 0.116 0.246 68 ksynMdm2mRNAGSK3b
p53 
0.013 0.899 0.094 0.350 0.171 0.086 
32 kdephospTau -0.068 0.494 -0.066 0.512 0.021 0.832 69 ksynp53 -0.077 0.442 0.072 0.474 0.048 0.632 
33 kdisaggAbeta -0.073 0.464 0.178 0.073 0.025 0.802 70 ksynp53mRNA 0.002 0.988 -0.141 0.158 -0.172 0.084 
34 kdisaggAbeta1 -0.004 0.969 0.162 0.104 -0.011 0.914 71 ksynp53mRNAAbeta 0.009 0.926 0.178 0.073 0.220 0.026 
35 kdisaggAbeta2 0.077 0.445 -0.054 0.591 -0.033 0.739 72 ksynTau 0.080 0.423 0.210 0.034 0.061 0.543 
36 kgenROSAbeta -0.088 0.380 0.065 0.515 -0.123 0.220 73 ktangfor -0.013 0.896 0.008 0.932 -0.060 0.552 
37 kgenROSGlia 0.140 0.161 0.034 0.735 0.015 0.884         


















































1 kactATM -0.019 0.852 -0.047 0.642 -0.047 0.642 38 kgenROSPlaque -0.094 0.350 -0.099 0.321 -0.100 0.320 
2 kactDUBMdm2 0.013 0.893 0.000 0.999 0.004 0.971 39 kinactATM -0.003 0.980 -0.015 0.884 -0.016 0.871 
3 kactDUBp53 0.010 0.924 0.043 0.670 0.042 0.674 40 kinactglia1 -0.093 0.350 -0.076 0.448 -0.076 0.445 
4 kactDUBProtp53 0.045 0.655 0.048 0.633 0.048 0.630 41 kinactglia2 0.025 0.802 0.015 0.884 0.014 0.892 
5 kactglia1 -0.056 0.577 -0.081 0.419 -0.082 0.414 42 kinhibprot -0.045 0.656 -0.038 0.703 -0.040 0.687 
6 Kactglia2 -0.129 0.197 -0.135 0.177 -0.134 0.179 43 kMdm2PolyUb 0.030 0.763 0.020 0.842 0.019 0.846 
7 kaggAbeta 0.100 0.315 0.101 0.310 0.101 0.310 44 kMdm2PUb -0.132 0.186 -0.125 0.211 -0.120 0.228 
8 kaggTau 0.231 0.020 0.228 0.021 0.229 0.021 45 kMdm2Ub -0.045 0.651 -0.069 0.492 -0.069 0.493 
9 kaggTauP1 -0.231 0.020 -0.228 0.021 -0.229 0.021 46 kp53PolyUb -0.083 0.406 -0.107 0.286 -0.109 0.274 
10 kaggTauP2 0.023 0.820 -0.005 0.962 -0.005 0.960 47 kp53Ub -0.065 0.518 -0.041 0.680 -0.041 0.684 
11 kbinAbantiAb 0.159 0.111 0.162 0.104 0.162 0.103 48 kpf 0.045 0.657 0.017 0.865 0.017 0.867 
12 kbinAbetaGlia -0.066 0.507 -0.071 0.476 -0.072 0.469 49 kpg 0.007 0.942 0.044 0.663 0.044 0.660 
13 kbinE1Ub -0.070 0.486 -0.075 0.451 -0.075 0.455 50 kpghalf 0.133 0.181 0.137 0.170 0.137 0.170 
14 kbinE2Ub 0.620 0.002 0.232 0.019 0.232 0.019 51 kphosMdm2 0.050 0.617 0.046 0.647 0.046 0.647 
15 kbinGSK3bp53 0.671 4.2E-
05 
-0.077 0.439 -0.077 0.444 52 kphosMdm2GSK3b -0.120 0.231 -0.106 0.287 -0.104 0.297 
16 kbinMdm2p53 -0.592 0.0016
705 
-0.262 0.008 -0.262 0.008 53 kphosMdm2GSK3bp53 -0.024 0.809 -0.030 0.763 -0.030 0.766 
17 kbinMTTau 0.057 0.572 0.026 0.798 0.024 0.811 54 kphosp53 0.104 0.300 0.110 0.270 0.111 0.269 
18 kbinProt 0.006 0.954 -0.007 0.948 -0.011 0.914 55 kphospTauGSK3b 0.128 0.199 0.138 0.166 0.139 0.163 
19 kbinTauProt -0.010 0.921 -0.009 0.930 -0.010 0.922 56 kphospTauGSK3bp53 -0.160 0.109 -0.157 0.116 -0.155 0.121 
20 kdam 0.046 0.650 0.056 0.576 0.056 0.576 57 kprodAbeta -0.025 0.805 0.000 1.000 0.001 0.994 
21 kdamROS 0.047 0.642 0.045 0.653 0.044 0.657 58 kprodAbeta2 -0.054 0.588 -0.039 0.701 -0.039 0.701 
22 kdegAbeta -0.086 0.393 -0.051 0.613 -0.051 0.613 59 kproteff -0.016 0.870 0.003 0.976 0.006 0.956 
23 kdegAbetaGlia -0.040 0.686 -0.052 0.602 -0.053 0.599 60 krelAbetaGlia 0.088 0.381 0.082 0.415 0.084 0.400 
24 kdegAntiAb 0.105 0.295 0.106 0.288 0.108 0.280 61 krelGSK3bp53 0.113 0.258 0.112 0.261 0.112 0.261 
25 kdegMdm2 -0.088 0.380 -0.078 0.434 -0.076 0.446 62 krelMdm2p53 -0.004 0.965 -0.029 0.776 -0.028 0.782 
26 kdegMdm2mRNA 0.042 0.676 0.041 0.685 0.043 0.666 63 krelMTTau -0.148 0.137 -0.167 0.094 -0.168 0.091 
27 kdegp53 0.013 0.894 0.040 0.688 0.039 0.695 64 kremROS 0.111 0.265 0.117 0.240 0.114 0.252 
28 kdegp53mRNA -0.094 0.348 -0.085 0.397 -0.086 0.390 65 krepair 0.032 0.751 0.007 0.945 0.005 0.962 
29 kdegTau20SProt 0.184 0.064 0.198 0.046 0.197 0.047 66 ksynMdm2 0.288 0.003 0.264 0.007 0.264 0.007 
30 kdephosMdm2 0.042 0.674 0.009 0.928 0.008 0.938 67 ksynMdm2mRNA -0.159 0.111 -0.149 0.135 -0.151 0.131 
31 kdephosp53 -0.011 0.911 0.026 0.796 0.025 0.805 68 ksynMdm2mRNAGSK3bp
53 
-0.033 0.741 -0.035 0.731 -0.036 0.718 
32 kdephospTau 0.003 0.973 0.003 0.974 0.005 0.961 69 ksynp53 0.064 0.520 0.042 0.673 0.042 0.678 
33 kdisaggAbeta -0.067 0.504 -0.066 0.507 -0.065 0.517 70 ksynp53mRNA 0.042 0.676 0.029 0.769 0.031 0.755 
34 kdisaggAbeta1 -0.113 0.256 -0.109 0.277 -0.107 0.284 71 ksynp53mRNAAbeta 0.173 0.082 0.179 0.071 0.180 0.071 
35 kdisaggAbeta2 0.111 0.265 0.136 0.174 0.136 0.173 72 ksynTau 0.095 0.344 0.115 0.249 0.116 0.248 
36 kgenROSAbeta -0.091 0.361 -0.066 0.508 -0.066 0.507 73 ktangfor -0.044 0.662 -0.052 0.607 -0.052 0.607 
37 kgenROSGlia 0.200 0.044 0.153 0.125 0.151 0.129         


















































1 kactATM -0.116 0.244 -0.134 0.179 0.091 0.361 38 kgenROSPlaque -0.155 0.119 -0.014 0.890 0.035 0.730 
2 kactDUBMdm2 -0.031 0.756 0.080 0.422 0.141 0.158 39 kinactATM -0.060 0.548 -0.180 0.070 -0.001 0.991 
3 kactDUBp53 -0.004 0.972 0.137 0.168 -0.061 0.546 40 kinactglia1 0.031 0.761 -0.090 0.368 0.055 0.581 
4 kactDUBProtp53 0.046 0.645 0.007 0.944 0.039 0.696 41 kinactglia2 -0.155 0.119 0.022 0.824 0.033 0.742 
5 kactglia1 -0.186 0.061 0.008 0.938 0.086 0.391 42 kinhibprot 0.052 0.601 -0.045 0.655 -0.094 0.349 
6 Kactglia2 -0.073 0.464 -0.206 0.038 -0.133 0.182 43 kMdm2PolyUb -0.010 0.924 -0.058 0.565 -0.138 0.167 
7 kaggAbeta -0.034 0.732 -0.103 0.305 0.048 0.631 44 kMdm2PUb -0.108 0.278 0.004 0.972 -0.057 0.570 
8 kaggTau 0.246 0.013 0.100 0.316 0.110 0.273 45 kMdm2Ub 0.098 0.326 0.038 0.706 -0.080 0.424 
9 kaggTauP1 -0.246 0.013 -0.100 0.316 -0.110 0.273 46 kp53PolyUb -0.095 0.341 -0.091 0.363 -0.146 0.142 
10 kaggTauP2 -0.014 0.892 -0.136 0.173 0.026 0.794 47 kp53Ub 0.146 0.143 -0.070 0.483 0.151 0.131 
11 kbinAbantiAb 0.196 0.048 0.156 0.118 0.064 0.520 48 kpf -0.104 0.297 0.019 0.847 -0.164 0.099 
12 kbinAbetaGlia -0.117 0.240 0.033 0.739 0.022 0.824 49 kpg 0.128 0.198 -0.030 0.763 0.164 0.100 
13 kbinE1Ub -0.103 0.304 -0.084 0.403 -0.057 0.567 50 kpghalf 0.159 0.110 0.152 0.126 0.156 0.116 
14 kbinE2Ub 0.180 0.070 0.043 0.671 0.080 0.422 51 kphosMdm2 -0.093 0.350 0.032 0.746 0.003 0.979 
15 kbinGSK3bp53 -0.151 0.129 -0.004 0.969 -0.041 0.684 52 kphosMdm2GSK3b -0.131 0.189 -0.010 0.922 0.035 0.728 
16 kbinMdm2p53 -0.173 0.081 -0.012 0.905 -0.240 0.015 53 kphosMdm2GSK3bp53 -0.011 0.916 0.042 0.673 0.126 0.205 
17 kbinMTTau 0.005 0.963 0.065 0.519 0.015 0.882 54 kphosp53 0.004 0.969 0.107 0.284 0.068 0.494 
18 kbinProt -0.029 0.776 0.090 0.366 -0.150 0.132 55 kphospTauGSK3b -0.043 0.669 0.024 0.813 0.067 0.503 
19 kbinTauProt -0.001 0.995 -0.075 0.451 -0.046 0.649 56 kphospTauGSK3bp53 -0.082 0.410 -0.133 0.184 -0.060 0.547 
20 kdam 0.013 0.896 0.048 0.631 0.047 0.641 57 kprodAbeta 0.078 0.434 0.036 0.722 -0.155 0.120 
21 kdamROS -0.217 0.028 -0.055 0.586 -0.052 0.602 58 kprodAbeta2 0.005 0.960 -0.082 0.411 0.063 0.528 
22 kdegAbeta 0.046 0.643 -0.015 0.883 0.032 0.749 59 kproteff -0.122 0.221 0.047 0.637 -0.089 0.373 
23 kdegAbetaGlia 0.042 0.676 0.000 1.000 0.016 0.874 60 krelAbetaGlia -0.027 0.787 0.077 0.444 0.142 0.155 
24 kdegAntiAb 0.102 0.310 0.103 0.304 0.043 0.669 61 krelGSK3bp53 0.043 0.664 0.171 0.086 0.030 0.768 
25 kdegMdm2 -0.080 0.426 0.019 0.852 0.005 0.956 62 krelMdm2p53 0.115 0.251 0.044 0.658 -0.009 0.930 
26 kdegMdm2mRNA 0.006 0.956 -0.035 0.725 0.075 0.451 63 krelMTTau -0.079 0.432 -0.094 0.348 -0.102 0.308 
27 kdegp53 0.111 0.265 -0.024 0.811 0.025 0.803 64 kremROS 0.160 0.107 0.105 0.294 0.073 0.468 
28 kdegp53mRNA -0.063 0.530 0.025 0.804 -0.125 0.210 65 krepair -0.002 0.983 -0.159 0.110 0.066 0.508 
29 kdegTau20SProt 0.191 0.055 0.082 0.411 0.193 0.052 66 ksynMdm2 0.349 3.180E-
04 
0.117 0.243 0.132 0.187 
30 kdephosMdm2 0.103 0.302 -0.017 0.865 -0.011 0.911 67 ksynMdm2mRNA -0.083 0.406 -0.033 0.745 -0.170 0.087 
31 kdephosp53 0.058 0.565 -0.028 0.777 -0.026 0.799 68 ksynMdm2mRNAGSK3bp
53 
-0.106 0.290 0.148 0.138 0.168 0.091 
32 kdephospTau -0.026 0.792 -0.069 0.491 0.025 0.806 69 ksynp53 -0.051 0.612 0.089 0.371 -0.096 0.338 
33 kdisaggAbeta 0.036 0.717 0.000 0.998 0.035 0.728 70 ksynp53mRNA 0.034 0.734 -0.134 0.179 0.057 0.569 
34 kdisaggAbeta1 -0.026 0.792 0.105 0.291 -0.135 0.176 71 ksynp53mRNAAbeta 0.174 0.081 0.214 0.031 0.086 0.391 
35 kdisaggAbeta2 0.107 0.286 -0.036 0.720 0.164 0.100 72 ksynTau 0.116 0.244 0.137 0.170 -0.062 0.534 
36 kgenROSAbeta 0.009 0.931 -0.136 0.173 -0.211 0.033 73 ktangfor 0.075 0.454 -0.097 0.334 -0.017 0.867 
37 kgenROSGlia 0.104 0.296 0.022 0.829 0.019 0.851         


















































1 kactATM -0.029 0.774 -0.047 0.638 -0.050 0.617 38 kgenROSPlaque -0.084 0.401 -0.100 0.318 -0.097 0.334 
2 kactDUBMdm2 0.010 0.920 -0.003 0.977 -0.002 0.987 39 kinactATM -0.001 0.990 -0.014 0.888 -0.017 0.867 
3 kactDUBp53 0.010 0.924 0.038 0.702 0.041 0.685 40 kinactglia1 -0.100 0.319 -0.079 0.428 -0.078 0.435 
4 kactDUBProtp53 0.053 0.599 0.051 0.609 0.053 0.599 41 kinactglia2 0.025 0.804 0.015 0.878 0.014 0.891 
5 kactglia1 -0.062 0.533 -0.082 0.412 -0.081 0.416 42 kinhibprot -0.047 0.637 -0.040 0.691 -0.039 0.697 
6 Kactglia2 -0.120 0.229 -0.126 0.206 -0.129 0.195 43 kMdm2PolyUb 0.026 0.793 0.019 0.850 0.017 0.868 
7 kaggAbeta 0.103 0.302 0.095 0.343 0.096 0.336 44 kMdm2PUb -0.142 0.155 -0.128 0.200 -0.126 0.207 
8 kaggTau 0.234 0.018 0.231 0.019 0.232 0.019 45 kMdm2Ub -0.047 0.639 -0.061 0.540 -0.066 0.513 
9 kaggTauP1 -0.234 0.018 -0.231 0.019 -0.232 0.019 46 kp53PolyUb -0.085 0.397 -0.110 0.270 -0.116 0.247 
10 kaggTauP2 0.033 0.742 0.005 0.958 0.003 0.979 47 kp53Ub -0.052 0.602 -0.033 0.746 -0.031 0.759 
11 kbinAbantiAb 0.151 0.131 0.154 0.121 0.156 0.117 48 kpf 0.044 0.663 0.020 0.841 0.020 0.839 
12 kbinAbetaGlia -0.067 0.505 -0.075 0.452 -0.074 0.458 49 kpg 0.010 0.917 0.050 0.616 0.051 0.614 
13 kbinE1Ub -0.068 0.497 -0.077 0.442 -0.076 0.450 50 kpghalf 0.137 0.170 0.137 0.170 0.133 0.181 
14 kbinE2Ub 0.224 0.023 0.237 0.017 0.238 0.016 51 kphosMdm2 0.047 0.637 0.046 0.647 0.045 0.657 
15 kbinGSK3bp53 -0.087 0.384 -0.070 0.486 -0.071 0.477 52 kphosMdm2GSK3b -0.119 0.234 -0.104 0.297 -0.100 0.318 
16 kbinMdm2p53 -0.389 0.003 -0.744 2E-05 -0.467 0.007 53 kphosMdm2GSK3bp53 -0.017 0.867 -0.021 0.831 -0.023 0.820 
17 kbinMTTau 0.046 0.643 0.019 0.852 0.014 0.890 54 kphosp53 0.110 0.271 0.116 0.246 0.113 0.258 
18 kbinProt 0.000 0.997 -0.010 0.924 -0.013 0.899 55 kphospTauGSK3b 0.123 0.220 0.135 0.176 0.137 0.171 
19 kbinTauProt -0.016 0.873 -0.010 0.917 -0.013 0.898 56 kphospTauGSK3bp53 -0.157 0.115 -0.156 0.118 -0.155 0.120 
20 kdam 0.047 0.637 0.053 0.599 0.057 0.569 57 kprodAbeta -0.027 0.786 -0.005 0.958 -0.004 0.970 
21 kdamROS 0.050 0.620 0.045 0.650 0.042 0.671 58 kprodAbeta2 -0.056 0.579 -0.037 0.713 -0.036 0.718 
22 kdegAbeta -0.088 0.380 -0.055 0.586 -0.051 0.608 59 kproteff -0.014 0.886 0.002 0.983 0.006 0.950 
23 kdegAbetaGlia -0.031 0.759 -0.051 0.614 -0.048 0.634 60 krelAbetaGlia 0.080 0.423 0.077 0.441 0.075 0.453 
24 kdegAntiAb 0.112 0.262 0.113 0.257 0.118 0.239 61 krelGSK3bp53 0.111 0.268 0.116 0.247 0.112 0.263 
25 kdegMdm2 -0.087 0.384 -0.075 0.455 -0.077 0.443 62 krelMdm2p53 -0.006 0.951 -0.029 0.771 -0.031 0.761 
26 kdegMdm2mRNA 0.036 0.716 0.040 0.690 0.041 0.686 63 krelMTTau -0.143 0.151 -0.166 0.095 -0.167 0.094 
27 kdegp53 0.010 0.923 0.037 0.716 0.036 0.722 64 kremROS 0.110 0.273 0.108 0.280 0.112 0.261 
28 kdegp53mRNA -0.094 0.349 -0.088 0.382 -0.086 0.389 65 krepair 0.025 0.807 0.004 0.968 -0.001 0.994 
29 kdegTau20SProt 0.181 0.069 0.192 0.054 0.192 0.053 66 ksynMdm2 0.388 0.003 0.7911 3.66E-06 0.365 0.007 
30 kdephosMdm2 0.052 0.605 0.007 0.940 0.008 0.938 67 ksynMdm2mRNA -0.159 0.110 -0.160 0.107 -0.157 0.115 
31 kdephosp53 -0.024 0.812 0.020 0.845 0.018 0.857 68 ksynMdm2mRNAGSK3bp
53 
-0.036 0.720 -0.038 0.702 -0.039 0.699 
32 kdephospTau 0.003 0.975 0.005 0.963 0.007 0.944 69 ksynp53 0.067 0.507 0.046 0.643 0.047 0.639 
33 kdisaggAbeta -0.072 0.473 -0.072 0.475 -0.072 0.469 70 ksynp53mRNA 0.051 0.609 0.039 0.695 0.037 0.713 
34 kdisaggAbeta1 -0.118 0.236 -0.105 0.294 -0.104 0.299 71 ksynp53mRNAAbeta 0.174 0.080 0.181 0.069 0.182 0.067 
35 kdisaggAbeta2 0.122 0.221 0.139 0.164 0.141 0.158 72 ksynTau 0.092 0.360 0.116 0.247 0.112 0.261 
36 kgenROSAbeta -0.084 0.402 -0.058 0.561 -0.058 0.565 73 ktangfor -0.038 0.708 -0.048 0.630 -0.047 0.639 
37 kgenROSGlia 0.201 0.043 0.157 0.115 0.154 0.122         



















































1 kactATM -0.209 0.035 0.008 0.938 0.053 0.599 38 kgenROSPlaque -0.093 0.354 -0.072 0.472 0.004 0.967 
2 kactDUBMdm2 0.069 0.490 0.025 0.799 -0.027 0.785 39 kinactATM 0.004 0.972 -0.093 0.351 -0.156 0.117 
3 kactDUBp53 -0.006 0.955 -0.106 0.288 -0.015 0.880 40 kinactglia1 -0.136 0.174 -0.086 0.390 -0.008 0.933 
4 kactDUBProtp53 0.129 0.197 -0.018 0.861 0.034 0.732 41 kinactglia2 -0.047 0.642 0.193 0.052 0.013 0.897 
5 kactglia1 -0.082 0.415 -0.023 0.816 -0.058 0.563 42 kinhibprot -0.018 0.857 -0.005 0.963 0.082 0.411 
6 Kactglia2 -0.039 0.695 0.014 0.893 0.042 0.675 43 kMdm2PolyUb -0.002 0.981 -0.064 0.524 -3.7E-04 0.997 
7 kaggAbeta 0.094 0.347 0.044 0.659 -0.054 0.592 44 kMdm2PUb 0.142 0.154 -0.017 0.868 0.054 0.588 
8 kaggTau 0.088 0.378 0.106 0.289 0.080 0.421 45 kMdm2Ub 0.012 0.902 -0.029 0.773 0.036 0.717 
9 kaggTauP1 -0.088 0.378 -0.106 0.289 -0.080 0.421 46 kp53PolyUb -0.146 0.144 0.015 0.878 -0.279 0.004 
10 kaggTauP2 0.047 0.637 0.131 0.190 -0.052 0.605 47 kp53Ub -0.061 0.543 -0.008 0.934 0.094 0.345 
11 kbinAbantiAb 0.123 0.218 -0.040 0.687 -0.039 0.700 48 kpf -0.006 0.952 0.071 0.476 -0.033 0.745 
12 kbinAbetaGlia 0.082 0.413 0.042 0.674 -0.151 0.130 49 kpg 0.087 0.384 0.005 0.960 0.079 0.428 
13 kbinE1Ub -0.091 0.363 -0.132 0.186 0.057 0.571 50 kpghalf 0.175 0.079 0.154 0.121 0.161 0.107 
14 kbinE2Ub 0.131 0.188 -0.009 0.928 0.099 0.324 51 kphosMdm2 0.003 0.976 0.028 0.782 -0.008 0.939 
15 kbinGSK3bp53 -0.127 0.202 -0.070 0.483 -0.066 0.509 52 kphosMdm2GSK3b -0.176 0.076 -0.030 0.764 -0.050 0.620 
16 kbinMdm2p53 -0.430 0.020 -0.70 2.48E-
05 
-0.385 0.003 53 kphosMdm2GSK3bp53 0.045 0.650 0.119 0.234 0.095 0.344 
17 kbinMTTau -0.034 0.735 -0.014 0.886 -0.018 0.859 54 kphosp53 -0.115 0.250 0.120 0.231 -0.006 0.949 
18 kbinProt -0.085 0.394 0.030 0.764 -0.196 0.049 55 kphospTauGSK3b 0.111 0.267 0.009 0.931 -0.103 0.304 
19 kbinTauProt -0.105 0.293 -0.069 0.491 0.015 0.885 56 kphospTauGSK3bp53 -0.046 0.646 -0.202 0.042 -0.095 0.345 
20 kdam 0.050 0.615 0.131 0.190 0.141 0.156 57 kprodAbeta 0.052 0.601 -0.065 0.513 -0.026 0.794 
21 kdamROS -0.180 0.070 -0.010 0.923 0.048 0.635 58 kprodAbeta2 -0.010 0.921 -0.030 0.768 0.040 0.689 
22 kdegAbeta -0.140 0.160 -0.139 0.163 0.019 0.846 59 kproteff -0.115 0.251 -0.039 0.695 -0.116 0.244 
23 kdegAbetaGlia 0.164 0.100 0.130 0.194 -0.047 0.639 60 krelAbetaGlia 0.188 0.059 0.168 0.091 0.194 0.051 
24 kdegAntiAb -0.023 0.816 -0.068 0.495 0.135 0.177 61 krelGSK3bp53 0.070 0.484 0.109 0.275 -0.121 0.226 
25 kdegMdm2 -0.130 0.193 0.010 0.921 0.013 0.897 62 krelMdm2p53 0.221 0.025 -0.050 0.616 0.135 0.175 
26 kdegMdm2mRNA 0.164 0.099 0.147 0.139 0.031 0.754 63 krelMTTau 0.046 0.649 0.052 0.605 -0.062 0.534 
27 kdegp53 0.030 0.763 -0.047 0.637 0.131 0.188 64 kremROS 0.153 0.124 -0.084 0.404 0.061 0.542 
28 kdegp53mRNA -0.054 0.591 -0.133 0.183 -0.184 0.064 65 krepair -0.004 0.972 -0.114 0.253 0.022 0.830 





30 kdephosMdm2 -0.055 0.583 -0.002 0.983 -0.075 0.452 67 ksynMdm2mRNA -0.075 0.455 -0.092 0.360 -0.059 0.556 
31 kdephosp53 0.042 0.672 -0.047 0.638 0.023 0.818 68 ksynMdm2mRNAGSK3bp
53 
-0.107 0.283 0.144 0.149 -0.123 0.219 
32 kdephospTau -0.040 0.689 0.026 0.797 0.087 0.385 69 ksynp53 0.111 0.265 0.046 0.646 -0.061 0.545 
33 kdisaggAbeta -0.052 0.601 0.171 0.086 0.170 0.088 70 ksynp53mRNA 0.065 0.515 -0.050 0.619 0.184 0.064 
34 kdisaggAbeta1 0.013 0.895 -0.053 0.595 -0.013 0.897 71 ksynp53mRNAAbeta 0.036 0.718 0.153 0.126 -0.093 0.351 
35 kdisaggAbeta2 0.106 0.288 -0.005 0.958 0.105 0.293 72 ksynTau -0.031 0.757 0.103 0.304 0.081 0.420 
36 kgenROSAbeta -0.143 0.153 0.002 0.983 -0.182 0.067 73 ktangfor -0.117 0.243 -0.204 0.040 0.055 0.580 
37 kgenROSGlia 0.136 0.172 0.153 0.126 -0.028 0.782         


















































1 kactATM -0.079 0.427 0.034 0.736 0.005 0.959 38 kgenROSPlaque 0.030 0.762 -0.077 0.440 -0.071 0.480 
2 kactDUBMdm2 -0.014 0.892 -0.047 0.638 -0.015 0.882 39 kinactATM 0.017 0.864 0.033 0.739 -0.001 0.991 
3 kactDUBp53 -0.028 0.778 -0.016 0.870 -0.014 0.890 40 kinactglia1 -0.186 0.061 -0.060 0.549 -0.072 0.473 
4 kactDUBProtp53 0.049 0.625 -0.022 0.830 -0.013 0.899 41 kinactglia2 0.009 0.927 0.106 0.287 0.089 0.373 
5 kactglia1 -0.025 0.806 -0.166 0.095 -0.131 0.189 42 kinhibprot -0.023 0.818 -0.026 0.794 -0.028 0.777 
6 Kactglia2 -0.187 0.059 -0.031 0.755 -0.070 0.482 43 kMdm2PolyUb 0.076 0.446 0.061 0.544 0.042 0.679 
7 kaggAbeta 0.082 0.415 0.049 0.622 0.060 0.552 44 kMdm2PUb -0.065 0.513 -0.048 0.629 -0.078 0.439 
8 kaggTau 0.190 0.056 0.171 0.085 0.232 0.019 45 kMdm2Ub -0.018 0.854 -0.094 0.349 -0.096 0.335 
9 kaggTauP1 -0.190 0.056 -0.171 0.085 -0.232 0.019 46 kp53PolyUb -0.106 0.291 -0.090 0.369 -0.117 0.244 
10 kaggTauP2 0.063 0.529 -0.004 0.966 -0.008 0.936 47 kp53Ub -0.087 0.387 -0.029 0.773 -0.026 0.795 
11 kbinAbantiAb 0.133 0.182 0.090 0.369 0.147 0.142 48 kpf 0.032 0.748 0.020 0.839 0.018 0.858 
12 kbinAbetaGlia 0.024 0.807 -0.077 0.444 -0.069 0.492 49 kpg -0.021 0.831 0.097 0.332 0.097 0.331 
13 kbinE1Ub -0.054 0.591 -0.092 0.357 -0.088 0.378 50 kpghalf 0.133 0.181 0.069 0.489 0.120 0.230 
14 kbinE2Ub 0.095 0.344 0.214 0.031 0.233 0.018 51 kphosMdm2 0.029 0.771 0.024 0.813 0.018 0.857 
15 kbinGSK3bp53 -0.134 0.179 -0.058 0.565 -0.100 0.316 52 kphosMdm2GSK3b -0.086 0.391 -0.202 0.041 -0.161 0.106 
16 kbinMdm2p53 -0.5786 1.1E-03 -0.208 0.036 -0.243 0.014 53 kphosMdm2GSK3bp53 0.005 0.956 0.016 0.870 0.001 0.990 
17 kbinMTTau 0.012 0.902 -0.106 0.288 -0.060 0.552 54 kphosp53 0.043 0.667 0.144 0.150 0.146 0.144 
18 kbinProt 0.030 0.762 -0.022 0.829 0.004 0.967 55 kphospTauGSK3b 0.042 0.673 0.044 0.663 0.088 0.378 
19 kbinTauProt -0.007 0.947 0.114 0.256 0.071 0.478 56 kphospTauGSK3bp53 -0.094 0.347 -0.054 0.589 -0.123 0.217 
20 kdam 0.067 0.507 0.042 0.672 0.067 0.504 57 kprodAbeta -0.031 0.756 0.068 0.497 0.063 0.528 
21 kdamROS 0.005 0.964 -0.018 0.855 -0.017 0.868 58 kprodAbeta2 -0.068 0.497 0.087 0.382 0.047 0.641 
22 kdegAbeta -0.128 0.199 -0.122 0.224 -0.109 0.273 59 kproteff 0.047 0.639 -0.061 0.546 -0.043 0.667 
23 kdegAbetaGlia 0.031 0.759 -0.048 0.635 -0.032 0.753 60 krelAbetaGlia 0.119 0.233 -0.076 0.450 -0.034 0.732 
24 kdegAntiAb 0.113 0.257 0.157 0.116 0.159 0.111 61 krelGSK3bp53 0.045 0.656 0.102 0.306 0.091 0.360 
25 kdegMdm2 -0.100 0.317 -0.053 0.594 -0.079 0.429 62 krelMdm2p53 0.017 0.868 -0.161 0.106 -0.124 0.214 
26 kdegMdm2mRNA 0.053 0.594 0.028 0.777 0.045 0.655 63 krelMTTau -0.070 0.486 -0.100 0.316 -0.131 0.189 
27 kdegp53 0.019 0.846 0.020 0.841 0.008 0.940 64 kremROS 0.146 0.142 0.130 0.193 0.155 0.120 
28 kdegp53mRNA -0.087 0.387 -0.109 0.277 -0.125 0.211 65 krepair 0.025 0.802 0.053 0.599 0.032 0.751 
29 kdegTau20SProt 0.138 0.166 0.201 0.043 0.230 0.020 66 ksynMdm2 0.6235 4.68E-04 0.196 0.048 0.253 0.010 
30 kdephosMdm2 0.130 0.194 0.023 0.818 0.025 0.801 67 ksynMdm2mRNA -0.034 0.731 -0.135 0.175 -0.135 0.176 
31 kdephosp53 -0.160 0.108 0.010 0.919 0.014 0.892 68 ksynMdm2mRNAGSK3bp
53 
0.009 0.930 -0.161 0.106 -0.132 0.185 
32 kdephospTau -0.026 0.794 0.031 0.755 0.030 0.762 69 ksynp53 0.038 0.704 0.031 0.758 0.030 0.764 
33 kdisaggAbeta -0.019 0.853 -0.059 0.556 -0.071 0.477 70 ksynp53mRNA 0.069 0.490 0.018 0.859 0.039 0.698 
34 kdisaggAbeta1 -0.093 0.354 -0.105 0.295 -0.110 0.270 71 ksynp53mRNAAbeta 0.201 0.042 0.071 0.481 0.112 0.263 
35 kdisaggAbeta2 0.130 0.191 0.133 0.182 0.124 0.213 72 ksynTau 0.032 0.750 0.176 0.077 0.145 0.145 
36 kgenROSAbeta -0.214 0.031 0.030 0.765 -0.015 0.884 73 ktangfor -0.023 0.819 0.089 0.371 0.049 0.626 
37 kgenROSGlia 0.175 0.078 0.142 0.155 0.161 0.106         


















































1 kactATM -0.087 0.387 0.016 0.873 0.122 0.221 38 kgenROSPlaque -0.099 0.324 -0.014 0.891 -0.110 0.270 
2 kactDUBMdm2 0.082 0.412 0.023 0.817 -0.118 0.236 39 kinactATM 0.144 0.147 -0.057 0.568 -0.041 0.680 
3 kactDUBp53 -0.025 0.802 -0.005 0.960 0.041 0.681 40 kinactglia1 -0.087 0.384 0.053 0.594 -0.050 0.619 
4 kactDUBProtp53 0.052 0.605 0.103 0.303 0.012 0.905 41 kinactglia2 -0.203 0.041 0.127 0.203 0.021 0.837 
5 kactglia1 -0.179 0.072 0.030 0.764 -0.009 0.925 42 kinhibprot -0.111 0.268 -0.021 0.833 0.112 0.264 
6 Kactglia2 -0.026 0.793 0.070 0.487 0.009 0.928 43 kMdm2PolyUb 0.039 0.697 0.126 0.208 0.055 0.584 
7 kaggAbeta 0.070 0.485 -0.066 0.511 0.105 0.292 44 kMdm2PUb -0.024 0.813 0.111 0.267 0.045 0.651 
8 kaggTau 0.167 0.094 0.079 0.431 0.142 0.154 45 kMdm2Ub -0.063 0.526 0.033 0.745 0.014 0.892 
9 kaggTauP1 -0.167 0.094 -0.079 0.431 -0.142 0.154 46 kp53PolyUb -0.082 0.415 -0.224 0.024 -0.151 0.129 
10 kaggTauP2 0.037 0.715 -0.030 0.761 0.029 0.771 47 kp53Ub -0.158 0.114 0.085 0.395 -0.039 0.699 
11 kbinAbantiAb 0.121 0.227 -0.023 0.816 -0.026 0.792 48 kpf -0.076 0.447 -0.045 0.650 -0.073 0.468 
12 kbinAbetaGlia 0.065 0.516 -0.002 0.983 -0.059 0.558 49 kpg -0.046 0.648 0.219 0.027 0.152 0.128 
13 kbinE1Ub -0.085 0.395 -0.025 0.801 -0.110 0.272 50 kpghalf 0.162 0.104 0.084 0.403 0.145 0.145 
14 kbinE2Ub 0.070 0.482 0.018 0.857 0.209 0.035 51 kphosMdm2 -0.116 0.247 0.078 0.437 -0.077 0.443 
15 kbinGSK3bp53 -0.060 0.547 0.069 0.494 -0.092 0.358 52 kphosMdm2GSK3b -0.147 0.141 0.268 0.006 -0.202 0.042 
16 kbinMdm2p53 -0.5041 0.0024 -0.026 0.798 -0.300 0.002 53 kphosMdm2GSK3bp53 -0.053 0.598 -0.027 0.787 0.111 0.266 
17 kbinMTTau 0.067 0.501 0.024 0.814 -0.024 0.810 54 kphosp53 0.120 0.231 0.010 0.921 -0.019 0.853 
18 kbinProt 0.113 0.257 -0.084 0.403 -0.047 0.640 55 kphospTauGSK3b 0.082 0.411 -0.144 0.147 0.072 0.475 
19 kbinTauProt 0.028 0.780 0.013 0.895 -0.074 0.461 56 kphospTauGSK3bp53 -0.038 0.702 -0.147 0.139 -0.096 0.335 
20 kdam 0.051 0.612 -0.074 0.458 0.058 0.563 57 kprodAbeta 0.089 0.376 0.065 0.514 0.041 0.684 
21 kdamROS -0.060 0.550 -0.095 0.340 -0.001 0.994 58 kprodAbeta2 -0.032 0.752 -0.029 0.771 -0.081 0.416 
22 kdegAbeta -0.053 0.600 0.038 0.703 0.077 0.443 59 kproteff 0.043 0.671 -0.104 0.299 -0.160 0.109 
23 kdegAbetaGlia 0.086 0.392 0.022 0.828 -0.154 0.122 60 krelAbetaGlia 0.112 0.264 -0.022 0.829 0.047 0.637 
24 kdegAntiAb 0.059 0.555 -0.066 0.510 0.070 0.483 61 krelGSK3bp53 0.019 0.849 0.032 0.751 0.160 0.107 
25 kdegMdm2 -0.103 0.304 -0.070 0.482 0.051 0.608 62 krelMdm2p53 0.042 0.675 -0.203 0.040 0.042 0.676 
26 kdegMdm2mRNA 0.032 0.751 0.073 0.465 0.026 0.792 63 krelMTTau -0.130 0.193 0.017 0.864 -0.160 0.108 
27 kdegp53 -0.003 0.974 -0.233 0.018 0.123 0.216 64 kremROS 0.205 0.039 -0.040 0.693 0.059 0.555 
28 kdegp53mRNA -0.113 0.257 -0.130 0.192 -0.075 0.455 65 krepair -0.008 0.940 -0.006 0.949 0.044 0.658 
29 kdegTau20SProt 0.501 0.0006
6 
-0.068 0.497 0.047 0.640 66 ksynMdm2 0.324 0.001 0.123 0.217 0.087 0.383 
30 kdephosMdm2 0.204 0.040 -0.040 0.691 -0.070 0.486 67 ksynMdm2mRNA -0.122 0.224 -0.088 0.377 -0.096 0.338 
31 kdephosp53 -0.113 0.257 0.131 0.188 0.096 0.336 68 ksynMdm2mRNAGSK3bp
53 
-0.027 0.788 0.074 0.459 -0.044 0.661 
32 kdephospTau -0.068 0.497 0.131 0.191 0.071 0.478 69 ksynp53 -0.004 0.964 0.003 0.979 0.089 0.372 
33 kdisaggAbeta -0.080 0.422 0.022 0.825 -0.023 0.821 70 ksynp53mRNA 0.028 0.778 0.078 0.434 0.024 0.810 
34 kdisaggAbeta1 -0.136 0.173 0.049 0.628 0.050 0.616 71 ksynp53mRNAAbeta 0.173 0.081 0.046 0.649 0.109 0.276 
35 kdisaggAbeta2 0.095 0.341 0.020 0.839 0.117 0.243 72 ksynTau 0.091 0.364 0.042 0.678 0.142 0.155 
36 kgenROSAbeta -0.137 0.170 0.090 0.369 -0.179 0.072 73 ktangfor -0.001 0.992 -0.096 0.336 0.042 0.677 
37 kgenROSGlia 0.163 0.101 -0.099 0.322 -0.007 0.944         


















































1 kactATM -0.018 0.861 -0.018 0.861 -0.026 0.793 38 kgenROSPlaque -0.090 0.371 -0.090 0.371 -0.092 0.358 
2 kactDUBMdm2 -0.007 0.946 -0.007 0.946 -0.011 0.916 39 kinactATM -0.002 0.983 -0.002 0.983 -0.008 0.936 
3 kactDUBp53 0.013 0.898 0.013 0.898 0.022 0.830 40 kinactglia1 -0.094 0.349 -0.094 0.349 -0.084 0.400 
4 kactDUBProtp53 0.045 0.652 0.045 0.652 0.041 0.680 41 kinactglia2 0.024 0.811 0.024 0.811 0.019 0.847 
5 kactglia1 -0.072 0.471 -0.072 0.471 -0.076 0.449 42 kinhibprot -0.039 0.701 -0.039 0.701 -0.034 0.732 
6 Kactglia2 -0.121 0.227 -0.121 0.227 -0.121 0.225 43 kMdm2PolyUb 0.028 0.777 0.028 0.777 0.027 0.784 
7 kaggAbeta 0.102 0.308 0.102 0.308 0.097 0.333 44 kMdm2PUb -0.137 0.171 -0.137 0.171 -0.131 0.191 
8 kaggTau 0.224 0.024 0.224 0.024 0.227 0.022 45 kMdm2Ub -0.035 0.723 -0.035 0.723 -0.042 0.674 
9 kaggTauP1 -0.224 0.024 -0.224 0.024 -0.227 0.022 46 kp53PolyUb -0.078 0.435 -0.078 0.435 -0.088 0.379 
10 kaggTauP2 0.030 0.764 0.030 0.764 0.022 0.825 47 kp53Ub -0.048 0.630 -0.048 0.630 -0.043 0.669 
11 kbinAbantiAb 0.160 0.108 0.160 0.108 0.156 0.118 48 kpf 0.036 0.719 0.036 0.719 0.031 0.757 
12 kbinAbetaGlia -0.075 0.451 -0.075 0.451 -0.077 0.440 49 kpg 0.033 0.744 0.033 0.744 0.042 0.676 
13 kbinE1Ub -0.077 0.440 -0.077 0.440 -0.073 0.467 50 kpghalf 0.133 0.181 0.133 0.181 0.133 0.181 
14 kbinE2Ub 0.222 0.025 0.222 0.025 0.226 0.022 51 kphosMdm2 0.042 0.677 0.042 0.677 0.043 0.667 
15 kbinGSK3bp53 -0.094 0.349 -0.094 0.349 -0.085 0.396 52 kphosMdm2GSK3b -0.117 0.241 -0.117 0.241 -0.114 0.253 
16 kbinMdm2p53 -0.275 0.005 -0.275 0.005 -0.6102 2.64E-
0.5 
53 kphosMdm2GSK3bp53 -0.017 0.862 -0.017 0.862 -0.016 0.873 
17 kbinMTTau 0.036 0.717 0.036 0.717 0.031 0.7 4 54 kphosp53 0.118 0.238 0.118 0.238 0.113 0.257 
18 kbinProt 0.007 0.948 0.007 0.948 0.003 0.979 55 kphospTauGSK3b 0.122 0.220 0.122 0.220 0.126 0.206 
19 kbinTauProt -0.005 0.964 -0.005 0.964 -0.005 0.957 56 kphospTauGSK3bp53 -0.150 0.131 -0.150 0.131 -0.154 0.122 
20 kdam 0.032 0.750 0.032 0.750 0.036 0.722 57 kprodAbeta -0.019 0.853 -0.019 0.853 -0.013 0.895 
21 kdamROS 0.039 0.695 0.039 0.695 0.036 0.719 58 kprodAbeta2 -0.049 0.625 -0.049 0.625 -0.043 0.671 
22 kdegAbeta -0.067 0.506 -0.067 0.506 -0.061 0.545 59 kproteff -0.002 0.983 -0.002 0.983 -0.007 0.946 
23 kdegAbetaGlia -0.038 0.701 -0.038 0.701 -0.041 0.682 60 krelAbetaGlia 0.073 0.465 0.073 0.465 0.070 0.487 
24 kdegAntiAb 0.104 0.297 0.104 0.297 0.105 0.295 61 krelGSK3bp53 0.120 0.230 0.120 0.230 0.124 0.215 
25 kdegMdm2 -0.085 0.397 -0.085 0.397 -0.085 0.396 62 krelMdm2p53 -0.023 0.822 -0.023 0.822 -0.027 0.786 
26 kdegMdm2mRNA 0.025 0.803 0.025 0.803 0.032 0.750 63 krelMTTau -0.136 0.174 -0.136 0.174 -0.145 0.147 
27 kdegp53 0.019 0.846 0.019 0.846 0.025 0.801 64 kremROS 0.099 0.320 0.099 0.320 0.104 0.297 
28 kdegp53mRNA -0.104 0.299 -0.104 0.299 -0.096 0.338 65 krepair 0.022 0.826 0.022 0.826 0.018 0.857 
29 kdegTau20SProt 0.176 0.077 0.176 0.077 0.180 0.071 66 ksynMdm2 0.293 0.003 0.293 0.003 0.288 0.003 
30 kdephosMdm2 0.023 0.820 0.023 0.820 0.018 0.854 67 ksynMdm2mRNA -0.169 0.089 -0.169 0.089 -0.164 0.099 
31 kdephosp53 -0.001 0.990 -0.001 0.990 0.007 0.945 68 ksynMdm2mRNAGSK3bp
53 
-0.021 0.832 -0.021 0.832 -0.031 0.760 
32 kdephospTau 0.003 0.977 0.003 0.977 0.005 0.959 69 ksynp53 0.052 0.600 0.052 0.600 0.051 0.608 
33 kdisaggAbeta -0.063 0.531 -0.063 0.531 -0.067 0.503 70 ksynp53mRNA 0.039 0.699 0.039 0.699 0.037 0.709 
34 kdisaggAbeta1 -0.116 0.246 -0.116 0.246 -0.115 0.249 71 ksynp53mRNAAbeta 0.174 0.081 0.174 0.081 0.176 0.077 
35 kdisaggAbeta2 0.115 0.249 0.115 0.249 0.125 0.211 72 ksynTau 0.104 0.299 0.104 0.299 0.111 0.267 
36 kgenROSAbeta -0.072 0.474 -0.072 0.474 -0.070 0.485 73 ktangfor -0.039 0.697 -0.039 0.697 -0.042 0.674 
37 kgenROSGlia 0.186 0.062 0.186 0.062 0.177 0.075         


















































1 kactATM -0.071 0.476 -0.054 0.589 0.002 0.982 38 kgenROSPlaque -0.119 0.234 -0.155 0.119 -0.094 0.348 
2 kactDUBMdm2 -0.007 0.944 -0.023 0.817 -0.023 0.816 39 kinactATM 0.086 0.389 0.023 0.818 -0.025 0.800 
3 kactDUBp53 0.043 0.670 -0.024 0.810 -0.017 0.868 40 kinactglia1 -0.086 0.391 -0.130 0.194 -0.109 0.274 
4 kactDUBProtp53 0.042 0.676 0.045 0.650 0.027 0.787 41 kinactglia2 -0.118 0.237 -0.049 0.625 -0.006 0.952 
5 kactglia1 -0.124 0.215 -0.154 0.122 -0.114 0.255 42 kinhibprot -0.001 0.991 0.023 0.817 0.017 0.869 
6 Kactglia2 -0.085 0.397 -0.047 0.641 -0.129 0.198 43 kMdm2PolyUb 0.049 0.625 0.042 0.675 0.028 0.779 
7 kaggAbeta 0.078 0.437 0.061 0.539 0.088 0.380 44 kMdm2PUb -0.041 0.684 -0.073 0.469 -0.113 0.258 
8 kaggTau 0.129 0.198 0.217 0.028 0.224 0.024 45 kMdm2Ub 0.058 0.563 0.068 0.498 0.050 0.620 
9 kaggTauP1 -0.129 0.198 -0.217 0.028 -0.224 0.024 46 kp53PolyUb -0.028 0.779 -0.029 0.771 -0.033 0.744 
10 kaggTauP2 -0.048 0.630 0.020 0.845 -0.005 0.959 47 kp53Ub -0.060 0.550 -0.066 0.511 -0.041 0.680 
11 kbinAbantiAb 0.226 0.022 0.177 0.075 0.150 0.133 48 kpf 0.000 0.998 -0.025 0.806 -0.023 0.817 
12 kbinAbetaGlia -0.101 0.314 -0.097 0.334 -0.076 0.445 49 kpg -0.024 0.814 0.035 0.729 0.076 0.446 
13 kbinE1Ub -0.098 0.328 -0.092 0.358 -0.076 0.446 50 kpghalf 0.127 0.202 0.157 0.115 0.166 0.095 
14 kbinE2Ub 0.137 0.171 0.191 0.054 -0.7167 1.3E-007 51 kphosMdm2 -0.041 0.683 0.021 0.837 0.006 0.953 
15 kbinGSK3bp53 -0.123 0.219 -0.097 0.333 -0.081 0.417 52 kphosMdm2GSK3b -0.141 0.158 -0.109 0.277 -0.092 0.356 
16 kbinMdm2p53 -0.264 0.007 -0.295 0.003 0.64
93 
2.93E-006 53 kphosMdm2GSK3bp53 0.016 0.871 0.067 0.503 0.040 0.690 
17 kbinMTTau 0.006 0.953 0.029 0.769 0.017 0.868 54 kphosp53 0.116 0.247 0.164 0.100 0.115 0.248 
18 kbinProt -0.013 0.896 -0.023 0.816 -0.037 0.711 55 kphospTauGSK3b 0.154 0.122 0.091 0.364 0.090 0.370 
19 kbinTauProt 0.017 0.864 0.012 0.909 0.037 0.716 56 kphospTauGSK3bp53 -0.040 0.693 -0.079 0.429 -0.118 0.238 
20 kdam 0.023 0.819 0.010 0.917 0.019 0.852 57 kprodAbeta 0.041 0.681 0.046 0.649 -0.015 0.877 
21 kdamROS -0.041 0.681 0.027 0.789 0.028 0.782 58 kprodAbeta2 -0.049 0.625 -0.069 0.492 -0.051 0.610 
22 kdegAbeta -0.041 0.679 -0.093 0.355 -0.053 0.600 59 kproteff -0.003 0.980 -0.063 0.530 -0.045 0.656 
23 kdegAbetaGlia 0.019 0.850 -0.006 0.954 -0.025 0.801 60 krelAbetaGlia 0.019 0.847 0.033 0.744 0.044 0.662 
24 kdegAntiAb 0.074 0.462 0.070 0.482 0.088 0.379 61 krelGSK3bp53 0.044 0.663 0.096 0.339 0.137 0.170 
25 kdegMdm2 -0.118 0.236 -0.074 0.459 -0.065 0.519 62 krelMdm2p53 -0.031 0.759 -0.013 0.894 -0.032 0.752 
26 kdegMdm2mRNA 0.056 0.575 0.024 0.809 0.041 0.680 63 krelMTTau -0.093 0.352 -0.104 0.297 -0.106 0.288 
27 kdegp53 0.007 0.941 0.024 0.809 0.010 0.922 64 kremROS 0.105 0.295 0.074 0.461 0.083 0.405 
28 kdegp53mRNA -0.127 0.204 -0.102 0.309 -0.134 0.180 65 krepair 0.018 0.855 0.074 0.461 0.076 0.450 





30 kdephosMdm2 0.028 0.782 0.024 0.807 0.046 0.645 67 ksynMdm2mRNA -0.185 0.063 -0.169 0.090 -0.181 0.068 
31 kdephosp53 0.000 1.000 -0.018 0.860 -0.022 0.829 68 ksynMdm2mRNAGSK3bp
53 
-0.017 0.865 -0.004 0.967 0.023 0.818 
32 kdephospTau -0.039 0.695 -0.063 0.526 -0.027 0.790 69 ksynp53 0.034 0.734 0.013 0.894 0.015 0.883 
33 kdisaggAbeta -0.007 0.941 -0.039 0.694 -0.042 0.674 70 ksynp53mRNA 0.060 0.550 0.061 0.540 0.049 0.624 
34 kdisaggAbeta1 -0.190 0.056 -0.167 0.094 -0.143 0.152 71 ksynp53mRNAAbeta 0.149 0.134 0.165 0.098 0.117 0.240 
35 kdisaggAbeta2 0.052 0.607 0.102 0.308 0.157 0.115 72 ksynTau 0.177 0.075 0.185 0.062 0.163 0.101 
36 kgenROSAbeta -0.032 0.750 -0.106 0.288 -0.102 0.309 73 ktangfor 0.017 0.865 -0.018 0.858 -0.016 0.872 
37 kgenROSGlia 0.246 0.013 0.265 0.007 -0.6057 0.00033         



















































1 kactATM -0.026 0.799 -0.158 0.113 -0.080 0.425 38 kgenROSPlaque -0.094 0.347 0.047 0.637 0.060 0.548 
2 kactDUBMdm2 -0.010 0.920 0.087 0.387 0.073 0.468 39 kinactATM 0.000 0.997 -0.147 0.141 -0.065 0.516 
3 kactDUBp53 0.016 0.876 0.047 0.643 0.075 0.455 40 kinactglia1 -0.086 0.389 0.000 0.997 0.075 0.455 
4 kactDUBProtp53 0.038 0.708 0.021 0.835 0.036 0.721 41 kinactglia2 0.018 0.859 -0.123 0.219 -0.099 0.322 
5 kactglia1 -0.074 0.458 0.119 0.232 0.167 0.094 42 kinhibprot -0.033 0.740 0.029 0.769 0.001 0.993 
6 Kactglia2 -0.127 0.205 -0.122 0.220 0.002 0.985 43 kMdm2PolyUb 0.036 0.721 -0.102 0.306 -0.091 0.364 
7 kaggAbeta 0.096 0.336 -0.027 0.787 -0.063 0.533 44 kMdm2PUb -0.125 0.211 -0.018 0.861 0.069 0.489 
8 kaggTau 0.219 0.027 0.061 0.541 -0.130 0.193 45 kMdm2Ub -0.032 0.751 0.004 0.970 0.027 0.787 
9 kaggTauP1 -0.219 0.027 -0.061 0.541 0.130 0.193 46 kp53PolyUb -0.077 0.443 -0.074 0.461 -0.001 0.996 
10 kaggTauP2 0.021 0.833 -0.060 0.547 -0.055 0.580 47 kp53Ub -0.050 0.619 0.049 0.623 0.054 0.591 
11 kbinAbantiAb 0.157 0.116 0.110 0.269 -0.075 0.451 48 kpf 0.036 0.719 -0.077 0.442 -0.028 0.782 
12 kbinAbetaGlia -0.079 0.430 0.083 0.409 0.098 0.328 49 kpg 0.026 0.796 -0.016 0.873 -0.075 0.454 
13 kbinE1Ub -0.063 0.529 0.041 0.682 0.076 0.445 50 kpghalf 0.133 0.181 0.103 0.303 -0.059 0.555 
14 kbinE2Ub 0.227 0.022 -0.070 0.484 -0.186 0.061 51 kphosMdm2 0.046 0.647 -0.063 0.532 -0.021 0.835 
15 kbinGSK3bp53 -0.088 0.377 -0.028 0.779 0.096 0.336 52 kphosMdm2GSK3b -0.120 0.228 0.216 0.029 0.208 0.036 
16 kbinMdm2p53 -0.280 0.004 0.086 0.389 0.217 0.029 53 kphosMdm2GSK3bp53 -0.027 0.790 -0.049 0.626 -0.014 0.889 
17 kbinMTTau 0.044 0.658 0.124 0.216 0.070 0.483 54 kphosp53 0.109 0.277 -0.070 0.484 -0.145 0.146 
18 kbinProt 0.009 0.927 0.047 0.636 -0.015 0.882 55 kphospTauGSK3b 0.119 0.233 0.101 0.315 -0.004 0.965 
19 kbinTauProt 0.005 0.962 -0.133 0.181 -0.116 0.247 56 kphospTauGSK3bp53 -0.148 0.137 -0.137 0.169 0.024 0.807 
20 kdam 0.027 0.787 0.095 0.340 0.024 0.813 57 kprodAbeta -0.025 0.805 -0.033 0.741 -0.061 0.545 
21 kdamROS 0.039 0.694 0.030 0.765 0.032 0.748 58 kprodAbeta2 -0.047 0.636 -0.110 0.270 -0.054 0.592 
22 kdegAbeta -0.061 0.542 0.113 0.259 0.109 0.276 59 kproteff -0.006 0.956 0.081 0.417 0.050 0.615 
23 kdegAbetaGlia -0.042 0.673 -0.076 0.447 -0.028 0.779 60 krelAbetaGlia 0.078 0.438 0.176 0.076 0.081 0.419 
24 kdegAntiAb 0.094 0.349 -0.062 0.536 -0.119 0.234 61 krelGSK3bp53 0.117 0.240 -0.103 0.302 -0.093 0.350 
25 kdegMdm2 -0.086 0.392 0.013 0.896 0.079 0.428 62 krelMdm2p53 -0.022 0.828 0.175 0.079 0.140 0.162 
26 kdegMdm2mRNA 0.029 0.770 0.074 0.459 0.009 0.929 63 krelMTTau -0.140 0.160 -0.066 0.510 0.023 0.815 
27 kdegp53 0.024 0.813 -0.010 0.923 -0.006 0.951 64 kremROS 0.102 0.309 0.016 0.874 -0.104 0.296 
28 kdegp53mRNA -0.097 0.334 0.022 0.825 0.132 0.185 65 krepair 0.025 0.802 -0.117 0.240 -0.069 0.490 
29 kdegTau20SProt 0.180 0.070 0.010 0.921 -0.142 0.155 66 ksynMdm2 0.294 0.003 0.016 0.877 -0.251 0.011 
30 kdephosMdm2 0.023 0.815 0.024 0.808 -0.029 0.774 67 ksynMdm2mRNA -0.169 0.089 0.113 0.256 0.154 0.122 
31 kdephosp53 0.008 0.938 0.005 0.962 0.001 0.995 68 ksynMdm2mRNAGSK3bp
53 
-0.026 0.797 0.146 0.143 0.115 0.251 
32 kdephospTau -0.003 0.979 -0.052 0.604 -0.013 0.895 69 ksynp53 0.052 0.604 -0.052 0.604 -0.026 0.799 
33 kdisaggAbeta -0.063 0.529 0.006 0.950 0.021 0.838 70 ksynp53mRNA 0.042 0.672 0.012 0.905 -0.013 0.897 
34 kdisaggAbeta1 -0.117 0.241 0.073 0.467 0.135 0.175 71 ksynp53mRNAAbeta 0.169 0.090 0.066 0.508 -0.069 0.490 
35 kdisaggAbeta2 0.117 0.241 -0.059 0.555 -0.104 0.297 72 ksynTau 0.112 0.263 -0.156 0.118 -0.166 0.096 
36 kgenROSAbeta -0.074 0.457 -0.136 0.171 0.005 0.957 73 ktangfor -0.094 0.347 -0.167 0.094 -0.097 0.335 
37 kgenROSGlia 0.190 0.056 -0.060 0.549 -0.176 0.077         

















































1 kactATM -0.054 0.589 -0.108 0.280 -0.120 0.230 38 kgenROSPlaque -0.145 0.146 -0.061 0.545 0.076 0.446 
2 kactDUBMdm2 -0.040 0.688 -0.011 0.915 0.074 0.461 39 kinactATM 0.043 0.669 -0.039 0.695 -0.089 0.373 
3 kactDUBp53 0.122 0.220 -0.061 0.540 0.028 0.782 40 kinactglia1 -0.047 0.637 -0.001 0.989 0.018 0.856 
4 kactDUBProtp53 0.109 0.273 0.071 0.479 0.025 0.803 41 kinactglia2 -0.115 0.250 -0.047 0.638 -0.159 0.110 
5 kactglia1 -0.173 0.083 -0.003 0.974 0.043 0.666 42 kinhibprot -0.117 0.243 -0.118 0.238 -0.079 0.431 
6 Kactglia2 -0.060 0.551 0.026 0.795 -0.058 0.561 43 kMdm2PolyUb 0.173 0.082 0.076 0.446 -0.153 0.124 
7 kaggAbeta -0.094 0.348 -0.023 0.816 -0.022 0.823 44 kMdm2PUb 0.159 0.111 -0.002 0.983 0.035 0.729 
8 kaggTau 0.046 0.643 0.073 0.467 -0.173 0.082 45 kMdm2Ub -0.040 0.687 -0.079 0.427 -0.017 0.861 
9 kaggTauP1 -0.046 0.643 -0.073 0.467 0.173 0.082 46 kp53PolyUb -0.040 0.689 0.018 0.858 0.038 0.704 
10 kaggTauP2 0.120 0.228 0.192 0.053 0.044 0.657 47 kp53Ub -0.173 0.083 -0.021 0.835 -0.108 0.281 
11 kbinAbantiAb 0.025 0.805 0.031 0.759 0.036 0.721 48 kpf -0.017 0.863 0.068 0.497 -0.041 0.682 
12 kbinAbetaGlia -0.085 0.398 0.028 0.779 0.176 0.077 49 kpg 0.133 0.181 -0.079 0.430 -0.039 0.698 
13 kbinE1Ub -0.037 0.712 -0.115 0.249 0.024 0.814 50 kpghalf 0.102 0.309 -0.108 0.281 0.177 0.075 
14 kbinE2Ub 0.173 0.083 0.212 0.032 -0.128 0.199 51 kphosMdm2 -0.007 0.947 -0.007 0.947 -0.039 0.694 
15 kbinGSK3bp53 0.167 0.093 0.078 0.438 -0.017 0.864 52 kphosMdm2GSK3b -0.003 0.978 0.167 0.093 0.059 0.554 
16 kbinMdm2p53 -0.246 0.013 -0.169 0.090 0.212 0.032 53 kphosMdm2GSK3bp53 -0.079 0.429 -0.073 0.469 0.010 0.922 
17 kbinMTTau -0.022 0.825 0.170 0.088 0.044 0.661 54 kphosp53 -0.061 0.545 0.126 0.209 -0.011 0.913 
18 kbinProt 0.085 0.398 0.121 0.225 0.059 0.555 55 kphospTauGSK3b 0.115 0.248 0.084 0.399 -0.084 0.401 
19 kbinTauProt -0.102 0.306 -0.017 0.869 -0.061 0.546 56 kphospTauGSK3bp53 -0.200 0.044 -0.280 0.004 -0.115 0.249 
20 kdam 0.093 0.350 0.154 0.122 0.136 0.172 57 kprodAbeta -0.071 0.479 -0.124 0.215 -0.037 0.709 
21 kdamROS 0.134 0.181 0.041 0.680 0.010 0.924 58 kprodAbeta2 -0.117 0.241 -0.038 0.703 -0.037 0.709 
22 kdegAbeta 0.135 0.177 -0.063 0.530 -0.008 0.936 59 kproteff -0.033 0.740 0.048 0.632 0.026 0.798 
23 kdegAbetaGlia -0.503 0.0004
1 
0.001 0.991 0.066 0.507 60 krelAbetaGlia 0.107 0.284 0.121 0.228 0.038 0.707 
24 kdegAntiAb -0.011 0.910 -0.109 0.277 -0.122 0.224 61 krelGSK3bp53 0.072 0.472 -0.089 0.376 -0.046 0.645 
25 kdegMdm2 -0.042 0.672 -0.084 0.400 -0.038 0.706 62 krelMdm2p53 0.080 0.422 0.156 0.118 0.065 0.514 
26 kdegMdm2mRNA 0.060 0.548 0.111 0.267 0.134 0.180 63 krelMTTau -0.170 0.087 -0.208 0.036 -0.005 0.960 
27 kdegp53 0.194 0.050 -0.006 0.954 0.195 0.050 64 kremROS 0.049 0.624 0.252 0.011 0.066 0.511 
28 kdegp53mRNA -0.035 0.729 -0.060 0.546 0.176 0.076 65 krepair -0.013 0.898 0.031 0.761 -0.102 0.310 
29 kdegTau20SProt -0.068 0.497 -0.052 0.606 0.048 0.634 66 ksynMdm2 0.543 0.00023 0.255 0.010 -0.013 0.900 
30 kdephosMdm2 0.163 0.101 0.063 0.530 0.009 0.925 67 ksynMdm2mRNA -0.059 0.559 -0.078 0.438 0.006 0.950 
31 kdephosp53 -0.028 0.779 -0.017 0.863 0.009 0.930 68 ksynMdm2mRNAGSK3bp
53 
0.027 0.791 0.064 0.524 0.177 0.075 
32 kdephospTau 0.051 0.613 -0.004 0.972 -0.110 0.271 69 ksynp53 -0.057 0.571 -0.082 0.413 -0.054 0.591 
33 kdisaggAbeta -0.066 0.508 0.071 0.478 -0.067 0.503 70 ksynp53mRNA -0.045 0.654 -0.036 0.720 -0.105 0.294 
34 kdisaggAbeta1 0.091 0.365 0.002 0.984 0.077 0.442 71 ksynp53mRNAAbeta 0.156 0.117 0.135 0.177 0.007 0.946 
35 kdisaggAbeta2 0.112 0.262 -0.085 0.395 -0.048 0.634 72 ksynTau 0.056 0.575 -0.139 0.164 -0.121 0.226 
36 kgenROSAbeta -0.112 0.261 -0.080 0.425 -0.012 0.904 73 ktangfor -0.582 0.2E-04 -0.109 0.274 -0.247 0.012 
37 kgenROSGlia -0.042 0.676 -0.003 0.978 0.059 0.556         
Table D.14: Output from PRCC Analysis for GilaA using MRM/GSSA 
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